Science.gov

Sample records for 99mtc-labelled radiopharmaceuticals version

  1. Radiopharmaceuticals

    SciTech Connect

    Theobald, A.E.

    1989-01-01

    This book is a review of the latest developments in radiopharmaceuticals. It covers the development of radiopharmaceutical compounds, the theory and practice of their synthesis, and examples of their application. Also covers safe handling of radiopharmaceuticals, legislation affecting their use, radiation monitoring, radiochromatography, and computer techniques.

  2. 'Naked' radiopharmaceuticals

    SciTech Connect

    Wallner, Paul E. . E-mail: pwallner@rtsx.com

    2006-10-01

    The term 'naked' radiopharmaceuticals, more appropriately, 'unbound' radiopharmaceuticals, refers to any radioisotope used for clinical research or clinical purposes that is not attached to a chemical or biological carrier, and that localizes in various tissues because of a physiologic or chemical propensity/affinity, or secondary to focal anatomic placement. Although they remain useful in selected clinical circumstances, the available agents (except for Iodine-131) have been relegated to an unfortunate and somewhat secondary role. The agents remain useful and worthy of consideration for new clinical investigation and clinical use.

  3. Organometallic Radiopharmaceuticals

    NASA Astrophysics Data System (ADS)

    Alberto, Roger

    Although molecular imaging agents have to be synthesized ultimately from aqueous solutions, organometallic complexes are becoming more and more important as flexible yet kinetically stable building blocks for radiopharmaceutical drug discovery. The diversity of ligands, targets, and targeting molecules related to these complexes is an essential base for finding novel, noninvasive imaging agents to diagnose and eventually treat widespread diseases such as cancer. This review article covers the most important findings toward these objectives accomplished during the past 3-4 years. The two major available organometallic building blocks will be discussed in the beginning together with constraints for market introduction as imposed by science and industry. Since targeting radiopharmaceuticals are a major focus of current research in molecular imaging, attempts toward so-called technetium essential radiopharmaceuticals will be briefly touched in the beginning followed by the main discussion about the labeling of targeting molecules such as folic acid, nucleosides, vitamins, carbohydrates, and fatty acids. At the end, some new strategies for drug discovery will be introduced together with results from organometallic chemistry in water. The majority of the new results have been achieved with the [99mTc(OH2)3(CO)3]+ complex which will, though not exclusively, be a focus of this review.

  4. Medicinal Radiopharmaceutical Chemistry of Metal Radiopharmaceuticals

    NASA Astrophysics Data System (ADS)

    Saw, Maung Maung

    2012-06-01

    Metal complexes have been used as medicinal compounds. Metals have advantageous features over organic compounds. Significant applications of metal complexes are in the field of nuclear medicine. Radiopharmaceuticals are drugs containing radioisotopes used for diagnostic and therapeutic purposes. The generalized targeting strategy for molecular imaging probe consists of three essential parts: (i) reporter unit or payload, (ii) carrier, and (iii) targeting system. Medicinal radiopharmaceutical chemistry pays special consideration to radioisotopes, as a reporter unit for diagnostic application or as a payload for therapeutic application. Targeting is achieved by a few approaches but the most common is the bifunctional chelator approach. While designing a radiopharmaceutical, a range of issues needs to be considered including properties of metal radioisotopes, bifunctional chelators, linkers, and targeting molecules. Designing radiopharmaceuticals requires consideration of two key words: "compounds of biological interest" and "fit for intended use." The ultimate goal is the development of new diagnostic methods and treatment. Diagnostic metal radiopharmaceuticals are used for SPECT and PET applications. Technetium chemistry constitutes a major portion of SPECT and gallium chemistry constitutes a major portion of PET. Therapeutic radiopharmaceuticals can be constructed by using alpha-, beta minus-, or Auger electron-emitting radiometals. Special uses of medicinal radiopharmaceuticals include internal radiation therapy, brachytherapy, immunoPET, radioimmunotherapy, and peptide receptor radionuclide imaging and therapy.

  5. Eleventh international symposium on radiopharmaceutical chemistry

    SciTech Connect

    1995-12-31

    This document contains abstracts of papers which were presented at the Eleventh International Symposium on Radiopharmaceutical Chemistry. Sessions included: radiopharmaceuticals for the dopaminergic system, strategies for the production and use of labelled reactive small molecules, radiopharmaceuticals for measuring metabolism, radiopharmaceuticals for the serotonin and sigma receptor systems, labelled probes for molecular biology applications, radiopharmaceuticals for receptor systems, radiopharmaceuticals utilizing coordination chemistry, radiolabelled antibodies, radiolabelling methods for small molecules, analytical techniques in radiopharmaceutical chemistry, and analytical techniques in radiopharmaceutical chemistry.

  6. Method for preparing radiopharmaceutical complexes

    DOEpatents

    Jones, Alun G.; Davison, Alan; Abrams, Michael J.

    1989-05-02

    A method for preparing radiopharmaceutical complexes that are substantially free of the reaction materials used to produce the radiopharmaceutical complex is disclosed. The method involves admixing in a suitable first solvent in a container a target seeking ligand or salt or metal adduct thereof, a radionuclide label, and a reducing agent for said radionuclide, thereby forming said radiopharmaceutical complex; coating the interior walls of the container with said pharmaceutical complex; discarding the solvent containing by-products and unreacted starting reaction materials; and removing the radiopharmaceutical complex from said walls by dissolving it in a second solvent, thereby obtaining said radiopharmaceutical complex substantially free of by-products and unreacted starting materials.

  7. Process for preparing radiopharmaceuticals

    DOEpatents

    Barak, Morton; Winchell, Harry S.

    1977-01-04

    A process for the preparation of technetium-99m labeled pharmaceuticals is disclosed. The process comprises initially isolating technetium-99m pertechnetate by adsorption upon an adsorbent packing in a chromatographic column. The technetium-99m is then eluted from the packing with a biological compound to form a radiopharmaceutical.

  8. Audits of radiopharmaceutical formulations

    SciTech Connect

    Castronovo, F.P. Jr. )

    1992-03-01

    A procedure for auditing radiopharmaceutical formulations is described. To meet FDA guidelines regarding the quality of radiopharmaceuticals, institutional radioactive drug research committees perform audits when such drugs are formulated away from an institutional pharmacy. All principal investigators who formulate drugs outside institutional pharmacies must pass these audits before they can obtain a radiopharmaceutical investigation permit. The audit team meets with the individual who performs the formulation at the site of drug preparation to verify that drug formulations meet identity, strength, quality, and purity standards; are uniform and reproducible; and are sterile and pyrogen free. This team must contain an expert knowledgeable in the preparation of radioactive drugs; a radiopharmacist is the most qualified person for this role. Problems that have been identified by audits include lack of sterility and apyrogenicity testing, formulations that are open to the laboratory environment, failure to use pharmaceutical-grade chemicals, inadequate quality control methods or records, inadequate training of the person preparing the drug, and improper unit dose preparation. Investigational radiopharmaceutical formulations, including nonradiolabeled drugs, must be audited before they are administered to humans. A properly trained pharmacist should be a member of the audit team.

  9. Melanin-binding radiopharmaceuticals

    SciTech Connect

    Packer, S; Fairchild, R G; Watts, K P; Greenberg, D; Hannon, S J

    1980-01-01

    The scope of this paper is limited to an analysis of the factors that are important to the relationship of radiopharmaceuticals to melanin. While the authors do not attempt to deal with differences between melanin-binding vs. melanoma-binding, a notable variance is assumed. (PSB)

  10. Pharmacovigilance in radiopharmaceuticals

    PubMed Central

    Kumar, Rishi; Kalaiselvan, Vivekanandan; Kumar, Rakesh; Verma, Ravendra; Singh, Gyanendra Nath

    2016-01-01

    Indian Pharmacopoeia Commission is Committed for maintaining the standards of drugs including Radiopharmaceuticals (RPs) by publishing Indian Pharmacopoeia. These RPs are being used in India for diagnostic or therapeutic purpose. RPs though contain relatively small quantities of active ingredient and administered in small volumes could cause some adverse reactions to the patients. The objective of presenting this article is to introduce the system of adverse drug reaction reporting to the nuclear medicine fraternity who are dealing with RPs. PMID:27095855

  11. Radiopharmaceuticals for diagnosis

    SciTech Connect

    Kuhl, D.E.

    1990-06-01

    During this grant period 1 January 1988--31 December 1990, we have successfully developed a number of new approaches to fluorine-18 labeled compounds, prepared several new radiotracers for both animal studies and eventual clinical trials, and explored the utility of a high-quality industrial robot in radiopharmaceutical applications. The progress during the last grant period is summarized briefly in the following sections. Publications arising from this research are listed below and can be found in Appendix I. 1 fig.

  12. Cyclotrons and positron emitting radiopharmaceuticals

    SciTech Connect

    Wolf, A.P.; Fowler, J.S.

    1984-01-01

    The state of the art of Positron Emission Tomography (PET) technology as related to cyclotron use and radiopharmaceutical production is reviewed. The paper discusses available small cyclotrons, the positron emitters which can be produced and the yields possible, target design, and radiopharmaceutical development and application. 97 refs., 12 tabs. (ACR)

  13. Dosimetry for Radiopharmaceutical Therapy

    PubMed Central

    Sgouros, George; Hobbs, Robert F.

    2014-01-01

    Radiopharmaceutical therapy (RPT) involves the use of radionuclides that are either conjugated to tumor-targeting agents (eg, nanoscale constructs, antibodies, peptides, and small molecules) or concentrated in tissue through natural physiological mechanisms that occur predominantly in neoplastic or otherwise targeted cells (eg, Graves disease). The ability to collect pharmacokinetic data by imaging and use this to perform dosimetry calculations for treatment planning distinguishes RPT from other systemic treatment modalities. Treatment planning has not been widely adopted, in part, because early attempts to relate dosimetry to outcome were not successful. This was partially because a dosimetry methodology appropriate to risk evaluation rather than efficacy and toxicity was being applied to RPT. The weakest links in both diagnostic and therapeutic dosimetry are the accuracy of the input and the reliability of the radiobiological models used to convert dosimetric data to the relevant biologic end points. Dosimetry for RPT places a greater demand on both of these weak links. To date, most dosimetric studies have been retrospective, with a focus on tumor dose-response correlations rather than prospective treatment planning. In this regard, transarterial radioembolization also known as intra-arterial radiation therapy, which uses radiolabeled (90Y) microspheres of glass or resin to treat lesions in the liver holds much promise for more widespread dosimetric treatment planning. The recent interest in RPT with alpha-particle emitters has highlighted the need to adopt a dosimetry methodology that specifically accounts for the unique aspects of alpha particles. The short range of alpha-particle emitters means that in cases in which the distribution of activity is localized to specific functional components or cell types of an organ, the absorbed dose will be equally localized and dosimetric calculations on the scale of organs or even voxels (~5 mm) are no longer sufficient

  14. Recent advances in copper radiopharmaceuticals.

    PubMed

    Hao, Guiyang; Singh, Ajay N; Oz, Orhan K; Sun, Xiankai

    2011-04-01

    Copper has five radioisotopes ((60)Cu, (61)Cu, (62)Cu, (64)Cu, and (67)Cu) that can be used in copper radiopharmaceuticals. These radioisotopes decay by mixed emissions of β+, β-, and γ with a wide range of half-lives from 9.74 min ((62)Cu) to 2.58 d ((67)Cu), which enable the design and synthesis of a variety of radiopharmaceuticals for different biomedical applications in diagnostic and therapeutic nuclear medicine. However, due to the availability and production cost, the research efforts in copper radiopharmaceuticals are mainly focused on the use of (64)Cu (t(1/2) = 12.7 h; 17.4% β+, 43% EC, 39% β-), a radioisotope with low positron energy (E β+max = 0.656 MeV) that is ideal for positron emission tomography (PET) imaging quantification and β- emissions along with Auger electron for radiotherapy. Driven by the ever-increasing availability of preclinical and clinical PET scanners, a considerable interest has been seen in the development of novel copper radiopharmaceuticals in the past decade for a variety of diseases as represented by PET imaging of cancer. To avoid unnecessary literature redundancy, this review focuses on the unrepresented research aspects of copper chemistry (e.g. electrochemistry) and their uses in the evaluation of novel nuclear imaging probe design and recent advances in the field towards the practical use of copper radiopharmaceuticals.

  15. Radiopharmaceuticals for diagnosis and treatment

    SciTech Connect

    Kuhl, D.E.

    1992-01-01

    We report on our efforts in PET basic radiochemistry, radiopharmaceutical synthesis, and preclinical radiopharmaceutical evaluation. These efforts are focused on three fronts. First predictive abilities in nucleophilic aromatic substitution with [[sup 18]F]fluorination of substituted aromatic rings. Although radiochemical yields can be predicted within a very similar group of compounds with similar leaving groups and substituent patterns, generalization to all nucleophilic substitutions with [[sup 18]F] fluoride is not warranted. Kinetic studies indicate significantly different rates of reactions, depending on ring substituents. Second, preclinical evaluation of new radiopharmaceuticals. We have synthesized and begun the preclinical evaluation of [[sup 11]C]tetrabenazine, a new radioligand based on the vesicular monoamine transport system. Third, our work, on [[sup 18]F]fluorination/decarbonylation reactions, structure-activity relationships in dopamine uptake inhibitors and effects of chronic drugs on radioligand binding is described.

  16. Preparation of radiopharmaceuticals labeled with metal radionuclides

    SciTech Connect

    Welch, M.J.

    1992-06-01

    We recently developed a useful zinc-62/copper-62 generator and are presently evaluating copper-62 radiopharmaceuticals for clinical studies. While developing these copper-62 radiopharmaceuticals, in collaboration with the University of Missouri Research Reactor, Columbia we have also explored copper-64 radiopharmaceuticals. The PET images we obtained with copper-64 tracers were of such high quality that we have developed and evaluated copper-64 labeled antibodies for PET imaging. The major research activities described herein include: the development and assessment of gallium-68 radiopharmaceuticals; the development and evaluation of a new zinc-62/copper-62 generator and the assessment of copper-62 radiopharmaceuticals; mechanistic studies on proteins labeled with metal radionuclides.

  17. Bioinorganic Activity of Technetium Radiopharmaceuticals.

    ERIC Educational Resources Information Center

    Pinkerton, Thomas C.; And Others

    1985-01-01

    Technetium radiopharmaceuticals are diagnostic imaging agents used in the field of nuclear medicine to visualize tissues, anatomical structures, and metabolic disorders. Bioavailability of technetium complexes, thyroid imaging, brain imaging, kidney imaging, imaging liver function, bone imaging, and heart imaging are the major areas discussed. (JN)

  18. Radiopharmaceuticals for diagnosis. Final report

    SciTech Connect

    Not Available

    1994-03-01

    In the period 1969-1986, this project was directed to the evolution of target-specific labeled chemicals useful for nuclear medical imaging, especially radioactive indicators suited to tracing adrenal functions and localizing tumors in the neuroendocrine system. Since 1986, this project research has focused on the chemistry of positron emission tomography (PET) ligands. This project has involved the evaluation of methods for radiochemical syntheses with fluorine-18, as well as the development and preliminary evaluation of new radiopharmaceuticals for positron emission tomography. In the radiochemistry area, the ability to predict fluorine-18 labeling yields for aromatic substitution reactions through the use of carbon-13 NMR analysis was studied. Radiochemical yields can be predicted for some structurally analogous aromatic compounds, but this correlation could not be generally applied to aromatic substrates for this reaction, particularly with changes in ring substituents or leaving groups. Importantly, certain aryl ring substituents, particularly methyl groups, appeared to have a negative effect on fluorination reactions. These observations are important in the future design of syntheses of complicated organic radiopharmaceuticals. In the radiopharmaceutical area, this project has supported the development of a new class of radiopharmaceuticals based on the monoamine vesicular uptake systems. The new radioligands, based on the tetrabenazine structure, offer a new approach to the quantification of monoaminergic neurons in the brain. Preliminary primate imaging studies support further development of these radioligands for PET studies in humans. If successful, such radiopharmaceuticals will find application in studies of the causes and treatment of neurodegenerative disorders such as Parkinson`s disease.

  19. Prospective of 68Ga-Radiopharmaceutical Development

    PubMed Central

    Velikyan, Irina

    2014-01-01

    Positron Emission Tomography (PET) experienced accelerated development and has become an established method for medical research and clinical routine diagnostics on patient individualized basis. Development and availability of new radiopharmaceuticals specific for particular diseases is one of the driving forces of the expansion of clinical PET. The future development of the 68Ga-radiopharmaceuticals must be put in the context of several aspects such as role of PET in nuclear medicine, unmet medical needs, identification of new biomarkers, targets and corresponding ligands, production and availability of 68Ga, automation of the radiopharmaceutical production, progress of positron emission tomography technologies and image analysis methodologies for improved quantitation accuracy, PET radiopharmaceutical regulations as well as advances in radiopharmaceutical chemistry. The review presents the prospects of the 68Ga-based radiopharmaceutical development on the basis of the current status of these aspects as well as wide range and variety of imaging agents. PMID:24396515

  20. Radiopharmaceuticals for imaging the heart

    DOEpatents

    Green, M.A.; Tsang, B.W.

    1994-06-28

    Radiopharmaceuticals for imaging myocardial tissues are prepared by forming lipophilic, cationic complexes of radioactive metal ions with metal chelating ligands comprising the Schiff base adducts of triamines and tetraamines with optionally substituted salicylaldehydes. The lipophilic, cationic, radioactive complexes of the invention exhibit high uptake and retention in myocardial tissues. Preferred gallium-68(III) complexes in accordance with this invention can be used to image the heart using positron emission tomography. 6 figures.

  1. Radiopharmaceuticals for imaging the heart

    DOEpatents

    Green, Mark A.; Tsang, Brenda W.

    1994-01-01

    Radiopharmaceuticals for imaging myocardial tissues are prepared by forming lipophilic, cationic complexes of radioactive metal ions with metal chelating ligands comprising the Schiff base adducts of triamines and tetraamines with optionally substituted salicylaldehydes. The lipophilic, cationic, radioactive complexes of the invention exhibit high uptake and retention in myocardial tissues. Preferred gallium-68(III) complexes in accordance with this invention can be used to image the heart using positron emission tomography.

  2. Radiation dose estimates for radiopharmaceuticals

    SciTech Connect

    Stabin, M.G.; Stubbs, J.B.; Toohey, R.E.

    1996-04-01

    Tables of radiation dose estimates based on the Cristy-Eckerman adult male phantom are provided for a number of radiopharmaceuticals commonly used in nuclear medicine. Radiation dose estimates are listed for all major source organs, and several other organs of interest. The dose estimates were calculated using the MIRD Technique as implemented in the MIRDOSE3 computer code, developed by the Oak Ridge Institute for Science and Education, Radiation Internal Dose Information Center. In this code, residence times for source organs are used with decay data from the MIRD Radionuclide Data and Decay Schemes to produce estimates of radiation dose to organs of standardized phantoms representing individuals of different ages. The adult male phantom of the Cristy-Eckerman phantom series is different from the MIRD 5, or Reference Man phantom in several aspects, the most important of which is the difference in the masses and absorbed fractions for the active (red) marrow. The absorbed fractions for flow energy photons striking the marrow are also different. Other minor differences exist, but are not likely to significantly affect dose estimates calculated with the two phantoms. Assumptions which support each of the dose estimates appears at the bottom of the table of estimates for a given radiopharmaceutical. In most cases, the model kinetics or organ residence times are explicitly given. The results presented here can easily be extended to include other radiopharmaceuticals or phantoms.

  3. The development of new radiopharmaceuticals.

    PubMed

    Britton, K E

    1990-01-01

    The development of new radiopharmaceuticals is the basis of the continuing growth of nuclear medicine. Chemical interactions of electron clouds in their three-dimensional conformations bring together, in the process of molecular recognition, the reaction of antibody and antigen, receptor and ligand, enzyme and substrate, hormone and response site. This convergence enables the computer design of molecules such as ligands to fit computer-displayed conformational models showing active centres, positive and negative charges and other interactions. Indeed, given a particular molecule, a complementary binding structure can be devised. The hybridoma approach to monoclonal antibody production is being superceded by the bacterial bioengineer. The gene for the hypervariable region from the spleen cells of immunized mouse can be coupled with the myeloma gene. The polymerase chain reaction can duplicate the DNA a million times over in 20 min and the result transfected into a bacterial plasmid to produce the antibody. These scientific problems are soluble in principle and are being solved. However, so much damage to this developing biological field is being done by regulatory authorities that one must ask who should or can regulate the regulators. These problems have to be overcome in order to provide the new radiopharmaceuticals that are the food and wine of nuclear medicine.

  4. Renal radiopharmaceuticals--an update

    SciTech Connect

    Chervu, L.R.; Blaufox, M.D.

    1982-07-01

    Noninvasive radionuclide procedures in the evaluation of renal disease have been accepted increasingly as effective and valuable alternatives to older clinical methods. The development of suitable radiopharmaceuticals labeled with high photon intensity radionuclides and with /sup 99m/Tc in particular has stimulated this modality during the last few years. Currently several nearly ideal agents are available for anatomical and functional studies of kidney imparting very low absorbed radiation doses. These include /sup 99m/Tc-GHA and /sup 99m/Tc-DMSA for renal morphology and differential function evaluation, /sup 99m/Tc-DTPA for GFR and /sup 123/I orthoiodohippurate for ERPF measurements. A suitable agent as a replacement for the latter labeled with /sup 99m/Tc is actively being sought. Computer-assisted processing of dynamic renal function studies enables the observer to obtain a wealth of information related to the renal extraction, uptake, parenchymal transit and pelvic transit parameters of the agent administered into the bloodstream. Each of these parameters either globally or differentially contributes to a detailed evaluation of renal disease states. Several of these procedures have been validated against classical techniques clinically but more detailed information is being sought with the recently introduced radiopharmaceuticals. With the detailed validation and increasing recognition of the clinical utility of several of the radionuclidic procedures at many centers, it is hoped that radionuclide assessment of renal disorders ultimately will be made available routinely at all medical facilities.

  5. Hot atom chemistry and radiopharmaceuticals

    SciTech Connect

    Krohn, Kenneth A.; Moerlein, Stephen M.; Link, Jeanne M.; Welch, Michael J.

    2012-12-19

    The chemical products made in a cyclotron target are a combined result of the chemical effects of the nuclear transformation that made the radioactive atom and the bulk radiolysis in the target. This review uses some well-known examples to understand how hot atom chemistry explains the primary products from a nuclear reaction and then how radiation chemistry is exploited to set up the optimal product for radiosynthesis. It also addresses the chemical effects of nuclear decay. There are important principles that are common to hot atom chemistry and radiopharmaceutical chemistry. Both emphasize short-lived radionuclides and manipulation of high specific activity nuclides. Furthermore, they both rely on radiochromatographic separation for identification of no-carrieradded products.

  6. Radiopharmaceuticals for diagnosis and treatment

    SciTech Connect

    Kuhl, D.E.

    1991-01-01

    In this grant period we have continued our efforts in the areas of PE basic radiochemistry, radiopharmaceutical synthesis, and preclinical radiopharmaceutical evaluation. A new synthetic sequence, consisting, of no-carrier-added fluorine-18 labeling of substituted benzaldehydes followed by reductive decarbonylation, has been developed. This new methodology can be applied to the fluorine-18 labeling of a wide variety of drugs not previously accessible through existing fluorine-18 labeling methods. Following up on a literature report that the ability to radiolabel aromatic rings can be predicted by {sup 13}C-NMR chemical shifts, we have examined the generality of this correlation in aromatic rings bearing a variety of substituents. Although the original correlation holds for nitro substituted anisaldehydes, it cannot be extended to other rings substitution patterns. We have examined the relationship of in vivo localization of various fluorine-18 labeled dopamine uptake inhibitors to their in vitro binding affinities and lipophilicities. We have found that remarkably small decreases in binding affinity result in dramatic losses of in vivo binding to the desired high affinity binding sites. In order to probe the effects of endogenous neurotransmitter on the in vivo binding of radiolabeled dopamine uptake inhibitors, we have examined the in vivo regional localization of (18{sub F}) GBR 13119 after acute and chronic drug treatments which alter the endogenous levels of dopamine. We have found that acute changes in dopamine levels do not affect the binding of this radioligand, but chronic depletion of neurotransmitter results in down-regulation of the in vivo binding sites. 16 refs., 2 figs., 1 tab.

  7. Radiopharmaceuticals in PET, Progress and Promise

    DOE R&D Accomplishments Database

    Wolf, A. P.; Fowler, J. S.

    1988-11-01

    It is the intention of this presentation to focus on the current state of radiopharmaceuticals for PET and where this is leading us. PET radiopharmaceuticals can be broken down into perhaps seven categories at present with each being applicable to a different aspect of human biochemistry. These are: metabolic probes, neurochemical probes, enzyme probes, ion channel blockers, blood flow agents, ethical drugs and other positron emitters.

  8. Radiopharmaceuticals in PET, progress and promise

    SciTech Connect

    Wolf, A.P.; Fowler, J.S.

    1988-11-01

    It is the intention of this presentation to focus on the current state of radiopharmaceuticals for PET and where this is leading us. PET radiopharmaceuticals can be broken down into perhaps seven categories at present with each being applicable to a different aspect of human biochemistry. These are: metabolic probes, neurochemical probes, enzyme probes, ion channel blockers, blood flow agents, ethical drugs and other positron emitters. 7 refs.

  9. Astatine Radiopharmaceuticals: Prospects and Problems.

    PubMed

    Vaidyanathan, Ganesan; Zalutsky, Michael R

    2008-09-01

    For the treatment of minimum residual diseases such micrometastases and residual tumor margins that remain after debulking of the primary tumor, targeted radiotherapy using radiopharmaceuticals tagged with alpha-particle-emitting radionuclides is very attractive. In addition to the their short range in tissue, which helps minimize harmful effects on adjacent normal tissues, alpha-particles, being high LET radiation, have several radiobiological advantages. The heavy halogen, astatine-211 is one of the prominent alpha-particle-emitting radionuclides in practice. Being a halogen, it can often be incorporated into biomolecules of interest by adapting radioiodination chemistry. A wide spectrum of compounds from the simple [(211)At]astatide ion to small organic molecules, peptides, and large proteins labeled with (211)At have been investigated with at least two reaching the stage of clinical evaluation. The chemistry, cytotoxic advantages, biodistribution studies, and microdosimetry/pharmacokinetic modeling of some of these agents will be reviewed. In addition, potential problems such as the harmful effect of radiolysis on the synthesis, lack of sufficient in vivo stability of astatinated compounds, and possible adverse effects when they are systemically administered will be discussed. PMID:20150978

  10. Peptide targeted copper-64 radiopharmaceuticals.

    PubMed

    Ma, Michelle T; Donnelly, Paul S

    2011-01-01

    Peptide targeted ⁶⁴Cu-labelled diagnostic agents for positron emission tomography are viable candidates for molecular imaging of cancer. In a clinical setting, optimal image quality relies on selective tumor uptake of the ⁶⁴Cu-labelled radiotracer. The three components of the radiotracer construct--the chelate group, linker and targeting peptide--all influence the biodistribution of the ⁶⁴Cu-labelled radiotracer in vivo. Low or moderate Cu complex stability in vivo results in transmetallation of ⁶⁴Cu to endogenous proteins, giving rise to high background activity. The length and the nature of the linker group affect the affinity of the ⁶⁴Cu-labelled radiotracer for the target receptor. Variations in the peptide sequence can impact on the metabolic stability and therefore the bioavailability and tumor retention of the ⁶⁴Cu-labelled radiotracer in vivo. Lastly, the hydrophilicity of the construct can influence radiotracer metabolism and clearance pathways. Recent advances in the field of peptide targeted ⁶⁴Cu-labelled radiopharmaceuticals involve GRPR-targeted and αvβ3 integrin receptor-targeted constructs. These constructs are based on the bombesin peptide sequence and the RGD recognition motif respectively. These examples are reviewed as case studies in the optimisation of ⁶⁴Cu radiotracer design.

  11. Astatine Radiopharmaceuticals: Prospects and Problems.

    PubMed

    Vaidyanathan, Ganesan; Zalutsky, Michael R

    2008-09-01

    For the treatment of minimum residual diseases such micrometastases and residual tumor margins that remain after debulking of the primary tumor, targeted radiotherapy using radiopharmaceuticals tagged with alpha-particle-emitting radionuclides is very attractive. In addition to the their short range in tissue, which helps minimize harmful effects on adjacent normal tissues, alpha-particles, being high LET radiation, have several radiobiological advantages. The heavy halogen, astatine-211 is one of the prominent alpha-particle-emitting radionuclides in practice. Being a halogen, it can often be incorporated into biomolecules of interest by adapting radioiodination chemistry. A wide spectrum of compounds from the simple [(211)At]astatide ion to small organic molecules, peptides, and large proteins labeled with (211)At have been investigated with at least two reaching the stage of clinical evaluation. The chemistry, cytotoxic advantages, biodistribution studies, and microdosimetry/pharmacokinetic modeling of some of these agents will be reviewed. In addition, potential problems such as the harmful effect of radiolysis on the synthesis, lack of sufficient in vivo stability of astatinated compounds, and possible adverse effects when they are systemically administered will be discussed.

  12. Astatine Radiopharmaceuticals: Prospects and Problems

    PubMed Central

    Vaidyanathan, Ganesan; Zalutsky, Michael R.

    2010-01-01

    For the treatment of minimum residual diseases such micrometastases and residual tumor margins that remain after debulking of the primary tumor, targeted radiotherapy using radiopharmaceuticals tagged with α-particle-emitting radionuclides is very attractive. In addition to the their short range in tissue, which helps minimize harmful effects on adjacent normal tissues, α-particles, being high LET radiation, have several radiobiological advantages. The heavy halogen, astatine-211 is one of the prominent α-particle-emitting radionuclides in practice. Being a halogen, it can often be incorporated into biomolecules of interest by adapting radioiodination chemistry. A wide spectrum of compounds from the simple [211At]astatide ion to small organic molecules, peptides, and large proteins labeled with 211At have been investigated with at least two reaching the stage of clinical evaluation. The chemistry, cytotoxic advantages, biodistribution studies, and microdosimetry/pharmacokinetic modeling of some of these agents will be reviewed. In addition, potential problems such as the harmful effect of radiolysis on the synthesis, lack of sufficient in vivo stability of astatinated compounds, and possible adverse effects when they are systemically administered will be discussed. PMID:20150978

  13. Radiopharmaceuticals for diagnosis and treatment. Progress report

    SciTech Connect

    Kuhl, D.E.

    1992-12-01

    We report on our efforts in PET basic radiochemistry, radiopharmaceutical synthesis, and preclinical radiopharmaceutical evaluation. These efforts are focused on three fronts. First predictive abilities in nucleophilic aromatic substitution with [{sup 18}F]fluorination of substituted aromatic rings. Although radiochemical yields can be predicted within a very similar group of compounds with similar leaving groups and substituent patterns, generalization to all nucleophilic substitutions with [{sup 18}F] fluoride is not warranted. Kinetic studies indicate significantly different rates of reactions, depending on ring substituents. Second, preclinical evaluation of new radiopharmaceuticals. We have synthesized and begun the preclinical evaluation of [{sup 11}C]tetrabenazine, a new radioligand based on the vesicular monoamine transport system. Third, our work, on [{sup 18}F]fluorination/decarbonylation reactions, structure-activity relationships in dopamine uptake inhibitors and effects of chronic drugs on radioligand binding is described.

  14. Simplification of Methods for PET Radiopharmaceutical Syntheses

    SciTech Connect

    Kilbourn, Michael, R.

    2011-12-27

    In an attempt to develop simplified methods for radiochemical synthesis of radiopharmaceuticals useful in Positron Emission Tomography (PET), current commercially available automated synthesis apparati were evaluated for use with solid phase synthesis, thin-film techniques, microwave-accelerated chemistry, and click chemistry approaches. Using combinations of these techniques, it was shown that these automated synthesis systems can be simply and effectively used to support the synthesis of a wide variety of carbon-11 and fluorine-18 labeled compounds, representing all of the major types of compounds synthesized and using all of the common radiochemical precursors available. These techniques are available for use to deliver clinically useful amounts of PET radiopharmaceuticals with chemical and radiochemical purities and high specific activities, suitable for human administration.

  15. Preparation of Radiopharmaceuticals Labeled with Metal Radionuclides

    SciTech Connect

    Welch, M.J.

    2012-02-16

    The overall goal of this project was to develop methods for the production of metal-based radionuclides, to develop metal-based radiopharmaceuticals and in a limited number of cases, to translate these agents to the clinical situation. Initial work concentrated on the application of the radionuclides of Cu, Cu-60, Cu-61 and Cu-64, as well as application of Ga-68 radiopharmaceuticals. Initially Cu-64 was produced at the Missouri University Research Reactor and experiments carried out at Washington University. A limited number of studies were carried out utilizing Cu-62, a generator produced radionuclide produced by Mallinckrodt Inc. (now Covidien). In these studies, copper-62-labeled pyruvaldehyde Bis(N{sup 4}-methylthiosemicarbazonato)-copper(II) was studied as an agent for cerebral myocardial perfusion. A remote system for the production of this radiopharmaceutical was developed and a limited number of patient studies carried out with this agent. Various other copper radiopharmaceuticals were investigated, these included copper labeled blood imaging agents as well as Cu-64 labeled antibodies. Cu-64 labeled antibodies targeting colon cancer were translated to the human situation. Cu-64 was also used to label peptides (Cu-64 octriatide) and this is one of the first applications of a peptide radiolabeled with a positron emitting metal radionuclide. Investigations were then pursued on the preparation of the copper radionuclides on a small biomedical cyclotron. A system for the production of high specific activity Cu-64 was developed and initially the Cu-64 was utilized to study the hypoxic imaging agent Cu-64 ATSM. Utilizing the same target system, other positron emitting metal radionuclides were produced, these were Y-86 and Ga-66. Radiopharmaceuticals were labeled utilizing both of these radionuclides. Many studies were carried out in animal models on the uptake of Cu-ATSM in hypoxic tissue. The hypothesis is that Cu-ATSM retention in vivo is dependent upon the

  16. Labelled compounds and radiopharmaceuticals applied in nuclear medicine

    SciTech Connect

    Balaban, A.; Galateanu, I.; Geogescu, G.; Simionescu, L.

    1986-01-01

    This book includes material on radiopharmacy and nuclear medicine with a section on in vitro assays. Contents are divided into four parts: radioisotopes, labelled compounds and radiopharmaceuticals; radiopharmaceuticals used for diagnostic purposes; in vitro methods of analysis with labelled compounds and applications of radioimmunoassay to medicine.

  17. Consequences of electroplated targets on radiopharmaceutical preparations

    NASA Astrophysics Data System (ADS)

    Finn, R. D.; Tirelli, S.; Sheh, Y.; Knott, A.; Gelbard, A. S.; Larson, S. M.; Dahl, J. R.

    1991-05-01

    The staff of the cyclotron facility at Memorial Sloan-Kettering Cancer Center is involved in a comprehensive radionuclide preparation program which culminates with the formulation of numerous requested short-lived, positron-emitting radiopharmaceutical agents for clinical investigation. Both the produced radionuclide as well as the final radiolabeled compound are subjected to stringent quality control standards including assays for radiochemical and chemical purity. The subtle chemical consequences resulting from the irradiation of a nickel-plated target for 13N production serve to emphasize some of these potential technical difficulties.

  18. Placental transfer of radiopharmaceuticals and dosimetry in pregnancy

    SciTech Connect

    Russell, J.R.; Stabin, M.G.; Sparks, R.B.

    1999-01-01

    The calculation of radiation dose estimates to the fetus is often important in nuclear medicine. To obtain the best estimates of radiation dose to the fetus, the best biological and physical models should be employed. In this paper, after identification of radiopharmaceuticals often administered to women of childbearing age, the most recent data available on the placental crossover of these radiopharmaceuticals was used (with standard kinetic models describing the maternal distribution and retention and with the best available physical models) to obtain fetal dose estimates for these radiopharmaceuticals were identified as those most commonly administered to women of childbearing years. The literature yielded information on placental crossover of 15 radiopharmaceuticals, from animal or human data. Radiation dose estimates are presented in early pregnancy and at 3-, 6-, and 9-months gestation for these radiopharmaceuticals, as well as for many others used in nuclear medicine (the latter considering only maternal organ contributions to fetal dose). 46 refs., 1 fig., 5 tabs.

  19. Small Molecule Radiopharmaceuticals – A Review of Current Approaches

    PubMed Central

    Chaturvedi, Shubhra; Mishra, Anil K.

    2016-01-01

    Radiopharmaceuticals are an integral component of nuclear medicine and are widely applied in diagnostics and therapy. Though widely applied, the development of an “ideal” radiopharmaceutical can be challenging. Issues such as specificity, selectivity, sensitivity, and feasible chemistry challenge the design and synthesis of radiopharmaceuticals. Over time, strategies to address the issues have evolved by making use of new technological advances in the fields of biology and chemistry. This review presents the application of few advances in design and synthesis of radiopharmaceuticals. The topics covered are bivalent ligand approach and lipidization as part of design modifications for enhanced selectivity and sensitivity and novel synthetic strategies for optimized chemistry and radiolabeling of radiopharmaceuticals. PMID:26942181

  20. Development of peptide and protein based radiopharmaceuticals.

    PubMed

    Wynendaele, Evelien; Bracke, Nathalie; Stalmans, Sofie; De Spiegeleer, Bart

    2014-01-01

    Radiolabelled peptides and proteins have recently gained great interest as theranostics, due to their numerous and considerable advantages over small (organic) molecules. Developmental procedures of these radiolabelled biomolecules start with the radiolabelling process, greatly defined by the amino acid composition of the molecule and the radionuclide used. Depending on the radionuclide selection, radiolabelling starting materials are whether or not essential for efficient radiolabelling, resulting in direct or indirect radioiodination, radiometal-chelate coupling, indirect radiofluorination or (3)H/(14)C-labelling. Before preclinical investigations are performed, quality control analyses of the synthesized radiopharmaceutical are recommended to eliminate false positive or negative functionality results, e.g. changed receptor binding properties due to (radiolabelled) impurities. Therefore, radionuclidic, radiochemical and chemical purity are investigated, next to the general peptide attributes as described in the European and the United States Pharmacopeia. Moreover, in vitro and in vivo stability characteristics of the peptides and proteins also need to be explored, seen their strong sensitivity to proteinases and peptidases, together with radiolysis and trans-chelation phenomena of the radiopharmaceuticals. In vitro biomedical characterization of the radiolabelled peptides and proteins is performed by saturation, kinetic and competition binding assays, analyzing KD, Bmax, kon, koff and internalization properties, taking into account the chemical and metabolic stability and adsorption events inherent to peptides and proteins. In vivo biodistribution can be adapted by linker, chelate or radionuclide modifications, minimizing normal tissue (e.g. kidney and liver) radiation, and resulting in favorable dosimetry analyses. Finally, clinical trials are initiated, eventually leading to the marketing of radiolabelled peptides and proteins for PET/SPECT-imaging and therapy

  1. Radiopharmaceuticals for diagnosis and treatment. Progress report

    SciTech Connect

    Kuhl, D.E.

    1991-12-31

    In this grant period we have continued our efforts in the areas of PE basic radiochemistry, radiopharmaceutical synthesis, and preclinical radiopharmaceutical evaluation. A new synthetic sequence, consisting, of no-carrier-added fluorine-18 labeling of substituted benzaldehydes followed by reductive decarbonylation, has been developed. This new methodology can be applied to the fluorine-18 labeling of a wide variety of drugs not previously accessible through existing fluorine-18 labeling methods. Following up on a literature report that the ability to radiolabel aromatic rings can be predicted by {sup 13}C-NMR chemical shifts, we have examined the generality of this correlation in aromatic rings bearing a variety of substituents. Although the original correlation holds for nitro substituted anisaldehydes, it cannot be extended to other rings substitution patterns. We have examined the relationship of in vivo localization of various fluorine-18 labeled dopamine uptake inhibitors to their in vitro binding affinities and lipophilicities. We have found that remarkably small decreases in binding affinity result in dramatic losses of in vivo binding to the desired high affinity binding sites. In order to probe the effects of endogenous neurotransmitter on the in vivo binding of radiolabeled dopamine uptake inhibitors, we have examined the in vivo regional localization of [18{sub F}] GBR 13119 after acute and chronic drug treatments which alter the endogenous levels of dopamine. We have found that acute changes in dopamine levels do not affect the binding of this radioligand, but chronic depletion of neurotransmitter results in down-regulation of the in vivo binding sites. 16 refs., 2 figs., 1 tab.

  2. [Current Status and Prospects on PET Radiopharmaceuticals for Radiotherapy].

    PubMed

    Yoshimoto, Mitsuyoshi

    2015-01-01

    18F-FDG is a most popular radiopharmaceutical for tumor diagnosis in the world. In addition, 11C-methionine, 18F-FLT and 11C-choline have been used to compensate for drawbacks of 18F-FDG. Now, novel radiopharmaceuticals are required to estimate or predict therapeutic efficacy because we have many strategies to treat tumors. Radiotherapy which damage DNA by producing free radicals is commonly used to treat various types of tumors. Hypoxia is closely associated with resistance to chemo- and/or radiotherapy and is a common feature of solid tumors. Recently, understanding of tumor hypoxia in oncology has led to development of radiopharmaceuticals for hypoxia imaging. This review provides an overview of PET radiopharmaceuticals for hypoxia imaging and 18F-FBPA which is used for boron neutron capture therapy.

  3. [Current Status and Prospects on PET Radiopharmaceuticals for Radiotherapy].

    PubMed

    Yoshimoto, Mitsuyoshi

    2015-01-01

    18F-FDG is a most popular radiopharmaceutical for tumor diagnosis in the world. In addition, 11C-methionine, 18F-FLT and 11C-choline have been used to compensate for drawbacks of 18F-FDG. Now, novel radiopharmaceuticals are required to estimate or predict therapeutic efficacy because we have many strategies to treat tumors. Radiotherapy which damage DNA by producing free radicals is commonly used to treat various types of tumors. Hypoxia is closely associated with resistance to chemo- and/or radiotherapy and is a common feature of solid tumors. Recently, understanding of tumor hypoxia in oncology has led to development of radiopharmaceuticals for hypoxia imaging. This review provides an overview of PET radiopharmaceuticals for hypoxia imaging and 18F-FBPA which is used for boron neutron capture therapy. PMID:26753391

  4. Stroma Targeting Nuclear Imaging and Radiopharmaceuticals

    PubMed Central

    Shetty, Dinesh; Jeong, Jae-Min; Shim, Hyunsuk

    2012-01-01

    Malignant transformation of tumor accompanies profound changes in the normal neighboring tissue, called tumor stroma. The tumor stroma provides an environment favoring local tumor growth, invasion, and metastatic spreading. Nuclear imaging (PET/SPECT) measures biochemical and physiologic functions in the human body. In oncology, PET/SPECT is particularly useful for differentiating tumors from postsurgical changes or radiation necrosis, distinguishing benign from malignant lesions, identifying the optimal site for biopsy, staging cancers, and monitoring the response to therapy. Indeed, PET/SPECT is a powerful, proven diagnostic imaging modality that displays information unobtainable through other anatomical imaging, such as CT or MRI. When combined with coregistered CT data, [18F]fluorodeoxyglucose ([18F]FDG)-PET is particularly useful. However, [18F]FDG is not a target-specific PET tracer. This paper will review the tumor microenvironment targeting oncologic imaging such as angiogenesis, invasion, hypoxia, growth, and homing, and also therapeutic radiopharmaceuticals to provide a roadmap for additional applications of tumor imaging and therapy. PMID:22685650

  5. (Coordinated research of chemotherapeutic agents and radiopharmaceuticals)

    SciTech Connect

    Srivastava, P.C.

    1991-01-14

    The traveler received a United Nations Development Program (UNDP) Award for Distinguished Scientists to visit Indian Research Institutions including Central Drug Research Institute (CDRI), Lucknow, the host institution, in cooperation with the Council of Scientific and Industrial Research (CSIR) of India. At CDRI, the traveler had meetings to discuss progress and future directions of on-going collaborative research work on nucleosides and had the opportunity to initiate new projects with the divisions of pharmacology, biopolymers, and membrane biology. As a part of this program, the traveler also visited Sanjay Gandhi Post Graduate Institute (SGPI) of Medical Sciences, Lucknow; Board of Radiation and Isotope Technology (BRIT) and Bhabha Atomic Research Center (BARC), Bombay; Variable Energy Cyclotron Center (VECC) and Indian Institute of Chemical Biology, Calcutta. He also attended the Indo-American Society of Nuclear Medicine Meeting held in Calcutta. The traveler delivered five seminars describing various aspects of radiopharmaceutical development at the Oak Ridge National Laboratory (ORNL) and discussed the opportunities for exchange visits to ORNL by Indian scientists.

  6. Radiopharmaceutical stem cell tracking for neurological diseases.

    PubMed

    Rosado-de-Castro, Paulo Henrique; Pimentel-Coelho, Pedro Moreno; Gutfilen, Bianca; Lopes de Souza, Sergio Augusto; de Freitas, Gabriel Rodriguez; Mendez-Otero, Rosalia; Barbosa da Fonseca, Lea Mirian

    2014-01-01

    Although neurological ailments continue to be some of the main causes of disease burden in the world, current therapies such as pharmacological agents have limited potential in the restoration of neural functions. Cell therapies, firstly applied to treat different hematological diseases, are now being investigated in preclinical and clinical studies for neurological illnesses. However, the potential applications and mechanisms for such treatments are still poorly comprehended and are the focus of permanent research. In this setting, noninvasive in vivo imaging allows better understanding of several aspects of stem cell therapies. Amongst the various methods available, radioisotope cell labeling has become one of the most promising since it permits tracking of cells after injection by different routes to investigate their biodistribution. A significant increase in the number of studies utilizing this method has occurred in the last years. Here, we review the different radiopharmaceuticals, imaging techniques, and findings of the preclinical and clinical reports published up to now. Moreover, we discuss the limitations and future applications of radioisotope cell labeling in the field of cell transplantation for neurological diseases. PMID:24982880

  7. Radiobrominated triphenylethylenes as estrogen receptor binding radiopharmaceuticals

    SciTech Connect

    Seevers, R.H.; Meese, R.C.; Friedman, A.M.; DeSombre, E.R.

    1985-05-01

    Estrogen receptor binding radiopharmaceuticals have potential for use in the diagnosis and treatment of cancers of the female reproductive system. Tamoxifen is an antiestrogen derived from the triphenylethylene skeleton which is used in the treatment of mammary carcinoma. Hydroxytamoxifen is a metabolite of tamoxifen which binds tightly to the estrogen receptor. Two triphenylethylene derivatives based on the structure of hydroxytamoxifen have been prepared: 1-bromo-1-phenyl-2- (2-dimethylamino)-4-ethoxyphenyl -2-(4-hydroxyphenyl) ethene (1) where the ethyl group of hydroxytamoxifen has been replaced by a bromine, and 1-bromo-1-phenyl-2,2-(4-hydroxyphenyl) ethene (2) with a similar substitution and also lacking the aminoethoxy side chain believed to confer antiestrogenicity. Both 1 and 2 bind strongly to the estrogen receptor. 2 has been labeled with the Auger electron emitting nuclide Br-80m in moderate yields in high specific activity using either N-bromosuccinimide or N-bromophthalimide and shows promise as a potential radiotherapy agent.

  8. Aptamers as radiopharmaceuticals for nuclear imaging and therapy.

    PubMed

    Gijs, Marlies; Aerts, An; Impens, Nathalie; Baatout, Sarah; Luxen, André

    2016-04-01

    Today, radiopharmaceuticals belong to the standard instrumentation of nuclear medicine, both in the context of diagnosis and therapy. The majority of radiopharmaceuticals consist of targeting biomolecules which are designed to interact with a disease-related molecular target. A plethora of targeting biomolecules of radiopharmaceuticals exists, including antibodies, antibody fragments, proteins, peptides and nucleic acids. Nucleic acids have some significant advantages relative to proteinaceous biomolecules in terms of size, production, modifications, possible targets and immunogenicity. In particular, aptamers (non-coding, synthetic, single-stranded DNA or RNA oligonucleotides) are of interest because they can bind a molecular target with high affinity and specificity. At present, few aptamers have been investigated preclinically for imaging and therapeutic applications. In this review, we describe the use of aptamers as targeting biomolecules of radiopharmaceuticals. We also discuss the chemical modifications which are needed to turn aptamers into valuable (radio-)pharmaceuticals, as well as the different radiolabeling strategies that can be used to radiolabel oligonucleotides and, in particular, aptamers. PMID:26746572

  9. Auger Emitting Radiopharmaceuticals for Cancer Therapy

    NASA Astrophysics Data System (ADS)

    Falzone, Nadia; Cornelissen, Bart; Vallis, Katherine A.

    Radionuclides that emit Auger electrons have been of particular interest as therapeutic agents. This is primarily due to the short range in tissue, controlled linear paths and high linear energy transfer of these particles. Taking into consideration that ionizations are clustered within several cubic nanometers around the point of decay the possibility of incorporating an Auger emitter in close proximity to the cancer cell DNA has immense therapeutic potential thus making nuclear targeted Auger-electron emitters ideal for precise targeting of cancer cells. Furthermore, many Auger-electron emitters also emit γ-radiation, this property makes Auger emitting radionuclides a very attractive option as therapeutic and diagnostic agents in the molecular imaging and management of tumors. The first requirement for the delivery of Auger emitting nuclides is the definition of suitable tumor-selective delivery vehicles to avoid normal tissue toxicity. One of the main challenges of targeted radionuclide therapy remains in matching the physical and chemical characteristics of the radionuclide and targeting moiety with the clinical character of the tumor. Molecules and molecular targets that have been used in the past can be classified according to the carrier molecule used to deliver the Auger-electron-emitting radionuclide. These include (1) antibodies, (2) peptides, (3) small molecules, (4) oligonucleotides and peptide nucleic acids (PNAs), (5) proteins, and (6) nanoparticles. The efficacy of targeted radionuclide therapy depends greatly on the ability to increase intranuclear incorporation of the radiopharmaceutical without compromising toxicity. Several strategies to achieve this goal have been proposed in literature. The possibility of transferring tumor therapy based on the emission of Auger electrons from experimental models to patients has vast therapeutic potential, and remains a field of intense research.

  10. Applications of quantitative whole body autoradiographic technique in radiopharmaceutical research

    SciTech Connect

    Som, P.; Oster, Z.H.; Yonekura, Y.; Meyer, M.A.; Fand, I.; Brill, A.B.

    1982-01-01

    The routine evaluation of radiopharmaceuticals involves dissecting tissue distribution studies (DTDS) and gamma or positron imaging. DTDS have the following disadvantages: since not all tissues can always be sampled, sites of radiopharmaceutical uptake may be missed and because the procedure involves weighing of dissected tissue samples, the spatial resolution of this method is low and determined by the smallest amount that can be weighed accurately. Gamma camera imaging and positron emission tomography though more comprehensive in evaluating the global distribution of a compound, have relative low spatial resolution. Whole body autoradiography of small animals has a much higher spatial resolution as compared to the above and depicts the global distribution of radiopharmaceuticals. A computer-assisted quantification method of WBARG applied to positron, beta, and gamma emitters will complement the method by producing quantitative values comparable to those obtained by dissection and direct tissue counting, with the advantages of depicting the global distribution at high spatial resolution.

  11. Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview

    PubMed Central

    Mukherjee, Anirban

    2016-01-01

    Positron emission tomography-computed tomography (PET-CT) has changed cancer imaging in the last decade, for better. It can be employed for radiation treatment planning of different cancers with improved accuracy and outcomes as compared to conventional imaging methods. 18F-fluorodeoxyglucose remains the most widely used though relatively non-specific cancer imaging PET tracer. A wide array of newer PET radiopharmaceuticals has been developed for targeted imaging of different cancers. PET-CT with such new PET radiopharmaceuticals has also been used for radiotherapy planning with encouraging results. In the present review we have briefly outlined the role of PET-CT with newer radiopharmaceuticals for radiotherapy planning and briefly reviewed the available literature in this regard. PMID:26904575

  12. [Current trends in using PET radiopharmaceuticals for diagnostics in oncology].

    PubMed

    Adam, J; Kadeřávek, J; Kužel, F; Vašina, J; Rehák, Z

    2014-01-01

    Nuclear medicine is an important field of modern medicine, particularly thanks to its role in in vivo imaging of important processes in human organism. This is possible thanks to the use of radiopharmaceuticals, specific substances labeled by radioactive nuclide, its distribution in the body can be visualized by specialized scanners and, based on the knowledge of physiological patterns, dia-gnosis can be determined. Positron emission tomography (PET) is a modern and in many ways indispensable method of nuclear medicine. The spectrum of radiopharmaceuticals available in recent years is broadening thanks to a coordinated effort of manufacturers of synthesis equipment, chemists and potential users -  physicians. This review focuses on the development in the PET radiopharmaceutical field in the last five years, with an emphasis on oncological applications of PET. PMID:24945550

  13. Preparation of radiopharmaceuticals labeled with metal radionuclides. Progress report, July 1, 1988--June 30, 1992

    SciTech Connect

    Welch, M.J.

    1992-06-01

    We recently developed a useful zinc-62/copper-62 generator and are presently evaluating copper-62 radiopharmaceuticals for clinical studies. While developing these copper-62 radiopharmaceuticals, in collaboration with the University of Missouri Research Reactor, Columbia we have also explored copper-64 radiopharmaceuticals. The PET images we obtained with copper-64 tracers were of such high quality that we have developed and evaluated copper-64 labeled antibodies for PET imaging. The major research activities described herein include: the development and assessment of gallium-68 radiopharmaceuticals; the development and evaluation of a new zinc-62/copper-62 generator and the assessment of copper-62 radiopharmaceuticals; mechanistic studies on proteins labeled with metal radionuclides.

  14. Harvard-MIT research program in short-lived radiopharmaceuticals

    SciTech Connect

    Adelstein, S.J.

    1991-01-01

    This report presents research on radiopharmaceuticals. The following topics are discussed: antibody labeling with positron-emitting radionuclides; antibody modification for radioimmune imaging; labeling antibodies; evaluation of technetium acetlyacetonates as potential cerebral blood flow agents; and studies in technetium chemistry. (CBS)

  15. Nitroimidazole radiopharmaceuticals in bioimaging: part I: synthesis and imaging applications.

    PubMed

    Sharma, Rakesh

    2011-10-01

    The paper is review on synthesis of nitroimidazole radiosensitizers useful in imaging of tumor cells. Nitroimidazole compounds are radiolabeled probes for specific use in imaging such as 18F for positron emission tomography; 99mTc for single photon emission computed tomography; 123I, or 131I for computer assisted tomography and 19F for magnetic resonance imaging. In synthesis of radiopharmaceutical compounds, parent nitroimidazole is modified to thiopyranosyl nucleosides, neuraminic acid derivatives followed by nitro group deprotection-substitution and radiolabeling by specific isotopes. Commercial attempts have been made to radiolabel the nitroimidazole by [18F]fluorine, [131I or 123I]iodine, [99mTc]technicium and [64Cu]copper on modified side chain of nitroimidazole compounds to design multimodal and multifunctional imaging techniques to detect and monitor the tumor hypoxia by measuring distribution of radiatiolabel or radiation. Nitroimidazole initially showed poor diffusion and poor stability in tissues with neurotoxicity concern limited its use as radiosensitizer. In last decade, several nitroimidazole derivatives were developed as potent less toxic and highly stable radiopharmaceuticals with optimized radiolabel concentration with high detectability of tumor oxygen or hypoxia. Currently, nitroimidazole based radiopharmaceuticals have emerged as multimodal and multifunctional hypoxia reporters with antitumor, anti-ischemic, anti-inflammatory and tumor targeting properties. In conclusion, nitroimidazole based radiopharmaceuticals are a new generation hypoxia biosensors for localized theradiagnostic utility in clinical medicine.

  16. Process for producing astatine-211 for radiopharmaceutical use

    DOEpatents

    Mirzadeh, Saed; Lambrecht, Richard M.

    1987-01-01

    A process for reliably and consistently producing astatine-211 in small controlled volumes of a solution, which is selected from a choice of solvents that are useful in selected radiopharmaceutical procedures in which the At-211 activities are to be applied.

  17. Process for producing astatine-211 for radiopharmaceutical use

    DOEpatents

    Mirzadeh, S.; Lambrecht, R.M.

    1984-04-10

    A process is described for reliably and consistently producing astatine-211 in small controlled volumes of a solution, which is selected from a choice of solvents that are useful in selected radiopharmaceutical procedures in which the At-211 activities are to be applied. 4 figures, 1 table.

  18. Original Version

    Cancer.gov

    The EPEC-O (Education in Palliative and End-of-Life Care for Oncology) Self-Study Original Version is a free comprehensive multimedia curricula for health professionals caring for persons with cancer and their families. The curricula is available as an online Self-Study Section and as a CD-ROM you can order.

  19. Cerenkov Luminescence Tomography for In Vivo Radiopharmaceutical Imaging

    PubMed Central

    Zhong, Jianghong; Qin, Chenghu; Yang, Xin; Zhu, Shuping; Zhang, Xing; Tian, Jie

    2011-01-01

    Cerenkov luminescence imaging (CLI) is a cost-effective molecular imaging tool for biomedical applications of radiotracers. The introduction of Cerenkov luminescence tomography (CLT) relative to planar CLI can be compared to the development of X-ray CT based on radiography. With CLT, quantitative and localized analysis of a radiopharmaceutical distribution becomes feasible. In this contribution, a feasibility study of in vivo radiopharmaceutical imaging in heterogeneous medium is presented. Coupled with a multimodal in vivo imaging system, this CLT reconstruction method allows precise anatomical registration of the positron probe in heterogeneous tissues and facilitates the more widespread application of radiotracers. Source distribution inside the small animal is obtained from CLT reconstruction. The experimental results demonstrated that CLT can be employed as an available in vivo tomographic imaging of charged particle emitters in a heterogeneous medium. PMID:21747821

  20. [Computer simulated images of radiopharmaceutical distributions in anthropomorphic phantoms

    SciTech Connect

    Not Available

    1991-05-17

    We have constructed an anatomically correct human geometry, which can be used to store radioisotope concentrations in 51 various internal organs. Each organ is associated with an index number which references to its attenuating characteristics (composition and density). The initial development of Computer Simulated Images of Radiopharmaceuticals in Anthropomorphic Phantoms (CSIRDAP) over the first 3 years has been very successful. All components of the simulation have been coded, made operational and debugged.

  1. Improving radiopharmaceutical supply chain safety by implementing bar code technology.

    PubMed

    Matanza, David; Hallouard, François; Rioufol, Catherine; Fessi, Hatem; Fraysse, Marc

    2014-11-01

    The aim of this study was to describe and evaluate an approach for improving radiopharmaceutical supply chain safety by implementing bar code technology. We first evaluated the current situation of our radiopharmaceutical supply chain and, by means of the ALARM protocol, analysed two dispensing errors that occurred in our department. Thereafter, we implemented a bar code system to secure selected key stages of the radiopharmaceutical supply chain. Finally, we evaluated the cost of this implementation, from overtime, to overheads, to additional radiation exposure to workers. An analysis of the events that occurred revealed a lack of identification of prepared or dispensed drugs. Moreover, the evaluation of the current radiopharmaceutical supply chain showed that the dispensation and injection steps needed to be further secured. The bar code system was used to reinforce product identification at three selected key stages: at usable stock entry; at preparation-dispensation; and during administration, allowing to check conformity between the labelling of the delivered product (identity and activity) and the prescription. The extra time needed for all these steps had no impact on the number and successful conduct of examinations. The investment cost was reduced (2600 euros for new material and 30 euros a year for additional supplies) because of pre-existing computing equipment. With regard to the radiation exposure to workers there was an insignificant overexposure for hands with this new organization because of the labelling and scanning processes of radiolabelled preparation vials. Implementation of bar code technology is now an essential part of a global securing approach towards optimum patient management. PMID:25144560

  2. Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals

    PubMed Central

    Xu, Yu-Ping; Yang, Min

    2016-01-01

    Pancreatic cancer (PC) is a major health problem. Conventional imaging modalities show limited accuracy for reliable assessment of the tumor. Recent researches suggest that molecular imaging techniques with tracers provide more biologically relevant information and are benefit for the diagnosis of the cancer. In addition, radiopharmaceuticals also play more important roles in treatment of the disease. This review summaries the advancement of the radiolabeled compounds in the theranostics of PC. PMID:26909131

  3. Improving radiopharmaceutical supply chain safety by implementing bar code technology.

    PubMed

    Matanza, David; Hallouard, François; Rioufol, Catherine; Fessi, Hatem; Fraysse, Marc

    2014-11-01

    The aim of this study was to describe and evaluate an approach for improving radiopharmaceutical supply chain safety by implementing bar code technology. We first evaluated the current situation of our radiopharmaceutical supply chain and, by means of the ALARM protocol, analysed two dispensing errors that occurred in our department. Thereafter, we implemented a bar code system to secure selected key stages of the radiopharmaceutical supply chain. Finally, we evaluated the cost of this implementation, from overtime, to overheads, to additional radiation exposure to workers. An analysis of the events that occurred revealed a lack of identification of prepared or dispensed drugs. Moreover, the evaluation of the current radiopharmaceutical supply chain showed that the dispensation and injection steps needed to be further secured. The bar code system was used to reinforce product identification at three selected key stages: at usable stock entry; at preparation-dispensation; and during administration, allowing to check conformity between the labelling of the delivered product (identity and activity) and the prescription. The extra time needed for all these steps had no impact on the number and successful conduct of examinations. The investment cost was reduced (2600 euros for new material and 30 euros a year for additional supplies) because of pre-existing computing equipment. With regard to the radiation exposure to workers there was an insignificant overexposure for hands with this new organization because of the labelling and scanning processes of radiolabelled preparation vials. Implementation of bar code technology is now an essential part of a global securing approach towards optimum patient management.

  4. Radionuclides, radiotracers and radiopharmaceuticals for in vivo diagnosis

    NASA Astrophysics Data System (ADS)

    Wiebe, Leonard I.

    Radioactive tracers for in vivo clinical diagnosis fall within a narrow, strictly-defined set of specifications in respect of their physical properties, chemical and biochemical characteristics, and (approved) medical applications. The type of radioactive decay and physical half-life of the radionuclide are immutable properties which, along with the demands of production and supply, limit the choice of radionuclides used in medicine to only a small fraction of those known to exist. In use, the biochemical and physiological properties of a radiotracer are dictated by the chemical form of the radionuclide. This chemical form may range from elemental, molecular or ionic, to complex compounds formed by coordinate or covalent bonding of the radionuclide to either simple organic or inorganic molecules, or complex macromolecules. Few of the radiotracers which are tested in model systems ever become radiopharmaceuticals in the strictest sense. Radionuclides, radiotracers and radiopharmaceuticals in use are reviewed. Drug legislation and regulations concerning drug manufacture, as well as hospital ethical constraints and legislation concerning unsealed sources of radiation must all be satisfied in order to translate a radiopharmaceutical from the laboratory to clinical use.

  5. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.

    PubMed

    Vallabhajosula, Shankar

    2011-07-01

    Alzheimer's disease (AD) is defined histologically by the presence of extracellular β-amyloid (Aβ) plaques and intraneuronal neurofibrillary tangles in the cerebral cortex. The diagnosis of dementia, along with the prediction of who will develop dementia, has been assisted by magnetic resonance imaging and positron emission tomography (PET) by using [(18)F]fluorodeoxyglucose (FDG). These techniques, however, are not specific for AD. Based on the chemistry of histologic staining dyes, several Aβ-specific positron-emitting radiotracers have been developed to image neuropathology of AD. Among these, [(11)C]PiB is the most studied Aβ-binding PET radiopharmaceutical in the world. The histologic and biochemical specificity of PiB binding across different regions of the AD brain was demonstrated by showing a direct correlation between Aβ-containing amyloid plaques and in vivo [(11)C]PiB retention measured by PET imaging. Because (11)C is not ideal for commercialization, several (18)F-labeled tracers have been developed. At this time, [(18)F]3'-F-PiB (Flutemetamol), (18)F-AV-45 (Florbetapir), and (18)F-AV-1 (Florbetaben) are undergoing extensive phase II and III clinical trials. This article provides a brief review of the amyloid biology and chemistry of Aβ-specific (11)C and (18)F-PET radiopharmaceuticals. Clinical trials have clearly documented that PET radiopharmaceuticals capable of assessing Aβ content in vivo in the brains of AD subjects and subjects with mild cognitive impairment will be important as diagnostic agents to detect in vivo amyloid brain pathology. In addition, PET amyloid imaging will also help test the amyloid cascade hypothesis of AD and as an aid to assess the efficacy of antiamyloid therapeutics currently under development in clinical trials.

  6. Nuclear medicine and imaging research (quantitative studies in radiopharmaceutical science)

    SciTech Connect

    Cooper, M.D.; Beck, R.N.

    1990-09-01

    This is a report of progress in Year Two (January 1, 1990--December 31, 1990) of Grant FG02-86ER60438, Quantitative Studies in Radiopharmaceutical Science,'' awarded for the three-year period January 1, 1989--December 31, 1991 as a competitive renewal following site visit in the fall of 1988. This program addresses the problems involving the basic science and technology underlying the physical and conceptual tools of radioactive tracer methodology as they relate to the measurement of structural and functional parameters of physiologic importance in health and disease. The principal tool is quantitative radionuclide imaging. The overall objective of this program is to further the development and transfer of radiotracer methodology from basic theory to routine clinical practice in order that individual patients and society as a whole will receive the maximum net benefit from the new knowledge gained. The focus of the research is on the development of new instruments and radiopharmaceuticals, and the evaluation of these through the phase of clinical feasibility. 25 refs., 13 figs., 1 tab.

  7. Process for producing astatine-211 for radiopharmaceutical use

    SciTech Connect

    Mirzadeh, S.; Lambrecht, R.M.

    1987-07-21

    A one-step chemical manipulation is described in combination with a distillation and collection process for producing At-211 comprising; a. providing a target of irradiated Bismuth coated to a predetermined thickness of a backing member, b. providing a vapor-producing still operably connected with a condenser that has a water cooled condensate collector formed of a dry silica gel mesh maintained at a temperature above the freezing point of water, and providing an effluent gas filter that is operably connected to receive effluent gas from the condenser, c. heating the target in the still at a temperature in the range of about 630/sup 0/-680/sup 0/C for a time period in the range of 50 to 80 minutes, to evole At-211 vapor from the target, c. providing a dry carrier gas having an oxygen concentration that is sufficient to form Bi/sub 2/O/sub 3/ thereby to essentially preclude vaporization of Bi metal, passing the carrier gas through the still to carry the At-211 vapor to the condenser, and to carry effluent from the condenser to the effluent gas filter, e. eluting At-211 from the condensate collector of the condenser with a controlled volume of eluent containing predetermined solvents that are compatible with a given desired radiopharmaceutical procedure, and f. collecting the At-211 in the controlled volume of eluent for use in the given radiopharmaceutical procedure.

  8. HPLC-MS technique for radiopharmaceuticals analysis and quality control

    NASA Astrophysics Data System (ADS)

    Macášek, F.; Búriová, E.; Brúder, P.; Vera-Ruiz, H.

    2003-01-01

    Potentialities of liquid chromatography with mass spectrometric detector (MSD) were investigated with the objective of quality control of radiopharmaceuticals; 2-deoxy-2-[18F]fluoro-D-glucose (FDG) being an example. Screening of suitable MSD analytical lines is presented. Mass-spectrometric monitoring of acetonitrile— aqueous ammonium formate eluant by negatively charged FDG.HCO2 - ions enables isotope analysis (specific activity) of the radiopharmaceutical at m/z 227 and 226. Kryptofix® 222 provides an intense MSD signal of the positive ion associated with NH4 + at m/z 394. Expired FDG injection samples contain decomposition products from which at least one labelled by 18F and characterised by signal of negative ions at m/z 207 does not correspond to FDG fragments but to C5 decomposition products. A glucose chromatographic peak, characterised by m/z 225 negative ion is accompanied by a tail of a component giving a signal of m/z 227, which can belong to [18O]glucose; isobaric sorbitol signals were excluded but FDG-glucose association occurs in the co-elution of separation of model mixtures. The latter can actually lead to a convoluted chromatographic peak, but the absence of 18F makes this inconsistent. Quantification and validation of the FDG component analysis is under way.

  9. Cyclotron targets and production technologies used for radiopharmaceuticals in NPI

    NASA Astrophysics Data System (ADS)

    Fišer, M.; Kopička, K.; Hradilek, P.; Hanč, P.; Lebeda, O.; Pánek, J.; Vognar, M.

    2003-01-01

    This paper deals with some technical aspects of the development and production of cyclotronmade radiopharmaceuticals (excluding PET). In this field, nuclear chemistry and pharmacy are in a close contact; therefore, requirements of the both should be taken into account. The principles of cyclotron targetry, separation/recovery of materials and synthesis of active substances are given, as well as issues connected with formulation of pharmaceutical forms. As the radiopharmaceuticals should fulfil the requirements on in vivo preparations, there exist a variety of demands pertaining to Good Manufacturing Practice (GMP) concept, which is also briefly discussed. A typical production chain is presented and practical examples of real technologies based on cyclotron-made radionuclides are given as they have been used in Nuclear Physics Institute of CAS (NPI). Special attention is devoted to the technology of enriched cyclotron targets. Frequently used medicinal products employing cyclotron-produced active substances are characterised (Rb/Kr generators, 123I-labelled MIBG, OIH and MAB's). The cyclotron produced radioactive implants for transluminal coronary angioplasty (radioactive stents) are introduced as an example of a medical device developed for therapeutic application.

  10. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).

    PubMed

    Shokeen, Monica; Anderson, Carolyn J

    2009-07-21

    .653 MeV, 17.8%; beta(-), 0.579 MeV, 38.4 %; the remainder is electron capture) of (64)Cu make it an ideal radioisotope for PET imaging and radiotherapy. In addition, the well-established coordination chemistry of copper allows for its reaction with a wide variety of chelator systems that can potentially be linked to antibodies, proteins, peptides, and other biologically relevant molecules. New chelators with greater in vivo stability, such as the cross-bridged (CB) versions of tetraazamacrocyclic 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA), are now available. Finally, one of the major aspects of successful imaging is the identification and characterization of a relevant disease biomarker at the cellular and subcellular level and the ensuing development of a highly specific targeting moiety. In this Account, we discuss specific examples of PET imaging with new and improved (64)Cu-based radiopharmaceuticals, highlighting the study of some of the key cancer biomarkers, such as epidermal growth-factor receptor (EGFR), somatostatin receptors (SSRs), and integrin alpha(v)beta(3).

  11. A method to assess safety and resilience in radiopharmaceuticals production process.

    PubMed

    Grecco, Cláudio H S; Vidal, Mario C R; Santos, Isaac J A L; Carvalho, Paulo V R

    2012-01-01

    Radiopharmaceuticals are radiation-emitting substances used in medicine for radiotherapy and imaging diagnosis. A Research Institute, located in Rio de Janeiro, produces three radiopharmaceuticals: the sodium iodate is used in the diagnosis of thyroid dysfunctions, the meta-iodo-benzylguanidine is used in the diagnosis of cardiac diseases, and the fluordesoxyglucose is used in diagnosis in cardiology, oncology, neurology and neuropsychiatry. This paper presents a method to access safety and resilience in radiopharmaceuticals production processes. The method uses resilience indicators in order to proactively evaluate and manage the safety.

  12. New selenium-75 labeled radiopharmaceuticals: selenonium analogues of dopamine

    SciTech Connect

    Sadek, S.A.; Basmadjian, G.P.; Hsu, P.M.; Rieger, J.A.

    1983-07-01

    Selenium-75 labeled selenonium analogues of dopamine, (2-(3,4-dimethoxyphenyl)ethyl)dimethylselenonium iodide and its dihydroxy analogue, were prepared by reducing (/sup 75/Se)selenious acid with sodium borohydride at pH 6.0 and reacting the NaSeH produced with 1-(3,4-dimethoxyphenyl)-2-(p-toluenesulfonyloxy)ethane. Tissue distribution studies in rats given the /sup 75/Se-labeled selenonium agents intravenously demonstrated high initial heart uptake. Prolonged adrenal retention and high adrenal to blood ratio of compound 4 were observed. The high uptake and adrenal to blood ratio suggest the potential use of compound 4 as a radiopharmaceutical for the adrenal gland.

  13. Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors.

    PubMed

    Vallabhajosula, Shankar; Killeen, Ronan P; Osborne, Joseph R

    2010-07-01

    One of the most common problems associated with radiopharmaceuticals is an unanticipated or altered biodistribution, which can have a significant clinical impact on safety, scan interpretation, and diagnostic imaging accuracy. In their most extreme manifestations, unanticipated imaging results may even compromise the utility and or accuracy of nuclear medicine studies. We present here an overall summary of altered biodistribution of radiopharmaceuticals with a special emphasis on the molecular mechanisms involved. Important factors affecting the biodistribution of radiopharmaceuticals can be described in 5 major categories and include (1) radiopharmaceutical preparation and formulation problems; (2) problems caused by radiopharmaceutical administration techniques and procedures; (3) by changes in biochemical and pathophysiology; (4) previous medical procedures, such as surgery, radiation therapy and dialysis; and finally (5) by drug interactions. The altered biodistribution of (99m)Tc radiopharmaceuticals are generally associated with increased amounts of (99m)Tc radiochemical impurities, such as free (99m)TcO(4)(-) and particulate impurities, such as (99m)Tc colloids or (99m)Tc-reduced hydrolyzed species. Faulty injection, such as dose infiltration or contamination with antiseptics and aluminum during dose administration, may cause significant artifacts. The patient's own medical problems, such as abnormalities in the regulation of hormone levels; failure in the function of excretory organs and systems, such as hepatobiliary and genitourinary systems; and even simple conditions, such as excessive talking may contribute to altered biodistribution of radiopharmaceuticals. Previous medical procedures (chemotherapy, radiation therapy, dialysis) and drug interaction are the some of the nontechnical factors responsible for unanticipated biodistribution of radiotracers. This review provides a comprehensive summary of various factors and specific examples to illustrate

  14. USE OF RADIOPHARMACEUTICALS IN DIAGNOSTIC NUCLEAR MEDICINE IN THE UNITED STATES: 1960–2010

    PubMed Central

    Drozdovitch, Vladimir; Brill, Aaron B.; Callahan, Ronald J.; Clanton, Jeffrey A.; DePietro, Allegra; Goldsmith, Stanley J.; Greenspan, Bennett S.; Gross, Milton D.; Hays, Marguerite T.; Moore, Stephen C.; Ponto, James A.; Shreeve, Walton W.; Melo, Dunstana R.; Linet, Martha S.; Simon, Steven L.

    2014-01-01

    To reconstruct reliable nuclear medicine-related occupational radiation doses or doses received as patients from radiopharmaceuticals over the last five decades, we assessed which radiopharmaceuticals were used in different time periods, their relative frequency of use, and typical values of the administered activity. This paper presents data on the changing patterns of clinical use of radiopharmaceuticals and documents the range of activity administered to adult patients undergoing diagnostic nuclear medicine procedures in the U.S. between 1960 and 2010. Data are presented for 15 diagnostic imaging procedures that include thyroid scan and thyroid uptake, brain scan, brain blood flow, lung perfusion and ventilation, bone, liver, hepatobiliary, bone marrow, pancreas, and kidney scans, cardiac imaging procedures, tumor localization studies, localization of gastrointestinal bleeding, and non-imaging studies of blood volume and iron metabolism. Data on the relative use of radiopharmaceuticals were collected using key informant interviews and comprehensive literature reviews of typical administered activities of these diagnostic nuclear medicine studies. Responses of key informants on relative use of radiopharmaceuticals are in agreement with published literature. Results of this study will be used for retrospective reconstruction of occupational and personal medical radiation doses from diagnostic radiopharmaceuticals to members of the U.S. radiologic technologist’s cohort and in reconstructing radiation doses from occupational or patient radiation exposures to other U.S. workers or patient populations. PMID:25811150

  15. Use of radiopharmaceuticals in diagnostic nuclear medicine in the United States: 1960-2010.

    PubMed

    Drozdovitch, Vladimir; Brill, Aaron B; Callahan, Ronald J; Clanton, Jeffrey A; DePietro, Allegra; Goldsmith, Stanley J; Greenspan, Bennett S; Gross, Milton D; Hays, Marguerite T; Moore, Stephen C; Ponto, James A; Shreeve, Walton W; Melo, Dunstana R; Linet, Martha S; Simon, Steven L

    2015-05-01

    To reconstruct reliable nuclear medicine-related occupational radiation doses or doses received as patients from radiopharmaceuticals over the last five decades, the authors assessed which radiopharmaceuticals were used in different time periods, their relative frequency of use, and typical values of the administered activity. This paper presents data on the changing patterns of clinical use of radiopharmaceuticals and documents the range of activity administered to adult patients undergoing diagnostic nuclear medicine procedures in the U.S. between 1960 and 2010. Data are presented for 15 diagnostic imaging procedures that include thyroid scan and thyroid uptake; brain scan; brain blood flow; lung perfusion and ventilation; bone, liver, hepatobiliary, bone marrow, pancreas, and kidney scans; cardiac imaging procedures; tumor localization studies; localization of gastrointestinal bleeding; and non-imaging studies of blood volume and iron metabolism. Data on the relative use of radiopharmaceuticals were collected using key informant interviews and comprehensive literature reviews of typical administered activities of these diagnostic nuclear medicine studies. Responses of key informants on relative use of radiopharmaceuticals are in agreement with published literature. Results of this study will be used for retrospective reconstruction of occupational and personal medical radiation doses from diagnostic radiopharmaceuticals to members of the U.S. radiologic technologists' cohort and in reconstructing radiation doses from occupational or patient radiation exposures to other U.S. workers or patient populations.

  16. Radiopharmaceutical Therapy in the Era of Precision Medicine*

    PubMed Central

    Sgouros, George; Goldenberg, David M.

    2014-01-01

    Precision medicine is the selection of a treatment modality that is specifically tailored to the genetic and phenotypic characteristics of a particular patient’s disease. In cancer, the objective is to treat with agents that inhibit cell signaling pathways that drive uncontrolled proliferation and dissemination of the disease. To overcome the eventual resistance to pathway inhibition therapy, this treatment modality has been combined with chemotherapy. We propose that pathway inhibition therapy is more rationally combined with radiopharmaceutical therapy (RPT), a cytotoxic treatment that is also targeted. RPT exploits pharmaceuticals that either bind specifically to tumors or accumulate by a broad array of physiological mechanisms indigenous to the neoplastic cells to deliver radiation specifically to these cells. Consistent with pathway inhibition therapy and in contrast to chemotherapy, RPT is well tolerated. However, the potential of RPT has not been fully exploited; for the most part, treatment has been implemented without using the ability to customize RPT by imaging and deriving individual patient tumor and normal organ radiation absorbed doses. These are more closely related to biological response and their determination should enable RPT treatment administration to maximum therapeutic benefit by treating to normal organ tolerance or demonstrating futility via tumor dosimetry. This is the essence of precision medicine. PMID:24953565

  17. Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applications.

    PubMed

    Goldsmith, Stanley J; Vallabhajosula, Shankar

    2009-01-01

    Gallium-67 ((67)Ga)-citrate was initially introduced as a tumor imaging agent in the early 1970s, but it was soon recognized that it was useful in the identification of both acute and chronic inflammation. Because of its physical characteristics (multiple gamma photons energy; long half life) and binding to the plasma protein transferrin (resulting in relatively high background and therefore reduced lesion-to-background contrast), it was less than ideal as an imaging agent. Several years later, it became possible to radiolabel leukocytes, which had the advantage of greater specificity for acute infections characterized by a granulocytic response, but had the disadvantage of requiring the removal of blood and isolation of the leukocyte component. Several radiolabeled antibody preparations and a radiolabeled antibacterial agent have been introduced and evaluated, but none of these have been used widely. Most recently, it has been recognized that the use of (18)F-fluorodeoxyglucose can be used to identify infection/inflammation, probably based on the focal increase in anaerobic glucose metabolism associated with the cellular response. In this work, we review the features of each of these agents and discuss the issues involved in their use as radiopharmaceuticals for the identification of inflammation and/or infection.

  18. Synthesis and biological studies of positron-emitting radiopharmaceuticals

    SciTech Connect

    Dischino, D.D.

    1983-01-01

    The development and clinical evaluation of two-positron emitting radiopharmaceuticals designed to image myelin in humans is reported. Carbon-11-labeled benzyl methyl ether was synthesized by the reaction of carbon-11-labeled methanol and benzyl chloride in dimethyl sulfoxide containing powdered potassium hydroxide in a radiochemical yield of 43% and a synthesis and purification time of 40 minutes. Carbon-11-labeled diphenylmethanol was synthesized by the reaction of carbon-11-labeled carbon dioxide and phenyllithium followed by the reduction of the carbon-11-labeled intermediate to diphenylmethanol via lithium aluminum hydride in a radiochemical yield of 71% and a synthesis and purification time of 38 minutes. Carbon-11-labeled benzyl methyl ether and diphenylmethanol were each evaluated as myelin imaging agents in three patients with multiple sclerosis via positron-emission tomography. In two out of three patients studied with carbon-11-labeled benzyl methyl ether, the distribution of activity in the brain was not consistent with local lipid content. A new synthesis of carbon-11-labeled-DL-phenylalanine labeled in the benzylic position and the synthesis of fluorine-18-labeled 1-(2-nitro-1-imidazolyl)-3-fluoro-2-propanol, a potential in vivo marker of hypoxic tissue, are reported.

  19. The Next Generation of Positron Emission Tomography Radiopharmaceuticals in Oncology

    PubMed Central

    Rice, Samuel L.; Roney, Celeste A.; Daumar, Pierre; Lewis, Jason S.

    2015-01-01

    Although 18F-fluorodeoxyglucose (18F-FDG) is still the most widely used positron emission tomography (PET) radiotracer, there are a few well-known limitations to its use. The last decade has seen the development of new PET probes for in vivo visualization of specific molecular targets, along with important technical advances in the production of positron-emitting radionuclides and their related labeling methods. As such, a broad range of new PET tracers are in preclinical development or have recently entered clinical trials. The topics covered in this review include labeling methods, biological targets, and the most recent preclinical or clinical data of some of the next generation of PET radiopharmaceuticals. This review, which is by no means exhaustive, has been separated into sections related to the PET radionuclide used for radiolabeling: fluorine-18, for the labeling of agents such as FACBC, FDHT, choline, and Galacto-RGD; carbon-11, for the labeling of choline; gallium-68, for the labeling of peptides such as DOTATOC and bombesin analogs; and the long-lived radionuclides iodine-124 and zirconium-89 for the labeling of monoclonal antibodies cG250, and J591 and trastuzumab, respectively. PMID:21624561

  20. The next generation of positron emission tomography radiopharmaceuticals in oncology.

    PubMed

    Rice, Samuel L; Roney, Celeste A; Daumar, Pierre; Lewis, Jason S

    2011-07-01

    Although (18)F-fluorodeoxyglucose ((18)F-FDG) is still the most widely used positron emission tomography (PET) radiotracer, there are a few well-known limitations to its use. The last decade has seen the development of new PET probes for in vivo visualization of specific molecular targets, along with important technical advances in the production of positron-emitting radionuclides and their related labeling methods. As such, a broad range of new PET tracers are in preclinical development or have recently entered clinical trials. The topics covered in this review include labeling methods, biological targets, and the most recent preclinical or clinical data of some of the next generation of PET radiopharmaceuticals. This review, which is by no means exhaustive, has been separated into sections related to the PET radionuclide used for radiolabeling: fluorine-18, for the labeling of agents such as FACBC, FDHT, choline, and Galacto-RGD; carbon-11, for the labeling of choline; gallium-68, for the labeling of peptides such as DOTATOC and bombesin analogs; and the long-lived radionuclides iodine-124 and zirconium-89 for the labeling of monoclonal antibodies cG250, and J591 and trastuzumab, respectively.

  1. AUTOMATION FOR THE SYNTHESIS AND APPLICATION OF PET RADIOPHARMACEUTICALS.

    SciTech Connect

    Alexoff, D.L.

    2001-09-21

    The development of automated systems supporting the production and application of PET radiopharmaceuticals has been an important focus of researchers since the first successes of using carbon-11 (Comar et al., 1979) and fluorine-18 (Reivich et al., 1979) labeled compounds to visualize functional activity of the human brain. These initial successes of imaging the human brain soon led to applications in the human heart (Schelbert et al., 1980), and quickly radiochemists began to see the importance of automation to support PET studies in humans (Lambrecht, 1982; Langstrom et al., 1983). Driven by the necessity of controlling processes emanating high fluxes of 511 KeV photons, and by the tedium of repetitive syntheses for carrying out these human PET investigations, academic and government scientists have designed, developed and tested many useful and novel automated systems in the past twenty years. These systems, originally designed primarily by radiochemists, not only carry out effectively the tasks they were designed for, but also demonstrate significant engineering innovation in the field of laboratory automation.

  2. New SPECT and PET Radiopharmaceuticals for Imaging Cardiovascular Disease

    PubMed Central

    Sogbein, Oyebola O.; Pelletier-Galarneau, Matthieu; Schindler, Thomas H.; Wei, Lihui; Wells, R. Glenn; Ruddy, Terrence D.

    2014-01-01

    Nuclear cardiology has experienced exponential growth within the past four decades with converging capacity to diagnose and influence management of a variety of cardiovascular diseases. Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) with technetium-99m radiotracers or thallium-201 has dominated the field; however new hardware and software designs that optimize image quality with reduced radiation exposure are fuelling a resurgence of interest at the preclinical and clinical levels to expand beyond MPI. Other imaging modalities including positron emission tomography (PET) and magnetic resonance imaging (MRI) continue to emerge as powerful players with an expanded capacity to diagnose a variety of cardiac conditions. At the forefront of this resurgence is the development of novel target vectors based on an enhanced understanding of the underlying pathophysiological process in the subcellular domain. Molecular imaging with novel radiopharmaceuticals engineered to target a specific subcellular process has the capacity to improve diagnostic accuracy and deliver enhanced prognostic information to alter management. This paper, while not comprehensive, will review the recent advancements in radiotracer development for SPECT and PET MPI, autonomic dysfunction, apoptosis, atherosclerotic plaques, metabolism, and viability. The relevant radiochemistry and preclinical and clinical development in addition to molecular imaging with emerging modalities such as cardiac MRI and PET-MR will be discussed. PMID:24901002

  3. In Vitro Assessment of the In Vivo Stability of Cu-64 Radiopharmaceuticals

    SciTech Connect

    Packard, Alan B

    2011-12-15

    Research Plans: The successful development of Cu-64 radiopharmaceuticals depends upon retention of the Cu-64 atom in the radiopharmaceutical. To date, the focus has been on the development of chelators that better retain Cu-64, but there has been no effort to develop an effective method by which improved retention may be measured. In the absence of a suitable analytical method, the stability of Cu-64 radiopharmaceuticals is estimated indirectly, with decreased liver uptake suggesting higher in vivo complex stability. But this approach is inadequate for radiopharmaceuticals, such as radiolabeled antibodies, that are expected to accumulate in the liver even when there is no free Cu-64 present. The absence of such a method has also hampered efforts to systematically evaluate the chemical factors that may give rise to improved retention. The objective of this project is to develop and validate such a method. Accomplishments: The two primary accomplishments of this project will be 1) the development and validation of a method to measure the stability of Cu-64 radiopharmaceuticals and 2) the determination of the chemical factors that define the in vivo stability of Cu 64 radiopharmaceuticals. Because Cu(II) is extremely labile, the in vivo stability of Cu-64 radiopharmaceuticals is not primarily determined by the amount of free Cu that is present at any given time or by the thermodynamic stability constants, but rather by the rate at which Cu is lost from the complex, the dissociation rate constant, kd. The dissociation rate constants of the Cu-64 complexes from a series of bifunctional chelators (BFCs) will be measured using Free Ion Selective Radiotracer Extraction (FISRE), a technique originally developed to measure bioavailable Cu in environmental samples. FISRE will also be applied to the determination of the kd's of a series of reference Cu-64 complexes to determine the chemical factors that define the in vivo stability of Cu-64 radiopharmaceuticals. Potential

  4. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?

    PubMed

    Vallabhajosula, Shankar; Solnes, Lilja; Vallabhajosula, Brigitte

    2011-07-01

    Positron emission tomography (PET)/computed tomography (CT) is a rapidly expanding imaging modality, thanks to the availability of compact medical cyclotrons and automated chemistry synthesis modules for the production of PET radiopharmaceuticals. Despite the availability of many radiotracers, [(18)F]fluorodeoxyglucose (FDG) is currently the most widely used radiopharmaceutical in PET, and the field of molecular imaging is anxiously awaiting the introduction of new PET radiopharmaceuticals for routine clinical use. During the last five years, several proprietary PET radiopharmaceuticals have been developed by major companies, and these new agents are in different stages of clinical evaluation. These new PET drugs are designed for imaging brain beta amyloid, myocardial perfusion, amino acid transport, angiogenesis, and tumor antigen expression. In addition, the National Cancer Institute, Society of Nuclear Medicine Clinical Trials Network, and the American College of Radiology Imaging Network have been conducting multicenter clinical trials with several nonproprietary PET drugs such as sodium [(18)F]fluoride, [(18)F]fluorothymidine, [(18)F]fluoromisonidazole, and (64)Cu-labeled diacetyl-bis (N(4)-methylthiosemicarbazone. All new PET radiopharmaceuticals, like any other drugs, must be manufactured under current good manufacturing practices as required by the Food and Drug Administration before clinical evaluation (phases I, II, and III) and submission of new drug application. This review briefly describes the chemistry, mechanisms(s) of localization, and clinical application of both proprietary and nonproprietary new PET drugs under multicenter clinical evaluation.

  5. DOPASCAN Injection ([{sup 123}I]{beta}-CIT): A radiopharmaceutical with potential for the diagnosis of Parkinson's disease

    SciTech Connect

    Nowotnik, D. P.

    1999-06-10

    In conjunction with single photon emission computerized tomography (SPECT), the radiopharmaceutical [{sup 123}I]{beta}-CIT (DOPASCAN Injection) has demonstrated significant potential for the early diagnosis and monitoring of Parkinson's Disease. Well over 2000 patients worldwide have been studied with this product, which has completed phase II clinical studies. This review summarizes the development and clinical application of this new radiopharmaceutical product.

  6. Incorporation of radiohalogens via versatile organometallic reactions: applications in radiopharmaceutical chemistry

    SciTech Connect

    Srivastava, P.C.; Goodman, M.M.; Knapp, F.F. Jr.

    1985-01-01

    Factors that must be considered for the design of radiohalogenated radio-pharmaceuticals include the stability and availability of the substrate, the physical half-life of the radiohalogen and the in vivo stability of the radiolabel. Vinyl and phenyl radiohalogen bonds show more in vivo stability than the alkyl radiohalogen bonds. Consequently, a variety of methods suitable for the synthesis of tissue specific radiopharmaceuticals bearing a vinyl or phenyl radiohalogen have been developed involving the synthesis and halogenation of metallovinyl and phenyl intermediates. The halogens and metallation reactions include iodine and bromine and alanation, boronation, mercuration, stannylation, and thallation, respectively. 19 refs., 1 fig., 1 tab.

  7. Radiopharmaceuticals for diagnosis. [Final] report, 1 January 1991--31 December 1993

    SciTech Connect

    Kuhl, D.E.

    1993-06-01

    Since 1987, this grant has supported the development of new radiochemical methods for use with short-lived, positron-emitting radionuclides; new laboratory techniques for radiochemical syntheses; and development of new radiopharmaceuticals which will be of use in Positron Emission Tomography. For the period 1 January 1991 to 31 December 1993, the authors have continued their efforts in all of these areas, as they feel that an integrated approach to the synthesis and characterization of new PET Radiopharmaceuticals is crucial to the continued growth and application of this imaging technique in modern medicine. Progress in a number of these areas is described in this report.

  8. Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen

    PubMed Central

    Kiess, Ana P.; Hobbs, Robert; Sgouros, George; Mease, Ronnie C.; Pullambhatla, Mrudula; Shen, Colette J.; Foss, Catherine A.; Pomper, Martin G.

    2015-01-01

    Auger electron emitters such as 125I have a high linear energy transfer and short range of emission (<10 μm), making them suitable for treating micrometastases while sparing normal tissues. We used a highly specific small molecule targeting the prostate-specific membrane antigen (PSMA) to deliver 125I to prostate cancer cells. Methods The PSMA-targeting Auger emitter 2-[3-[1-carboxy-5-(4-125I-iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid (125I-DCIBzL) was synthesized. DNA damage (via phosphorylated H2A histone family member X staining) and clonogenic survival were tested in PSMA-positive (PSMA+) PC3 PIP and PSMA-negative (PSMA−) PC3 flu human prostate cancer cells after treatment with 125I-DCIBzL. Subcellular drug distribution was assessed with confocal microscopy using a related fluorescent PSMA-targeting compound YC-36. In vivo antitumor efficacy was tested in nude mice bearing PSMA+ PC3 PIP or PSMA− PC3 flu flank xenografts. Animals were administered (intravenously) 111 MBq (3 mCi) of 125I-DCIBzL, 111 MBq (3 mCi) of 125I-NaI, an equivalent amount of nonradiolabeled DCIBzL, or saline. Results After treatment with 125I-DCIBzL, PSMA+ PC3 PIP cells exhibited increased DNA damage and decreased clonogenic survival when compared with PSMA− PC3 flu cells. Confocal microscopy of YC-36 showed drug distribution in the perinuclear area and plasma membrane. Animals bearing PSMA+ PC3 PIP tumors had significant tumor growth delay after treatment with 125I-DCIBzL, with only 1 mouse reaching 5 times the initial tumor volume by 60 d after treatment, compared with a median time to 5 times volume of less than 15 d for PSMA− PC3 flu tumors and all other treatment groups (P = 0.002 by log-rank test). Conclusion PSMA-targeted radiopharmaceutical therapy with the Auger emitter 125I-DCIBzL yielded highly specific antitumor efficacy in vivo, suggesting promise for treatment of prostate cancer micrometastases. PMID:26182968

  9. Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System

    PubMed Central

    Aslani, Alireza; Snowdon, Graeme M; Bailey, Dale L; Schembri, Geoffrey P; Bailey, Elizabeth A; Pavlakis, Nick; Roach, Paul J

    2015-01-01

    Objective(s): Peptide Receptor Radionuclide Therapy (PRRT) with yttrium-90 (90Y) and lutetium-177 (177Lu)-labelled SST analogues are now therapy option for patients who have failed to respond to conventional medical therapy. In-house production with automated PRRT synthesis systems have clear advantages over manual methods resulting in increasing use in hospital-based radiopharmacies. We report on our one year experience with an automated radiopharmaceutical synthesis system. Methods: All syntheses were carried out using the Eckert & Ziegler Eurotope’s Modular-Lab Pharm Tracer® automated synthesis system. All materials and methods used were followed as instructed by the manufacturer of the system (Eckert & Ziegler Eurotope, Berlin, Germany). Sterile, GMP-certified, no-carrier added (NCA) 177Lu was used with GMP-certified peptide. An audit trail was also produced and saved by the system. The quality of the final product was assessed after each synthesis by ITLC-SG and HPLC methods. Results: A total of 17 [177Lu]-DOTATATE syntheses were performed between August 2013 and December 2014. The amount of radioactive [177Lu]-DOTATATE produced by each synthesis varied between 10-40 GBq and was dependant on the number of patients being treated on a given day. Thirteen individuals received a total of 37 individual treatment administrations in this period. There were no issues and failures with the system or the synthesis cassettes. The average radiochemical purity as determined by ITLC was above 99% (99.8 ± 0.05%) and the average radiochemical purity as determined by HPLC technique was above 97% (97.3 ± 1.5%) for this period. Conclusions: The automated synthesis of [177Lu]-DOTATATE using Eckert & Ziegler Eurotope’s Modular-Lab Pharm Tracer® system is a robust, convenient and high yield approach to the radiolabelling of DOTATATE peptide benefiting from the use of NCA 177Lu and almost negligible radiation exposure of the operators. PMID:27408890

  10. Sophia Daemon Version 12

    2012-08-09

    Sophia Daemon Version 12 contains the code that is exclusively used by the ‘sophiad’ application. It runs as a service on a Linux host and analyzes network traffic obtained from libpcap and produces a network fingerprint based on hosts and channels. Sophia Daemon Version 12 can, if desired by the user, produce alerts when its fingerprint changes. Sophia Daemon Version 12 can receive data from another Sophia Daemon or raw packet data. It can outputmore » data to another Sophia Daemon Version 12, OglNet Version 12 or MySQL. Sophia Daemon Version 12 runs in a passive real-time manner that allows it to be used on a SCADA network. Its network fingerprint is designed to be applicable to SCADA networks rather than general IT networks.« less

  11. Sophia Daemon Version 12

    SciTech Connect

    2012-08-09

    Sophia Daemon Version 12 contains the code that is exclusively used by the ‘sophiad’ application. It runs as a service on a Linux host and analyzes network traffic obtained from libpcap and produces a network fingerprint based on hosts and channels. Sophia Daemon Version 12 can, if desired by the user, produce alerts when its fingerprint changes. Sophia Daemon Version 12 can receive data from another Sophia Daemon or raw packet data. It can output data to another Sophia Daemon Version 12, OglNet Version 12 or MySQL. Sophia Daemon Version 12 runs in a passive real-time manner that allows it to be used on a SCADA network. Its network fingerprint is designed to be applicable to SCADA networks rather than general IT networks.

  12. Development of more efficacious Tc-99m organ imaging agents for use in nuclear medicine by characterization of radiopharmaceuticals. Final report, September 1, 1992--June 30, 1998

    SciTech Connect

    Heineman, W.R.; Seliskar, C.J.

    1998-08-04

    The primary goals of this project were twofold: (1) Development of a microsensor that would demonstrate the capability for in vivo monitoring of a radiopharmaceutical after its injection into a test animal; and (2) Exploration of capillary electrophoresis (CE) as a separation technique for the analysis of radiopharmaceuticals that are mixtures of different compounds. The combination of in vivo sensors for real-time monitoring of specific chemical states of a radiopharmaceutical in individual organs and CE for analysis of radiopharmaceuticals prior to injection would provide valuable information regarding the fate of an imaging agent after administration. Such information should give insight into strategies for the development of more efficacious radiopharmaceuticals.

  13. Harvard-MIT research program in short-lived radiopharmaceuticals. Technical progress report, 1991

    SciTech Connect

    Adelstein, S.J.

    1991-12-31

    This report presents research on radiopharmaceuticals. The following topics are discussed: antibody labeling with positron-emitting radionuclides; antibody modification for radioimmune imaging; labeling antibodies; evaluation of technetium acetlyacetonates as potential cerebral blood flow agents; and studies in technetium chemistry. (CBS)

  14. Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer.

    PubMed

    Frier, Malcolm

    2004-01-01

    The favourable nuclear properties of copper-67 and rhenium-188 for therapeutic application are described, together with methods for the chemical synthesis of a number of derivatives. Survival from invasive bladder cancer has changed little over the past 20 years. The intravesicular administration of Cu-67 or Re-188 radiopharmaceuticals in the treatment of bladder cancer offers some promise for improvement in this situation.

  15. Design of CGMP Production of 18F- and 68Ga-Radiopharmaceuticals

    PubMed Central

    Chu, Pei-Chun; Chao, Hao-Yu; Shieh, Wei-Chen; Chen, Chuck C.

    2014-01-01

    Objective. Radiopharmaceutical production process must adhere to current good manufacturing process (CGMP) compliance to ensure the quality of precursor, prodrug (active pharmaceutical ingredient, API), and the final drug product that meet acceptance criteria. We aimed to develop an automated system for production of CGMP grade of PET radiopharmaceuticals. Methods. The hardware and software of the automated synthesizer that fit in the hot cell under cGMP requirement were developed. Examples of production yield and purity for 68Ga-DOTATATE and 18F-FDG at CGMP facility were optimized. Analytical assays and acceptance criteria for cGMP grade of 68Ga-DOTATATE and 18F-FDG were established. Results. CGMP facility for the production of PET radiopharmaceuticals has been established. Radio-TLC and HPLC analyses of 68Ga-DOTATATE and 18F-FDG showed that the radiochemical purity was 92% and 96%, respectively. The products were sterile and pyrogenic-free. Conclusion. CGMP compliance of radiopharmaceuticals has been reviewed. 68Ga-DOTATATE and 18F-FDG were synthesized with high radiochemical yield under CGMP process. PMID:25276810

  16. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain.

    PubMed

    Paes, Fabio M; Serafini, Aldo N

    2010-03-01

    Bone pain due to skeletal metastases constitutes the most common type of chronic pain among patients with cancer. It significantly decreases the patient's quality of life and is associated with comorbidities, such as hypercalcemia, pathologic fractures and spinal cord compression. Approximately 65% of patients with prostate or breast cancer and 35% of those with advanced lung, thyroid, and kidney cancers will have symptomatic skeletal metastases. The management of bone pain is extremely difficult and involves a multidisciplinary approach, which usually includes analgesics, hormone therapies, bisphosphonates, external beam radiation, and systemic radiopharmaceuticals. In patients with extensive osseous metastases, systemic radiopharmaceuticals should be the preferred adjunctive therapy for pain palliation. In this article, we review the current approved radiopharmaceutical armamentarium for bone pain palliation, focusing on indications, patient selection, efficacy, and different biochemical characteristics and toxicity of strontium-89 chloride, samarium-153 lexidronam, and rhenium-186 etidronate. A brief discussion on the available data on rhenium-188 is presented focusing on its major advantages and disadvantages. We also perform a concise appraisal of the other available treatment options, including pharmacologic and hormonal treatment modalities, external beam radiation, and bisphosphonates. Finally, the available data on combination therapy of radiopharmaceuticals with bisphosphonates or chemotherapy are discussed. PMID:20113678

  17. Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases.

    PubMed

    Lange, Rogier; Ter Heine, Rob; Knapp, Russ Ff; de Klerk, John M H; Bloemendal, Haiko J; Hendrikse, N Harry

    2016-10-01

    Therapeutic phosphonate-based radiopharmaceuticals radiolabeled with beta, alpha and conversion electron emitting radioisotopes have been investigated for the targeted treatment of painful bone metastases for >35years. We performed a systematic literature search and focused on the pharmaceutical development, preclinical research and early human studies of these radiopharmaceuticals. The characteristics of an ideal bone-targeting therapeutic radiopharmaceutical are presented and compliance with these criteria by the compounds discussed is verified. The importance of both composition and preparation conditions for the stability and biodistribution of several agents is discussed. Very few studies have described the characterization of these products, although knowledge on the molecular structure is important with respect to in vivo behavior. This review discusses a total of 91 phosphonate-based therapeutic radiopharmaceuticals, of which only six agents have progressed to clinical use. Extensive clinical studies have only been described for (186)Re-HEDP, (188)Re-HEDP and (153)Sm-EDTMP. Of these, (153)Sm-EDTMP represents the only compound with worldwide marketing authorization. (177)Lu-EDTMP has recently received approval for clinical use in India. This review illustrates that a thorough understanding of the radiochemistry of these agents is required to design simple and robust preparation and quality control methods, which are needed to fully exploit the potential benefits of these theranostic radiopharmaceuticals. Extensive biodistribution and dosimetry studies are indispensable to provide the portfolios that are required for assessment before human administration is possible. Use of the existing knowledge collected in this review should guide future research efforts and may lead to the approval of new promising agents. PMID:27496068

  18. Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases.

    PubMed

    Lange, Rogier; Ter Heine, Rob; Knapp, Russ Ff; de Klerk, John M H; Bloemendal, Haiko J; Hendrikse, N Harry

    2016-10-01

    Therapeutic phosphonate-based radiopharmaceuticals radiolabeled with beta, alpha and conversion electron emitting radioisotopes have been investigated for the targeted treatment of painful bone metastases for >35years. We performed a systematic literature search and focused on the pharmaceutical development, preclinical research and early human studies of these radiopharmaceuticals. The characteristics of an ideal bone-targeting therapeutic radiopharmaceutical are presented and compliance with these criteria by the compounds discussed is verified. The importance of both composition and preparation conditions for the stability and biodistribution of several agents is discussed. Very few studies have described the characterization of these products, although knowledge on the molecular structure is important with respect to in vivo behavior. This review discusses a total of 91 phosphonate-based therapeutic radiopharmaceuticals, of which only six agents have progressed to clinical use. Extensive clinical studies have only been described for (186)Re-HEDP, (188)Re-HEDP and (153)Sm-EDTMP. Of these, (153)Sm-EDTMP represents the only compound with worldwide marketing authorization. (177)Lu-EDTMP has recently received approval for clinical use in India. This review illustrates that a thorough understanding of the radiochemistry of these agents is required to design simple and robust preparation and quality control methods, which are needed to fully exploit the potential benefits of these theranostic radiopharmaceuticals. Extensive biodistribution and dosimetry studies are indispensable to provide the portfolios that are required for assessment before human administration is possible. Use of the existing knowledge collected in this review should guide future research efforts and may lead to the approval of new promising agents.

  19. Versioning Complex Data

    SciTech Connect

    Macduff, Matt C.; Lee, Benno; Beus, Sherman J.

    2014-06-29

    Using the history of ARM data files, we designed and demonstrated a data versioning paradigm that is feasible. Assigning versions to sets of files that are modified with some special assumptions and domain specific rules was effective in the case of ARM data, which has more than 5000 datastreams and 500TB of data.

  20. CARE 3, Version 4 enhancements

    NASA Technical Reports Server (NTRS)

    Bryant, L. A.; Stiffler, J. J.

    1985-01-01

    The enhancements and error corrections to CARE III Version 4 are listed. All changes to Version 4 with the exception of the internal redundancy model were implemented in Version 5. Version 4 is the first public release version for execution on the CDC Cyber 170 series computers. Version 5 is the second release version and it is written in ANSI standard FORTRAN 77 for execution on the DEC VAX 11/700 series computers and many others.

  1. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.

    PubMed

    Sathekge, Mike; Maes, Alex; D'Asseler, Yves; Vorster, Mariza; Van de Wiele, Christophe

    2012-06-01

    In this paper, data available on nuclear medicine imaging using commercially available radiopharmaceuticals for the differentiation, staging, and prediction or assessment of the response to treatment in tuberculosis (TB) are reviewed. Limited available studies suggest that single photon emission computed tomography (SPECT) using either 201Tl, 99mTc-sestamibi, or 99mTc-tetrofosmin is accurate (≥85%) and has a high negative predictive value (≥90%) for the differentiation of TB from carcinoma in patients presenting with a solitary pulmonary nodule (SPN). The criteria for detection of TB on 201Tl SPECT are nondepiction of the suspicious lesion in the delayed image or a negative retention index [washout on the delayed images (3–4 h postinjection) vs. the early image (5–15 min postinjection)] and a comparable-to-background uptake on 99mTc-sestamibi or 99mTc-tetrofosmin SPECT. Another SPECT tracer of potential interest for the differentiation of TB from malignant SPN that warrants further exploration, is N-isopropyl-p-[123I]iodoamphetamine (123I-IMP). In contrast, 18F-fluorodeoxyglucose (18F-FDG) PET is unable to differentiate malignancy from TB and thus cannot be used as a tool to reduce futile biopsy/thoracotomy in these patients. A limited number of studies have reported on the potential of nuclear medicine imaging in assessment of the extent of disease in patients with extrapulmonary TB using 67Ga-citrate SPECT and 18F-FDG PET, respectively. 67Ga-citrate SPECT was shown to be as sensitive as bone scintigraphy for the detection of bone infection and was found to be complementary to computed tomography (CT) imaging. 18F-FDG PET was found to be significantly more efficient when compared with CT, respectively, in over half of patients for the identification of sites of lymph node involvement that were missed by CT and often the only sites of extrapulmonary TB identified. Unfortunately, 18F-FDG PET findings did not lead to alterations in treatment planning in any

  2. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.

    PubMed

    Sathekge, Mike; Maes, Alex; D'Asseler, Yves; Vorster, Mariza; Van de Wiele, Christophe

    2012-06-01

    In this paper, data available on nuclear medicine imaging using commercially available radiopharmaceuticals for the differentiation, staging, and prediction or assessment of the response to treatment in tuberculosis (TB) are reviewed. Limited available studies suggest that single photon emission computed tomography (SPECT) using either 201Tl, 99mTc-sestamibi, or 99mTc-tetrofosmin is accurate (≥85%) and has a high negative predictive value (≥90%) for the differentiation of TB from carcinoma in patients presenting with a solitary pulmonary nodule (SPN). The criteria for detection of TB on 201Tl SPECT are nondepiction of the suspicious lesion in the delayed image or a negative retention index [washout on the delayed images (3–4 h postinjection) vs. the early image (5–15 min postinjection)] and a comparable-to-background uptake on 99mTc-sestamibi or 99mTc-tetrofosmin SPECT. Another SPECT tracer of potential interest for the differentiation of TB from malignant SPN that warrants further exploration, is N-isopropyl-p-[123I]iodoamphetamine (123I-IMP). In contrast, 18F-fluorodeoxyglucose (18F-FDG) PET is unable to differentiate malignancy from TB and thus cannot be used as a tool to reduce futile biopsy/thoracotomy in these patients. A limited number of studies have reported on the potential of nuclear medicine imaging in assessment of the extent of disease in patients with extrapulmonary TB using 67Ga-citrate SPECT and 18F-FDG PET, respectively. 67Ga-citrate SPECT was shown to be as sensitive as bone scintigraphy for the detection of bone infection and was found to be complementary to computed tomography (CT) imaging. 18F-FDG PET was found to be significantly more efficient when compared with CT, respectively, in over half of patients for the identification of sites of lymph node involvement that were missed by CT and often the only sites of extrapulmonary TB identified. Unfortunately, 18F-FDG PET findings did not lead to alterations in treatment planning in any

  3. Understanding radioxenon isotopical ratios originating from radiopharmaceutical facilities

    NASA Astrophysics Data System (ADS)

    Saey, P. R. J.; Ringbom, A.; Bowyer, T. W.; Becker, A.; de Geer, L.-E.; Nikkinen, M.; Payne, R. F.

    2009-04-01

    It was recently shown that radiopharmaceutical facilities (RPF) are major contributors to the general background of 133Xe and other xenon isotopes both in the northern and southern hemisphere. To distinguish a nuclear explosion signal from releases from civil nuclear facilities, not only the activity concentrations but also the ratios of the four different CTBT relevant radioxenon isotopes (131mXe, 133mXe, 133Xe and 135Xe) have to be well understood. First measurements taken recently in and around two of the world's largest RPF's: NTP at Pelindaba, South Africa and IRE at Fleurus, Belgium have been presented. At both sites, also stack samples were taken in close cooperation with the facility operators. The radioxenon in Belgium could be classified in four classes: the normal European background (133Xe activity between 0 - 5 mBq/m3) on one hand and then the samples where all four isotopes were detected with 133mXe/131mXe > 1. In northern South Africa the Pelindaba RPF is in practice the sole source of radioxenon. It generated a background of 133Xe at the measurement site some 230 km to the west of the RPF of 0 - 5 mBq/m3. In the cases where the air from the Pelindaba facility reached the measurement site directly and in a short time period, the 133Xe was higher, also 135Xe was present and in some samples 133mXe as well. The ratios of the activity concentrations of 135Xe/133Xe vs. 133mXe/131mXe (Multiple Isotope Ratio Plot - MIRC) have been analysed. For both facilities, the possible theoretical ratio's for different scenarios were calculated with the information available and compared with the measurements. It was found that there is an excess of 131mXe present in the European samples compared to theoretical calculations. A similar excess has also been seen in samples measured in northern America. In South Africa, neither the environmental samples nor the stack ones contained 131mXe at measurable levels. This can probably be explained by different processes and

  4. Sophia Client Version 12

    SciTech Connect

    2012-08-09

    Sophia Client Version 12 offers command line access to the Sophia Daemon and the Sophia database files. It provides print, fingerprint, acknowledge, color coding and status access to these other resources.

  5. Underwire Version 12 (SOPHIA)

    2012-08-09

    Underwire Version 12 is code that provides generic functionality that is common between several projects of these authors. This functionality provides a common API for such things as logging and signal handling that speed up development of new applications.

  6. Version pressure feedback mechanisms for speculative versioning caches

    DOEpatents

    Eichenberger, Alexandre E.; Gara, Alan; O& #x27; Brien, Kathryn M.; Ohmacht, Martin; Zhuang, Xiaotong

    2013-03-12

    Mechanisms are provided for controlling version pressure on a speculative versioning cache. Raw version pressure data is collected based on one or more threads accessing cache lines of the speculative versioning cache. One or more statistical measures of version pressure are generated based on the collected raw version pressure data. A determination is made as to whether one or more modifications to an operation of a data processing system are to be performed based on the one or more statistical measures of version pressure, the one or more modifications affecting version pressure exerted on the speculative versioning cache. An operation of the data processing system is modified based on the one or more determined modifications, in response to a determination that one or more modifications to the operation of the data processing system are to be performed, to affect the version pressure exerted on the speculative versioning cache.

  7. Diagnostic radiopharmaceuticals for localization in target tissues exhibiting a regional PH shift relative to surrounding tissues

    SciTech Connect

    Blau, M.; Kung, H. F.

    1984-10-02

    A radiopharmaceutical chemical compound comprising a radioactive isotope, other than an isotope of iodine, in chemical combination with at least one amine group. The compound has a lipophilicity sufficiently high at a pH of 7.6 to permit passage of the compound from the blood of a mammal into a target organ or tissue and sufficiently low at a pH of 6.6 to prevent rapid return of the compound from the target organ or tissue to the blood. The compound has a percent protein binding of less than ninety percent. A method for selectively depositing a radiopharmaceutical compound in at least one target tissue or organ of a mammal, which tissue or organ has a significantly different intracellular pH than the blood of the mammal, by introducing the compound of the invention into the bloodstream of the mammal.

  8. Radiopharmaceutical stannic Sn-117m chelate compositions and methods of use

    DOEpatents

    Srivastava, Suresh C.; Meinken, George E.

    2001-01-01

    Radiopharmaceutical compositions including .sup.117m Sn labeled stannic (Sn.sup.4+) chelates are provided. The chelates are preferably polyhydroxycarboxylate, such as oxalates, tartrates, citrates, malonates, gluconates, glucoheptonates and the like. Methods of making .sup.117m Sn-labeled (Sn.sup.4+) polyhydroxycarboxylic chelates are also provided. The foregoing pharmaceutical compositions can be used in methods of preparing bone for scintigraphical analysis, for radiopharmaceutical skeletal imaging, treatment of pain resulting from metastatic bone involvement, treatment of primary bone cancer, treatment of cancer resulting from metastatic spread to bone from other primary cancers, treatment of pain resulting from rheumatoid arthritis, treatment of bone/joint disorders and to monitor radioactively the skeletal system.

  9. [Computer simulated images of radiopharmaceutical distributions in anthropomorphic phantoms]. Performance report

    SciTech Connect

    Not Available

    1991-05-17

    We have constructed an anatomically correct human geometry, which can be used to store radioisotope concentrations in 51 various internal organs. Each organ is associated with an index number which references to its attenuating characteristics (composition and density). The initial development of Computer Simulated Images of Radiopharmaceuticals in Anthropomorphic Phantoms (CSIRDAP) over the first 3 years has been very successful. All components of the simulation have been coded, made operational and debugged.

  10. Quantitative studies in radiopharmaceutical science. Progress report, January 1-December 31, 1985

    SciTech Connect

    Beck, R.N.; Cooper, M.

    1985-09-01

    This program, during the past 30 years, has developed with the constant awareness of the close interrelationships and interdependence between clinical needs, radiopharmaceutical and instrument developments, and clinical feasibility studies. This is a year of transition for this contract with two of the responsible investigators, Katherine Lathrop and Paul Harper, reaching the age of mandatory retirement. This report focuses on the completion and write-up of current research projects by Dr. Harper and Mrs. Lathrop. 4 refs.

  11. Development new radiopharmaceutical based on 5-thio-d- glucose labeled technetium-99m

    NASA Astrophysics Data System (ADS)

    Stasyuk, E. S.; Skuridin, V. S.; Ilina, E. A.; Rogov, A. S.; Nesterov, E. A.; Sadkin, V. L.; Larionova, L. A.; Varlamova, N. V.; Zelchan, R.

    2016-06-01

    The article considers the obtaining and possibility of using 5-thio-D-glucose labeled technetium-99m for the diagnosis of malignant tumors by single photon emission computed tomography. The analysis of the level of international developments of radiopharmaceuticals based on derivatives of glucose has been carried out. Also the article provides information on of using experimental batches of lyophilisate on the basis of 5-thio-D-glucose for preliminary biomedical testing on the mice.

  12. Internal dose assessment for 211At α-emitter in isotonic solution as radiopharmaceutical

    NASA Astrophysics Data System (ADS)

    Yuminov, O. A.; Fotina, O. V.; Priselkova, A. B.; Tultaev, A. V.; Platonov, S. Yu.; Eremenko, D. O.; Drozdov, V. A.

    2003-12-01

    The functional fitness of the α-emitter 211At for radiotherapy of the thyroid gland cancer is evaluated. Radiation doses are calculated using the MIRD method and previously obtained pharmacokinetic data for 211At in isotonic solution and for 123I as sodium iodide. Analysis of the 211At radiation dose to the thyroid gland suggests that this radiopharmaceutical may be predominantly used for the treatment of the thyroid cancer.

  13. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.

    PubMed

    Anderson, Peter M; Subbiah, Vivek; Rohren, Eric

    2014-01-01

    Osteosarcoma is a cancer characterized by formation of bone by malignant cells. Routine bone scan imaging with Tc-99m-MDP is done at diagnosis to evaluate primary tumor uptake and check for bone metastases. At time of relapse the Tc-99m-MDP bone scan also provides a specific means to assess formation of bone by malignant osteosarcoma cells and the potential for bone-seeking radiopharmaceuticals to deliver radioactivity directly into osteoblastic osteosarcoma lesions. This chapter will review and compare a bone-seeking radiopharmaceutical that emits beta-particles, samarium-153-EDTMP, with an alpha-particle emitter, radium-223. The charged alpha particles from radium-223 have far more mass and energy than beta particles (electrons) from Sm-153-EDTMP. Because radium-223 has less marrow toxicity and more radiobiological effectiveness, especially if inside the bone forming cancer cell than samarium-153-EDTMP, radium-223 may have greater potential to become widely used against osteosarcoma as a targeted therapy. Radium-223 also has more potential to be used with chemotherapy against osteosarcoma and bone metastases. Because osteosarcoma makes bone and radium-223 acts like calcium, this radiopharmaceutical could possibly become a new targeted means to achieve safe and effective reduction of tumor burden as well as facilitate better surgery and/or radiotherapy for difficult to resect large, or metastatic tumors.

  14. Harvard-MIT research program in short-lived radiopharmaceuticals. Final report

    SciTech Connect

    Adelstein, S.J.

    1995-02-01

    The Harvard-MIT Research Program in Short-lived Radiopharmaceuticals was established in 1977 to foster interaction among groups working in radiopharmaceutical chemistry at Harvard Medical School, the Massachusetts Institute of Technology, and the Massachusetts General Hospital. To this was added a group at The Childrens Hospital. From these collaborations and building upon the special strengths of the participating individuals, laboratories and institutions, it was hoped that original approaches would be found for the design of new, clinically useful, radiolabeled compounds. The original thrust of this proposal included: (a) examination of the coordination chemistry of technetium as a basis for rational radiopharmaceutical design, (b) development of an ultrashort-lived radionuclide generator for the diagnosis of congenital heart disease in newborns, (c) synthesis of receptor-site-directed halopharmaceuticals, (d) improved facile labeling of complex molecules with positron-emitting radionuclides. The authors` 1986 proposal was oriented toward organs and disease, emphasizing radiolabeled agents that delineate specific functions and the distribution of receptors in brain, heart, and tumors. In 1989, they further refined their purposes and focused on two major aims: (a) synthesis and utilization of neutral technetium and rhenium complexes of high specific activity, and (b) development of new approaches to the radiolabeling of proteins, peptides, immunoglobulins, and their fragments. In 1992, the authors amended this proposal to concentrate their efforts on biologically active peptides and proteins for targeted radiodiagnosis and therapy.

  15. Preparation of gallium-68 radiopharmaceuticals for positron tomography. Progress report, November 1, 1977-October 31, 1980

    SciTech Connect

    Welch, M.J.

    1980-06-01

    Although the germanium-68 ..-->.. gallium-68 generator is probably the only source of positron-emitting radionuclides that could enable the widespread application of positron tomography, the commercially available /sup 68/Ga//sup 68/Ge generator system suffers from several major disadvantages. The most important of these is that the generator is eluted with EDTA, which forms a very strong chelate with gallium. In order to produce radiopharmaceuticals other than /sup 68/Ga-EDTA, it is first necessary to break the stable EDTA complex and remove all traces of EDTA. This procedure adds several steps and a significant amount of time to procedures for preparing /sup 68/Ga-radiopharmaceuticals. We have developed a new generator using a solvent extraction system which will produce /sup 68/Ga-oxine (8-hydroxyquinoline), a weak chelate. Using this agent we have synthesized several /sup 68/Ga-radiopharmaceuticals and tested them in vitro and in vivo. We have also carried out some preliminary studies to compare generator systems which produce /sup 68/Ga in an ionic form. Attempts have been made using polarographic and chromatographic techniques, and in vivo distribution data to investigate the stability of radiogallium complexes with a series of potentially lipophilic complexing agents.

  16. Use of pressure-hold test for sterilizing filter membrane integrity in radiopharmaceutical manufacturing.

    PubMed

    Belanger, Anthony P; Byrne, John F; Paolino, Justin M; DeGrado, Timothy R

    2009-11-01

    The bubble point test is the de facto standard for postproduction filter membrane integrity test in the radiopharmaceutical community. However, the bubble point test depends on a subjective visual assessment of bubbling rate that can be obscured by significant diffusive gas flows below the manufacturer's prescribed bubble point. To provide a more objective means to assess filter membrane integrity, this study evaluates the pressure-hold test as an alternative to the bubble point test. In our application of the pressure-hold test, the nonsterile side of the sterilizing filter is pressurized to 85% of the predetermined bubble point with nitrogen, the filter system is closed off from the pressurizing gas and the pressure is monitored over a prescribed time interval. The drop in pressure, which has a known relationship with diffusive gas flow, is used as a quantitative measure of membrane integrity. Characterization of the gas flow vs. pressure relationship of each filter/solution combination provides an objective and quantitative means for defining a critical value of pressure drop over which the membrane is indicated to be nonintegral. The method is applied to sterilizing filter integrity testing associated with the commonly produced radiopharmaceuticals, [(18)F]FDG and [(11)C]PIB. The method is shown to be robust, practical and amenable to automation in radiopharmaceutical manufacturing environments (e.g., hot cells).

  17. Traceability from governmental producers of radiopharmaceuticals in measuring (18)F in Brazil.

    PubMed

    Oliveira, A E; Iwahara, A; Silva, C J; Cruz, P A L; Poledna, R; Silva, R L; Laranjeira, A S; Delgado, J U; Tauhata, L; Loureiro, J S; Toledo, B C; Braghirolli, A M S; Andrade, E A L; Silva, J L; Hernandes, H O K; Valente, E S; Dalle, H M; Almeida, V M; Silva, T G; Fragoso, M C F; Oliveira, M L; Nascimento, E S S; Oliveira, E M; Herrerias, R; Souza, A A; Bambalas, E; Bruzinga, W A

    2016-03-01

    Since the inception of its proficiency test program to evaluate radionuclide measurement in hospitals and clinics, the National Metrology Laboratory of Ionizing Radiation-LNMRI, that represents Brazilian National Metrology Institute (NMI) for ionizing radiation has expanded its measurement and calibration capability. Requirements from the National Health Surveillance Agency from Ministry of Health (ANVISA), to producers of radiopharmaceuticals provided an opportunity to improve the full traceability chain to the highest level. Fluorodeoxyglucose (FDG-(18)F) is the only radiopharmaceutical simultaneously produced by all Brazilian radiopharmaceutical production centers (RPCs). By running this proficiency test, LNMRI began to provide them with the required traceability. For evaluation, the ratio of RPC to reference value results and ISO/IEC17043:2010 criteria were used. The reference value established as calibration factor on the secondary standard ionization chamber was obtained from three absolute measurements systems, and routinely confirmed in each round of proficiency test by CIEMAT/NIST liquid scintillation counting. The γ-emitting impurities were checked using a High-Purity Germanium (HPGe) detector. The results show that Brazilian RPCs are in accordance with (accuracy within ±10%) the Brazilian standard for evaluation of measurements with radionuclide calibrators (CNEN NN 3.05., 2013). Nevertheless, the RPCs should improve the methodology of uncertainty estimates, essential when using the statistical criteria of ISO/IEC 17043 standard, in addition to improving accuracy to levels consistent with their position in the national traceability chain. PMID:26688362

  18. SU-E-I-82: PET Radiopharmaceuticals for Prostate Cancer Imaging: A Review

    SciTech Connect

    Fernandes, F; Silva, D da; Rodrigues, L

    2015-06-15

    Purpose: The aim of this work was to review new and clinical practice PET radiopharmaceuticals for prostate cancer imaging. Methods: PET radiopharmaceuticals were reviewed on the main databases. Availability, dosimetry, accuracy and limitations were considered. Results: The following radioisotopes with respective physical half-life and mean positron energy were found: {sup 18}F (109,7 min, 249,8 keV), {sup 89}Zr (78,4 hs, 395,5 keV), {sup 11}C (20,4 min, 385,7 keV) and {sup 68}Ga (67,8 min, 836 keV). {sup 68}Ga was the only one not produced by cyclotron. Radiopharmaceuticals uptake by glucose metabolism ({sup 18}F-FDG), lipogenesis ({sup 11}C-Choline and {sup 11}C-Acetate), amino acid transport (Anti-{sup 18}F-FACBC), bone matrix ({sup 18}F-NaF), prostatespecific membrane antigen ({sup 68}Ga-PSMA and {sup 89}Zr-J591), CXCR receptors ({sup 89}Ga-Pentixafor), adrenal receptors ({sup 18}F-FDHT) and gastrin release peptide receptor (bombesin analogue). Most of radiopharmaceuticals are urinary excretion, so bladder is the critical organ. 11C-choline (pancreas), Anti-{sup 18}FFACBC (liver) and {sup 18}F-FBDC (stomach wall) are the exception. Higher effective dose was seen {sup 18}F-NaF (27 μSv/MBq) while the lowest was {sup 11}CAcetate (3,5 μSv/MBq). Conclusion: Even though {sup 18}F-FDG has a large availability its high urinary excretion and poor uptake to slow growing disease offers weak results for prostate cancer. Better accuracy is obtained when {sup 18}F-NaF is used for bone metastatic investigation although physicians tend to choose bone scintigraphy probably due to its cost and practice. Many guidelines in oncology consider {sup 11}C or {sup 18}F labeled with Choline the gold standard for biochemical relapse after radical treatment. Local, lymph node and distant metastatic relapse can be evaluated at same time with this radiopharmaceutical. There is no consensus over bigger urinary excretion for {sup 18}F labeling. Anti-{sup 18}F-FACBC, {sup 68}Ga-PSMA and {sup

  19. Versioning of printed products

    NASA Astrophysics Data System (ADS)

    Tuijn, Chris

    2005-01-01

    During the definition of a printed product in an MIS system, a lot of attention is paid to the production process. The MIS systems typically gather all process-related parameters at such a level of detail that they can determine what the exact cost will be to make a specific product. This information can then be used to make a quote for the customer. Considerably less attention is paid to the content of the products since this does not have an immediate impact on the production costs (assuming that the number of inks or plates is known in advance). The content management is typically carried out either by the prepress systems themselves or by dedicated workflow servers uniting all people that contribute to the manufacturing of a printed product. Special care must be taken when considering versioned products. With versioned products we here mean distinct products that have a number of pages or page layers in common. Typical examples are comic books that have to be printed in different languages. In this case, the color plates can be shared over the different versions and the black plate will be different. Other examples are nation-wide magazines or newspapers that have an area with regional pages or advertising leaflets in different languages or currencies. When considering versioned products, the content will become an important cost factor. First of all, the content management (and associated proofing and approval cycles) becomes much more complex and, therefore, the risk that mistakes will be made increases considerably. Secondly, the real production costs are very much content-dependent because the content will determine whether plates can be shared across different versions or not and how many press runs will be needed. In this paper, we will present a way to manage different versions of a printed product. First, we will introduce a data model for version management. Next, we will show how the content of the different versions can be supplied by the customer

  20. Versioning of printed products

    NASA Astrophysics Data System (ADS)

    Tuijn, Chris

    2004-12-01

    During the definition of a printed product in an MIS system, a lot of attention is paid to the production process. The MIS systems typically gather all process-related parameters at such a level of detail that they can determine what the exact cost will be to make a specific product. This information can then be used to make a quote for the customer. Considerably less attention is paid to the content of the products since this does not have an immediate impact on the production costs (assuming that the number of inks or plates is known in advance). The content management is typically carried out either by the prepress systems themselves or by dedicated workflow servers uniting all people that contribute to the manufacturing of a printed product. Special care must be taken when considering versioned products. With versioned products we here mean distinct products that have a number of pages or page layers in common. Typical examples are comic books that have to be printed in different languages. In this case, the color plates can be shared over the different versions and the black plate will be different. Other examples are nation-wide magazines or newspapers that have an area with regional pages or advertising leaflets in different languages or currencies. When considering versioned products, the content will become an important cost factor. First of all, the content management (and associated proofing and approval cycles) becomes much more complex and, therefore, the risk that mistakes will be made increases considerably. Secondly, the real production costs are very much content-dependent because the content will determine whether plates can be shared across different versions or not and how many press runs will be needed. In this paper, we will present a way to manage different versions of a printed product. First, we will introduce a data model for version management. Next, we will show how the content of the different versions can be supplied by the customer

  1. Solergy (Beta Version 1)

    2009-03-30

    SOLERGY simulates the operation and power output of a user-defined solar central receiver power plant for a time period of up to one year. SOLERGY utilizes recorded or simulated weather data and plant component performance models to calculate the power flowing through each part of the solar plant. A plant control subroutine monitors these powers and determines when to operate the various plant subsystems. The original version of the code was released in May 1987,more » within SAND86-8060 and was widely distributed. The Beta Version 1 to be released in 2009, includes some relatively small modifications to the original code.« less

  2. Transport Version 3

    2008-05-16

    The Transport version 3 (T3) system uses the Network News Transfer Protocol (NNTP) to move data from sources to a Data Reporisoty (DR). Interested recipients subscribe to newsgroups to retrieve data. Data in transport is protected by AES-256 and RSA cryptographic services provided by the external OpenSSL cryptographic libraries.

  3. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.

    PubMed

    ter Heine, Rob; Lange, Rogier; Breukels, Oscar B; Bloemendal, Haiko J; Rummenie, Rob G; Wakker, Antoinette M; de Graaf, Hilly; Beekman, Freek J; van der Westerlaken, Monique M L; Malingré, Mirte M; Wielders, Jos P M; van den Berg, Leo; Hendrikse, N Harry; de Klerk, John M H

    2014-04-25

    Bone-targeting therapeutic radiopharmaceuticals are effective agents for treatment of painful bone metastases. Rhenium-188-HEDP is such a therapeutic radiopharmaceutical and has advantages over commercially available alternatives in terms of efficacy, safety and the ability to be produced on-site, allowing rapid treatment upon presentation of patients with pain. Unlike many other radiopharmaceuticals, there are no standardized preparation methods for Rhenium-188-HEDP. It is known, however, that drug composition may not only affect stability of the final drug product, but it may also influence bone affinity and, thus, efficacy. Furthermore, for support of clinical studies with Rhenium-188-HEDP as an investigational medicinal product, preparation of this radiopharmaceutical has to be performed under GMP conditions. To our knowledge, no group has reported on the preparation of Rhenium-188-HEDP under GMP conditions or on stock production of sterile non-radioactive starting materials. We present the production of GMP grade Rhenium-188-HEDP for application of this therapeutic radiopharmaceutical in routine clinical practice and for support of clinical studies. In addition, bio-distribution data of Rhenium-188-HEDP in mice and in patients with bone metastases originating from prostate cancer are presented.

  4. AERONET Version 3 processing

    NASA Astrophysics Data System (ADS)

    Holben, B. N.; Slutsker, I.; Giles, D. M.; Eck, T. F.; Smirnov, A.; Sinyuk, A.; Schafer, J.; Rodriguez, J.

    2014-12-01

    The Aerosol Robotic Network (AERONET) database has evolved in measurement accuracy, data quality products, availability to the scientific community over the course of 21 years with the support of NASA, PHOTONS and all federated partners. This evolution is periodically manifested as a new data version release by carefully reprocessing the entire database with the most current algorithms that fundamentally change the database and ultimately the data products used by the community. The newest processing, Version 3, will be released in 2015 after the entire database is reprocessed and real-time data processing becomes operational. All V 3 algorithms have been developed, individually vetted and represent four main categories: aerosol optical depth (AOD) processing, inversion processing, database management and new products. The primary trigger for release of V 3 lies with cloud screening of the direct sun observations and computation of AOD that will fundamentally change all data available for analysis and all subsequent retrieval products. This presentation will illustrate the innovative approach used for cloud screening and assesses the elements of V3 AOD relative to the current version. We will also present the advances in the inversion product processing with emphasis on the random and systematic uncertainty estimates. This processing will be applied to the new hybrid measurement scenario intended to provide inversion retrievals for all solar zenith angles. We will introduce automatic quality assurance criteria that will allow near real time quality assured aerosol products necessary for real time satellite and model validation and assimilation. Last we will introduce the new management structure that will improve access to the data database. The current version 2 will be supported for at least two years after the initial release of V3 to maintain continuity for on going investigations.

  5. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.

    PubMed

    Anderson, Carolyn J; Ferdani, Riccardo

    2009-08-01

    Copper-64 (T(1/2) = 12.7 hours; beta(+), 0.653 MeV [17.8 %]; beta(-), 0.579 MeV [38.4 %]) has decay characteristics that allow for positron emission tomography (PET) imaging and targeted radiotherapy of cancer. The well-established coordination chemistry of copper allows for its reaction with a wide variety of chelator systems that can potentially be linked to peptides and other biologically relevant small molecules, antibodies, proteins, and nanoparticles. The 12.7-hours half-life of 64Cu provides the flexibility to image both smaller molecules and larger, slower clearing proteins and nanoparticles. In a practical sense, the radionuclide or the 64Cu-radiopharmaceuticals can be easily shipped for PET imaging studies at sites remote to the production facility. Due to the versatility of 64Cu, there has been an abundance of novel research in this area over the past 20 years, primarily in the area of PET imaging, but also for the targeted radiotherapy of cancer. The biologic activity of the hypoxia imaging agent, 60/64Cu-ATSM, has been described in great detail in animal models and in clinical PET studies. An investigational new drug application for 64Cu-ATSM was recently approved by the U.S. Food and Drug Administration (FDA) in the United States, paving the way for a multicenter trial to validate the utility of this agent, with the hopeful result being FDA approval for routine clinical use. This article discusses state-of-the-art cancer imaging with 64Cu radiopharmaceuticals, including 64Cu-ATSM for imaging hypoxia, 64Cu-labeled peptides for tumor-receptor targeting, (64)Cu-labeled monoclonal antibodies for targeting tumor antigens, and 64Cu-labeled nanoparticles for cancer targeting. The emphasis of this article will be on the new scientific discoveries involving (64)Cu radiopharmaceuticals, as well as the translation of these into human studies.

  6. Radio-UHPLC: a tool for rapidly determining the radiochemical purity of technetium-99m radiopharmaceuticals?

    PubMed

    Kryza, David; Janier, Marc

    2013-08-01

    Determining the radiochemical purity (RCP) of technetium-99m ((99m)Tc) radiopharmaceuticals using the method described in the package insert is a time-consuming process, requiring particular attention in order to achieve accurate RCP results. The purpose of this study was to evaluate whether radio-ultra high performance liquid chromatography (radio-UHPLC) may be an alternative method for RCP testing of (99m)Tc-tetrofosmin, (99m)Tc-MAG3 and (99m)Tc-sestamibi. Results obtained using radio-UHPLC were in excellent agreement with the standard method, with total analysis time being reduced to less than 3 min.

  7. High--valent technetium chemistry-new opportunities for radiopharmaceutical developments.

    PubMed

    Braband, Henrik

    2014-04-01

    The rich coordination chemistry of (99m) Tc distinguishes this radiometal from other radiolabels applied for single-photon emission computed tomography (SPECT) or positron emission tomography (PET). This potential should be used to create novel opportunities for the development of effective imaging probes. In this context, the field of high-valent technetium chemistry has received much interest. It has been shown that fac-{(99m) TcO3 }(+) complexes are potential new synthons for radiopharmaceutical developments, due to their unique physicochemical properties and unprecedented reactivity. In this article, recent developments and the 'state of the art' in this field of technetium chemistry will be reviewed comprehensively.

  8. ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.

    PubMed

    Henkin, Robert E; Del Rowe, John D; Grigsby, Perry W; Hartford, Alan C; Jadvar, Hossein; Macklis, Roger M; Parker, J Anthony; Wong, Jeffrey Y C; Rosenthal, Seth A

    2011-08-01

    This guideline is intended to guide appropriately trained and licensed physicians performing therapy with unsealed radiopharmaceutical sources. Adherence to this guideline should help to maximize the efficacious use of these procedures, maintain safe conditions, and ensure compliance with applicable regulations. The topics dealt with in this guideline include indications for the use of iodine-131, both for the treatment of hyperthyroidism and thyroid carcinoma. In addition, indications for other less common procedures include those for the use of phosphorous-32 in its liquid and colloidal forms, strontium-89, samarium-153, and the use of Y-90 antibodies.

  9. USCEA/NIST measurement assurance programs for the radiopharmaceutical and nuclear power industries

    SciTech Connect

    Golas, D.B.

    1993-12-31

    In cooperation with the U.S. Council for Energy Awareness (USCEA), the National Institute of Standards and Technology (NIST) supervises and administers two measurement assurance programs for radioactivity measurement traceability. One, in existence since the mid 1970s, provides traceability to suppliers of radiochemicals and radiopharmaceuticals, dose calibrators, and nuclear pharmacy services. The second program, begun in 1987, provides traceability to the nuclear power industry for utilities, source suppliers, and service laboratories. Each program is described, and the results of measurements of samples of known, but undisclosed activity, prepared at NIST and measured by the participants are presented.

  10. Proliferation dangers associated with nuclear medicine: getting weapons-grade uranium out of radiopharmaceutical production.

    PubMed

    Williams, Bill; Ruff, Tilman A

    2007-01-01

    Abolishing the threat of nuclear war requires the outlawing of nuclear weapons and dismantling current nuclear weapon stockpiles, but also depends on eliminating access to fissile material (nuclear weapon fuel). The near-universal use of weapons-grade, highly enriched uranium (HEU) to produce radiopharmaceuticals is a significant proliferation hazard. Health professionals have a strategic opportunity and obligation to progress the elimination of medically-related commerce in HEU, closing one of the most vulnerable pathways to the much-feared 'terrorist bomb'.

  11. A Generator-Produced Gallium-68 Radiopharmaceutical for PET Imaging of Myocardial Perfusion

    PubMed Central

    Sharma, Vijay; Sivapackiam, Jothilingam; Harpstrite, Scott E.; Prior, Julie L.; Gu, Hannah; Rath, Nigam P.; Piwnica-Worms, David

    2014-01-01

    Lipophilic cationic technetium-99m-complexes are widely used for myocardial perfusion imaging (MPI). However, inherent uncertainties in the supply chain of molybdenum-99, the parent isotope required for manufacturing 99Mo/99mTc generators, intensifies the need for discovery of novel MPI agents incorporating alternative radionuclides. Recently, germanium/gallium (Ge/Ga) generators capable of producing high quality 68Ga, an isotope with excellent emission characteristics for clinical PET imaging, have emerged. Herein, we report a novel 68Ga-complex identified through mechanism-based cell screening that holds promise as a generator-produced radiopharmaceutical for PET MPI. PMID:25353349

  12. PVWatts Version 5 Manual

    SciTech Connect

    Dobos, A. P.

    2014-09-01

    The NREL PVWatts calculator is a web application developed by the National Renewable Energy Laboratory (NREL) that estimates the electricity production of a grid-connected photovoltaic system based on a few simple inputs. PVWatts combines a number of sub-models to predict overall system performance, and makes includes several built-in parameters that are hidden from the user. This technical reference describes the sub-models, documents assumptions and hidden parameters, and explains the sequence of calculations that yield the final system performance estimate. This reference is applicable to the significantly revised version of PVWatts released by NREL in 2014.

  13. Measurement and control of the air contamination generated in a medical cyclotron facility for PET radiopharmaceuticals.

    PubMed

    Calandrino, R; del Vecchio, A; Todde, S; Fazio, F

    2007-05-01

    The aim of this paper is to report the data concerning the contamination of the exhausted air from the hot cells dedicated to the large-scale synthesis of positron emission tomography (PET) radiopharmaceuticals. Two cyclotrons are currently operating in Ospedale San Raffaele for the routine production of C and F. They are linked with four radiochemistry laboratories by means of shielded radioisotope delivery lines. The above labs are dedicated both to the large scale preparation and to the research and development of PET radiopharmaceuticals. The department hosts four CT-PET scanners, which operate with a mean patient workload of 40 per day. Radiosyntheses are performed using automated modules located in 10 hot cells. The air outlets are monitored online by a 2-inch NaI(Tl) counter in a Marinelli geometry counting volume. Contamination values up to 10(5) Bq L(-1) have been measured at the hot cell exit point during the synthesis. The corresponding concentrations at the point of release in atmosphere are largely above the threshold of 1.29 Bq L(-1), defined by national regulations as the limit for free environmental release. A shielded gas storage system controlled by a dedicated, customized software program has thus been installed to prevent the potentially hazardous release of gaseous radioactive contaminants. The system has allowed us to maintain the effective dose to neighboring population groups below the limit of 10 muSv y(-1).

  14. Dose rate measurements from radiopharmaceuticals: implications for nuclear medicine staff and for children with radioactive parents.

    PubMed

    Greaves, C D; Tindale, W B

    1999-02-01

    Following the introduction of a number of radiopharmaceuticals, we assessed the dose received by staff working in the nuclear medicine department and also by children who may be in close contact with a radioactive parent. We measured departure dose rates (microSv.h-1) at distances of 0.1, 0.5 and 1.0 m from the skin surface at the level of the thyroid, chest and bladder of patients undergoing the following nuclear medicine procedures: MUGA scans using 99Tcm-labelled red blood cells, myocardial perfusion scans using 99Tcm-labelled radiopharmaceuticals, lymphoscintigraphy using colloidal 99Tcm (Re) sulphide, bone scans using 99Tcm-labelled oxidronate, 111In-octreotide scans, 111In-labelled leukocyte studies and cardiac reinjection studies using 201Tl. The maximum dose rates at 0.1 m were those from MUGA studies (167.3 microSv.h-1) and myocardial perfusion studies (one-day protocol = 391.7 microSv.h-1, two-day protocol = 121.8 microSv.h-1). The implications of these dose rates on both technical and nursing staff are assessed. Also, the dose received by an infant in close contact with a parent following a nuclear medicine investigation was estimated.

  15. Radiopharmaceuticals for radiation synovectomy: Evaluation of two yttrium-90 particulate agents

    SciTech Connect

    Davis, M.A.; Chinol, M.

    1989-06-01

    Radiation synovectomy, a noninvasive therapeutic alternative to surgical synovectomy, has not gained widespread acceptance in the United States because of the lack of a suitable radiopharmaceutical. Two new radioactive particles, (/sup 90/Y)Ca oxalate and (/sup 90/Y)ferric hydroxide macroaggregates (FHMA), were developed in our laboratory and evaluated for size, stability, and joint leakage. More than 90% of the (/sup 90/Y)Ca oxalate particles were in the optimal size range of 1-10 microns, and the unbound activity in serum and synovial fluid was 3.7% to 5.0%. Following injection in rabbit knees, leakage of (/sup 90/Y)Ca oxalate was 5 +/- 2%, with localization primarily in the bone and virtually no uptake by the lymph nodes or liver. Yttrium-90 FHMA particles were larger (95% greater than 10 microns), and at least on a microscopic level, appeared to distribute homogeneously over the articular surface. Leakage of (/sup 90/Y)FHMA was initially less but eventually slightly exceeded that of (/sup 90/Y)Ca oxalate. Nevertheless, both radiopharmaceuticals can provide a satisfactory therapeutic dose to the knee with less than half the leakage and a marked reduction in absorbed dose to nontarget tissues compared to previously tested agents. Ease of preparation, physical characteristics of the /sup 90/Y beta ray, and apparent lack of substantial leakage from the joint make these agents extremely attractive for clinical evaluation in rheumatoid arthritis patients who are unresponsive to medical therapy.

  16. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases

    PubMed Central

    Goyal, Jatinder; Antonarakis, Emmanuel S.

    2014-01-01

    Patients with castration-resistant prostate cancer (CRPC) frequently have metastases to the bone, which may cause pain and lead to a deterioration in quality-of-life. Bone-seeking radiopharmaceuticals are agents which, when administered systemically, localize to the site of bone metastases and deliver focal radiation there. In this review, we will summarize the current literature on bone-targeting radiopharmaceuticals for CRPC, focusing on strontium-89, samarium-153, rhenium-186 and radium-223. We will discuss their indications, clinical efficacy, and toxicities and highlight some of the challenges in optimizing treatment with these agents. Historically, clinical trials with these drugs have failed to demonstrate survival improvements, restricting their use for palliative purposes only. Radium-223 is the first agent in this class to show an overall survival advantage in CRPC patients with bone metastases. This landmark finding will likely have a considerable impact on the treatment paradigm of bone-metastatic CRPC, and will pave the way for further developments in the future. PMID:22521546

  17. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. [Baboons

    SciTech Connect

    Dischino, D.D.; Welch, M.J.; Kilbourn, M.R.; Raichle, M.E.

    1983-11-01

    The brain extraction of fifteen C-11-labeled compounds during a single capillary transit was studied in adult baboons by external detection of these tracers after injection into the internal carotid artery. The log P/sub oct/ (partition coefficient for octanol/water) values of these compounds range from -0.7 to greater than 4.0. A parabolic relationship was found between the log P/sub oct/value of the C-11-labeled compounds and the fraction of the radiopharmaceutical entering the brain. Compounds with log P/sub oct/ values between 0.9 and 2.5 were found to pass freely across the blood-brain barrier at a cerebral blood flow of 100 ml-min/sup -1/-hg/sup -1/. An apparently decreased extraction of very lipophilic compounds was shown to be related to binding of the tracer to blood components and macromolecules (red blood cells, albumin, etc.). These data suggest that a radiopharmaceutical designed to measure blood flow should have a log P/sub oct/ value of between 0.9 and 2.5.

  18. 18F-Labeled Silicon-Based Fluoride Acceptors: Potential Opportunities for Novel Positron Emitting Radiopharmaceuticals

    PubMed Central

    Bernard-Gauthier, Vadim; Wängler, Carmen; Wängler, Bjoern; Schirrmacher, Ralf

    2014-01-01

    Background. Over the recent years, radiopharmaceutical chemistry has experienced a wide variety of innovative pushes towards finding both novel and unconventional radiochemical methods to introduce fluorine-18 into radiotracers for positron emission tomography (PET). These “nonclassical” labeling methodologies based on silicon-, boron-, and aluminium-18F chemistry deviate from commonplace bonding of an [18F]fluorine atom (18F) to either an aliphatic or aromatic carbon atom. One method in particular, the silicon-fluoride-acceptor isotopic exchange (SiFA-IE) approach, invalidates a dogma in radiochemistry that has been widely accepted for many years: the inability to obtain radiopharmaceuticals of high specific activity (SA) via simple IE. Methodology. The most advantageous feature of IE labeling in general is that labeling precursor and labeled radiotracer are chemically identical, eliminating the need to separate the radiotracer from its precursor. SiFA-IE chemistry proceeds in dipolar aprotic solvents at room temperature and below, entirely avoiding the formation of radioactive side products during the IE. Scope of Review. A great plethora of different SiFA species have been reported in the literature ranging from small prosthetic groups and other compounds of low molecular weight to labeled peptides and most recently affibody molecules. Conclusions. The literature over the last years (from 2006 to 2014) shows unambiguously that SiFA-IE and other silicon-based fluoride acceptor strategies relying on 18F− leaving group substitutions have the potential to become a valuable addition to radiochemistry. PMID:25157357

  19. Current activities in the ICRP concerning estimation of radiation doses to patients from radiopharmaceuticals for diagnostic use

    NASA Astrophysics Data System (ADS)

    Mattsson, S.; Johansson, L.; Leide-Svegborn, S.; Liniecki, J.; Nosske, D.; Riklund, K.; Stabin, M.; Taylor, D.

    2011-09-01

    A Task Group within the ICRP Committees 2 and 3 is continuously working to improve absorbed dose estimates to patients investigated with radiopharmaceuticals. The work deals with reviews of the literature, initiation of new or complementary studies of the biokinetics of a compound and dose estimates. Absorbed dose calculations for organs and tissues have up to now been carried out using the MIRD formalism. There is still a lack of necessary biokinetic data from measurements in humans. More time series obtained by nuclear medicine imaging techniques such as whole-body planar gamma-camera imaging, SPECT or PET are highly desirable for this purpose. In 2008, a new addendum to ICRP Publication 53 was published under the name of ICRP Publication 106 containing biokinetic data and absorbed dose information to organs and tissues of patients of various ages for radiopharmaceuticals in common use. That report also covers a number of generic models and realistic maximum models covering other large groups of substances (e.g. "123I-brain receptor substances"). Together with ICRP Publication 80, most radiopharmaceuticals in clinical use at the time of publication were covered except the radioiodine labeled compounds for which the ICRP dose estimates are still found in Publication 53. There is an increasing use of new radiopharmaceuticals, especially PET-tracers and the TG has recently finished its work with biokinetic and dosimetric data for 18F-FET, 18F-FLT and 18F-choline. The work continues now with new data for 11C-raclopride, 11C-PiB and 123I-ioflupan as well as re-evaluation of published data for 82Rb-chloride, 18F-fluoride and radioiodide. This paper summarises published ICRP-information on dose to patients from radiopharmaceuticals and gives some preliminary data for substances under review.

  20. Enantiopure bifunctional chelators for copper radiopharmaceuticals--does chirality matter in radiotracer design?

    PubMed

    Singh, Ajay N; Dakanali, Marianna; Hao, Guiyang; Ramezani, Saleh; Kumar, Amit; Sun, Xiankai

    2014-06-10

    It is well recognized that carbon chirality plays a critical role in the design of drug molecules. However, very little information is available regarding the effect of stereoisomerism of macrocyclic bifunctional chelators (BFC) on biological behaviors of the corresponding radiopharmaceuticals. To evaluate such effects, three enantiopure stereoisomers of a copper radiopharmaceutical BFC bearing two chiral carbon atoms were synthesized in forms of R,R-, S,S-, and R,S-. Their corresponding peptide conjugates were prepared by coupling with a model peptide sequence, c(RGDyK), which targets the αvβ3 integrin for in vitro and in vivo evaluation of their biological behaviors as compared to the racemic conjugate. Despite the chirality differences, all the conjugates showed a similar in vitro binding affinity profile to the αvβ3 integrin (106, 108, 85 and 100 nM for rac-H2-1, RR-H2-1, SS-H2-1, and RS-H2-1 respectively with all p values > 0.05) and a similar level of in vivo tumor uptake (2.72 ± 0.45, 2.60 ± 0.52, 2.45 ± 0.48 and 2.88 ± 0.59 for rac-(64)Cu-1, RR-(64)Cu-1, SS-(64)Cu-1, and RS-(64)Cu-1 at 1 h p.i. respectively). Furthermore, they demonstrated a nearly identical biodistribution pattern in major organs (e.g. 2.07 ± 0.21, 2.13 ± 0.58, 1.70 ± 0.20 and 1.90 ± 0.46 %ID/g at 24 h p.i. in liver for rac-(64)Cu-1, RR-(64)Cu-1, SS-(64)Cu-1, and RS-(64)Cu-1 respectively; 1.80 ± 0.46, 2.30 ± 1.49, 1.73 ± 0.31 and 2.23 ± 0.71 at 24 h p.i. in kidneys for rac-(64)Cu-1, RR-(64)Cu-1, SS-(64)Cu-1, and RS-(64)Cu-1 respectively). Therefore we conclude that the chirality of BFC plays a negligible role in αvβ3-targeted copper radiopharmaceuticals. However, we believe it is still worthwhile to consider the chirality effects of BFCs on other targeted imaging or therapeutic agents.

  1. Improved dose-volume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters

    NASA Astrophysics Data System (ADS)

    Cheng, Lishui; Hobbs, Robert F.; Segars, Paul W.; Sgouros, George; Frey, Eric C.

    2013-06-01

    In radiopharmaceutical therapy, an understanding of the dose distribution in normal and target tissues is important for optimizing treatment. Three-dimensional (3D) dosimetry takes into account patient anatomy and the nonuniform uptake of radiopharmaceuticals in tissues. Dose-volume histograms (DVHs) provide a useful summary representation of the 3D dose distribution and have been widely used for external beam treatment planning. Reliable 3D dosimetry requires an accurate 3D radioactivity distribution as the input. However, activity distribution estimates from SPECT are corrupted by noise and partial volume effects (PVEs). In this work, we systematically investigated OS-EM based quantitative SPECT (QSPECT) image reconstruction in terms of its effect on DVHs estimates. A modified 3D NURBS-based Cardiac-Torso (NCAT) phantom that incorporated a non-uniform kidney model and clinically realistic organ activities and biokinetics was used. Projections were generated using a Monte Carlo (MC) simulation; noise effects were studied using 50 noise realizations with clinical count levels. Activity images were reconstructed using QSPECT with compensation for attenuation, scatter and collimator-detector response (CDR). Dose rate distributions were estimated by convolution of the activity image with a voxel S kernel. Cumulative DVHs were calculated from the phantom and QSPECT images and compared both qualitatively and quantitatively. We found that noise, PVEs, and ringing artifacts due to CDR compensation all degraded histogram estimates. Low-pass filtering and early termination of the iterative process were needed to reduce the effects of noise and ringing artifacts on DVHs, but resulted in increased degradations due to PVEs. Large objects with few features, such as the liver, had more accurate histogram estimates and required fewer iterations and more smoothing for optimal results. Smaller objects with fine details, such as the kidneys, required more iterations and less

  2. Scaling animal to human biodistribution of the radiopharmaceutical [68Ga]Ga-PSMA-HBED-CC

    NASA Astrophysics Data System (ADS)

    Parra, Pamela Ochoa; Veloza, Stella

    2016-07-01

    The radiotracer called 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) is a novel radiophar-maceutical for the detection of prostate cancer lesions by positron emission tomography (PET) imaging. Setting up a cost-effective manual synthesis of this radiotracer and making its clinical translation in Colombia will require two important elements: the evaluation of the procedure to yield a consistent product, meeting standards of radio-chemical purity and low toxicity and then, the evaluation of the radiation dosimetry. In this paper a protocol to extrapolate the biokinetic model made in normal mice to humans by using the computer software for internal dose assessment OLINDA/EXM® is presented as an accurate and standardized method for the calculation of radiation dosimetry estimates.

  3. The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals.

    PubMed

    Zeng, Dexing; Zeglis, Brian M; Lewis, Jason S; Anderson, Carolyn J

    2013-06-01

    Click chemistry has become a ubiquitous chemical tool with applications in nearly all areas of modern chemistry, including drug discovery, bioconjugation, and nanoscience. Radiochemistry is no exception, as the canonical Cu(I)-catalyzed azide-alkyne cycloaddition, strain-promoted azide-alkyne cycloaddition, inverse electron demand Diels-Alder reaction, and other types of bioorthogonal click ligations have had a significant impact on the synthesis and development of radiopharmaceuticals. This review will focus on recent applications of click chemistry ligations in the preparation of imaging agents for SPECT and PET, including small molecules, peptides, and proteins labeled with radionuclides such as (18)F, (64)Cu, (111)In, and (99m)Tc.

  4. Highway accident involving radiopharmaceuticals near Brookhaven, Mississippi on December 3, 1983

    SciTech Connect

    Mohr, P.B.; Mount, M.E.; Schwartz, M.W.

    1985-04-01

    A rear-end collision occurred between a passenger automobile and a luggage trailer carrying 84 packages, 76 of which contained radiopharmaceuticals, on US Highway 84 near Brookhaven, Mississippi on the afternoon of December 3, 1983. The purpose of this report is to document the mechanical circumstances of the accident, confirm the nature and quantity of radioactive materials involved, and assess the nature of the physical environment to which the packages were exposed and the response of the packages. The report consists of three major sections. The first deals wth the nature and circumstances of the accident and findings of fact. The second gives an accounting and description of the materials involved and the consequences of their exposure. The third gives an assessment and analysis of the mechanisms of damage and the conclusions which may be drawn from the investigation. 4 refs., 24 figs., 4 tabs.

  5. Click-to-Chelate: development of technetium and rhenium-tricarbonyl labeled radiopharmaceuticals.

    PubMed

    Kluba, Christiane A; Mindt, Thomas L

    2013-03-12

    The Click-to-Chelate approach is a highly efficient strategy for the radiolabeling of molecules of medicinal interest with technetium and rhenium-tricarbonyl cores. Reaction of azide-functionalized molecules with alkyne prochelators by the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC; click reaction) enables the simultaneous synthesis and conjugation of tridentate chelating systems for the stable complexation of the radiometals. In many cases, the functionalization of (bio)molecules with the ligand system and radiolabeling can be achieved by convenient one-pot procedures. Since its first report in 2006, Click-to-Chelate has been applied to the development of numerous novel radiotracers with promising potential for translation into the clinic. This review summarizes the use of the Click-to-Chelate approach in radiopharmaceutical sciences and provides a perspective for future applications.

  6. Evaluation of alternative rapid thin layer chromatography systems for quality control of technetium-99m radiopharmaceuticals.

    PubMed

    Mang'era, Kennedy; Wong, Derek; Douglas, David; Franz, Kellie; Biru, Taddese

    2014-04-01

    Whatman 3MM™ and Tec-Control™ systems were evaluated as ITLC-SG alternatives for 99mTc-radiopharmaceuticals. They compare well in accuracy and reproducibility, and are faster and more convenient than ITLC-SG. Tec-Control™ radiochemical purity values for 99mTc-sestamibi were more conservative than ITLC-SG. Full solvent migration was not reproduced for 99mTc-tetrofosmin in Tec-Control™, and for this Whatman 3MM™ is preferred. Developing times were 10-15 min, 7-9 min and ~1min for ITLC-SG, Whatman 3MM™ and Tec-Control™, respectively. Overall, Tec-Control™ strips are preferred due to speed and ease of use.

  7. Cage-like bifunctional chelators, copper-64 radiopharmaceuticals and PET imaging using the same

    DOEpatents

    Conti, Peter S.; Cai, Hancheng; Li, Zibo; Liu, Shuanglong

    2016-08-02

    Disclosed is a class of versatile Sarcophagine based bifunctional chelators (BFCs) containing a hexa-aza cage for labeling with metals having either imaging, therapeutic or contrast applications radiolabeling and one or more linkers (A) and (B). The compounds have the general formula ##STR00001## where A is a functional group selected from group consisting of an amine, a carboxylic acid, an ester, a carbonyl, a thiol, an azide and an alkene, and B is a functional group selected from the group consisting of hydrogen, an amine, a carboxylic acid, and ester, a carbonyl, a thiol, an azide and an alkene. Also disclosed are conjugate of the BFC and a targeting moiety, which may be a peptide or antibody. Also disclosed are metal complexes of the BFC/targeting moiety conjugates that are useful as radiopharmaceuticals, imaging agents or contrast agents.

  8. Receptor-specific positron emission tomography radiopharmaceuticals: /sup 75/Br-labeled butyrophenone neuroleptics

    SciTech Connect

    Moerlein, S.M.; Stoecklin, G.; Weinhard, K.; Pawlik, G.; Heiss, W.D.

    1985-11-01

    Cerebral dopaminergic D/sub 2/ receptors are involved in several common disease states, such as schizophrenia, Parkinson's disease, and Huntington's chorea. The use of radiolabeled D/sub 2/ receptor-binding ligands with positron emission tomography (PET) to noninvasively quantitate D/sub 2/ receptor densities thus has potential application in medicine. Butyrophenone neuroleptics have a high in vitro and in vivo binding affinity for cerebral D/sub 2/ receptors, and due to the useful chemical and nuclear decay properties of /sup 74/Br (76% ..beta../sup +/, half-life = 1.6 h), the authors have evaluated radiobrominated bromospiperone (BSP), brombenperidol (BBP), and bromperidol (BP) as radiopharmaceuticals for use with PET.

  9. Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals.

    PubMed

    Paterson, Brett M; Donnelly, Paul S

    2011-05-01

    The molecules known as bis(thiosemicarbazones) derived from 1,2-diones can act as tetradentate ligands for Cu(II), forming stable, neutral complexes. As a family, these complexes possess fascinating biological activity. This critical review presents an historical perspective of their progression from potential chemotherapeutics through to more recent applications in nuclear medicine. Methods of synthesis are presented followed by studies focusing on their potential application as anti-cancer agents and more recent investigations into their potential as therapeutics for Alzheimer's disease. The Cu(II) complexes are of sufficient stability to be used to coordinate copper radioisotopes for application in diagnostic and therapeutic radiopharmaceuticals. Detailed understanding of the coordination chemistry has allowed careful manipulation of the metal based properties to engineer specific biological activities. Perhaps the most promising complex radiolabelled with copper radioisotopes to date is Cu(II)(atsm), which has progressed to clinical trials in humans (162 references).

  10. Development of specific radiopharmaceuticals for infection imaging by targeting infectious micro-organisms.

    PubMed

    Ferro-Flores, Guillermina; Ocampo-Garcia, Blanca E; Melendez-Alafort, Laura

    2012-01-01

    Infectious diseases remain a major health problem and cause of death worldwide. A variety of radiopharmaceuticals are used for the imaging of infections and inflammation in the practice of nuclear medicine. Long-term clinical use has shown that the majority of radiolabeled probes cannot distinguish between inflammation and infection. Gallium-67-citrate binds to bacteria, but also to proteins accumulating at both sterile inflammation and bacterial infection sites. Other agents are used to interact with receptors or domains on circulating and infiltrating leukocytes or to label them directly. However, these probes cannot distinguish between infection and inflammation because they are not specific to infectious micro-organisms. This review examines the recent developments and applications of radiolabeled specific agents, such as antiviral drugs, antifungal, antibiotics and antimicrobial peptides, to visualize infectious foci by targeting viruses, fungi or bacteria.

  11. Design Features Of Microfluidic Reactor For [18F]FDG Radiopharmaceutical Synthesis

    NASA Astrophysics Data System (ADS)

    Oh, J. H.; Lee, B. N.; Nam, K. R.; Attla, G. A.; Lee, K. C.; Cjai, J. S.

    2011-06-01

    Microfluidic reactor exhibits advantages for radiopharmaceutical synthesis. Microfluidic chips can reduce the time for radiosynthesis using tiny quantities of chemical compounds. It also has a good heat transfer, performance and provides an integrated system including synthesis, separation, and purification. These advantages make FDG production. So we have designed a microreactor chip which included the whole chemical processing; water evaporation, solvent exchange, radiofluorination and so on. It was designed by using a commercial 3D CAD modeling program CATIA V5, heat transfer performance was analyzed by ANSYS, and CFX was used for analyzing fluid performance. This paper described the design of FDG synthesis system on a microchip, the relevant locations of its parts, both heat and fluid performance efficiency analysis.

  12. Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals.

    PubMed

    Paterson, Brett M; Donnelly, Paul S

    2011-05-01

    The molecules known as bis(thiosemicarbazones) derived from 1,2-diones can act as tetradentate ligands for Cu(II), forming stable, neutral complexes. As a family, these complexes possess fascinating biological activity. This critical review presents an historical perspective of their progression from potential chemotherapeutics through to more recent applications in nuclear medicine. Methods of synthesis are presented followed by studies focusing on their potential application as anti-cancer agents and more recent investigations into their potential as therapeutics for Alzheimer's disease. The Cu(II) complexes are of sufficient stability to be used to coordinate copper radioisotopes for application in diagnostic and therapeutic radiopharmaceuticals. Detailed understanding of the coordination chemistry has allowed careful manipulation of the metal based properties to engineer specific biological activities. Perhaps the most promising complex radiolabelled with copper radioisotopes to date is Cu(II)(atsm), which has progressed to clinical trials in humans (162 references). PMID:21409228

  13. Differential renal function in unilateral renal injury: possible effects of radiopharmaceutical choice. [Rats

    SciTech Connect

    Taylor, A. Jr.; Lallone, R.

    1985-01-01

    An abnormal filtration fraction or a significant divergence between a kidney's ability to extract Tc-99m dimercaptosuccinic acid (DMSA) and other function parameters, such as the glomerular filtration rate (GFR) or the effective renal plasma flow (ERPF, could lead to different estimates of relative or absolute renal function, depending on the radiopharmaceutical administered. To evaluate this possible divergence, the authors measured the relative GFR (I-125 iothalamate), ERPF (I-131 hippurate), and Tc-99m DMSA accumulation in adult male Sprague-Dawley rats with unilateral ureteral obstruction or unilateral ischemia at various times after renal injury. The relative ERPF of the obstructed kidney was significantly greater than the relative GFR at all time periods studied; significant but less dramatic differences were noted comparing DMSA with GFR in obstruction and DMSA and ERPF with GRF in ischemia.

  14. Complexation study on no-carrier-added astatine with insulin: a candidate radiopharmaceutical.

    PubMed

    Lahiri, Susanta; Roy, Kamalika; Sen, Souvik

    2008-12-01

    No-carrier-added astatine radionuclides produced in the (7)Li-irradiated lead matrix were separated from bulk lead nitrate target by complexing At with insulin, followed by dialysis. The method offers simultaneous separation of At from lead as well as its complexation with insulin. The At-insulin complex might be a potential radiopharmaceutical in the treatment of hepatocellular carcinoma. The stability of At-insulin complex was checked by dialysis against deionized water and Ringer lactate (RL) solution. It has been found that the half-life of At-insulin complex is about approximately 12h, when dialyzed against deionized water and is only 6h, when dialyzed against RL solution having the same composition as blood serum. The 6h half-life of this Insulin-At complex is perfect for killing cancer cells from external cell surfaces as the half-life of internalization of insulin molecule inside the cell is 7-12h.

  15. In vivo nanoparticle-mediated radiopharmaceutical-excited fluorescence molecular imaging

    PubMed Central

    Hu, Zhenhua; Qu, Yawei; Wang, Kun; Zhang, Xiaojun; Zha, Jiali; Song, Tianming; Bao, Chengpeng; Liu, Haixiao; Wang, Zhongliang; Wang, Jing; Liu, Zhongyu; Liu, Haifeng; Tian, Jie

    2015-01-01

    Cerenkov luminescence imaging utilizes visible photons emitted from radiopharmaceuticals to achieve in vivo optical molecular-derived signals. Since Cerenkov radiation is weak, non-optimum for tissue penetration and continuous regardless of biological interactions, it is challenging to detect this signal with a diagnostic dose. Therefore, it is challenging to achieve useful activated optical imaging for the acquisition of direct molecular information. Here we introduce a novel imaging strategy, which converts γ and Cerenkov radiation from radioisotopes into fluorescence through europium oxide nanoparticles. After a series of imaging studies, we demonstrate that this approach provides strong optical signals with high signal-to-background ratios, an ideal tissue penetration spectrum and activatable imaging ability. In comparison with present imaging techniques, it detects tumour lesions with low radioactive tracer uptake or small tumour lesions more effectively. We believe it will facilitate the development of nuclear and optical molecular imaging for new, highly sensitive imaging applications. PMID:26123615

  16. Overview and perspectives on automation strategies in (68)Ga radiopharmaceutical preparations.

    PubMed

    Boschi, Stefano; Malizia, Claudio; Lodi, Filippo

    2013-01-01

    The renaissance of (68)Ga radiopharmacy has led to great advances in automation technology. The availability of a highly efficient, reliable, long-lived (68)Ge/(68)Ga generator system along with a well-established coordination chemistry based on bifunctional chelating agents have been the bases of this development in (68)Ga radiopharmacy. Syntheses of (68)Ga peptides were originally performed by manual or semiautomated systems, but increasing clinical demand, radioprotection, and regulatory issues have driven extensive automation of their production process. Several automated systems, based on different post-processing of the (68)Ga generator eluate, on different engineering, and on fixed tubing or disposable cassette approaches, have been developed and are discussed in this chapter. Since automatic systems for preparation of radiopharmaceuticals should comply with qualification and validation protocols established by regulations such as current Good Manufacturing Practices (cGMP) and local regulations, some regulatory issues and the more relevant qualification protocols are also discussed.

  17. Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with (177)Lu and Conjugated to Peptides.

    PubMed

    Ferro-Flores, Guillermina; Ocampo-García, Blanca E; Santos-Cuevas, Clara L; de María Ramírez, Flor; Azorín-Vega, Erika P; Meléndez-Alafort, Laura

    2015-01-01

    Gold nanoparticles (AuNPs) have been proposed for a variety of medical applications such as localized heat sources for cancer treatment and drug delivery systems. The conjugation of peptides to AuNPs produces stable multimeric systems with target-specific molecular recognition. Lutetium- 177 ((177)Lu) has been successfully used in peptide radionuclide therapy. Recently, (177)Lu-AuNPs conjugated to different peptides have been proposed as a new class of theranostic radiopharmaceuticals. These radioconjugates may function simultaneously as molecular imaging agents, radiotherapy systems and thermal-ablation systems. This article covers advancements in the design, synthesis, physicochemical characterization, molecular recognition assessment and preclinical therapeutic efficacy of gold nanoparticles radiolabeled with (177)Lu and conjugated to RGD (-Arg-Gly-Asp-), Lys(3)-Bombesin and Tat(49-57) peptides.

  18. Effect of altered thyroid status on the transport of hepatobiliary radiopharmaceuticals

    SciTech Connect

    Pahuja, D.N.; Noronha, O.P.

    1985-10-01

    The effect of induced hypothyroidism (by feeding an antithyroid drug-propylthiouracil) on the transport and clearance of the routinely used hepatobiliary radiopharmaceuticals--radioiodinated iodine- T (131I) rose bengal and technetium-99m-N-(4-n-butylphenylcarbamoylmethyl) iminodiacetate, was studied in the rats. Hypothyroidism was associated with depressed growth and retarded clearance of these radiotracers from the in vivo system. Treatment of the hypothyroid rats with thyroxine (2-5 micrograms/100 g b.w. day) for 6 wk, restored these parameters towards normal values. These data suggest that delayed clearance of these hepatobiliary tracers could be related to reduced metabolic rate accompanied with the hypotonia and hypomotility of intestine normally observed in the hypothyroid state.

  19. The role of coordination chemistry in the development of copper and rhenium radiopharmaceuticals.

    PubMed

    Donnelly, Paul S

    2011-02-01

    There are several isotopes of copper and rhenium that are of interest in the development of new molecular imaging or radiotherapeutic agents. This perspective article highlights the role of coordination chemistry in the design of copper and rhenium radiopharmaceuticals engineered to selectively target tissue of interest such as cancer cells or pathological features associated with Alzheimer's disease. The coordination chemistry of copper bis(thiosemicarbazone) derivatives and copper macrocyclic complexes is discussed in terms of their potential application as targeted positron emission tomography tracers for non-invasive diagnostic imaging. A range of rhenium complexes with different ligands with rhenium in different oxidation states are introduced and their potential to be translated to new radiotherapeutic agents discussed.

  20. Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with (177)Lu and Conjugated to Peptides.

    PubMed

    Ferro-Flores, Guillermina; Ocampo-García, Blanca E; Santos-Cuevas, Clara L; de María Ramírez, Flor; Azorín-Vega, Erika P; Meléndez-Alafort, Laura

    2015-01-01

    Gold nanoparticles (AuNPs) have been proposed for a variety of medical applications such as localized heat sources for cancer treatment and drug delivery systems. The conjugation of peptides to AuNPs produces stable multimeric systems with target-specific molecular recognition. Lutetium- 177 ((177)Lu) has been successfully used in peptide radionuclide therapy. Recently, (177)Lu-AuNPs conjugated to different peptides have been proposed as a new class of theranostic radiopharmaceuticals. These radioconjugates may function simultaneously as molecular imaging agents, radiotherapy systems and thermal-ablation systems. This article covers advancements in the design, synthesis, physicochemical characterization, molecular recognition assessment and preclinical therapeutic efficacy of gold nanoparticles radiolabeled with (177)Lu and conjugated to RGD (-Arg-Gly-Asp-), Lys(3)-Bombesin and Tat(49-57) peptides. PMID:25771363

  1. Implementation and validation of collapsed cone superposition for radiopharmaceutical dosimetry of photon emitters

    NASA Astrophysics Data System (ADS)

    Sanchez-Garcia, Manuel; Gardin, Isabelle; Lebtahi, Rachida; Dieudonné, Arnaud

    2015-10-01

    Two collapsed cone (CC) superposition algorithms have been implemented for radiopharmaceutical dosimetry of photon emitters. The straight CC (SCC) superposition method uses a water energy deposition kernel (EDKw) for each electron, positron and photon components, while the primary and scatter CC (PSCC) superposition method uses different EDKw for primary and once-scattered photons. PSCC was implemented only for photons originating from the nucleus, precluding its application to positron emitters. EDKw are linearly scaled by radiological distance, taking into account tissue density heterogeneities. The implementation was tested on 100, 300 and 600 keV mono-energetic photons and 18F, 99mTc, 131I and 177Lu. The kernels were generated using the Monte Carlo codes MCNP and EGSnrc. The validation was performed on 6 phantoms representing interfaces between soft-tissues, lung and bone. The figures of merit were γ (3%, 3 mm) and γ (5%, 5 mm) criterions corresponding to the computation comparison on 80 absorbed doses (AD) points per phantom between Monte Carlo simulations and CC algorithms. PSCC gave better results than SCC for the lowest photon energy (100 keV). For the 3 isotopes computed with PSCC, the percentage of AD points satisfying the γ (5%, 5 mm) criterion was always over 99%. A still good but worse result was found with SCC, since at least 97% of AD-values verified the γ (5%, 5 mm) criterion, except a value of 57% for the 99mTc with the lung/bone interface. The CC superposition method for radiopharmaceutical dosimetry is a good alternative to Monte Carlo simulations while reducing computation complexity.

  2. Implementation and validation of collapsed cone superposition for radiopharmaceutical dosimetry of photon emitters.

    PubMed

    Sanchez-Garcia, Manuel; Gardin, Isabelle; Lebtahi, Rachida; Dieudonné, Arnaud

    2015-10-21

    Two collapsed cone (CC) superposition algorithms have been implemented for radiopharmaceutical dosimetry of photon emitters. The straight CC (SCC) superposition method uses a water energy deposition kernel (EDKw) for each electron, positron and photon components, while the primary and scatter CC (PSCC) superposition method uses different EDKw for primary and once-scattered photons. PSCC was implemented only for photons originating from the nucleus, precluding its application to positron emitters. EDKw are linearly scaled by radiological distance, taking into account tissue density heterogeneities. The implementation was tested on 100, 300 and 600 keV mono-energetic photons and (18)F, (99m)Tc, (131)I and (177)Lu. The kernels were generated using the Monte Carlo codes MCNP and EGSnrc. The validation was performed on 6 phantoms representing interfaces between soft-tissues, lung and bone. The figures of merit were γ (3%, 3 mm) and γ (5%, 5 mm) criterions corresponding to the computation comparison on 80 absorbed doses (AD) points per phantom between Monte Carlo simulations and CC algorithms. PSCC gave better results than SCC for the lowest photon energy (100 keV). For the 3 isotopes computed with PSCC, the percentage of AD points satisfying the γ (5%, 5 mm) criterion was always over 99%. A still good but worse result was found with SCC, since at least 97% of AD-values verified the γ (5%, 5 mm) criterion, except a value of 57% for the (99m)Tc with the lung/bone interface. The CC superposition method for radiopharmaceutical dosimetry is a good alternative to Monte Carlo simulations while reducing computation complexity. PMID:26406778

  3. [A new radiopharmaceutical for bone imaging: experimental study of 99mTc-HEDTMP].

    PubMed

    Hu, Shu; Deng, Houfu; Jiang, Shubin; Luo, Shunzhong; Lei, Yong

    2010-08-01

    The purpose of this study is to prepare 99mTc-HEDTMP [N-(2-hydroxyethyl) ethlenediamine-1,1,2-tri (methylene phosphonic acid), a new kind of bone seeking compound; to investigate its biological properties; and to explore the possibility of using it as a potential radiopharmaceutical for skeleton scintigraphy. HEDTMP was labeled with 99mTc by "pretinning" method, the radiochemical purity was 97.00% +/- 0.34%. 99mTc-HEDTMP was found to be stable in 5 hours in vitro with the radiochemical purity over 95% even after being diluted by physiological saline with the factor of dilution 100. The plane bone scanning of rabbits showed that 99mTc-HEDTMP was principally absorbed by skeletal system. Skull, spine and legs could be observed clearly, and were more legible than the images of 99mTc-MDP. Mice trial also indicated the high bone seeking of 99mTc-HEDTMP. The skeletal uptake was 11.92% ID/g, 13.19% ID/g, 10.14% ID/g, 10.04% ID/g, 7.71% ID/g separately at 30 minutes, 1 hour, 3 hours, 6 hours and 24 hours after the injection. Kidney seemed to be the major excretory organ. The clearance of blood was quick and the retaining amount in non-target organs was small. These results indicate that 99mTc-HEDTMP can be prepared easily, and its biological properties can be compared favorably with the commonly used bone imaging agent, and it is well worth further researching as a promising potential radiopharmaceutical in nuclide diagnosis for skeleton diseases. PMID:20842850

  4. (177) Lu-5-Fluorouracil a potential theranostic radiopharmaceutical: radiosynthesis, quality control, biodistribution, and scintigraphy.

    PubMed

    Rasheed, Rashid; Tariq, Saleha; Naqvi, Syed Ali Raza; Gillani, Syed Jawad Hussain; Rizvi, Faheem Askari; Sajid, Muhammad; Rasheed, Shahid

    2016-08-01

    The aim of this study is to develop (177) Lu-5-Flourouracil as a potential cancer therapeutic radiopharmaceutical. 5-Flourouracil (5-FU) is widely accepted as an anticancer drug of broad spectrum fame. The labeling of 5-FU was carried out at different set of experimental conditions using high specific activity of (177) LuCl3 . The optimum conditions for maximum radiochemical yield was set: 5-FU (5 mg), (177) LuCl3 (185 MBq), diethylenetriaminepentaacetic acid (10 µg), reaction volume (2 mL), pH (5.5), temperature (80°C), and reaction time (20 min). The radiochemical labeling was assessed with Whatman No. 2 paper, instant thin layer chromatographic, and radio-HPLC, which revealed >94% labeling results with sufficient stability up to 6 h. Serum stability study also showed (177) Lu-5-FU promising stability. Biodistribution study in normal rats and rabbits showed liver, stomach, kidney, and heart as area of increased tracer accumulation just after injection, which decreased to 1.4%, 0.4%, 0.2%, and 0.39% ID/g, respectively, after 72 h. Glomerular filtration rate and cytotoxicity study results of (177) Lu-5-FU showed it had no adverse effect on renal function and nontoxic to blood cells. The promising characteristics of (177) Lu-5-FU, that is, clever elimination from kidney and nontoxic nature toward blood cells make it the radiopharmaceutical for further testing in patients for therapeutic purposes. PMID:27444959

  5. Implementation and validation of collapsed cone superposition for radiopharmaceutical dosimetry of photon emitters.

    PubMed

    Sanchez-Garcia, Manuel; Gardin, Isabelle; Lebtahi, Rachida; Dieudonné, Arnaud

    2015-10-21

    Two collapsed cone (CC) superposition algorithms have been implemented for radiopharmaceutical dosimetry of photon emitters. The straight CC (SCC) superposition method uses a water energy deposition kernel (EDKw) for each electron, positron and photon components, while the primary and scatter CC (PSCC) superposition method uses different EDKw for primary and once-scattered photons. PSCC was implemented only for photons originating from the nucleus, precluding its application to positron emitters. EDKw are linearly scaled by radiological distance, taking into account tissue density heterogeneities. The implementation was tested on 100, 300 and 600 keV mono-energetic photons and (18)F, (99m)Tc, (131)I and (177)Lu. The kernels were generated using the Monte Carlo codes MCNP and EGSnrc. The validation was performed on 6 phantoms representing interfaces between soft-tissues, lung and bone. The figures of merit were γ (3%, 3 mm) and γ (5%, 5 mm) criterions corresponding to the computation comparison on 80 absorbed doses (AD) points per phantom between Monte Carlo simulations and CC algorithms. PSCC gave better results than SCC for the lowest photon energy (100 keV). For the 3 isotopes computed with PSCC, the percentage of AD points satisfying the γ (5%, 5 mm) criterion was always over 99%. A still good but worse result was found with SCC, since at least 97% of AD-values verified the γ (5%, 5 mm) criterion, except a value of 57% for the (99m)Tc with the lung/bone interface. The CC superposition method for radiopharmaceutical dosimetry is a good alternative to Monte Carlo simulations while reducing computation complexity.

  6. MCNP™ Version 5

    NASA Astrophysics Data System (ADS)

    Forster, R. Arthur; Cox, Lawrence J.; Barrett, Richard F.; Booth, Thomas E.; Briesmeister, Judith F.; Brown, Forrest B.; Bull, Jeffrey S.; Geisler, Gregg C.; Goorley, John T.; Mosteller, Russell D.; Post, Susan E.; Prael, Richard E.; Selcow, Elizabeth C.; Sood, Avneet

    2004-01-01

    The Monte Carlo transport workhorse, MCNP [Los Alamos National Laboratory report LA-13709-M, 2000], is undergoing a massive renovation at Los Alamos National Laboratory (LANL) in support of the Eolus Project of the Advanced Simulation and Computing (ASCI) Program. MCNP Version 5 (V5) (expected to be released to RSICC in Fall 2002) will consist of a major restructuring from FORTRAN-77 (with extensions) to ANSI-standard FORTRAN-90 [American National Standard for Programming Language - Fortran-Extended, ANSI X3. 198-1992, 1992] with support for all of the features available in the present release (MCNP-4C2/4C3). To most users, the look-and-feel of MCNP will not change much except for the improvements (improved graphics, easier installation, better online documentation). For example, even with the major format change, full support for incremental patching will still be provided. In addition to the language and style updates, MCNP V5 will have various new user features. These include improved photon physics, neutral particle radiography, enhancements and additions to variance reduction methods, new source options, improved parallelism support (PVM, MPI, OpenMP), and new nuclear and atomic data libraries. MCNP is a trademark of the Regents of the University of California, Los Alamos National Laboratory.

  7. Femaxi-6 Version 1

    SciTech Connect

    Suzuki, Motoe

    2006-10-01

    FEMAXI-6(Updated) predicts the thermal and mechanical behaviour of a light water reactor fuel rod during normal and transient (not accident) conditions. It can analyse the integral behaviour of a whole fuel rod throughout its life as well as the localised behaviour of a small part of fuel rod. Temperature distribution, radial and axial deformations, fission gas release, and inner gas pressure are calculated as a function of irradiation time and axial position. Stresses and strains in the pellet and cladding are calculated and PCMI analysis is performed. Also, thermal conductivity degradation of pellet and cladding waterside oxidation are modeled. Its analytical capabilities also cover the boiling transient anticipated in BWR. RODBURN calculates the power generation density profile in the radial and axial directions and fast neutron flux, and concentrations of fission product isotopes and fissile materials of a single rod irradiated in PWR, BWR and Halden BWR. RODBURN gives an output file which can be read by FEMAXI-6. NEA-1080/10: This version differs from the previous one in the following: a few formulae were updated in the manual and the source code. the input options were expanded in the following points: Thermal expansion modelling; Pellet swelling option; Pellet plasticity model; Cladding surface heat transfer model All changes are marked in red in the reference report.

  8. Femaxi-6 Version 1

    2006-10-01

    FEMAXI-6(Updated) predicts the thermal and mechanical behaviour of a light water reactor fuel rod during normal and transient (not accident) conditions. It can analyse the integral behaviour of a whole fuel rod throughout its life as well as the localised behaviour of a small part of fuel rod. Temperature distribution, radial and axial deformations, fission gas release, and inner gas pressure are calculated as a function of irradiation time and axial position. Stresses and strainsmore » in the pellet and cladding are calculated and PCMI analysis is performed. Also, thermal conductivity degradation of pellet and cladding waterside oxidation are modeled. Its analytical capabilities also cover the boiling transient anticipated in BWR. RODBURN calculates the power generation density profile in the radial and axial directions and fast neutron flux, and concentrations of fission product isotopes and fissile materials of a single rod irradiated in PWR, BWR and Halden BWR. RODBURN gives an output file which can be read by FEMAXI-6. NEA-1080/10: This version differs from the previous one in the following: a few formulae were updated in the manual and the source code. the input options were expanded in the following points: Thermal expansion modelling; Pellet swelling option; Pellet plasticity model; Cladding surface heat transfer model All changes are marked in red in the reference report.« less

  9. A Treatment Planning Method for Sequentially Combining Radiopharmaceutical Therapy and External Radiation Therapy;External beam therapy; Radiopharmaceutical therapy; Three-dimensional dosimetry; Treatment planning

    SciTech Connect

    Hobbs, Robert F.; McNutt, Todd; Baechler, Sebastien; He Bin; Esaias, Caroline E.; Frey, Eric C.; Loeb, David M.; Wahl, Richard L.; Shokek, Ori; Sgouros, George

    2011-07-15

    Purpose: Effective cancer treatment generally requires combination therapy. The combination of external beam therapy (XRT) with radiopharmaceutical therapy (RPT) requires accurate three-dimensional dose calculations to avoid toxicity and evaluate efficacy. We have developed and tested a treatment planning method, using the patient-specific three-dimensional dosimetry package 3D-RD, for sequentially combined RPT/XRT therapy designed to limit toxicity to organs at risk. Methods and Materials: The biologic effective dose (BED) was used to translate voxelized RPT absorbed dose (D{sub RPT}) values into a normalized total dose (or equivalent 2-Gy-fraction XRT absorbed dose), NTD{sub RPT} map. The BED was calculated numerically using an algorithmic approach, which enabled a more accurate calculation of BED and NTD{sub RPT}. A treatment plan from the combined Samarium-153 and external beam was designed that would deliver a tumoricidal dose while delivering no more than 50 Gy of NTD{sub sum} to the spinal cord of a patient with a paraspinal tumor. Results: The average voxel NTD{sub RPT} to tumor from RPT was 22.6 Gy (range, 1-85 Gy); the maximum spinal cord voxel NTD{sub RPT} from RPT was 6.8 Gy. The combined therapy NTD{sub sum} to tumor was 71.5 Gy (range, 40-135 Gy) for a maximum voxel spinal cord NTD{sub sum} equal to the maximum tolerated dose of 50 Gy. Conclusions: A method that enables real-time treatment planning of combined RPT-XRT has been developed. By implementing a more generalized conversion between the dose values from the two modalities and an activity-based treatment of partial volume effects, the reliability of combination therapy treatment planning has been expanded.

  10. How is Version 6 different than earlier versions?

    Atmospheric Science Data Center

    2015-10-28

    ... integrated a priori CO profile. Second, the diagnostic 'Water Vapor Climatology Content' has been deleted. This diagnostic was ... More details can be found in the: MOPITT (Measurements of Pollution in the Troposphere) Version 6 Product User's Guide: ...

  11. Estrogen receptor binding radiopharmaceuticals: II. Tissue distribution of 17. cap alpha. -methylestradiol in normal and tumor-bearing rats

    SciTech Connect

    Feenstra, A.; Vaalburg, W.; Nolten, G.M.J.; Reiffers, S.; Talma, A.G.; Wiegman, T.; van der Molen, H.D.; Woldring, M.G.

    1983-06-01

    Tritiated 17..cap alpha..-methylestradiol was synthesized to investigate the potential of the carbon-11-labeled analog as an estrogen-receptor-binding radiopharmaceutical. In vitro, 17..cap alpha..-methylestradiol is bound with high affinity to the cytoplasmic estrogen receptor from rabbit uterus (K/sub d/ = 1.96 x 10/sup -10/M), and it sediments as an 8S hormone-receptor complex in sucrose gradients. The compound shows specific uptake in the uterus of the adult rat, within 1 h after injection. In female rats bearing DMBA-induced tumors, specific uterine and tumor uptakes were observed, although at 30 min the tumor uptake was only 23 to 30% of the uptake in the uterus. Tritiated 17..cap alpha..-methylestradiol with a specific activity of 6 Ci/mmole showed a similar tissue distribution. Our results indicate that a 17 ..cap alpha..-methylestradiol is promising as an estrogen-receptor-binding radiopharmaceutical.

  12. A new approach to the analysis of radiopharmaceuticals. Final technical report, January 15, 1987--June 30, 1991

    SciTech Connect

    Jones, A.G.; Davison, A.; Costello, C.E.

    1998-03-01

    The objective of this research was to investigate analytical techniques that could be used in the study of both the basic chemistry and the radiopharmaceutical chemistry of {sup 99m}Tc. First funded in 1981, the work focused initially upon the use of high performance liquid chromatography (HPLC) and various forms of mass spectrometry for the identification of technetium species. This funding allowed the authors to combine HPLC and mass spectrometry to identify radiopharmaceuticals which, although in clinical use, had not previously been characterized. Other techniques that have been examined include resonance Raman spectroscopy and, more significantly, {sup 99}Tc nuclear magnetic resonance spectroscopy (NMR), with the latter not only being used in purely chemical experiments but also in biologic studies. In 1985 a grant to the Department of Chemistry at MIT from DOE allowed the purchase of an X-ray diffractometer and access to this instrument has enabled them to broaden the analytical base with routine structural determinations.

  13. brulilo, Version 0.x

    2015-04-16

    effectively remove some of the stiffness and allow for efficient explicit integration techniques to be used. The original intent of brulilo was to implement these stiffness-alleviating techniques with explicit integrators and compare the performance to traditional implicit integrations of the full stiff system. This is still underway, as the code is very much in an alpha-release state. Furthermore, explicit integrators are often much easier to parallelize than their implicit counterparts. brulilo will implement parallelization of these techniques, leveraging both the Python implementation of MPI, mpi4py, as well as highly parallelized versions targeted at GPUs with PyOpenCL and/or PyCUDA.« less

  14. brulilo, Version 0.x

    SciTech Connect

    Malone, Chris

    2015-04-16

    remove some of the stiffness and allow for efficient explicit integration techniques to be used. The original intent of brulilo was to implement these stiffness-alleviating techniques with explicit integrators and compare the performance to traditional implicit integrations of the full stiff system. This is still underway, as the code is very much in an alpha-release state. Furthermore, explicit integrators are often much easier to parallelize than their implicit counterparts. brulilo will implement parallelization of these techniques, leveraging both the Python implementation of MPI, mpi4py, as well as highly parallelized versions targeted at GPUs with PyOpenCL and/or PyCUDA.

  15. What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?

    PubMed

    Slavikova, K; Montravers, F; Treglia, G; Kunikowska, J; Kaliska, L; Vereb, M; Talbot, J N; Balogova, S

    2013-06-01

    Among thyroid malignancies, medullary thyroid carcinoma (MTC) has some very specific features. Production and secretion of large amounts of peptides occur in malignant transformed C cells with few exceptions, leading to high serum levels of calcitonin (Ctn) and carcinoembryonic antigen (CEA), that act after thyroidectomy as tumour markers warning for the presence of persistent or metastatic MTC. The availability of those serum biomarkers with an excellent sensitivity challenges medical imaging to localise the recurrent cancer tissue, since surgery is a major therapeutic option. The aims of this article are (i) to review literature evidence about the efficacy and tolerance of radiopharmaceuticals for 3 targets of PET/CT imaging (glucose metabolism, bioamines metabolism and somatostatin receptors) and also bone scintigraphy which is recommended in the Guidelines of European Society for Medical Oncology (ESMO; (ii) to compare the availability and the costs in relation with those radiopharmaceuticals, (iii) and to discuss a possible sequence of those examinations, in order to optimise spending and to minimise the overall radiation dose. In this context of recurrent MTC suspected on rising tumour markers levels after thyroidectomy, this survey of literature confirms that FDOPA is the best radiopharmaceutical for PET/CT with significant diagnostic performance if Ctn>150 pg/mL; an early image acquisition starting during the first 15 min is advised. In negative cases, FDG should be the next PET radiopharmaceutical, in particular if Ctn and CEA levels are rapidly rising, and PET with a somatostatin analogue labelled with gallium-68 when neither FDOPA nor FDG PET are conclusive. Bone scintigraphy could complement FDG-PET/CT if FDOPA is not available.

  16. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.

    PubMed

    Vallabhajosula, Shankar

    2007-11-01

    Molecular imaging is the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in a living system. At present, positron emission tomography/computed tomography (PET/CT) is one the most rapidly growing areas of medical imaging, with many applications in the clinical management of patients with cancer. Although [(18)F]fluorodeoxyglucose (FDG)-PET/CT imaging provides high specificity and sensitivity in several kinds of cancer and has many applications, it is important to recognize that FDG is not a "specific" radiotracer for imaging malignant disease. Highly "tumor-specific" and "tumor cell signal-specific" PET radiopharmaceuticals are essential to meet the growing demand of radioisotope-based molecular imaging technology. In the last 15 years, many alternative PET tracers have been proposed and evaluated in preclinical and clinical studies to characterize the tumor biology more appropriately. The potential clinical utility of several (18)F-labeled radiotracers (eg, fluoride, FDOPA, FLT, FMISO, FES, and FCH) is being reviewed by several investigators in this issue. An overview of design and development of (18)F-labeled PET radiopharmaceuticals, radiochemistry, and mechanism(s) of tumor cell uptake and localization of radiotracers are presented here. The approval of clinical indications for FDG-PET in the year 2000 by the Food and Drug Administration, based on a review of literature, was a major breakthrough to the rapid incorporation of PET into nuclear medicine practice, particularly in oncology. Approval of a radiopharmaceutical typically involves submission of a "New Drug Application" by a manufacturer or a company clearly documenting 2 major aspects of the drug: (1) manufacturing of PET drug using current good manufacturing practices and (2) the safety and effectiveness of a drug with specific indications. The potential routine clinical utility of (18)F-labeled PET radiopharmaceuticals depends also on

  17. Enigma Version 12

    NASA Technical Reports Server (NTRS)

    Shores, David; Goza, Sharon P.; McKeegan, Cheyenne; Easley, Rick; Way, Janet; Everett, Shonn; Guerra, Mark; Kraesig, Ray; Leu, William

    2013-01-01

    Enigma Version 12 software combines model building, animation, and engineering visualization into one concise software package. Enigma employs a versatile user interface to allow average users access to even the most complex pieces of the application. Using Enigma eliminates the need to buy and learn several software packages to create an engineering visualization. Models can be created and/or modified within Enigma down to the polygon level. Textures and materials can be applied for additional realism. Within Enigma, these models can be combined to create systems of models that have a hierarchical relationship to one another, such as a robotic arm. Then these systems can be animated within the program or controlled by an external application programming interface (API). In addition, Enigma provides the ability to use plug-ins. Plugins allow the user to create custom code for a specific application and access the Enigma model and system data, but still use the Enigma drawing functionality. CAD files can be imported into Enigma and combined to create systems of computer graphics models that can be manipulated with constraints. An API is available so that an engineer can write a simulation and drive the computer graphics models with no knowledge of computer graphics. An animation editor allows an engineer to set up sequences of animations generated by simulations or by conceptual trajectories in order to record these to highquality media for presentation. Enigma Version 12 Lyndon B. Johnson Space Center, Houston, Texas 28 NASA Tech Briefs, September 2013 Planetary Protection Bioburden Analysis Program NASA's Jet Propulsion Laboratory, Pasadena, California This program is a Microsoft Access program that performed statistical analysis of the colony counts from assays performed on the Mars Science Laboratory (MSL) spacecraft to determine the bioburden density, 3-sigma biodensity, and the total bioburdens required for the MSL prelaunch reports. It also contains numerous

  18. Production and Clinical Applications of Radiopharmaceuticals and Medical Radioisotopes in Iran.

    PubMed

    Jalilian, Amir Reza; Beiki, Davood; Hassanzadeh-Rad, Arman; Eftekhari, Arash; Geramifar, Parham; Eftekhari, Mohammad

    2016-07-01

    During past 3 decades, nuclear medicine has flourished as vibrant and independent medical specialty in Iran. Since that time, more than 200 nuclear physicians have been trained and now practicing in nearly 158 centers throughout the country. In the same period, Tc-99m generators and variety of cold kits for conventional nuclear medicine were locally produced for the first time. Local production has continued to mature in robust manner while fulfilling international standards. To meet the ever-growing demand at the national level and with international achievements in mind, work for production of other Tc-99m-based peptides such as ubiquicidin, bombesin, octreotide, and more recently a kit formulation for Tc-99m TRODAT-1 for clinical use was introduced. Other than the Tehran Research Reactor, the oldest facility active in production of medical radioisotopes, there is one commercial and three hospital-based cyclotrons currently operational in the country. I-131 has been one of the oldest radioisotope produced in Iran and traditionally used for treatment of thyrotoxicosis and differentiated thyroid carcinoma. Since 2009, (131)I-meta-iodobenzylguanidine has been locally available for diagnostic applications. Gallium-67 citrate, thallium-201 thallous chloride, and Indium-111 in the form of DTPA and Oxine are among the early cyclotron-produced tracers available in Iran for about 2 decades. Rb-81/Kr-81m generator has been available for pulmonary ventilation studies since 1996. Experimental production of PET radiopharmaceuticals began in 1998. This work has culminated with development and optimization of the high-scale production line of (18)F-FDG shortly after installation of PET/CT scanner in 2012. In the field of therapy, other than the use of old timers such as I-131 and different forms of P-32, there has been quite a significant advancement in production and application of therapeutic radiopharmaceuticals in recent years. Application of (131)I

  19. Cardiac blood-pool scintigraphy in rats and hamsters: comparison of five radiopharmaceuticals and three pinhole collimator apertures

    SciTech Connect

    Pieri, P.; Fischman, A.J.; Ahmad, M.; Moore, R.H.; Callahan, R.J.; Strauss, H.W. )

    1991-05-01

    Preclinical evaluation of cardiac drugs may require evaluation of cardiac function in intact animals. To optimize the quality of radionuclide measurements of ventricular function in small animals, a comparison was made of gated blood-pool scans recorded with five blood-pool radiopharmaceuticals ({sup 99}mTc-labeled human polyclonal IgG, {sup 99}mTc-human serum albumin labeled by two methods, and red blood cells radiolabeled with {sup 99}mTc via in vivo and in vitro methods) in rats and three pinhole apertures in hamsters. The quality of the radiopharmaceuticals was evaluated by comparing count density ratios (LV/BACKGROUND and LV/LIVER) and ejection fractions recorded with each agent. The edge definition of the left ventricle and count rate performance of the 1-, 2-, and 3-mm apertures was evaluated in hamsters. In general, the images obtained with the radiolabeled cells were superior to those obtained with the labeled proteins and no significant differences between the protein preparations were detected. Left ventricular ejection fractions calculated with all five radiopharmaceuticals were not significantly different. The best quality images were obtained with the 1-mm pinhole collimator. Ejection fraction and acquisition time were inversely related to aperture size. A good compromise between resolution and sensitivity was obtained with the 2-mm pinhole collimator.

  20. Development of more efficacious [Tc]-99m organ imaging agents for use in nuclear medicine by analytical characterization of radiopharmaceuticals

    SciTech Connect

    Heineman, W.R.

    1993-05-03

    This research program is detailed at development of more efficacious technetium-99m radiopharmaceuticals for use as imaging agents in diagnostic nuclear medicine. We seek to isolate and develop distinct site imaging agents to provide diagnostic information concerning a given pathological condition. Analytical techniques are being developed to enable complete analysis of radiopharmaceutical preparations so that individual complexes can be characterized with respect to imaging efficacy and to enable a radiopharmaceutical to be monitored after injection into a test animal to determine the species that actually accumulates in an organ to provide the image. Administration of the isolated, single most effective imaging complex, rather than a mixture of technetium-containing complexes, wi-11 minimize radiation exposure to the patient and maximize diagnostic information available to the clinician. This report specifically describes the development of capillary electrophoresis (CE) for characterizating diphosphonate skeletal imaging agents. Advances in the development of electrochemical and fiber optic sensors for Tc and Re imaging agents are described. These sensors will ultimately be capable of monitoring a specific chemical state of an imaging agent in vivo after injection into a test animal by implantation in the organ of interest.

  1. New rhenium complexes with ciprofloxacin as useful models for understanding the properties of [99mTc]-ciprofloxacin radiopharmaceutical.

    PubMed

    Lecina, Joan; Cortés, Pilar; Llagostera, Montserrat; Piera, Carlos; Suades, Joan

    2014-07-01

    Rhenium complexes with the antibiotic ciprofloxacin have been prepared to be studied as models of technetium radiopharmaceuticals. With this aim, the new rhenium complexes 1 {[ReO(Cpf)2]Cl}, 2 {[ReO(CpfH)2]Cl3} and 3 {fac-[Re(CO)3(H2O)(Cpf)]} with ciprofloxacin (CpfH=ciprofloxacin; Cpf=conjugated base of ciprofloxacin) have been synthesised and characterised by elemental analyses, IR, NMR ((1)H, (19)F and (13)C CP-MAS) spectroscopy, as well as MS measurements. All spectroscopic data are consistent with the coordination of ciprofloxacin in all these complexes through the carbonyl and the carboxylate oxygen atoms with the formation of a six member chelate ring. The study of a Tc-ciprofloxacin solution by ESI-MS reveals the presence of [TcO(Cpf)2](+) cations, which agrees with the hypothesis that complexes 1 and 2 can be seen as model rhenium complexes of this radiopharmaceutical. Antimicrobial and DNA gyrase inhibition studies performed with complexes 2 and 3 have shown a very similar behaviour between complex 2 and the free antibiotic, whereas complex 3 exhibit a lower antimicrobial activity. Based on a joint analysis of the data reported in the literature and the chemical and biological results obtained in this study, a tentative proposal to explain some aspects of the behaviour of Tc-ciprofloxacin radiopharmaceutical has been made.

  2. Checkpointing in speculative versioning caches

    DOEpatents

    Eichenberger, Alexandre E; Gara, Alan; Gschwind, Michael K; Ohmacht, Martin

    2013-08-27

    Mechanisms for generating checkpoints in a speculative versioning cache of a data processing system are provided. The mechanisms execute code within the data processing system, wherein the code accesses cache lines in the speculative versioning cache. The mechanisms further determine whether a first condition occurs indicating a need to generate a checkpoint in the speculative versioning cache. The checkpoint is a speculative cache line which is made non-speculative in response to a second condition occurring that requires a roll-back of changes to a cache line corresponding to the speculative cache line. The mechanisms also generate the checkpoint in the speculative versioning cache in response to a determination that the first condition has occurred.

  3. Experimental study of radiopharmaceuticals based on technetium-99m labeled derivative of glucose for tumor diagnosis

    NASA Astrophysics Data System (ADS)

    Zeltchan, R.; Medvedeva, A.; Sinilkin, I.; Bragina, O.; Chernov, V.; Stasyuk, E.; Rogov, A.; Il'ina, E.; Larionova, L.; Skuridin, V.; Dergilev, A.

    2016-06-01

    Purpose: to study the potential utility of 1-thio-D-glucose labeled with 99mTc for cancer imaging in laboratory animals. Materials and method: the study was carried out in cell cultures of normal CHO (Chinese hamster ovary cells CHO) and malignant tissues MCF-7 (human breast adenocarcinoma MCF-7). To evaluate the uptake of 99mTc-1-thio-D-glucose in normal and tumor tissue cells, 25 MBq of 1-thio-D-glucose labeled with 99mTc was added to the vials with 3 million cells and incubated for 30 minutes at room temperature. After centrifugation of the vials with cells, the supernatant was removed. Radioactivity in vials with normal and tumor cells was then measured. In addition, the study included 40 mice of C57B 1/6j lines with tumor lesion of the right femur. For neoplastic lesions, Lewis lung carcinoma model was used. Following anesthesia, mice were injected intravenously with 25MBq of 99mTc-1-thio-D-glucose. Planar scintigraphy was performed 15 minutes later in a matrix of 512x512 pixels for 5 minutes. Results: when measuring the radioactivity of normal and malignant cells after incubation with 99mTc-1-thio-D- glucose, it was found that the radioactivity of malignant cells was higher than that of normal cells. The mean values of radioactivity levels in normal and malignant cells were 0.3±0.15MBq and 1.07±0.6MBq, respectively. All examined animals had increased accumulation of 99mTc-1-thio- D-glucose at the tumor site. The accumulation of 99mTc-1-thio-D-glucose in the tumor was on average twice as high as compared to the symmetric region. Conclusion: The present study demonstrated that 99mTc-1-thio-D-glucose is a prospective radiopharmaceutical for cancer visualization. In addition, high accumulation of 99mTc-1-thio-D-glucose in the culture of cancer cells and in tumor tissue of animals demonstrates tumor tropism of the radiopharmaceutical.

  4. Study of potential utility of new radiopharmaceuticals based on technetium-99m labeled derivative of glucose

    NASA Astrophysics Data System (ADS)

    Zeltchan, R.; Medvedeva, A.; Sinilkin, I.; Chernov, V.; Stasyuk, E.; Rogov, A.; Il'ina, E.; Larionova, L.; Skuridin, V.

    2016-08-01

    Purpose: to study the potential utility of 1-thio-D-glucose labeled with 99mTc for cancer imaging in laboratory animals. Materials and method: the study was carried out in cell cultures of normal CHO (Chinese hamster ovary cells CHO) and malignant tissues MCF-7 (human breast adenocarcinoma MCF-7). To evaluate the uptake of 99mTc-1-thio-D-glucose in normal and tumor tissue cells, 25 MBq of 1-thio-D-glucose labeled with 99mTc was added to the vials with 3 million cells and incubated for 30 min at room temperature. After centrifugation of the vials with cells, the supernatant was removed. The radioactivity in vials with normal and tumor cells was then measured. In addition, the study included 40 mice of C57B1/6j lines with tumor lesion of the right femur. For neoplastic lesions, Lewis lung carcinoma model was used. Following anesthesia, mice were injected intravenously with 25 MBq of 99mTc-1-thio-D-glucose. Planar scintigraphy was performed 15 minutes later in a matrix of 512x512 pixels for 5 min. Results: when measuring the radioactivity of normal and malignant cells after incubation with 99mTc-1-thio-D-glucose, it was found that the radioactivity of malignant cells was higher than that of normal cells. The mean values of radioactivity levels in normal and malignant cells were 0.3 ± 0.15 MBq and 1.07 ± 0.6 MBq, respectively. All examined animals had increased accumulation of 99mTc-1-thio-D-glucose at the tumor site. The accumulation of 99mTc-1-thio-D-glucose in the tumor was on average twice as high as compared to the symmetric region. Conclusion: The present study demonstrated that 99mTc-1-thio-D-glucose is a prospective radiopharmaceutical for cancer visualization. In addition, high accumulation of 99mTc-1-thio-D-glucose in the culture of cancer cells and in tumor tissue of animals demonstrates tumor tropism of the radiopharmaceutical.

  5. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature.

    PubMed

    Velikyan, I; Maecke, H; Langstrom, B

    2008-02-01

    A straightforward labeling using generator produced positron emitting (68)Ga, which provides high quality images, may result in kit type production of PET radiopharmaceuticals and make PET examinations possible also at centers lacking accelerators. The introduction of macrocyclic bifunctional chelators that would provide fast (68)Ga-complexation at room temperature would simplify even further tracer preparation and open wide possibilities for (68)Ga-labeling of fragile and potent macromolecules. Gallium-68 has the potential to facilitate development of clinically practical PET and to promote PET technique for individualized medicine. The macrocyclic chelator, 1,4,7-triazacyclononanetriacetic acid (NOTA), and its derivative coupled to an eight amino acid residue peptide (NODAGA-TATE, [NODAGA (0), Tyr(3)]Octreotate) were labeled with (68)Ge/(68)Ga-generator produced positron emitting (68)Ga. Formation kinetics of (68)Ga-NOTA was studied as a function of pH and formation kinetics of (68)Ga-NODAGA-TATE was studied as a function of the bioconjugate concentration. The nearly quantitative radioactivity incorporation (RAI>95%) for (68)Ga-NOTA was achieved within less than 10 min at room temperature and pH 3.5. The concentrations of NODAGA-TATE required for RAI of >90% and >95% were, respectively, 2-5 and 10 microM. In both cases the purification of the (68)Ga-labeled products was not necessary since the radiochemical purity was >95% and the preparation buffer, 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) is suitable for human use. In order to confirm the identity of the products, complexes comprising (nat)Ga were synthesized and analyzed by mass spectrometry. The complex was found to be stable in the reaction mixture, phosphate buffer, and human plasma during 4.5 h incubation. Free and peptide conjugated NOTA formed stable complexes with (68)Ga at room temperature within 10 min. This might be of special interest for the labeling of fragile and potent

  6. Packet Daemon Version 12(SOPHIA)

    SciTech Connect

    2012-08-09

    Packet Daemon Version 12 is the code exclusively used by the ‘packetd’ executable. It provides packet data to the OglNet Version 12 visualization tool. It reads PCAP data and sends an abstraction of the packets to the ‘oglnet’ executable for display. ‘packetd’will run as a service on a Linux host thereby capturing data continuously and make that data available for ‘oglnet’ whenever it connects to the service.

  7. MISR File Naming and Versioning Conventions

    Atmospheric Science Data Center

    2013-06-26

    ... The MISR Product LocalGranuleID (filename) contains a string supplying version information. Prior to Software version V2.1.3, this version string consisted of two numerals in the last subfield of the LocalGranuleId. ...

  8. Direct solid-phase synthesis of octreotide conjugates: precursors for use as tumor-targeted radiopharmaceuticals.

    PubMed

    Hsieh, H P; Wu, Y T; Chen, S T; Wang, K T

    1999-09-01

    Somatostatin analogues, such as octreotide, are useful for the visualization and treatment of tumors. Unfortunately, these compounds were produced synthetically using complex and inefficient procedures. Here, we describe a novel approach for the synthesis of octreotide and its analogues using p-carboxybenzaldehyde to anchor Fmoc-threoninol to solid phase resins. The reaction of the two hydroxyl groups of Fmoc-threoninol with p-carboxybenzaldehyde was catalyzed with p-toluenesulphonic acid in chloroform using a Dean-Stark apparatus to form Fmoc-threoninol p-carboxybenzacetal in 91% yield. The Fmoc-threoninol p-carboxybenzacetal acted as an Fmoc-amino acid derivative and the carboxyl group of Fmoc-threoninol p-carboxybenzacetal was coupled to an amine-resin via a DCC coupling reaction. The synthesis of protected octreotide and its conjugates were carried out in their entirety using a conventional Fmoc protocol and an autosynthesizer. The acetal was stable during the stepwise elongation of each Fmoc-amino acid as shown by the averaged coupling yield (> 95%). Octreotide (74 to 78% yield) and five conjugated derivatives were synthesized with high yields using this procedure, including three radiotherapy octreotides (62 to 75% yield) and two cellular markers (72 to 76% yield). This novel approach provides a strategy for the rapid and efficient large-scale synthesis of octreotide and its analogues for radiopharmaceutical and tagged conjugates.

  9. Kinetic sensitivity of a receptor-binding radiopharmaceutical: Technetium-99m galactosyl-neoglycoalbumin

    SciTech Connect

    Vera, D.R.; Woodle, E.S.; Stadalnik, R.C. )

    1989-09-01

    Kinetic sensitivity is the ability of a physiochemical parameter to alter the time-activity curve of a radiotracer. The kinetic sensitivity of liver and blood time-activity data resulting from a single bolus injection of ({sup 99m}Tc)galactosyl-neoglycoalbumin (( Tc)NGA) into healthy pigs was examined. Three parameters, hepatic plasma flow scaled as flow per plasma volume, ligand-receptor affinity, and total receptor concentration, were tested using (Tc)NGA injections of various molar doses and affinities. Simultaneous measurements of plasma volume (iodine-125 human serum albumin dilution), and hepatic plasma flow (indocyanine green extraction) were performed during 12 (Tc)NGA studies. Paired data sets demonstrated differences (P(chi v2) less than 0.01) in liver and blood time-activity curves in response to changes in each of the tested parameters. We conclude that the (Tc)NGA radiopharmacokinetic system is therefore sensitive to hepatic plasma flow, ligand-receptor affinity, and receptor concentration. In vivo demonstration of kinetic sensitivity permits delineation of the physiologic parameters that determine the biodistribution of a radiopharmaceutical. This delineation is a prerequisite to a valid analytic assessment of receptor biochemistry via kinetic modeling.

  10. Development of dopamine receptor radiopharmaceuticals for the study of neurological and psychiatric disorders

    SciTech Connect

    Dr. Jogeshwar Mukherjee

    2009-01-02

    Our goals in this grant application are directed towards the development of radiotracers that may allow the study of the high-affinity state (functional state) of the dopamine receptors. There have been numerous reports on the presence of two inter-convertible states of these (G-protein coupled) receptors in vitro. However, there is no report that establishes the presence of these separate affinity states in vivo. We have made efforts in this direction in order to provide such direct in vivo evidence about the presence of the high affinity state. This understanding of the functional state of the receptors is of critical significance in our overall diagnosis and treatment of diseases that implicate the G-protein coupled receptors. Four specific aims have been listed in the grant application: (1). Design and syntheses of agonists (2). Radiosyntheses of agonists (3). In vitro pharmacology of agonists (4). In vivo distribution and pharmacology of labeled derivatives. We have accomplished the syntheses and radiosyntheses of three agonist radiotracers labeled with carbon-11. In vitro and in vivo pharmacological experiments have been accomplished in rats and preliminary PET studies in non-human primates have been carried out. Various accomplishments during the funded years, briefly outlined in this document, have been disseminated by several publications in various journals and presentations in national and international meetings (Society of Nuclear Medicine, Society for Neuroscience and International Symposium on Radiopharmaceutical Chemistry).

  11. Monte Carlo determination of emerging energy spectra for diagnostically realistic radiopharmaceutical distributions

    NASA Astrophysics Data System (ADS)

    Zubal, L. G.; Harrell, C. R.; Esser, P. D.

    1990-12-01

    In order to realistically define the internal organs of a representative human, 150 transverse CT scans of an (average) male patient were acquired from head to mid-thigh on the GE 9800 Quick scanner. The reconstructed transverse slices were read into a microVAX 3500 and members of the medical staff outlined 42 separate internal organs contained in the transverse slice. This digitized human phantom serves as an input to a Monte Carlo program which models photoelectric absorption and scatter processes of gamma-rays in matter. The organs can be "filled" with variable amounts of radiopharmaceuticals and the simulation computes the emerging energy spectra for a given source distribution and detector position. The simulation follows gamma-ray histories out to a maximum of 32 scatter events. Scatter spectra are histogrammed into energy distributions of gamma-rays which have undergone a specific number of scatter events before emerging from the phantom. A sum of all these scatter spectra yields the simulated total spectra. Simulated total spectra of diagnostically relevant human distributions are compared to spectra acquired from nuclear medicine clinical patients.

  12. Complexation study on no-carrier-added astatine with insulin: a candidate radiopharmaceutical.

    PubMed

    Lahiri, Susanta; Roy, Kamalika; Sen, Souvik

    2008-12-01

    No-carrier-added astatine radionuclides produced in the (7)Li-irradiated lead matrix were separated from bulk lead nitrate target by complexing At with insulin, followed by dialysis. The method offers simultaneous separation of At from lead as well as its complexation with insulin. The At-insulin complex might be a potential radiopharmaceutical in the treatment of hepatocellular carcinoma. The stability of At-insulin complex was checked by dialysis against deionized water and Ringer lactate (RL) solution. It has been found that the half-life of At-insulin complex is about approximately 12h, when dialyzed against deionized water and is only 6h, when dialyzed against RL solution having the same composition as blood serum. The 6h half-life of this Insulin-At complex is perfect for killing cancer cells from external cell surfaces as the half-life of internalization of insulin molecule inside the cell is 7-12h. PMID:18674921

  13. A Concise Radiosynthesis of the Tau Radiopharmaceutical, [18F]T807

    PubMed Central

    Shoup, Timothy M.; Yokell, Daniel L.; Rice, Peter A.; Jackson, Raul N.; Livni, Eli; Johnson, Keith A.; Brady, Thomas J.; Vasdev, Neil

    2014-01-01

    Fluorine-18 labelled 7-(6-fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole ([18F]T807) is a potent and selective agent for imaging paired helical filaments of tau (PHF-tau) and is among the most promising PET radiopharmaceuticals for this target in early clinical trials. The present study reports a simplified one-step method for the synthesis of [18F]T807 that is broadly applicable for routine clinical production using a GE Tracerlab™ FXFN radiosynthesis module. Key facets of our optimized radiosynthesis include development and use of a more soluble protected precursor, tert-butyl 7-(6-nitropyridin-3-yl)-5H-pyrido[4,3-b]indole-5-carboxylate, as well as new HPLC separation conditions that enable a facile one-step synthesis. During the nucleophilic fluorinating reaction with potassium cryptand [18F]fluoride (K[18F]/K222) in DMSO at 130 °C over 10 min, the precursor is concurrently deprotected. Formulated [18F]T807 was prepared in an uncorrected radiochemical yield of 14 ± 3%, with a specific activity of 216 ± 60 GBq/μmol (5837 ± 1621 mCi/μmol) at the end of synthesis (60 min; n = 3) and validated for human use. This methodology offers the advantage of faster synthesis in fewer steps, with simpler automation which we anticipate will facilitate widespread clinical use of [18F]T807. PMID:24339014

  14. Diagnostic and therapeutic potential of new radiopharmaceutical agents in medullary thyroid carcinoma

    SciTech Connect

    Troncone, L.; Rufini, V.; De Rosa, G.; Testa, A.

    1989-01-01

    Recently developed radiopharmaceuticals have been proposed for imaging medullary thyroid carcinoma (MTC) with some having therapeutic potential. This study compares the imaging results obtained with radioiodinated meta-iodo-benzylguanidine (MIBG), {sup 99m}Tc (V) DMSA, and {sup 131}I F(ab')2 anti-carcinoembryonic antigen (anti-CEA) in a group of MTC patients. In 23 patients {sup 131}I MIBG imaging showed a high specificity (no false-positive results) but a less satisfactory sensitivity (50%). In 12 patients {sup 99m}Tc (V) DMSA revealed a better sensitivity (77%) but a lower specificity (three false-positive results). Positive results were obtained in two of three patients studied with {sup 131}I F(ab')2 anti-CEA. These data suggest that the highly sensitive {sup 99m}Tc (V) DMSA should be considered as a first choice procedure followed by the highly specific radioiodinated MIBG to confirm the initial results. Since radioiodinated MIBG imaging may have therapeutic usefulness, {sup 131}I MIBG was evaluated in an integrated treatment protocol in four cases of proven MTC. The preliminary results obtained were encouraging.

  15. Uncertainty and sensitivity analysis of biokinetic models for radiopharmaceuticals used in nuclear medicine.

    PubMed

    Li, W B; Hoeschen, C

    2010-01-01

    Mathematical models for kinetics of radiopharmaceuticals in humans were developed and are used to estimate the radiation absorbed dose for patients in nuclear medicine by the International Commission on Radiological Protection and the Medical Internal Radiation Dose (MIRD) Committee. However, due to the fact that the residence times used were derived from different subjects, partially even with different ethnic backgrounds, a large variation in the model parameters propagates to a high uncertainty of the dose estimation. In this work, a method was developed for analysing the uncertainty and sensitivity of biokinetic models that are used to calculate the residence times. The biokinetic model of (18)F-FDG (FDG) developed by the MIRD Committee was analysed by this developed method. The sources of uncertainty of all model parameters were evaluated based on the experiments. The Latin hypercube sampling technique was used to sample the parameters for model input. Kinetic modelling of FDG in humans was performed. Sensitivity of model parameters was indicated by combining the model input and output, using regression and partial correlation analysis. The transfer rate parameter of plasma to other tissue fast is the parameter with the greatest influence on the residence time of plasma. Optimisation of biokinetic data acquisition in the clinical practice by exploitation of the sensitivity of model parameters obtained in this study is discussed. PMID:20185457

  16. Production of 64Cu and 67Cu radiopharmaceuticals using zinc target irradiated with accelerator neutrons

    NASA Astrophysics Data System (ADS)

    Kawabata, Masako; Hashimoto, Kazuyuki; Saeki, Hideya; Sato, Nozomi; Motoishi, Shoji; Nagai, Yasuki

    2014-09-01

    Copper radioisotopes have gained a lot of attention in radiopharmaceuticals owing to their unique decay characteristics. The longest half-life β emitter, 67Cu, is thought to be suitable for targeted radio-immunotherapy. Adequate production of 67Cu to meet the demands of clinical studies has not been fully established. Another attractive copper isotope, 64Cu has possible applications as a diagnostic imaging tracer combined with a therapeutic effect. This work proposes a production method using accelerator neutrons in which two copper radioisotopes can be produced: 1) 68Zn(n,x)67Cu and 2) 64Zn(n,p)64Cu using ~14 MeV neutrons generated by natC(d, n) reaction, both from natural or enriched zinc oxides. The generated 64,67Cu were separated from the target zinc oxide using a chelating and an anion exchange columns and were labelled with two widely studied chelators where the labelling efficiency was found to be acceptably good. The major advantage of this method is that a significant amount of 64,67Cu with a very few impurity radionuclides are produced which also makes the separation procedure simple. Provided an accelerator supplying an Ed = ~ 40 MeV, a wide application of 64,67Cu based drugs in nuclear medicine is feasible in the near future. We will present the characteristics of this production method using accelerator neutrons including the chemical separation processes.

  17. Biokinetics and dosimetry of target-specific radiopharmaceuticals for molecular imaging and therapy

    NASA Astrophysics Data System (ADS)

    Ferro-Flores, Guillermina; Torres-García, Eugenio; Gonz&Ález-v&Ázquez, Armando; de Murphy, Consuelo Arteaga

    Molecular imaging techniques directly or indirectly monitor and record the spatiotemporal distribution of molecular or cellular processes for biochemical, biologic, diagnostic or therapeutic applications. 99mTc-HYNIC-TOC has shown high stability both in vitro and in vivo and rapid detection of somatostatin receptor-positive tumors. Therapies using radiolabeled anti-CD20 have demonstrated their efficacy in patients with B-cell non-Hodgkin's lymphoma (NHL). The aim of this study was to establish biokinetic models for 99mTc-HYNIC-TOC and 188Re-anti-CD20 and to evaluate their dosimetry as target-specific radiopharmaceuticals. The OLINDA/EXM code was used to calculate patient-specific internal radiation dose estimates. 99mTc-HYNIC-TOC images showed an average tumor/blood ratio of 4.3±0.7 in receptor-positive tumors with an average effective dose of 4.4 mSv. Dosimetric studies indicated that after administration of 5.8 to 7.5 GBq of 188Re-anti-CD20 the absorbed dose to total body would be 0.75 Gy which corresponds to the recommended dose for NHL therapies.

  18. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence

    PubMed Central

    Lopci, Egesta; Grassi, Ilaria; Chiti, Arturo; Nanni, Cristina; Cicoria, Gianfranco; Toschi, Luca; Fonti, Cristina; Lodi, Filippo; Mattioli, Sandro; Fanti, Stefano

    2014-01-01

    Hypoxia is a pathological condition arising in living tissues when oxygen supply does not adequately cover the cellular metabolic demand. Detection of this phenomenon in tumors is of the utmost clinical relevance because tumor aggressiveness, metastatic spread, failure to achieve tumor control, increased rate of recurrence, and ultimate poor outcome are all associated with hypoxia. Consequently, in recent decades there has been increasing interest in developing methods for measurement of oxygen levels in tumors. Among the image-based modalities for hypoxia assessment, positron emission tomography (PET) is one of the most extensively investigated based on the various advantages it offers, i.e., broad range of radiopharmaceuticals, good intrinsic resolution, three-dimensional tumor representation, possibility of semiquantification/quantification of the amount of hypoxic tumor burden, overall patient friendliness, and ease of repetition. Compared with the other non-invasive techniques, the biggest advantage of PET imaging is that it offers the highest specificity for detection of hypoxic tissue. Starting with the 2-nitroimidazole family of compounds in the early 1980s, a great number of PET tracers have been developed for the identification of hypoxia in living tissue and solid tumors. This paper provides an overview of the principal PET tracers applied in cancer imaging of hypoxia and discusses in detail their advantages and pitfalls. PMID:24982822

  19. GENII Version 2 Users’ Guide

    SciTech Connect

    Napier, Bruce A.

    2004-03-08

    The GENII Version 2 computer code was developed for the Environmental Protection Agency (EPA) at Pacific Northwest National Laboratory (PNNL) to incorporate the internal dosimetry models recommended by the International Commission on Radiological Protection (ICRP) and the radiological risk estimating procedures of Federal Guidance Report 13 into updated versions of existing environmental pathway analysis models. The resulting environmental dosimetry computer codes are compiled in the GENII Environmental Dosimetry System. The GENII system was developed to provide a state-of-the-art, technically peer-reviewed, documented set of programs for calculating radiation dose and risk from radionuclides released to the environment. The codes were designed with the flexibility to accommodate input parameters for a wide variety of generic sites. Operation of a new version of the codes, GENII Version 2, is described in this report. Two versions of the GENII Version 2 code system are available, a full-featured version and a version specifically designed for demonstrating compliance with the dose limits specified in 40 CFR 61.93(a), the National Emission Standards for Hazardous Air Pollutants (NESHAPS) for radionuclides. The only differences lie in the limitation of the capabilities of the user to change specific parameters in the NESHAPS version. This report describes the data entry, accomplished via interactive, menu-driven user interfaces. Default exposure and consumption parameters are provided for both the average (population) and maximum individual; however, these may be modified by the user. Source term information may be entered as radionuclide release quantities for transport scenarios, or as basic radionuclide concentrations in environmental media (air, water, soil). For input of basic or derived concentrations, decay of parent radionuclides and ingrowth of radioactive decay products prior to the start of the exposure scenario may be considered. A single code run can

  20. [Software version and medical device software supervision].

    PubMed

    Peng, Liang; Liu, Xiaoyan

    2015-01-01

    The importance of software version in the medical device software supervision does not cause enough attention at present. First of all, the effect of software version in the medical device software supervision is discussed, and then the necessity of software version in the medical device software supervision is analyzed based on the discussion of the misunderstanding of software version. Finally the concrete suggestions on software version naming rules, software version supervision for the software in medical devices, and software version supervision scheme are proposed.

  1. Synthesis and radioiodination of ergoline derivatives: potential in-vivo dopamine receptor site mapping radiopharmaceuticals

    SciTech Connect

    Mikhail, E.A.

    1985-01-01

    The need of a dopamine-receptor based radiopharmaceutical for brain imaging is apparent. If such an agent is made available to physicians, it could provide means for detecting brain tumors, and diagnose such mental disorders as parkinsonism, schizophrenia and psychosis. Currently, such agents are yet to be discovered. Procedures were developed to synthesize and label four ergoline derivatives which could potentially exhibit affinity to dopamine receptors. Labelling with /sup 125/I was accomplished in some cases by displacing a suitably positioned leaving group with /sup 125/I-anion, while in other cases iodine exchange procedures were utilized. Formulations of the labeled derivatives were achieved via the formation of their water soluble tartarate salts. Biodistribution studies in mature Sprague-Dawley rats showed that of the four radioactive compounds injected, the highest uptake in the brain and adrenals was achieved with 8 ..beta..-(I-125)-iodomethyl-6-propylergoline. In addition, high target/nontarget ratios were obtained with the above mentioned compound. On the other hand, the least brain and adrenal uptake as well as the lowest target/nontarget ratios were exhibited by 8 ..beta..-(I-125)-(p-iodobenzenesulfonyl)-lysergol presumably due to its in-vivo instability. A comparative biodistribution study for ergoline derivatives and N-isopropyl-(I-123)-p-iodoamphetamine was conducted. The biodistribution studies showed that the brain to blood ratio for the ergoline derivative 8 ..beta..-(I-125)-iodomethyl-6-propylergoline to be very close to that for /sup 125/I-IMP at 1 minute after dose administration. However after 15 minutes the brain/blood ratio of compound XLVI was half the value of /sup 123/I-IMP. Different mechanisms of brain influx and efflux are known to occur with the amphetamine and ergoline derivatives.

  2. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters

    PubMed Central

    Wieder, Hinrich A; Lassmann, Michael; Allen-Auerbach, Martin S; Czernin, Johannes; Herrmann, Ken

    2014-01-01

    Various single or multi-modality therapeutic options are available to treat pain of bone metastasis in patients with prostate cancer. Different radionuclides that emit β-rays such as 153Samarium and 89Strontium and achieve palliation are commercially available. In contrast to β-emitters, 223Radium as a α-emitter has a short path-length. The advantage of the α-emitter is thus a highly localized biological effect that is caused by radiation induced DNA double-strand breaks and subsequent cell killing and/or limited effectiveness of cellular repair mechanisms. Due to the limited range of the α-particles the bone surface to red bone marrow dose ratio is also lower for 223Radium which is expressed in a lower myelotoxicity. The α emitter 223Radium dichloride is the first radiopharmaceutical that significantly prolongs life in castrate resistant prostate cancer patients with wide-spread bone metastatic disease. In a phase III, randomized, double-blind, placebo-controlled study 921 patients with castration-resistant prostate cancer and bone metastases were randomly assigned. The analysis confirmed the 223Radium survival benefit compared to the placebo (median, 14.9 mo vs 11.3 mo; P < 0.001). In addition, the treatment results in pain palliation and thus, improved quality of life and a delay of skeletal related events. At the same time the toxicity profile of 223Radium was favourable. Since May 2013, 223Radium dichloride (Xofigo®) is approved by the US Food and Drug Administration. PMID:25071888

  3. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals.

    PubMed

    Holland, Jason P; Barnard, Peter J; Collison, David; Dilworth, Jonathan R; Edge, Ruth; Green, Jennifer C; McInnes, Eric J L

    2008-01-01

    Detailed chemical, spectroelectrochemical and computational studies have been used to investigate the mechanism of hypoxia selectivity of a range of copper radiopharmaceuticals. A revised mechanism involving a delicate balance between cellular uptake, intracellular reduction, reoxidation, protonation and ligand dissociation is proposed. This mechanism accounts for observed differences in the reported cellular uptake and washout of related copper bis(thiosemicarbazonato) complexes. Three copper and zinc complexes have been characterised by X-ray crystallography and the redox chemistry of a series of copper complexes has been investigated by using electronic absorption and EPR spectroelectrochemistry. Time-dependent density functional theory (TD-DFT) calculations have also been used to probe the electronic structures of intermediate species and assign the electronic absorption spectra. DFT calculations also show that one-electron oxidation is ligand-based, leading to the formation of cationic triplet species. In the absence of protons, metal-centred one-electron reduction gives the reduced anionic copper(I) species, [CuIATSM](-), and for the first time it is shown that molecular oxygen can reoxidise this anion to give the neutral, lipophilic parent complexes, which can wash out of cells. The electrochemistry is pH dependent and in the presence of stronger acids both chemical and electrochemical reduction leads to quantitative and rapid dissociation of copper(I) ions from the mono- or diprotonated complexes, [CuIATSMH] and [Cu(I)ATSMH2]+. In addition, a range of protonated intermediate species have been identified at lower acid concentrations. The one-electron reduction potential, rate of reoxidation of the copper(I) anionic species and ease of protonation are dependent on the structure of the ligand, which also governs their observed behaviour in vivo. PMID:18494010

  4. Basic Program Plan. Condensed Version.

    ERIC Educational Resources Information Center

    Stanford Univ., CA. Stanford Center for Research and Development in Teaching.

    This condensed version of the Basic Program Plan for the Stanford Center for Research and Development in Teaching (SCDRT) outlines the proposed plans of substantive programs over the next several years (beginning December 1, 1972). Information on projected costs and the Center's institutional capabilities for administering, reviewing, and…

  5. MEASUREMENT AND PRECISION, EXPERIMENTAL VERSION.

    ERIC Educational Resources Information Center

    Harvard Univ., Cambridge, MA. Harvard Project Physics.

    THIS DOCUMENT IS AN EXPERIMENTAL VERSION OF A PROGRAMED TEXT ON MEASUREMENT AND PRECISION. PART I CONTAINS 24 FRAMES DEALING WITH PRECISION AND SIGNIFICANT FIGURES ENCOUNTERED IN VARIOUS MATHEMATICAL COMPUTATIONS AND MEASUREMENTS. PART II BEGINS WITH A BRIEF SECTION ON EXPERIMENTAL DATA, COVERING SUCH POINTS AS (1) ESTABLISHING THE ZERO POINT, (2)…

  6. CCAIN, Version 1.0

    2005-05-26

    CCAIN, Version 1.0 Date: 06/15/2005 This software is an instantiation of Common Component Architecture (CCA) framework written in C. The framework is used to compose (create, register, destroy) C, C++, and Fortran components into a running CCA application. Language bindings are provided for F90 and F03 to allow codes in these languages to interface with the framework.

  7. MISR Level 3 Radiance Versioning

    Atmospheric Science Data Center

    2013-04-01

    ... summary of Level 1. This page covers changes to the Level 3 software itself for each product version, but you should also consult the  ... Data Product Specification Rev K  (PDF). Update to work with new format of the input PGE 1 files.   ...

  8. SophiNet Version 12

    SciTech Connect

    2012-08-09

    SophiNet Version 12 is part of the code contained in the application ‘oglnet’ and comprises the portions that make ‘oglnet’ receive and display Sophia data from the Sophia Daemon ‘sophiad’. Specifically this encompasses the channel, host and alert receiving and the treeview HUD widget.

  9. Montage Version 3.0

    NASA Technical Reports Server (NTRS)

    Jacob, Joseph; Katz, Daniel; Prince, Thomas; Berriman, Graham; Good, John; Laity, Anastasia

    2006-01-01

    The final version (3.0) of the Montage software has been released. To recapitulate from previous NASA Tech Briefs articles about Montage: This software generates custom, science-grade mosaics of astronomical images on demand from input files that comply with the Flexible Image Transport System (FITS) standard and contain image data registered on projections that comply with the World Coordinate System (WCS) standards. This software can be executed on single-processor computers, multi-processor computers, and such networks of geographically dispersed computers as the National Science Foundation s TeraGrid or NASA s Information Power Grid. The primary advantage of running Montage in a grid environment is that computations can be done on a remote supercomputer for efficiency. Multiple computers at different sites can be used for different parts of a computation a significant advantage in cases of computations for large mosaics that demand more processor time than is available at any one site. Version 3.0 incorporates several improvements over prior versions. The most significant improvement is that this version is accessible to scientists located anywhere, through operational Web services that provide access to data from several large astronomical surveys and construct mosaics on either local workstations or remote computational grids as needed.

  10. ALSSAT Version 6.0

    NASA Technical Reports Server (NTRS)

    Yeh, Hue-Hsia; Brown, Cheryl; Jeng, Frank

    2012-01-01

    Advanced Life Support Sizing Analysis Tool (ALSSAT) at the time of this reporting has been updated to version 6.0. A previous version was described in Tool for Sizing Analysis of the Advanced Life Support System (MSC- 23506), NASA Tech Briefs, Vol. 29, No. 12 (December 2005), page 43. To recapitulate: ALSSAT is a computer program for sizing and analyzing designs of environmental-control and life-support systems for spacecraft and surface habitats to be involved in exploration of Mars and the Moon. Of particular interest for analysis by ALSSAT are conceptual designs of advanced life-support (ALS) subsystems that utilize physicochemical and biological processes to recycle air and water and process human wastes to reduce the need of resource resupply. ALSSAT is a means of investigating combinations of such subsystems technologies featuring various alternative conceptual designs and thereby assisting in determining which combination is most cost-effective. ALSSAT version 6.0 has been improved over previous versions in several respects, including the following additions: an interface for reading sizing data from an ALS database, computational models of a redundant regenerative CO2 and Moisture Removal Amine Swing Beds (CAMRAS) for CO2 removal, upgrade of the Temperature & Humidity Control's Common Cabin Air Assembly to a detailed sizing model, and upgrade of the Food-management subsystem.

  11. Analysis of radionuclide concentration in air released through the stack of a radiopharmaceutical production facility based on a medical cyclotron

    NASA Astrophysics Data System (ADS)

    Giardina, M.; Tomarchio, E.; Greco, D.

    2015-11-01

    Positron emitting radionuclides are increasingly used in medical diagnostics and the number of radiopharmaceutical production facilities have been estimated to be growing worldwide. During the process of production and/or patient administration of radiopharmaceuticals, an amount of these radionuclides might become airborne and escape into the environment. Therefore, the analysis of radionuclide concentration in the air released to the stack is a very important issue to evaluate the dose to the population living around the plant. To this end, sampling and measurement of radionuclide concentration in air released through the stack of a Nuclear Medicine Center (NMC), provided with a cyclotron for radiopharmaceuticals production, must be routinely carried out with an automatic measurement system. In this work is presented the air monitoring system realized at "San Gaetano" NMC at Bagheria (Italy) besides the analysis of the recorded stack relesead air concentration data. Sampling of air was carried out continuously and gamma-ray spectrometric measurement are made on-line and for a short time by using a shielded Marinelli beaker filled with sampled air and a gamma detector. The use of this system allows to have 1440 values of air concentration per day from 2002, year of the start of operation with the cyclotron. Therefore, the concentration values are very many and an analysis software is needed to determine the dose to the population. A comparison with the results of a simulation code based on a Gaussian Plume air dispersion modelling allow us to confirm the no-radiological significance of the stack effluent releases in terms of dose to population and to evaluate possible improvements in the plant devices to reduce the air concentration at stack.

  12. Preclinical assessment of dopaminergic system in rats by MicroPET using three positron-emitting radiopharmaceuticals

    SciTech Connect

    Lara-Camacho, V. M. Ávila-García, M. C. Ávila-Rodríguez, M. A.

    2014-11-07

    Different diseases associated with dysfunction of dopaminergic system such as Parkinson, Alzheimer, and Schizophrenia are being widely studied with positron emission tomography (PET) which is a noninvasive method useful to assess the stage of these illnesses. In our facility we have recently implemented the production of [{sup 11}C]-DTBZ, [{sup 11}C]-RAC, and [{sup 18}F]-FDOPA, which are among the most common PET radiopharmaceuticals used in neurology applications to get information about the dopamine pathways. In this study two healthy rats were imaged with each of those radiotracers in order to confirm selective striatum uptake as a proof of principle before to release them for human use.

  13. Preclinical assessment of dopaminergic system in rats by MicroPET using three positron-emitting radiopharmaceuticals

    NASA Astrophysics Data System (ADS)

    Lara-Camacho, V. M.; Ávila-García, M. C.; Ávila-Rodríguez, M. A.

    2014-11-01

    Different diseases associated with dysfunction of dopaminergic system such as Parkinson, Alzheimer, and Schizophrenia are being widely studied with positron emission tomography (PET) which is a noninvasive method useful to assess the stage of these illnesses. In our facility we have recently implemented the production of [11C ]-DTBZ, [11C ]-RAC, and [18F ]-FDOPA, which are among the most common PET radiopharmaceuticals used in neurology applications to get information about the dopamine pathways. In this study two healthy rats were imaged with each of those radiotracers in order to confirm selective striatum uptake as a proof of principle before to release them for human use.

  14. MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy.

    PubMed

    Ljungberg, Michael; Celler, Anna; Konijnenberg, Mark W; Eckerman, Keith F; Dewaraja, Yuni K; Sjögreen-Gleisner, Katarina; Bolch, Wesley E; Brill, A Bertrand; Fahey, Frederic; Fisher, Darrell R; Hobbs, Robert; Howell, Roger W; Meredith, Ruby F; Sgouros, George; Zanzonico, Pat; Bacher, Klaus; Chiesa, Carlo; Flux, Glenn; Lassmann, Michael; Strigari, Lidia; Walrand, Stephan

    2016-01-01

    The accuracy of absorbed dose calculations in personalized internal radionuclide therapy is directly related to the accuracy of the activity (or activity concentration) estimates obtained at each of the imaging time points. MIRD Pamphlet no. 23 presented a general overview of methods that are required for quantitative SPECT imaging. The present document is next in a series of isotope-specific guidelines and recommendations that follow the general information that was provided in MIRD 23. This paper focuses on (177)Lu (lutetium) and its application in radiopharmaceutical therapy. PMID:26471692

  15. MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy.

    PubMed

    Ljungberg, Michael; Celler, Anna; Konijnenberg, Mark W; Eckerman, Keith F; Dewaraja, Yuni K; Sjögreen-Gleisner, Katarina; Bolch, Wesley E; Brill, A Bertrand; Fahey, Frederic; Fisher, Darrell R; Hobbs, Robert; Howell, Roger W; Meredith, Ruby F; Sgouros, George; Zanzonico, Pat; Bacher, Klaus; Chiesa, Carlo; Flux, Glenn; Lassmann, Michael; Strigari, Lidia; Walrand, Stephan

    2016-01-01

    The accuracy of absorbed dose calculations in personalized internal radionuclide therapy is directly related to the accuracy of the activity (or activity concentration) estimates obtained at each of the imaging time points. MIRD Pamphlet no. 23 presented a general overview of methods that are required for quantitative SPECT imaging. The present document is next in a series of isotope-specific guidelines and recommendations that follow the general information that was provided in MIRD 23. This paper focuses on (177)Lu (lutetium) and its application in radiopharmaceutical therapy.

  16. Untangling the web of European regulations for the preparation of unlicensed radiopharmaceuticals: a concise overview and practical guidance for a risk-based approach.

    PubMed

    Lange, Rogier; ter Heine, Rob; Decristoforo, Clemens; Peñuelas, Iván; Elsinga, Philip H; van der Westerlaken, Monique M L; Hendrikse, N Harry

    2015-05-01

    Radiopharmaceuticals are highly regulated, because they are controlled both as regular medicinal products and as radioactive substances. This can pose a hurdle for their development and clinical use. Radiopharmaceuticals are fundamentally different from other medicinal products and these regulations are not always adequate for their production. Strict compliance may have a huge resource impact, without further improving product quality. In this paper we give an overview of the applicable legislation and guidelines and propose a risk-based approach for their implementation. We focus on a few controversial Good Manufacturing Practice topics: cleanroom classification, air pressure regime, cleanroom qualification and microbiological monitoring. We have developed an algorithm to assess the combined risk of microbiological contamination of a radiopharmaceutical preparation process and propose corresponding Good Manufacturing Practice classification levels. In our opinion, the risk of carry-over of radiopharmaceuticals by individuals cannot be contained by pressure differences, and complicated regimes with underpressured rooms are not necessary in most situations. We propose a sterility assurance level of 10 for radiopharmaceuticals that are administered within a working day, irrespective of their use. We suggest the adoption of limits for environmental monitoring of microbial contamination, as proposed by Bruel and colleagues, on behalf of the French Society of Radiopharmacy. Recently launched regulatory documents seem to breathe a more liberal spirit than current legislation and recognize the need for the use of risk assessment. We argue that future legislation be further harmonized and state risk assessment as the gold standard for implementation of drug quality regulations for the preparation of unlicensed radiopharmaceuticals.

  17. Autogen Version 2.0

    NASA Technical Reports Server (NTRS)

    Gladden, Roy

    2007-01-01

    Version 2.0 of the autogen software has been released. "Autogen" (automated sequence generation) signifies both a process and software used to implement the process of automated generation of sequences of commands in a standard format for uplink to spacecraft. Autogen requires fewer workers than are needed for older manual sequence-generation processes and reduces sequence-generation times from weeks to minutes.

  18. Radiation absorbed dose estimates for oxygen-15 radiopharmaceuticals (H2( V)O, C VO, O VO) in newborn infants

    SciTech Connect

    Powers, W.J.; Stabin, M.; Howse, D.; Eichling, J.O.; Herscovitch, P.

    1988-12-01

    In preparation for measurement of regional cerebral oxygen metabolism by positron emission tomography, radiation absorbed dose estimates for 19 internal organs, blood, and total body were calculated for newborn infants following bolus intravenous administration of H2( V)O and brief inhalation of C VO and O VO. Cumulated activity for each radiopharmaceutical was calculated from a compartmental model based on the known biologic behavior of the compound. Values for mean absorbed dose/unit cumulated activity (S) for internal organs and total body were based on a newborn phantom. S was separately calculated for blood. Total radiopharmaceutical absorbed dose estimates necessary to measure cerebral oxygen metabolism in a 3.51-kg infant based on 0.7 mCi/kg H2( V)O and 1 mCi/kg C VO and O VO were determined to be 1.6 rad to the lung (maximum organ dose), 0.28 rad to the marrow, 0.46 rad to the gonads, and 0.22 rad to total body. These values are similar to those for current clinical nuclear medicine procedures employing /sup 99m/Tc in newborn infants.

  19. The effect of radiopharmaceutical choice on the determination of relative renal function in rats with unilateral renal obstruction

    SciTech Connect

    Taylor, A.; Lallone, R.

    1984-01-01

    A significant divergence of GFR and ERPF within a single kidney could lead to different estimates of relative renal function depending on which radiopharmaceutical is administered. To address this question, the authors studied adult male Sprague-Dawley rats with unilateral ureteral obstruction by giving each animal an intravenous injection of 10 ..mu..Ci of I-125 iothalamate (GFR), I-131 hippurate (ERPF), and TC-99m DMSA and measuring the 30 minute clearance (renal uptake and urine excretion) of each agent. Normal control animals were sham operated; 25 experimental animals were subjected to permanent unilateral ureteral occlusion and studied at 6 hours, 1, 3, 7 and 14 days. Acute ureteral obstruction impaired the clearance of iothalamate to a much greater degree than OIH or DMSA at 6 hours and 1 day (rho<.005) and 3 days (rho<.05). The decline in DMSA clearance reflected ERPF more closely than GFR. In evaluating renal disease, one should consider the functional parameter reflected by the radiopharmaceutical as well as the underlying disease state.

  20. Biocellion Version 2.0

    SciTech Connect

    Seunghwa Kang, PNNL

    2015-01-09

    This work extends Biocellion 1.0 to solve advection-reaction-diffusion and incompressible Navier-Stokes partial differential equations to model water/blood flow. Biocellion is a software framework to simulate a large number of cells using high-performance parallel computers. The version 1.0 allows software users to describe biological system behaviors as a set of rules describing how individual cells behave and how cells locally interact with neighboring cells or the surrounding micro-environment. However, the version 1.0 does not support users to incorporate water/blood flow into the model, which is important to properly capture long distance communications between distant cells. This extension (version 2.0) integrates two partial differential equation solvers to the Biocellion framework to solve this limitation. Navier-Stokes equation solvers (for incompressible flow) are added to compute flow rate, and advection-reaction-diffusion equation solvers are added to update molecular concentrations considering both advection (due to flow) and local diffusion.

  1. Biocellion Version 2.0

    2015-01-09

    This work extends Biocellion 1.0 to solve advection-reaction-diffusion and incompressible Navier-Stokes partial differential equations to model water/blood flow. Biocellion is a software framework to simulate a large number of cells using high-performance parallel computers. The version 1.0 allows software users to describe biological system behaviors as a set of rules describing how individual cells behave and how cells locally interact with neighboring cells or the surrounding micro-environment. However, the version 1.0 does not support usersmore » to incorporate water/blood flow into the model, which is important to properly capture long distance communications between distant cells. This extension (version 2.0) integrates two partial differential equation solvers to the Biocellion framework to solve this limitation. Navier-Stokes equation solvers (for incompressible flow) are added to compute flow rate, and advection-reaction-diffusion equation solvers are added to update molecular concentrations considering both advection (due to flow) and local diffusion.« less

  2. SITE CHARACTERIZATION LIBRARY VERSION 3.0

    EPA Science Inventory

    The Site Characterization Library is a CD that provides a centralized, field-portable source for site characterization information. Version 3 of the Site Characterization Library contains additional (from earlier versions) electronic documents and computer programs related to th...

  3. FORM version 4.0

    NASA Astrophysics Data System (ADS)

    Kuipers, J.; Ueda, T.; Vermaseren, J. A. M.; Vollinga, J.

    2013-05-01

    We present version 4.0 of the symbolic manipulation system FORM. The most important new features are manipulation of rational polynomials and the factorization of expressions. Many other new functions and commands are also added; some of them are very general, while others are designed for building specific high level packages, such as one for Gröbner bases. New is also the checkpoint facility, that allows for periodic backups during long calculations. Finally, FORM 4.0 has become available as open source under the GNU General Public License version 3. Program summaryProgram title: FORM. Catalogue identifier: AEOT_v1_0 Program summary URL:http://cpc.cs.qub.ac.uk/summaries/AEOT_v1_0.html Program obtainable from: CPC Program Library, Queen's University, Belfast, N. Ireland Licensing provisions: GNU General Public License, version 3 No. of lines in distributed program, including test data, etc.: 151599 No. of bytes in distributed program, including test data, etc.: 1 078 748 Distribution format: tar.gz Programming language: The FORM language. FORM itself is programmed in a mixture of C and C++. Computer: All. Operating system: UNIX, LINUX, Mac OS, Windows. Classification: 5. Nature of problem: FORM defines a symbolic manipulation language in which the emphasis lies on fast processing of very large formulas. It has been used successfully for many calculations in Quantum Field Theory and mathematics. In speed and size of formulas that can be handled it outperforms other systems typically by an order of magnitude. Special in this version: The version 4.0 contains many new features. Most important are factorization and rational arithmetic. The program has also become open source under the GPL. The code in CPC is for reference. You are encouraged to upload the most recent sources from www.nikhef.nl/form/formcvs.php because of frequent bug fixes. Solution method: See "Nature of Problem", above. Additional comments: NOTE: The code in CPC is for reference. You are encouraged

  4. BUCKY instruction manual, version 3.3

    NASA Technical Reports Server (NTRS)

    Smith, James P.

    1994-01-01

    The computer program BUCKY is a p-version finite element package for the solution of structural problems. The current version of BUCKY solves the 2-D plane stress, 3-D plane stress plasticity, 3-D axisymmetric, Mindlin and Kirchoff plate bending, and buckling problems. The p-version of the finite element method is a highly accurate version of the traditional finite element method. Example cases are presented to show the accuracy and application of BUCKY.

  5. SRT Status and Plans for Version-7

    NASA Technical Reports Server (NTRS)

    Susskind, Joel; Blaisdell, John M.; Iredell, Lena

    2013-01-01

    Status of Version-6 at GSFC-GSFC version-6 must match JPL version-6 before we can improve it. Short-range plans evolutionary improvements. Mid-Range plans- New thrusts, Higher spatial resolution retrievals cloud spectral emissivity. Long-range plans- more challenging ideas

  6. Embrittlement data base, version 1

    SciTech Connect

    Wang, J.A.

    1997-08-01

    The aging and degradation of light-water-reactor (LWR) pressure vessels is of particular concern because of their relevance to plant integrity and the magnitude of the expected irradiation embrittlement. The radiation embrittlement of reactor pressure vessel (RPV) materials depends on many different factors such as flux, fluence, fluence spectrum, irradiation temperature, and preirradiation material history and chemical compositions. These factors must be considered to reliably predict pressure vessel embrittlement and to ensure the safe operation of the reactor. Based on embrittlement predictions, decisions must be made concerning operating parameters and issues such as low-leakage-fuel management, possible life extension, and the need for annealing the pressure vessel. Large amounts of data from surveillance capsules and test reactor experiments, comprising many different materials and different irradiation conditions, are needed to develop generally applicable damage prediction models that can be used for industry standards and regulatory guides. Version 1 of the Embrittlement Data Base (EDB) is such a comprehensive collection of data resulting from merging version 2 of the Power Reactor Embrittlement Data Base (PR-EDB). Fracture toughness data were also integrated into Version 1 of the EDB. For power reactor data, the current EDB lists the 1,029 Charpy transition-temperature shift data points, which include 321 from plates, 125 from forgoings, 115 from correlation monitor materials, 246 from welds, and 222 from heat-affected-zone (HAZ) materials that were irradiated in 271 capsules from 101 commercial power reactors. For test reactor data, information is available for 1,308 different irradiated sets (352 from plates, 186 from forgoings, 303 from correlation monitor materials, 396 from welds and 71 from HAZs) and 268 different irradiated plus annealed data sets.

  7. The Basis version of LASNEX

    NASA Astrophysics Data System (ADS)

    Dubois, P. F.

    1990-10-01

    We have made major changes to the computer science aspects of our laser fusion simulation program LASNEX. LASNEX is now using the Basis system, a FORTRAN development system developed over the last six years at Lawrence Livermore National Laboratory. This has given users greatly increased power and flexibility. We have eliminated all non-standard usage and macros, enabling us to begin the port of LASNEX to workstations. At the same time, we have completely redone the system used to maintain the source and create new versions of LASNEX, resulting in major gains in capability and productivity.

  8. The Basis version of LASNEX

    SciTech Connect

    Dubois, P.F.

    1990-10-26

    We have made major changes to the computer science aspects of our laser fusion simulation program LASNEX. LASNEX is now using the Basis system, a Fortran development system developed over the last six years at Lawrence Livermore National Laboratory. This has given users greatly increased power and flexibility. We have eliminated all non-standard usage and macros, enabling us to begin the port of LASNEX to workstations. At the same time, we have completely redone the system used to maintain the source and create new versions of LASNEX, resulting in major gains in capability and productivity. 5 refs.

  9. CANFOR Portuguese version: validation study

    PubMed Central

    2013-01-01

    Background The increase in prisoner population is a troublesome reality in several regions of the world. Along with this growth there is increasing evidence that prisoners have a higher proportion of mental illnesses and suicide than the general population. In order to implement strategies that address criminal recidivism and the health and social status of prisoners, particularly in mental disordered offenders, it is necessary to assess their care needs in a comprehensive, but individual perspective. This assessment must include potential harmful areas like comorbid personality disorder, substance misuse and offending behaviours. The Camberwell Assessment of Need – Forensic Version (CANFOR) has proved to be a reliable tool designed to accomplish such aims. The present study aimed to validate the CANFOR Portuguese version. Methods The translation, adaptation to the Portuguese context, back-translation and revision followed the usual procedures. The sample comprised all detainees receiving psychiatric care in four forensic facilities, over a one year period. A total of 143 subjects, and respective case manager, were selected. The forensic facilities were chosen by convenience: one prison hospital psychiatric ward (n=68; 47.6%), one male (n=24; 16.8%) and one female (n=22; 15.4%) psychiatric clinic and one civil security ward (n=29; 20.3%), all located nearby Lisbon. Basic descriptive statistics and Kappa weighted coefficients were calculated for the inter-rater and the test-retest reliability studies. The convergent validity was evaluated using the Global Assessment of Functioning and the Brief Psychiatric Rating Scale scores. Results The majority of the participants were male and single, with short school attendance, and accused of a crime involving violence against persons. The most frequent diagnosis was major depression (56.1%) and almost half presented positive suicide risk. The reliability study showed average Kappa weighted coefficients of 0.884 and 0

  10. Computer version of astronomical ephemerides.

    NASA Astrophysics Data System (ADS)

    Choliy, V. Ya.

    A computer version of astronomical ephemerides for bodies of the Solar System, stars, and astronomical phenomena was created at the Main Astronomical Observatory of the National Academy of Sciences of Ukraine and the Astronomy and Cosmic Physics Department of the Taras Shevchenko National University. The ephemerides will be distributed via INTERNET or in the file form. This information is accessible via the web servers space.ups.kiev.ua and alfven.ups.kiev.ua or the address choliy@astrophys.ups.kiev.ua.

  11. Two alternative versions of strangeness

    PubMed Central

    Nishijima, Kazuhikoa

    2008-01-01

    The concept of strangeness emerged from the low energy phenomenology before the entry of quarks in particle physics. The connection between strangeness and isospin is rather accidental and loose and we recognize later that the definition of strangeness is model-dependent. Indeed, in Gell-Mann’s triplet quark model we realize that there is a simple alternative representation of strangeness. When the concept of generations is incorporated into the quark model we find that only the second alternative version of strangeness remains meaningful, whereas the original one does no longer keep its significance. PMID:18997448

  12. ASPEN Version 3.0

    NASA Technical Reports Server (NTRS)

    Rabideau, Gregg; Chien, Steve; Knight, Russell; Schaffer, Steven; Tran, Daniel; Cichy, Benjamin; Sherwood, Robert

    2006-01-01

    The Automated Scheduling and Planning Environment (ASPEN) computer program has been updated to version 3.0. ASPEN is a modular, reconfigurable, application software framework for solving batch problems that involve reasoning about time, activities, states, and resources. Applications of ASPEN can include planning spacecraft missions, scheduling of personnel, and managing supply chains, inventories, and production lines. ASPEN 3.0 can be customized for a wide range of applications and for a variety of computing environments that include various central processing units and random access memories.

  13. SRT Status and Plans for Version-7

    NASA Technical Reports Server (NTRS)

    Susskind, Joel; Blaisdell, John; Iredell, Lena; Kouvaris, Louis

    2015-01-01

    The AIRS Science Team Version-6 retrieval algorithm is currently producing level-3 Climate Data Records (CDRs) from AIRS that have been proven useful to scientists in understanding climate processes. CDRs are gridded level-3 products which include all cases passing AIRS Climate QC. SRT has made significant further improvements to AIRS Version-6. Research is continuing at SRT toward the development of AIRS Version-7. At the last Science Team Meeting, we described results using SRT AIRS Version-6.19. SRT Version-6.19 is now an official build at JPL called 6.2. SRTs latest version is AIRS Version-6.22. We have also adapted AIRS Version-6.22 to run with CrISATMS. AIRS Version-6.22 and CrIS Version- 6.22 both run now on JPL computers, but are not yet official builds. The main reason for finalization of Version-7, and using it in the relatively near future for the future processing and reprocessing of old AIRS data, is to produce even better CDRs for use by climate scientists. For this reason all results shown in this talk use only AIRS Climate QC.

  14. Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.

    PubMed

    Ning, Yang-Min; Maher, V Ellen

    2015-03-01

    Regulatory advice and assessment play an important role in the successful development of new drugs and radiopharmaceuticals for the treatment of urologic malignancies. Cooperation between the US Food and Drug Administration (FDA) and the pharmaceutical industry has led to the approval of more than 20 new urologic oncology products in the last 2 decades. Despite these advances, more effective treatments need to be developed and approved for the treatment of urologic malignancies. This review provides general information about the FDA's role in the development of investigational new drugs, with an emphasis on the regulatory process and the requirements for marketing approval. In addition, this review summarizes the products for the treatment of urologic malignancies that were approved by the FDA in the last 30 years and the key issues concerning urologic oncology products that were discussed publicly at Oncologic Drug Advisory Committee meetings in the past 10 years.

  15. Studying the General Toxicity and Cumulative Properties of a Radiopharmaceutical Nanocolloid, (99m)Tc-Al2O3.

    PubMed

    Varlamova, N V; Churin, A A; Fomina, T I; Ermolaeva, L A; Vetoshkina, T V; Dubskaya, T Yu; Lamzina, T Yu; Fedorova, E P; Neupokoeva, O V; Skuridin, V S; Nesterov, E A; Larionova, L A; Chernov, V I

    2016-07-01

    We studied toxicity of a new Russian radiopharmaceutical Nanocolloid, (99m)Tc-Al2O3. Tests for acute toxicity showed that this agent belongs to a class of moderate-toxicity substances and does not have cumulative properties. The evaluation of subchronic toxicity after subcutaneous injection of this product to rats (0.04, 0.2, and 0.4 ml/kg) and rabbits (0.02 and 0.2 ml/kg) for 7 days did not reveal changes in the general state, temperature, body weight, indices of the peripheral blood and bone marrow, functions of the heart, liver, kidneys, and nervous system, and morphological characteristics of the internal organs in animals. The drug does not produce a local irritant effect. PMID:27502539

  16. Performance of a Lanthanum Bromide Detector and a New Conception Collimator for Radiopharmaceuticals Molecular Imaging in Oncology

    SciTech Connect

    Pani, Roberto; Pellegrini, Rosanna; Bennati, Paolo; Cinti, Maria Nerina; Scafe, Raffaele; De Vincentis, Giuseppe; Navarria, Francesco; Moschini, Giuliano; Rossi, Paolo; Cencelli, Valentino Orsolini; De Notaristefani, Francesco

    2009-03-10

    We have realized and tested a new-design compact gamma camera for high resolution SPET (Single Photon Emission Tomography), and small animals' radio-pharmaceutical molecular imaging. The camera is based on a 'continuous' Lanthanum tri-Bromide crystal, and a new Low Energy (LE) collimator. The crystal is interfaced to a 2x2 array of Hamamatsu-H8500 position sensitive photo-multipliers. The lead collimator features parallel hexagonal 1.0 mm holes, 18 mm length, 0.2 mm septa and 10x10 cm{sup 2} detection area. It was newly designed to fully exploit the high spatial resolution a Lanthanum crystal may provide. To better evaluate its role, we have compared our camera to three other systems with similar crystals and photomultipliers, but employing traditional collimators, either pinhole or parallel. The new camera seems to be complementary to pinhole systems and shows a very attractive trade-off between spatial resolution and detection area.

  17. Performance of a Lanthanum Bromide Detector and a New Conception Collimator for Radiopharmaceuticals Molecular Imaging in Oncology

    NASA Astrophysics Data System (ADS)

    Pani, Roberto; Pellegrini, Rosanna; Bennati, Paolo; Cinti, Maria Nerina; Scafè, Raffaele; De Vincentis, Giuseppe; Navarria, Francesco; Moschini, Giuliano; Cencelli, Valentino Orsolini; De Notaristefani, Francesco; Rossi, Paolo

    2009-03-01

    We have realized and tested a new-design compact gamma camera for high resolution SPET (Single Photon Emission Tomography), and small animals' radio-pharmaceutical molecular imaging. The camera is based on a "continuous" Lanthanum tri-Bromide crystal, and a new Low Energy (LE) collimator. The crystal is interfaced to a 2×2 array of Hamamatsu-H8500 position sensitive photo-multipliers. The lead collimator features parallel hexagonal 1.0 mm holes, 18 mm length, 0.2 mm septa and 10×10 cm2 detection area. It was newly designed to fully exploit the high spatial resolution a Lanthanum crystal may provide. To better evaluate its role, we have compared our camera to three other systems with similar crystals and photomultipliers, but employing traditional collimators, either pinhole or parallel. The new camera seems to be complementary to pinhole systems and shows a very attractive trade-off between spatial resolution and detection area.

  18. NQS - NETWORK QUEUING SYSTEM, VERSION 2.0 (UNIX VERSION)

    NASA Technical Reports Server (NTRS)

    Walter, H.

    1994-01-01

    ; device queues hold and prioritize device requests; pipe queues transport both batch and device requests to other batch, device, or pipe queues at local or remote machines. Unique to batch queues are resource quota limits that restrict the amounts of different resources that a batch request can consume during execution. Unique to each device queue is a set of one or more devices, such as a line printer, to which requests can be sent for execution. Pipe queues have associated destinations to which they route and deliver requests. If the proper destination machine is down or unreachable, pipe queues are able to requeue the request and deliver it later when the destination is available. All NQS network conversations are performed using the Berkeley socket mechanism as ported into the respective vendor kernels. NQS is written in C language. The generic UNIX version (ARC-13179) has been successfully implemented on a variety of UNIX platforms, including Sun3 and Sun4 series computers, SGI IRIS computers running IRIX 3.3, DEC computers running ULTRIX 4.1, AMDAHL computers running UTS 1.3 and 2.1, platforms running BSD 4.3 UNIX. The IBM RS/6000 AIX version (COS-10042) is a vendor port. NQS 2.0 will also communicate with the Cray Research, Inc. and Convex, Inc. versions of NQS. The standard distribution medium for either machine version of NQS 2.0 is a 60Mb, QIC-24, .25 inch streaming magnetic tape cartridge in UNIX tar format. Upon request the generic UNIX version (ARC-13179) can be provided in UNIX tar format on alternate media. Please contact COSMIC to discuss the availability and cost of media to meet your specific needs. An electronic copy of the NQS 2.0 documentation is included on the program media. NQS 2.0 was released in 1991. The IBM RS/6000 port of NQS was developed in 1992. IRIX is a trademark of Silicon Graphics Inc. IRIS is a registered trademark of Silicon Graphics Inc. UNIX is a registered trademark of UNIX System Laboratories Inc. Sun3 and Sun4 are trademarks of

  19. EnergyPlus Version 6

    SciTech Connect

    2011-01-14

    EnergyPlus is a whole building energy simulation program that engineers, architects, and researchers use to model energy and water use in buildings. Modeling the performance of a building with EnergyPlus enables building professionals to optimize the building design to use less energy and water. Each version of EnergyPlus is tested extensively before release. EnergyPlus models heating, cooling, lighting, ventilation, other energy flows, and water use. EnergyPlus includes many innovative simulation capabilities: time-steps less than an hour, modular systems and plant integrated with heat balance-based zone simulation, multizone air flow, thermal comfort, water use, natural ventilation, and photovoltaic systems. Read about new features. EnergyPlus runs on the Windows, Macintosh, and Linux platforms. Free add-ons and other third-party software products are available for use with EnergyPlus.

  20. EnergyPlus Version 7

    SciTech Connect

    Wetter, Michael

    2011-11-01

    EnergyPlus is a whole building energy simulation program that engineers, architects and researchers use to model energy and water use in buildings. Modeling the performance of a building with EnergyPlus enables building professionals to optimize the building design to use less energy and water. Each version of EnergyPlus is tested extensively before release. EnergyPlus models heating, cooling, lighting, ventilation, other energy flows, and water use. EnergyPlus includes many innovation simulation capabilities: time-steps less than an hour, modular systems and plant integrated with heat balance-based zone simulation, multizone air flow, thermal comfort, water use, natural ventilation, and photovoltaic systems. EnergyPlus runs on the Windows, Macintosh, and Linux platforms. Free add-ons and other third party software products are available for use with EnergyPlus.

  1. BINSYN a Publicly Available Version

    NASA Astrophysics Data System (ADS)

    Linnell, Albert P.; DeStefano, P.

    2012-01-01

    A public version of the Binsyn program package now is available for download. Binsyn is a set of programs, running on Linux, that simulate binary star systems, either with or without an optically thick accretion disk. The package includes facilities for parameter optimization by differentials correction. Light curve generation optionally is on the black body approximation or by synthetic photometry. In the latter case, the filter response curves provided with the release are on the Bessell, 1990, PASP, 102, 1181 (Table 2) tabulation. Substitution of different response curves to represent other photometric systems can be accomplished easily. The package produces synthetic spectra and calculated radial velocities of system components as function of orbital phase for comparison with observational data. It has been used extensively in studies of cataclysmic variables (e.g., Linnell et al., 2010, ApJ, 719, 271). The presentation will demonstrate program performance in a variety of contexts.

  2. EnergyPlus Version 7

    2011-11-01

    EnergyPlus is a whole building energy simulation program that engineers, architects and researchers use to model energy and water use in buildings. Modeling the performance of a building with EnergyPlus enables building professionals to optimize the building design to use less energy and water. Each version of EnergyPlus is tested extensively before release. EnergyPlus models heating, cooling, lighting, ventilation, other energy flows, and water use. EnergyPlus includes many innovation simulation capabilities: time-steps less than anmore » hour, modular systems and plant integrated with heat balance-based zone simulation, multizone air flow, thermal comfort, water use, natural ventilation, and photovoltaic systems. EnergyPlus runs on the Windows, Macintosh, and Linux platforms. Free add-ons and other third party software products are available for use with EnergyPlus.« less

  3. SAMRSolvers Version 0.1

    2006-09-01

    SAMRSolvers is a collection of multilevel solvers for systems of linear equations that result from finite volume discretization of an elliptic partial differential equation on a block-structure (or patch-based) locally refined grid. SAMRSolvers provides implementations of the Fast Adaptive Composite grid (FAC) method, and the AFACx method, which is a less expensive version of AFAC that smooths the error instead of solving for it on all but the coarsest level. These methods can be shownmore » to converge at rates that are independent of the number of refinement levels. SAMRSolvers is intended for use with SAMRAIV2.0 and requires the SAMRUtilities package.« less

  4. EnergyPlus Version 6

    2011-01-14

    EnergyPlus is a whole building energy simulation program that engineers, architects, and researchers use to model energy and water use in buildings. Modeling the performance of a building with EnergyPlus enables building professionals to optimize the building design to use less energy and water. Each version of EnergyPlus is tested extensively before release. EnergyPlus models heating, cooling, lighting, ventilation, other energy flows, and water use. EnergyPlus includes many innovative simulation capabilities: time-steps less than anmore » hour, modular systems and plant integrated with heat balance-based zone simulation, multizone air flow, thermal comfort, water use, natural ventilation, and photovoltaic systems. Read about new features. EnergyPlus runs on the Windows, Macintosh, and Linux platforms. Free add-ons and other third-party software products are available for use with EnergyPlus.« less

  5. HST archive primer, version 4.1

    NASA Technical Reports Server (NTRS)

    Fruchter, A. (Editor); Baum, S. (Editor)

    1994-01-01

    This version of the HST Archive Primer provides the basic information a user needs to know to access the HST archive via StarView the new user interface to the archive. Using StarView, users can search for observations interest, find calibration reference files, and retrieve data from the archive. Both the terminal version of StarView and the X-windows version feature a name resolver which simplifies searches of the HST archive based on target name. In addition, the X-windows version of StarView allows preview of all public HST data; compressed versions of public images are displayed via SAOIMAGE, while spectra are plotted using the public plotting package, XMGR. Finally, the version of StarView described here features screens designed for observers preparing Cycle 5 HST proposals.

  6. ROSE Version 1.0

    2005-02-17

    ROSE is an object-oriented software infrastructure for source-to-source translation that provides an interface for programmers to write their own specialized translators for optimizing scientific applications. ROSE is a part of current research on telescoping languages, which provides optimizations of the use of libraries in scientific applications. ROSE defines approaches to extend the optimization techniques, common in well defined languages, to the optimization of scientific applications using well defined libraries. ROSE includes a rich set ofmore » tools for generating customized transformations to support optimization of applications codes. We currently support full C and C++ (including template instantiation etc.), with Fortran 90 support under development as part of a collaboration and contract with Rice to use their version of the open source Open64 F90 front-end. ROSE represents an attempt to define an open compiler infrastructure to handle the full complexity of full scale DOE applications codes using the languages common to scientific computing within DOE. We expect that such an infrastructure will also be useful for the development of numerous tools that may then realistically expect to work on DOE full scale applications.« less

  7. MCNP(TM) Version 5.

    SciTech Connect

    Cox, L. J.; Barrett, R. F.; Booth, Thomas Edward; Briesmeister, Judith F.; Brown, F. B.; Bull, J. S.; Giesler, G. C.; Goorley, J. T.; Mosteller, R. D.; Forster, R. A.; Post, S. E.; Prael, R. E.; Selcow, Elizabeth Carol,; Sood, A.

    2002-01-01

    The Monte Carlo transport workhorse, MCNP, is undergoing a massive renovation at Los Alamos National Laboratory (LANL) in support of the Eolus Project of the Advanced Simulation and Computing (ASCI) Program. MCNP Version 5 (V5) (expected to be released to RSICC in Spring, 2002) will consist of a major restructuring from FORTRAN-77 (with extensions) to ANSI-standard FORTRAN-90 with support for all of the features available in the present release (MCNP-4C2/4C3). To most users, the look-and-feel of MCNP will not change much except for the improvements (improved graphics, easier installation, better online documentation). For example, even with the major format change, full support for incremental patching will still be provided. In addition to the language and style updates, MCNP V5 will have various new user features. These include improved photon physics, neutral particle radiography, enhancements and additions to variance reduction methods, new source options, and improved parallelism support (PVM, MPI, OpenMP).

  8. VOSpace specification Version 1.15

    NASA Astrophysics Data System (ADS)

    Graham, Matthew; Morris, Dave; Rixon, Guy; Graham, Matthew

    2009-10-01

    VOSpace is the IVOA interface to distributed storage. This version extends the existing VOSpace 1.0 (SOAP-based) specification to support containers, links between individual VOSpace instances, third party APIs, and a find mechanism. Note, however, that VOSpace-1.0 compatible clients will not work with this new version of the interface.

  9. VOSpace specification Version 2.0

    NASA Astrophysics Data System (ADS)

    Graham, Matthew; Morris, Dave; Rixon, Guy; Dowler, Pat; Schaaff, Andre; Tody, Doug; Graham, Matthew

    2013-03-01

    VOSpace is the IVOA interface to distributed storage. This specification presents the first RESTful version of the interface, which is functionally equivalent to the SOAP-based VOSpace 1.1 specification. Note that all prior VOSpace clients will not work with this new version of the interface.

  10. MISR Level 2 TOA/Cloud Versioning

    Atmospheric Science Data Center

    2013-04-02

    ... All version F04_0007 files covering orbits 31669 to 32870 have been affected by errors in the TC_STEREO data. See ... 12/08/2003 All version F03_0005 files covering orbits 15707-16930 and 21023-21823 were removed from the archive because they ...

  11. UPGRADES TO Monteburns, VERSION 3.0

    SciTech Connect

    Galloway, Jack D; Trellue, Holly R

    2012-06-22

    Monteburns VERSION 3.0 is an upgrade of the existing Monteburns code available through RSICC. The new version includes modern programming style, increased parallel computing, more accurate capture gamma calculations and an automated input generator. This capability was demonstrated through a small PWR core simulation.

  12. VruiNet Version 12(SOPHIA)

    SciTech Connect

    None, None

    2012-08-09

    VruiNet Version 12 is the code used exclusively by the executable ‘vruinet’. VruiNet Version 12 provides a wrapper around the code for ‘oglnet’ that makes it compatible for VRUI systems such as the CAVE at CAES.

  13. A simple low-cost of liquid I-131 dispenser for routine radiopharmaceutical dispensing at nuclear medicine department, Institut Kanser Negara

    NASA Astrophysics Data System (ADS)

    Said, M. A.; Ashhar, Z. N.; Suhaimi, N. E. F.; Zainon, R.

    2016-01-01

    In routine radiopharmaceutical Iodine-131 (131I) dispensing, the amount of radiation dose received by the personnel depends on the distance between the personnel and the source, the time spent manipulating the source and the amount of shielding used to reduce the dose rate from the source. The novel iRAD-I131 dispenser using recycle 131I liquid lead pot will lead into low cost production, less maintenance and low dose received by the personnel that prepared the 131I. The new fabricated of low cost 131I dispenser was tested and the dose received by personnel were evaluated. The body of lead material is made from 2.5 cm lead shielded coated with epoxy paint to absorb the radiation dose up to 7.4 GBq of 131 I. The lead pot was supported with two stainless steel rod. The Optically Stimulated Luminescence (OSL) nanodot was used in this study to measure the dose rate at both extremities for every personnel who prepared the 131I. Each OSL nanodot was attached at the fingertip. Three different personnel (experienced between one to ten years above in preparing the radiopharmaceuticals) were participated in this study. The average equivalent dose at right and left hand were 122.694 ± 121.637 µSv/GBq and 77.281 ± 62.146 µSv/GBq respectively. This study found that the dose exposure received using iRAD-I131 was less up to seven times compared to the conventional method. The comparison of experimental data using iRAD-I131 and established radiopharmaceutical dispenser was also discussed. The innovation of 131I dispenser is highly recommended in a small radiopharmaceutical facility with limited budget. The novel iRAD-I131 enables implementation of higher output liquid dispensing with low radiation dose to the personnel.

  14. Comparison of effective dose and lifetime risk of cancer incidence of CT attenuation correction acquisitions and radiopharmaceutical administration for myocardial perfusion imaging

    PubMed Central

    Szczepura, K; Hogg, P

    2014-01-01

    Objective: To measure the organ dose and calculate effective dose from CT attenuation correction (CTAC) acquisitions from four commonly used gamma camera single photon emission CT/CT systems. Methods: CTAC dosimetry data was collected using thermoluminescent dosemeters on GE Healthcare's Infinia™ Hawkeye™ (GE Healthcare, Buckinghamshire, UK) four- and single-slice systems, Siemens Symbia™ T6 (Siemens Healthcare, Erlangen, Germany) and the Philips Precedence (Philips Healthcare, Amsterdam, Netherlands). Organ and effective dose from the administration of 99mTc-tetrofosmin and 99mTc-sestamibi were calculated using International Commission of Radiological Protection reports 80 and 106. Using these data, the lifetime biological risk was calculated. Results: The Siemens Symbia gave the lowest CTAC dose (1.8 mSv) followed by the GE Infinia Hawkeye single-slice (1.9 mSv), GE Infinia Hawkeye four-slice (2.5 mSv) and Philips Precedence v. 3.0. Doses were significantly lower than the calculated doses from radiopharmaceutical administration (11 and 14 mSv for 99mTc-tetrofosmin and 99mTc-sestamibi, respectively). Overall lifetime biological risks were lower, which suggests that using CTAC data posed minimal risk to the patient. Comparison of data for breast tissue demonstrated a higher risk than that from the radiopharmaceutical administration. Conclusion: CTAC doses were confirmed to be much lower than those from radiopharmaceutical administration. The localized nature of the CTAC exposure compared to the radiopharmaceutical biological distribution indicated dose and risk to the breast to be higher. Advances in knowledge: This research proved that CTAC is a comparatively low-dose acquisition. However, it has been shown that there is increased risk for breast tissue especially in the younger patients. As per legislation, justification is required and CTAC should only be used in situations that demonstrate sufficient net benefit. PMID:24998249

  15. Alternative chromatographic system for the quality control of lipophilic technetium-99m radiopharmaceuticals such as [(99m)Tc(MIBI)₆].

    PubMed

    Faria, D P; Buchpiguel, C A; Marques, F L N

    2015-10-01

    Knowledge of the radiochemical purity of radiopharmaceuticals is mandatory and can be evaluated by several methods and techniques. Planar chromatography is the technique normally employed in nuclear medicine since it is simple, rapid and usually of low cost. There is no standard system for the chromatographic technique, but price, separation efficiency and short time for execution must be considered. We have studied an alternative system using common chromatographic stationary phase and alcohol or alcohol:chloroform mixtures as the mobile phase, using the lipophilic radiopharmaceutical [(99m)Tc(MIBI)₆]⁺ as a model. Whatman 1 modified phase paper and absolute ethanol, Whatman 1 paper and methanol:chloroform (25:75), Whatman 3MM paper and ethanol:chloroform (25:75), and the more expensive ITLC-SG and 1-propanol:chloroform (10:90) were suitable systems for the direct determination of radiochemical purity of [(99m)Tc(MIBI)₆]⁺ since impurities such as (99m)Tc-reduced-hydrolyzed (RH), (99m)TcO(4)(-) and [(99m)Tc(cysteine)₂]⁻ complex were completely separated from the radiopharmaceutical, which moved toward the front of chromatographic systems while impurities were retained at the origin. The time required for analysis was 4 to 15 min, which is appropriate for nuclear medicine routines.

  16. An energy-subtraction Compton scatter camera design for in vivo medical imaging of radiopharmaceuticals

    SciTech Connect

    Rohe, R.C.; Valentine, J.D.

    1996-12-01

    A Compton scatter camera (CSC) design is proposed for imaging radioisotopes used as biotracers. A clinical version may increase sensitivity by a factor of over 100, while maintaining or improving spatial resolution, as compared with existing Anger cameras that use lead collimators. This novel approach is based on using energy subtraction ({Delta}E = E{sub 0} {minus} E{sub SC}, where E{sub 0}, {Delta}E, and E{sub SC} are the energy of the emitted gamma ray, the energy deposited by the initial Compton scatter, and the energy of the Compton scattered photon) to determine the amount of energy deposited in the primary system. The energy subtraction approach allows the requirement of high energy resolution to be placed on a secondary detector system instead of the primary detector system. Requiring primary system high energy resolution has significantly limited previous CSC designs for medical imaging applications. Furthermore, this approach is dependent on optimizing the camera design for data acquisition of gamma rays that undergo only one Compton scatter in a low-Z primary detector system followed by a total absorption of the Compton scattered photon in a high-Z secondary detector system. The proposed approach allows for a more compact primary detector system, a more simplified pulse processing interface, and a much less complicated detector cooling scheme as compared with previous CSC designs. Analytical calculations and Monte Carlo simulation results for some specific detector materials and geometries are presented.

  17. OASIS, LLNL version: Software maintenance manual

    SciTech Connect

    Auerbach, J.M.

    1990-03-01

    The OASIS laser beam propagation code has been used extensively to support design and analysis in the Free Electron Laser Master Oscillator Program, the Medium Power Solid State Laser Program, and the Active Optical Countermeasures Program. The version of OASIS currently used at LLNL is significantly enhanced compared to the initial version supplied by the Air Force Weapons Laboratory. This software maintenance manual presents the details of the LLNL version of OASIS so it can be modified as necessary by new personnel. The manual presents in great detail the content and organization of the OASIS software configured for the VMS operating system.

  18. CHARICE version 1.1 update.

    SciTech Connect

    Davis, Jean-Paul

    2008-10-01

    CHARICE (CHARacteristics-based inverse analysis of Isentropic Compression Experiments) is a computer application, previously documented in SAND2007-4948, that analyzes velocity waveform data from ramp-wave experiments to determine a material's quasi-isentropic loading response in stress and density using an iterative characteristics-based approach. This short report documents only the changes in CHARICE release version 1.1 relative to release version 1.0, and is not intended to stand alone. CHARICE version 1.1 corrects an error in the algorithm of the method, fixes several bugs, improves robustness and performance, provides more useful error descriptions, and adds a number of minor features.

  19. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.

    PubMed

    Pandit-Taskar, Neeta; Larson, Steven M; Carrasquillo, Jorge A

    2014-02-01

    Metastatic disease to bone is commonly seen in the advanced stages of many cancers. The cardinal symptom, pain, is often the cause of significant morbidity and reduced quality of life. Treatment of bone pain includes nonsteroidal analgesics and opiates; however, long-term use of these drugs is commonly associated with significant side effects, and tolerance is common. External-beam radiation therapy is effective mainly in localized disease sites. Bone-targeting radiopharmaceuticals are beneficial in the management of patients with multiple metastatic lesions. This article focuses on the 3 most commonly used agents: the Food and Drug Administration-approved (89)Sr-chloride, (153)Sm-ethylenediaminetetramethylene phosphonic acid (EDTMP), and (223)Ra-dichloride. We will discuss the physical characteristics, clinical data, dosage, and administration of these agents, including optimal patient selection and toxicity associated with their use. These radioactive agents have proven efficacy in the treatment of painful osseous metastases from prostate cancer and breast cancer. Significant recent advances include use of these agents in combination with chemotherapy and the use of the α emitter (223)Ra-dichloride in prostate cancer, primarily to improve survival and skeletal related events. The review is presented in 2 parts. The first will discuss the characteristics and clinical use of (223)Ra-dichloride, and the second will discuss the β emitters (89)Sr and (153)Sm-EDTMP.

  20. Environmental effects on the structure of metal ion-DOTA complexes: An ab initio study of radiopharmaceutical metals.

    SciTech Connect

    Lau, E Y; Lightstone, F C; Colvin, M E

    2006-02-10

    Quantum mechanical calculations were performed to study the differences between the important radiopharmaceutical metals yttrium (Y) and indium (In) bound by DOTA and modified DOTA molecules. Energies were calculated at the MP2/6-31+G(d)//HF/6-31G(d) levels, using effective core potentials on the Y and In ions. Although the minimum energy structures obtained are similar for both metal ion-DOTA complexes, changes in coordination and local environment significantly affect the geometries and energies of these complexes. Coordination by a single water molecule causes a change in the coordination number and a change in the position of the metal ion in In-DOTA; but, Y-DOTA is hardly affected by water coordination. When one of the DOTA carboxylates is replaced by an amide, the coordination energy for the amide arm shows a large variation between the Y and In ions. Optimizations including water and guandinium moieties to approximate the effects of antibody binding indicate a large energy cost for the DOTA-chelated In to adopt the ideal conformation for antibody binding.

  1. Molecular modeling in the development of metal radiopharmaceuticals. Final progress report, July 15, 1989--July 14, 1993

    SciTech Connect

    Green, M.A.

    1993-10-01

    We began this project with a compilation of a structural library to serve as a data base containing descriptions of the molecular features of metal-labeled radiopharmaceuticals known to efficiently cross the blood-brain barrier. Such a data base is needed in order to identify structural features (size, shape, molecular surface areas and volumes) that are critical in allowing blood-brain barrier penetration. Nine metal complexes have been added to this structural library. We have completed a detailed comparison of four molecular mechanics computer programs QUANTA, SYBYL, BOYD, and MM2DREW to assess their applicability to modeling the structures of low molecular weight metal complexes. We tested the ability of each program to reproduce the crystallographic structures of 38 complexes between nickel(II) and saturated N-donor ligands. The programs were evaluated in terns of their ability to reproduce structural features such as bond lengths, bond angles, and torsion angles. Recently, we investigated the synthesis and characterization of lipophilic cationic gallium complexes with hexadentate bis(salicylaldimine) ligands. This work identified the first gallium-68 radiopharrnaceuticals that can be injected intravenously and that subsequently exhibit significant myocardial uptake followed by prolonged myocardial retention of {sup 68}Ga radioactivity. Tracers of this type remain under investigation as agents for evaluation of myocardial perfusion with positron emission tomography.

  2. Automated synthesis of radiopharmaceuticals for positron emission tomography: an apparatus for labelling with [11C] methyl iodide (MIASA)

    PubMed Central

    Cork, D. G.; Yamato, H.; Yajima, K.; Hayashi, N.; Sugawara, T.; Kato, S.

    1994-01-01

    A fully automated apparatus for the routine synthesis and formulation of short-lived 11C (t1/2 = 20 min) labelled radiopharmaceuticals for positron emission tomography (PET) has been developed. [11C]Carbon dioxide is converted to [11C]methyl iodide, which can be used to label a wide variety of substrates by methylation at C, N, O, or S electron rich centres. The apparatus, MIASA (methyl iodide automated synthesis apparatus), was designed to operate as part of an automated labelling system in a shielded ‘hot’ laboratory. The apparatus was designed without the size constraints of typical instrumentation used in hot cells, although it is compact where necessary. Ample use of indicators and sensors, together with compact design of the reaction flasks for small dead space and efficient evaporation, led to good reliability and performance. The design of the hardware and software is described in this paper, together with a preparation of 3-N-[11C]methylspiperone as a sterile injectable solution in physiological saline. PMID:18924994

  3. (11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals.

    PubMed

    Rotstein, Benjamin H; Liang, Steven H; Placzek, Michael S; Hooker, Jacob M; Gee, Antony D; Dollé, Frédéric; Wilson, Alan A; Vasdev, Neil

    2016-08-22

    The positron-emitting radionuclide carbon-11 ((11)C, t1/2 = 20.3 min) possesses the unique potential for radiolabeling of any biological, naturally occurring, or synthetic organic molecule for in vivo positron emission tomography (PET) imaging. Carbon-11 is most often incorporated into small molecules by methylation of alcohol, thiol, amine or carboxylic acid precursors using [(11)C]methyl iodide or [(11)C]methyl triflate (generated from [(11)C]carbon dioxide or [(11)C]methane). Consequently, small molecules that lack an easily substituted (11)C-methyl group are often considered to have non-obvious strategies for radiolabeling and require a more customized approach. [(11)C]Carbon dioxide itself, [(11)C]carbon monoxide, [(11)C]cyanide, and [(11)C]phosgene represent alternative reactants to enable (11)C-carbonylation. Methodologies developed for preparation of (11)C-carbonyl groups have had a tremendous impact on the development of novel PET tracers and provided key tools for clinical research. (11)C-Carbonyl radiopharmaceuticals based on labeled carboxylic acids, amides, carbamates and ureas now account for a substantial number of important imaging agents that have seen translation to higher species and clinical research of previously inaccessible targets, which is a testament to the creativity, utility and practicality of the underlying radiochemistry. PMID:27276357

  4. SU-C-303-03: Dosimetric Model of the Beagle Needed for Pre-Clinical Testing of Radiopharmaceuticals

    SciTech Connect

    Shang, M; Sands, M; Bolch, W

    2015-06-15

    Purpose: Large animal models, most popularly beagles, have been crucial surrogates to humans in determining radiation safety levels of radiopharmaceuticals. This study aims to develop a detailed beagle phantom to accurately approximate organ absorbed doses for therapy nuclear medicine preclinical studies. Methods: A 3D NURBS model was created subordinate to a whole body CT of an adult beagle. Bones were harvested and CT imaged to offer macroscopic skeletal detail. Samples of trabecular spongiosa were cored and imaged to offer microscopic skeletal detail for bone trabeculae and marrow volume fractions. Results: Organ masses in the model are typical of an adult beagle. Trends in volume fractions for skeletal dosimetry are fundamentally similar to those found in existing models of other canine species. Conclusion: This work warrants its use in further investigations of radiation transport calculation for electron and photon dosimetry. This model accurately represents the anatomy of a beagle, and can be directly translated into a useable geometry for a voxel-based Monte Carlo radiation transport program such as MCNP6. Work supported by a grant from the Hyundai Hope on Wheels Foundation for Pediatric Cancer Research.

  5. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro.

    PubMed

    Dearling, J L; Lewis, J S; Mullen, G E; Rae, M T; Zweit, J; Blower, P J

    1998-07-01

    The well-known perfusion tracer CuPTSM, labelled with 62Cu or 64Cu, is believed to be trapped in cells non-selectively by a bioreductive mechanism. It is proposed that by modifying the ligand to increase its electron donor strength (for example by adding alkyl functionality or replacing sulphur ligands with oxygen ligands), the copper complexes will become less easily reduced and tracers with selectivity for hypoxic tissues could thus be developed. The aim of this work was to prepare 64Cu-labelled complexes of two series of ligands, based on the bis(thiosemicarbazone) (13 ligands) and bis(salicylaldimine) (3 ligands) skeletons, and to evaluate the hypoxia dependence of their uptake in cells. The complexes were incubated with Chinese hamster ovary cells under normoxic and hypoxic conditions, and the cells isolated by centrifugation to determine radioactivity uptake at various time points up to 90 min. Several members of both series demonstrated significant (P<0.05) or highly significant (P<0.01) hypoxia selectivity, indicating that both series of complexes offer a basis for development of hypoxia-targeting radiopharmaceuticals for positron emission tomography (60Cu, 61Cu, 62Cu, 64Cu) and targeted radiotherapy (64Cu, 67Cu).

  6. In vivo binding in rat brain and radiopharmaceutical preparation of radioiodinated HEAT, an alpha-1 adrenoceptor ligand

    SciTech Connect

    Couch, M.W.; Greer, D.M.; Thonoor, C.M.; Williams, C.M.

    1988-03-01

    In vivo binding of (/sup 125/I)-2-(beta-(3-iodo-4-hydroxyphenyl)ethylaminomethyl tetralone) ((/sup 125/I)HEAT) to alpha-1 adrenoceptors in the rat brain was determined over 4 hr. Uptake in the thalamus and frontal cortex was approximately 0.1% injected dose per gram tissue. Thalamus/cerebellum ratios of 10:1 and frontal cortex/cerebellum ratios of 5:1 were found at 4 hr. Pretreatment with prazosin, an alpha-1 antagonist, completely inhibited the accumulation of (/sup 125/I)HEAT in thalamus and frontal cortex; yet uptake of radioactivity was not significantly affected by antagonists and agonists for other receptors classes (propranolol, beta-1; apomorphine, D-1; spiperone, D-2). Binding of (/sup 125/I)HEAT is saturable. At 4 hr, (/sup 125/I)HEAT or (/sup 123/I)HEAT was shown to be the only radioactive material in rat thalamus and frontal cortex. Iodine-123 HEAT and (/sup 125/I)HEAT were synthesized as radiopharmaceuticals within 3 hr in 99% radiochemical purity.

  7. DATAMAP upgrade version 4.0

    NASA Technical Reports Server (NTRS)

    Watts, Michael E.; Dejpour, Shabob R.

    1989-01-01

    The changes made on the data analysis and management program DATAMAP (Data from Aeromechanics Test and Analytics - Management and Analysis Package) are detailed. These changes are made to Version 3.07 (released February, 1981) and are called Version 4.0. Version 4.0 improvements were performed by Sterling Software under contract to NASA Ames Research Center. The increased capabilities instituted in this version include the breakout of the source code into modules for ease of modification, addition of a more accurate curve fit routine, ability to handle higher frequency data, additional data analysis features, and improvements in the functionality of existing features. These modification will allow DATAMAP to be used on more data sets and will make future modifications and additions easier to implement.

  8. Source code management with version control software

    NASA Astrophysics Data System (ADS)

    Arraki, Kenza S.

    2016-01-01

    Developing and maintaining software is an important part of astronomy research. As time progresses projects can move in unexpected directions or simply last longer than expected. Making changes to software can quickly result in many different versions of the code, wanting to return to a previous lost version, and problems sharing updated code with others. It is simple to update and collaboratively edit source code when you use version control software. This short talk will highlight the version control softwares svn, git, and hg for use with local and remote software repositories. In addition I will touch on using GitHub and BitBucket as excellent ways to share your code using an online interface.

  9. An MPI version of the BLACS

    SciTech Connect

    Walker, D.W.

    1994-12-31

    In this paper, issues related to implementing an MPI version of the Basic Linear Communication Subprograms (BLACS) are investigated. A set of routines, the MPI Linear Algebra Communication Subprograms (MLACS), are presented, and these arc used to implement an MPI version of the BLACS, The MLACS provide the same functionality as the BLACS, but extend the functionality of the BLACS to include both blocking and nonblocking communication, and all four of the MPI communication modes.

  10. 99mtc-Ubiquicidin [29–41], a Promising Radiopharmaceutical to Differentiate Orthopedic Implant Infections from Sterile Inflammation

    PubMed Central

    Beiki, Davood; Yousefi, Gholamali; Fallahi, Babak; Tahmasebi, Mohammad Naghi; Gholamrezanezhad, Ali; Fard-Esfahani, Armaghan; Erfani, Mostafa; Eftekhari, Mohammad

    2013-01-01

    Ubiquicidin (UBI) [29-41] is a synthetic cationic antimicrobial peptide that preferentially binds to bacterial cell membrane at the site of infection. We aimed to assess diagnostic value of 99mTc-UBI [29-41] as a radiopharmaceutical in differentiation of bacterial infection from sterile inflammation in suspected orthopedic implants. Nine patients suspected for orthopedic implant infection, all males with the mean age of 41.6 ± 20.9 years, were studied. A dose of 10 MBq/Kg (range : 555-740 MBq) 99mTc-UBI [29-41] was injected intravenously. A dynamic study followed by static whole body imaging at 30, 60 and 120 min post-radiotracer injection was acquired. Periprosthetic tissue culture was considered the closest test to a gold standard for diagnosing infections and scintigraphic scans were categorized as true- or false-positive and true- or false-negative, considering the bacterial culture as the gold standard. No adverse reaction was observed during or after the radiotracer injection days. There were five true positive, four true negative and no false positive and false negative scans. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were all calculated as 100%. We found a high diagnostic accuracy for 99mTc-UBI [29-41] scintigraphy in differentiation of bacterial infection from sterile inflammation in suspected orthopedic implants. Therefore, 99mTc-UBI [29-41] scintigraphy might be potentially recommended as a safe and promising imaging modality in these settings. However, further studies on a larger number of patients and different pathologies are still needed. PMID:24250609

  11. Radioprotective effect of the Barbados Cherry (Malpighia glabra L.) against radiopharmaceutical Iodine-131 in Wistar rats in vivo

    PubMed Central

    2014-01-01

    Background The increasing consumption of fruits and vegetables has contributed to the improvement of populational health, due in part, to the abundance of antioxidants in these foods. Antioxidants reduce the level of oxidative damage to DNA caused by free radicals and ionizing radiation, including the radioisotope iodine-131 (131I). This isotope is used for the diagnosis and treatment of thyroid injuries, such as hyperthyroidism and cancer. Methods This study aimed to evaluate the radioprotective and cytotoxic activity of acute and subchronic treatments with Barbados Cherry (BC) (Malpighia glabra L.) fruit juice (5 mg), which is rich in potent antioxidants such as vitamin C, phenols, carotenoids, anthocyanins and yellow flavonoids and its activity against the mutagenic activity of the therapeutic dose of 25 μCi of radioiodine for hyperthyroidism. The test system used was the bone marrow cells of Wistar rats (Rattus norvegicus) that were treated in vivo by gavage. Results BC showed radioprotective activity in acute treatments, which is most likely due to the joint action of its antioxidant components. In subchronic treatments, the continuous treatment presented an effective radioprotective activity, which was significantly different from treatment with the radiopharmaceutical only. Treatment with BC prior to (PRE) and simultaneous with (SIM) ionizing radiation decreased the number of induced chromosomal alterations, while post-treatment produced no protective effect. In addition, BC exhibited no cytotoxic activity. Conclusions These data serve as evidence that BC can be used as a preventive health measure to improve public health quality by countering the action of inevitable exposure to mutagens, such as 131I. PMID:24479389

  12. Cu(II) Bis(thiosemicarbazone) Radiopharmaceutical Binding to Serum Albumin: Further Definition of Species-Dependence and Associated Substituent Effects

    PubMed Central

    Basken, Nathan E.; Green, Mark A.

    2009-01-01

    Introduction The Cu-PTSM (pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II)) and Cu-ATSM (diacetyl bis(N4-methylthiosemicarbazonato)copper(II)) radiopharmaceuticals exhibit strong, species-dependent binding to the IIA site of human serum albumin (HSA), while the related Cu-ETS (ethylglyoxal bis(thiosemicarbazonato)copper(II)) radiopharmaceutical appears to only exhibit non-specific binding to human and animal serum albumins. Methods To further probe the structural basis for the species-dependence of this albumin binding interaction, protein binding of these three radiopharmaceuticals was examined in solutions of albumin and/or serum from a broader array of mammalian species (rat, sheep, donkey, rabbit, cow, pig, dog, baboon, mouse, cat, elephant). We also evaluated the albumin binding of several copper(II) bis(thiosemicarbazone) chelates offering more diverse substitution of the ligand backbone. Results Cu-PTSM and Cu-ATSM exhibit a strong interaction with HSA that is not apparent with the albumins of other species, while the binding of Cu-ETS to albumin is much less species-dependent. The strong interaction of Cu-PTSM with HSA does not appear to simply correlate with variation, relative to the animal albumins, of a single amino acid lining HSA's IIA site. Those agents that selectively interact with HSA share the common feature of only methyl or hydrogen substitution at the carbon atoms of the diimine fragment of the ligand backbone. Conclusions The interspecies variations in albumin binding of Cu-PTSM and Cu-ATSM are not simply explained by unique amino acid substitutions in the IIA binding pocket of the serum albumins. However, the specific affinity for this region of HSA is disrupted when substituents bulkier than a methyl group appear on the imine carbons of the copper bis(thiosemicarbazone) chelate. PMID:19520290

  13. STRANAL-PMC Version 2.0

    NASA Technical Reports Server (NTRS)

    Goldberg, Robert; Carney, Kelly S.; Binienda, Wieslaw; Chattopadhyay, Aditi

    2006-01-01

    Version 2.0 of the Strain Rate Dependent Analysis of Polymer Matrix Composites (STRANAL-PMC) software has been released. A prior version was reported in Analyzing Loads and Strains in Polymer- Matrix Composites (LEW-17227), NASA Tech Briefs, Vol. 26, No. 11 (November 2002), page 36. To recapitulate: Modified versions of constitutive equations of viscoplasticity of metals are used to represent deformation of a polymeric matrix. The equations are applied in a micromechanical approach, proceeding upward from slices of unit cells, through the ply level, to the laminate level. The constitutive equations are integrated in time by a Runge- Kutta technique. To predict the ultimate strength of each composite ply, failure criteria are implemented within the micromechanics. The inputs to STRANAL-PMC are the laminate geometry, properties of the fiber and matrix materials, and applied stress or strain versus time. The outputs are time-dependent stresses and strains at the slice, ply, and laminate levels. The improvements in version 2.0 include more rigorous representation of hydrostatic- stress effects in the matrix, refinement and extension of ply failure models, and capabilities to analyze transverse shear stresses. Version 2.0 can be implemented as a material-model code within transient dynamic finite-element codes.

  14. Effect of cyclodextrin complexation on the in vivo disposition of the brain imaging radiopharmaceutical 99mTechnetium ethyl cysteinate dimer (99mTc-ECD).

    PubMed

    Oliver, D W; Dormehl, I C; Louw, W; Kilian, E; de Beco, V; Morretti, J L

    2000-08-01

    The brain imaging radiopharmaceutical, 99mTechnetium ethyl cysteinate dimer (99mTc-ECD, 99mTc-bicisate) is the most recent addition to the available set of radiopharmaceuticals for measuring cerebral blood flow. Ideally radiotracers should be trapped in the brain long enough so that their distribution can be quantitated and should demonstrate good spatial resolution. Furthermore, the stability (chemical and metabolic) and bioavailability of radiopharmaceuticals have in general proved to be a challenge during development and clinical administration. In view of these challenges and background, this study with 99mTc-ECD is presented. The aims of this research program were to develop novel approaches to improve the chemical and metabolic stability and the bioavailability of 99mTc-ECD across the blood brain barrier for cerebral blood flow determinations, using the well known non-human primate in vivo baboon model. These aims were addressed by investigating the influence of cyclodextrin--99mTc-ECD complexation on normal cerebral blood flow patterns, using two different cyclodextrins, i.e., gamma-cyclodextrin (CAS 17465-86-0) and beta-trimethylcyclodextrin (CAS 55216-11-0). The effect of incubation of 99mTc-ECD (with or without cyclodextrin complexation) in plasma, on metabolic esterase action, was also investigated. Possible protection against plasma esterase by acetylcholine (CAS 51-84-3) of 99mTc-ECD was further determined. The current study has shown that cyclodextrin complexation of 99mTc-ECD indeed offers a useful approach to improve the stability of the radiopharmaceutical against peripheral metabolism. The acetylcholine shows also potential to protect 99mTc-ECD. However, it is clear from the current data that the choice of cyclodextrin is of utmost importance, as has been observed from significantly reduced the bioavailability of 99mTc-ECD when complexed with beta-trimethylcyclodextrin. The plasma incubation procedures showed that gamma-cyclodextrin offers

  15. Online Information Searching Strategy Inventory (OISSI): A Quick Version and a Complete Version

    ERIC Educational Resources Information Center

    Tsai, Meng-Jung

    2009-01-01

    This study developed an instrument to evaluate student online information searching strategies based on a framework comprising three domains and seven aspects. Two versions of the Online Information Searching Strategies Inventory (OISSI), including both quick and complete versions, were finally established and exhibited good validities and…

  16. Examining Equivalency of the Driver Risk Inventory Test Versions: Does It Matter Which Version I Use?

    ERIC Educational Resources Information Center

    Degiorgio, Lisa

    2015-01-01

    Equivalency of test versions is often assumed by counselors and evaluators. This study examined two versions, paper-pencil and computer based, of the Driver Risk Inventory, a DUI/DWI (driving under the influence/driving while intoxicated) risk assessment. An overview of computer-based testing and standards for equivalency is also provided. Results…

  17. New GCVS Versions for Three Southern Constellations

    NASA Astrophysics Data System (ADS)

    Samus, N. N.; Pastukhova, E. N.; Durlevich, O. V.

    2007-10-01

    We are currently working on a version of the General Catalogue of Variable Stars (GCVS) revised taking into account the new data accumulated since the 4th GCVS edition. A draft new version will be released for each constellation as soon as the work for the constellation is finished. It will contain all stars of the 4th GCVS edition plus a complete catalogue of the stars added to the GCVS in the Name Lists of Variable Stars Nos. 67 - 78. Now we are ready for the first release, containing more than 1300 variable stars in the constellations of Antlia, Ara, and Telescopium. When preparing the release, we actively used modern data-mining possibilities to improve variability types and light elements. This paper introduces the first release of the new GCVS version and presents new results (types, light elements), based mainly on data mining, for 213 stars.

  18. New developments in program STANSOL version 3

    SciTech Connect

    Gray, W.H.

    1981-10-01

    STANSOL is a computer program that applied a solution for the mechanical displacement, stress, and strain in rotationally-transversely isotropic, homogeneous, axisymmetric solenoids. Careful application of the solution permits the complex mechanical behavior of multilayered, nonhomogeneous solenoids to be examined in which the loads may vary arbitrarily from layer to layer. Loads applied to the solenoid model by program STANSOL may consist of differential temperature, winding preload, internal and/or external surface pressure, and electromagnetic Lorentz body forces. STANSOL version 3, the latest update to the original version of the computer program, also permits structural analysis of solenoid magnets in which frictionless interlayer gaps may open or close. This paper presents the new theory coded into version 3 of the STANSOL program, as well as the new input data format and graphical output display of the resulting analysis.

  19. Praxis release notes: version 7. 3

    SciTech Connect

    Holloway, F.W.; DeGroot, A.

    1985-05-03

    These release notes are intended as a guide to those responsible for Nova software. They assume extensive knowledge of the present Praxis language. Each improvement made in Praxis is described. Many of the improvements have example programs which are contained within the chapter on example programs. For completeness, details are also included on the specific areas within the compiler which were modified. These will only be useful to those working on the compiler itself. The principal improvements made in this version of the compiler are: support under version 4.1 of the VMS operating system, ability to directly call the VMS Run Time Library, repair of two bugs introduced by version 7.2, and reintroduction and cleanup of the VMS System Service routines (OSI).

  20. AutoGen Version 5.0

    NASA Technical Reports Server (NTRS)

    Gladden, Roy E.; Khanampornpan, Teerapat; Fisher, Forest W.

    2010-01-01

    Version 5.0 of the AutoGen software has been released. Previous versions, variously denoted Autogen and autogen, were reported in two articles: Automated Sequence Generation Process and Software (NPO-30746), Software Tech Briefs (Special Supplement to NASA Tech Briefs), September 2007, page 30, and Autogen Version 2.0 (NPO- 41501), NASA Tech Briefs, Vol. 31, No. 10 (October 2007), page 58. To recapitulate: AutoGen (now signifying automatic sequence generation ) automates the generation of sequences of commands in a standard format for uplink to spacecraft. AutoGen requires fewer workers than are needed for older manual sequence-generation processes, and greatly reduces sequence-generation times. The sequences are embodied in spacecraft activity sequence files (SASFs). AutoGen automates generation of SASFs by use of another previously reported program called APGEN. AutoGen encodes knowledge of different mission phases and of how the resultant commands must differ among the phases. AutoGen also provides means for customizing sequences through use of configuration files. The approach followed in developing AutoGen has involved encoding the behaviors of a system into a model and encoding algorithms for context-sensitive customizations of the modeled behaviors. This version of AutoGen addressed the MRO (Mars Reconnaissance Orbiter) primary science phase (PSP) mission phase. On previous Mars missions this phase has more commonly been referred to as mapping phase. This version addressed the unique aspects of sequencing orbital operations and specifically the mission specific adaptation of orbital operations for MRO. This version also includes capabilities for MRO s role in Mars relay support for UHF relay communications with the MER rovers and the Phoenix lander.

  1. Using Versions of Literary Texts to Improve Comprehension.

    ERIC Educational Resources Information Center

    Samuel, Moses

    1995-01-01

    Discusses the use of the original text of Shakespeare's "Macbeth," a simplified version, and a comic-book version of the play in a college-level English-as-a-Second-Language (ESL) course. The results indicate that multiple versions of a text can help offset the shortcomings of using only the original text or a simplified version. (three…

  2. Validity of the Spanish version of the Emotional Labour Scale.

    PubMed

    Picardo, Juan M; López-Fernández, Consuelo; Hervás, María José Abellán

    2014-06-01

    In this article we address concerns raised by Brumit and Glenn (2013) regarding the validity of the Spanish version of the Emotional Labour Scale (ELS). We respond to requests in relation to the translated version of the scale and the eigenvalue series. We also give an explanation of the differences in results between the original version and the Spanish version of the scale.

  3. ⁶⁸Ge content quality control of ⁶⁸Ge/⁶⁸Ga-generator eluates and ⁶⁸Ga radiopharmaceuticals--a protocol for determining the ⁶⁸Ge content using thin-layer chromatography.

    PubMed

    Eppard, Elisabeth; Loktionova, Natalia S; Rösch, Frank

    2014-09-01

    (68)Ge breakthrough from a (68)Ge/(68)Ga-generator appears to be one of the most critical parameters for the routine clinical application of this generator and (68)Ga-radiopharmaceuticals. We report a TLC-based (thin-layer chromatography) protocol which allows the (68)Ge breakthrough of a generator to be determined within 1 h post-initial elution. The protocol can also be adapted to allow the (68)Ge content of a (68)Ga-radiopharmaceutical preparation to be determined prior to in vivo application.

  4. An Improved Version of TOPAZ 3D

    SciTech Connect

    Krasnykh, Anatoly

    2003-07-29

    An improved version of the TOPAZ 3D gun code is presented as a powerful tool for beam optics simulation. In contrast to the previous version of TOPAZ 3D, the geometry of the device under test is introduced into TOPAZ 3D directly from a CAD program, such as Solid Edge or AutoCAD. In order to have this new feature, an interface was developed, using the GiD software package as a meshing code. The article describes this method with two models to illustrate the results.

  5. Insider Alert 1.0 Beta Version

    2004-02-01

    Insider Alert 1.0 Beta Version supports interactive selection and graphical display of data generated by the Sandia Cognitive Framework, which simulates the examination of security data by experts of various specialties. Insider Alert also encompasses the configuration and data files input to the Cognitive Framework for this application. Insider Alert 1.0 Beta Version is a computer program for analyzing data indicative of possible espionage or improper handling of data by employees at Sandia National Laboratoriesmore » (or other facilities with comparable policies and procedures for managing sensitive information) It prioritizes and displays information for review by security analysts.« less

  6. Changes in the TRMM Version-5 and Version-6 Precipitation Radar Products Due to Orbit Boost

    NASA Technical Reports Server (NTRS)

    Liao, Liang; Meneghini, Robert

    2010-01-01

    The performance of the version-5 and version-6 Tropical Rainfall Measuring Mission (TRMM) Precipitation Radar (PR) products before and after the satellite orbit boost is assessed through a series of comparisons with Weather Surveillance Radar (WSR)-88D ground-based radar in Melbourne, Florida. Analysis of the comparisons of radar reflectivity near the storm top from the ground radar and both versions of the PR indicates that the PR bias relative to the WSR radar at Melbourne is on the order of 1dB for both pre- and post-boost periods, indicating that the PR products maintain accurate calibration after the orbit boost. Comparisons with the WSR-88D near-surface reflectivity factors indicate that both versions of the PR products accurately correct for attenuation in stratiform rain. However, in convective rain, both versions exhibit negative biases in the near-surface radar reflectivity with version-6 products having larger negative biases than version-5. Rain rate comparisons between the ground and space radars show similar characteristics

  7. Relationships between versional and vergent quick phases of the involuntary version-vergence nystagmus.

    PubMed

    Zhu, Mingxia; Hertle, Richard W; Yang, Dongsheng

    2008-07-23

    We used ground-plane motion stimuli displayed on a computer monitor positioned below eye level to induce involuntary version-vergence nystagmus (VVN). The VVN was recorded with a search coil system. It was shown that the VVN had both vertical versional and horizontal vergence components. The VVN induced by backward motion (toward subjects) had upward versional and divergence quick phases, whereas those induced by forward motion (away from subjects) had downward and biphasic divergence-convergence quick phases. The versional and vergence components of the VVN quick phases were analyzed. A temporal dissociation of about 20 ms between version velocity peak and convergence velocity peak was revealed, which supported a modified saccade-related vergence burst neuron (SVBN) model. We suggest that the temporal dissociation may be partly because of a lower-level OKN control mechanism. Vergence peak time was dependent on version peak time. Linear relationships between vergence peak velocity and versional saccadic peak velocity were demonstrated, which was in line with the new multiplicative model. Our data support the hypothesis that the vergence system and the saccadic system can act separately but interact with each other whenever their movements occur simultaneously.

  8. Version Control in Project-Based Learning

    ERIC Educational Resources Information Center

    Milentijevic, Ivan; Ciric, Vladimir; Vojinovic, Oliver

    2008-01-01

    This paper deals with the development of a generalized model for version control systems application as a support in a range of project-based learning methods. The model is given as UML sequence diagram and described in detail. The proposed model encompasses a wide range of different project-based learning approaches by assigning a supervisory…

  9. Breast Cancer, Version 3.2013

    PubMed Central

    Theriault, Richard L.; Carlson, Robert W.; Allred, Craig; Anderson, Benjamin O.; Burstein, Harold J.; Edge, Stephen B.; Farrar, William B.; Forero, Andres; Giordano, Sharon Hermes; Goldstein, Lori J.; Gradishar, William J.; Hayes, Daniel F.; Hudis, Clifford A.; Isakoff, Steven J.; Ljung, Britt-Marie E.; Mankoff, David A.; Marcom, P. Kelly; Mayer, Ingrid A.; McCormick, Beryl; Pierce, Lori J.; Reed, Elizabeth C.; Schwartzberg, Lee S.; Smith, Mary Lou; Soliman, Hatem; Somlo, George; Ward, John H.; Wolff, Antonio C.; Zellars, Richard; Shead, Dorothy A.; Kumar, Rashmi

    2014-01-01

    These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These include new first-line and subsequent therapy options for patients with HER2-positive metastatic breast cancer. PMID:23847214

  10. Methods for Identifying Versioned and Plagiarized Documents.

    ERIC Educational Resources Information Center

    Hoad, Timothy C.; Zobel, Justin

    2003-01-01

    Describes research that was conducted to develop and evaluate techniques for identifying plagiarism, revisions, and different versions of online documents. Highlights include ranking; parsing; similarity measures; identity measures; fingerprinting documents; measuring effectiveness via recall and precision; and experiments on two document…

  11. Two Versions of "Common" Test Eyed

    ERIC Educational Resources Information Center

    Gewertz, Catherine

    2012-01-01

    An unprecedented assessment project involving half the states is planning a significant shift: Instead of designing one test for all of them, it will offer a choice of a longer and a shorter version. The pivot came in response to some states' resistance to spending more time and money on testing for the common standards. The plan under discussion…

  12. Interpreting Graphic Versions of Shakespearean Plays

    ERIC Educational Resources Information Center

    Wolfe, Paula; Kleijwegt, Danielle

    2012-01-01

    The emergence of quality multimodal texts such as graphic novels may provide new vistas that allow adolescents access to more complex readings of difficult texts. This is especially true for the large number of graphic versions of Shakespearean text that have recently come on the market. However, it is still unclear as to what students actually…

  13. The OBIS Trail Module. Trial Version.

    ERIC Educational Resources Information Center

    Fairwell, Kay, Ed.; And Others

    Designed to allow youngsters aged 10 to 15 to experience the challenges and problems environmental investigators might face making an environmental impact study, the trial version of the Outdoor Biology Instructional Strategies (OBIS) Trail Module focuses on aspects of construction-related environment problems. Four activities are included in the…

  14. An experimental model to study the effects of a senna extract on the blood constituent labeling and biodistribution of a radiopharmaceutical in rats.

    PubMed

    Souza, Deise Elizabeth; Pereira, Marcia Oliveira; Bernardo, Luciana Camargo; Carmo, Fernanda Santos; Fonseca, Adenilson de Souza da; Bernardo-Filho, Mario

    2011-01-01

    Cassia angustifolia Vahl (senna) is a natural product that contains sennosides, which are active components that affect the intestinal tract and induce diarrhea. Authors have shown that senna produces DNA (deoxyribonucleic acid) lesions in Escherichia coli cultures and can act as an antifungal agent. Natural drugs can alter the labeling of blood constituents with technetium-⁹⁹m (⁹⁹mTc) and can affect the biodistribution of radiopharmaceuticals. In this work, we have evaluated the influence of a senna extract on the radiolabeling of blood constituents and on the biodistribution of the radiopharmaceutical sodium pertechnetate (Na⁹⁹mTcO₄)in Wistar rats. Twelve animals were treated with senna extract for 7 days. Blood samples were withdrawn from the animals and the radiolabeling procedure was carried out. The senna extract did not modify the radiolabeling of the blood constituents. A biodistributional assay was performed by administering Na⁹⁹mTcO₄ and determining its activity in different organs and in blood. The senna extract altered the biodistribution of Na⁹⁹mTcO₄ in the thyroid, liver, pancreas, lungs and blood. These results are associated with properties of the chemical substances present in the aqueous senna extract. Although these assays were performed in animals, our findings suggest that caution should be exercised when nuclear medicine examinations using Na⁹⁹mTcO₄ are conducted in patients who are using senna extract. PMID:21552677

  15. An experimental model to study the effects of a senna extract on the blood constituent labeling and biodistribution of a radiopharmaceutical in rats

    PubMed Central

    Souza, Deise Elizabeth; Pereira, Marcia Oliveira; Bernardo, Luciana Camargo; Carmo, Fernanda Santos; de Souza da Fonseca, Adenilson; Bernardo-Filho, Mario

    2011-01-01

    ABSTRACT Cassia angustifolia Vahl (senna) is a natural product that contains sennosides, which are active components that affect the intestinal tract and induce diarrhea. Authors have shown that senna produces DNA (deoxyribonucleic acid) lesions in Escherichia coli cultures and can act as an antifungal agent. Natural drugs can alter the labeling of blood constituents with technetium-99m (99mTc) and can affect the biodistribution of radiopharmaceuticals. In this work, we have evaluated the influence of a senna extract on the radiolabeling of blood constituents and on the biodistribution of the radiopharmaceutical sodium pertechnetate (Na99mTcO4) in Wistar rats. Twelve animals were treated with senna extract for 7 days. Blood samples were withdrawn from the animals and the radiolabeling procedure was carried out. The senna extract did not modify the radiolabeling of the blood constituents. A biodistributional assay was performed by administering Na99mTcO4 and determining its activity in different organs and in blood. The senna extract altered the biodistribution of Na99mTcO4 in the thyroid, liver, pancreas, lungs and blood. These results are associated with properties of the chemical substances present in the aqueous senna extract. Although these assays were performed in animals, our findings suggest that caution should be exercised when nuclear medicine examinations using Na99mTcO4 are conducted in patients who are using senna extract. PMID:21552677

  16. ( sup 111 In-DTPA-D-Phe sup 1 )-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation

    SciTech Connect

    Bakker, W.H.; Albert, R.; Bruns, C.; Breeman, W.A.P.; Hofland, L.J.; Marbach, P.; Pless, J.; Pralet, D.; Stolz, B.; Koper, J.W.; Lamberts, S.W.J.; Visser, T.J.; Krenning, E.P. Sandoz Pharma AG, Basel )

    1991-01-01

    As starting material for a potentially convenient radiopharmaceutical, a diethylenetriaminopentaacetic acid (DTPA) conjugated derivative of octreotide (SMS 201-995) was prepared. This peptide, (DTPA-D-Phe{sup 1})-octreotide (SDZ 215-811) binds more than 95% of added {sup 111}In in an easy, single-step labeling procedure without necessity of further purification. The specific somatostatin-like biologic effect of these analogues was proven by the inhibition of growth hormone secretion by cultured rat pituitary cells in a dose-dependent fashion by octreotide, (DTPA-D-Phe{sup 1})-octreotide and non-radioactive ({sup 115}In-DTPA-D-Phe{sup 1})-octreotide. The binding of ({sup 111}In-DTPA-D-Phe{sup 1})-octreotide to rat brain cortex membranes proved to be displaced similarly by natural somatosatin as well as by octreotide, suggesting specific binding of ({sup 111}In-DTPA-D-Phe{sup 1})-octreotide to somatostatin receptors. The binding of the indium-labeled compound showed a somewhat lower affinity when compared with the iodinated (Tyr{sup 3})-octreotide, but indium-labeled (DTPA-D-Phe{sup 1})-octreotide still binds with nanomolar affinity. In conjunction with in vivo studies, these results suggest that ({sup 111}In-DTPA-D-Phe{sup 1})-octreotide is a promising radiopharmaceutical for scintigraphic imaging of somatostatin receptor-positive tumors.

  17. An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications

    PubMed Central

    Cona, Marlein Miranda; de Witte, Peter; Verbruggen, Alfons; Ni, Yicheng

    2013-01-01

    Translational medicine pursues the conversion of scientific discovery into human health improvement. It aims to establish strategies for diagnosis and treatment of diseases. Cancer treatment is difficult. Radio-pharmaceutical research has played an important role in multiple disciplines, particularly in translational oncology. Based on the natural phenomenon of necrosis avidity, OncoCiDia has emerged as a novel generic approach for treating solid malignancies. Under this systemic dual targeting strategy, a vascular disrupting agent first selectively causes massive tumor necrosis that is followed by iodine-131 labeled-hypericin (123I-Hyp), a necrosis-avid compound that kills the residual cancer cells by crossfire effect of beta radiation. In this review, by emphasizing the potential clinical applicability of OncoCiDia, we summarize our research activities including optimization of radioiodinated hypericin Hyp preparations and recent studies on the biodistribution, dosimetry, pharmacokinetic and, chemical and radiochemical toxicities of the preparations. Myocardial infarction is a global health problem. Although cardiac scintigraphy using radioactive perfusion tracers is used in the assessment of myocardial viability, searching for diagnostic imaging agents with authentic necrosis avidity is pursued. Therefore, a comparative study on the biological profiles of the necrosis avid 123I-Hyp and the commercially available 99mTc-Sestamibi was conducted and the results are demonstrated. Cholelithiasis or gallstone disease may cause gallbladder inflammation, infection and other severe complications. While studying the mechanisms underlying the necrosis avidity of Hyp and derivatives, their naturally occurring fluorophore property was exploited for targeting cholesterol as a main component of gallstones. The usefulness of Hyp as an optical imaging agent for cholelithiasis was studied and the results are presented. Multiple uses of automatic contrast injectors may reduce costs

  18. Major Upgrades to the AIRS Version-6 Ozone Profile Methodology

    NASA Technical Reports Server (NTRS)

    Susskind, Joel; Blaisdell, John; Iredell, Lena

    2015-01-01

    This research is a continuation of part of what was shown at the last AIRS Science Team Meeting in the talk Improved Water Vapor and Ozone Profiles in SRT AIRS Version-6.X and the AIRS February 11, 2015 NetMeeting Further improvements in water vapor and ozone profiles compared to Version-6.AIRS Version-6 was finalized in late 2012 and is now operational. Version-6 contained many significant improvements in retrieval methodology compared to Version-5. However, Version-6 retrieval methodology used for the water vapor profile q(p) and ozone profile O3(p) retrievals is basically unchanged from Version-5, or even from Version-4. Subsequent research has made significant improvements in both water vapor and O3 profiles compared to Version-6. This talk will concentrate on O3 profile retrievals. Improvements in water vapor profile retrievals are given in a separate presentation.

  19. A comparison of the Space Station version of ASTROMAG with two free-flyer versions

    SciTech Connect

    Green, M.A.

    1992-06-01

    This Report compares the Space Station version of ASTROMAG with free-flyer versions of ASTROMAG which could fly on an Atlas lla rocket and a Delta rocket. Launch with either free-flyer imposes severe weight limits on the magnet and its cryogenic system. Both versions of ASTROMAG magnet which fly on free-flying satellites do not have to be charged more than once during the mission. This permits one to simplify the charging system and the cryogenic system. The helium ll pump loop which supplies helium to the gas cooled electrical leads can be eliminated in both of the free-flyer versions of the ASTROMAG magnet. This report describes the superconducting dipole moment correction coils which are necessary for the magnet to operate on a free-flying satellite.

  20. DOE SBIR Phase I Grant No. DE-FG02-00ER83067, ''A Flexible and Economical Automated Nucleophilic [{sup 18}F]Fluorination synthesis System for PET Radiopharmaceuticals.'' Final Technical Report

    SciTech Connect

    Padgett, Henry C.

    2001-08-04

    Phase I Final Report. A prototype manual remote synthesis system based on the unit operations approach was designed, constructed, and functionally tested. This general-purpose system was validated by its configuration and initial use for the preparation of the PET radiopharmaceutical [F-18]FLT using [F-18]fluoride ion.

  1. ICAN - INTEGRATED COMPOSITE ANALYZER (IBM PC VERSION)

    NASA Technical Reports Server (NTRS)

    Murthy, P. L.

    1994-01-01

    , macromechanics, and laminate analysis including the hygrothermal response of fiber composites. ICAN output includes the various ply and composite properties, composite structural response, and composite stress analysis results with details of failure. Output can be tailored to specific needs by choosing the appropriate options. Two machine versions of ICAN are available. The IBM 370 series version (LEW-14468) is written in FORTRAN IV for the IBM 370 series computers running OS/TSS. The IBM PC version (LEW-15592) is written in FORTRAN 77 for use on the IBM PC series computers running MS-DOS and Microsoft FORTRAN 5.1. The IBM 370 version requires 3.5Mb of memory for execution. No sample executable is provided. For the IBM PC version, a sample executable, along with sample input and output data, is included on the distribution medium. Although the included executable requires a math coprocessor, the ICAN source can be recompiled into an executable which does not require a math coprocessor. The standard distribution medium for the IBM 370 version of ICAN is a 9-track 1600 BPI magnetic tape in EBCDIC CARD IMAGE format. The standard distribution medium for the IBM PC version is one 5.25 inch 360K MS-DOS format diskette. The contents of the diskette are compressed using the PKWARE archiving tools. The utility to unarchive the files, PKUNZIP.EXE, is included. ICAN was developed in 1986 and the IBM PC version was released in 1992.

  2. ICAN - INTEGRATED COMPOSITE ANALYZER (IBM 370 VERSION)

    NASA Technical Reports Server (NTRS)

    Murthy, P. L.

    1994-01-01

    , macromechanics, and laminate analysis including the hygrothermal response of fiber composites. ICAN output includes the various ply and composite properties, composite structural response, and composite stress analysis results with details of failure. Output can be tailored to specific needs by choosing the appropriate options. Two machine versions of ICAN are available. The IBM 370 series version (LEW-14468) is written in FORTRAN IV for the IBM 370 series computers running OS/TSS. The IBM PC version (LEW-15592) is written in FORTRAN 77 for use on the IBM PC series computers running MS-DOS and Microsoft FORTRAN 5.1. The IBM 370 version requires 3.5Mb of memory for execution. No sample executable is provided. For the IBM PC version, a sample executable, along with sample input and output data, is included on the distribution medium. Although the included executable requires a math coprocessor, the ICAN source can be recompiled into an executable which does not require a math coprocessor. The standard distribution medium for the IBM 370 version of ICAN is a 9-track 1600 BPI magnetic tape in EBCDIC CARD IMAGE format. The standard distribution medium for the IBM PC version is one 5.25 inch 360K MS-DOS format diskette. The contents of the diskette are compressed using the PKWARE archiving tools. The utility to unarchive the files, PKUNZIP.EXE, is included. ICAN was developed in 1986 and the IBM PC version was released in 1992.

  3. Nimbus-7 TOMS Version 7 Calibration

    NASA Technical Reports Server (NTRS)

    Wellemeyer, C. G.; Taylor, S. L.; Jaross, G.; DeLand, M. T.; Seftor, C. J.; Labow, G.; Swissler, T. J.; Cebula, R. P.

    1996-01-01

    This report describes an improved instrument characterization used for the Version 7 processing of the Nimbus-7 Total Ozone Mapping Spectrometer (TOMS) data record. An improved internal calibration technique referred to as spectral discrimination is used to provide long-term calibration precision of +/- 1%/decade in total column ozone amount. A revised wavelength scale results in a day one calibration that agrees with other satellite and ground-based measurements of total ozone, while a wavelength independent adjustment of the initial radiometric calibration constants provides good agreement with surface reflectivity measured by other satellite-borne ultraviolet measurements. The impact of other aspects of the Nimbus-7 TOMS instrument performance are also discussed. The Version 7 data should be used in all future studies involving the Nimbus-7 TOMS measurements of ozone. The data are available through the NASA Goddard Space Flight Center's Distributive Active Archive Center (DAAC).

  4. MCNPX version 2.5.c

    SciTech Connect

    Hendricks, J. S.

    2003-01-01

    MCNPX is a Fortran 90 Monte Carlo radiation transport computer code that transports all particles at all energies. It is a superset of MCNP4C3, and has many capabilities beyond MCNP4C3. These capabilities are summarized along with their quality guarantee and code availability. Then the user interface changes from MCNP are described. Finally, the n.ew capabilities of the latest version, MCNPX 2.5.c, are documented. Future plans and references are also provided.

  5. [Personal contextual factors (short version), part II].

    PubMed

    Viol, M; Grotkamp, S; Seger, W

    2007-01-01

    In this journal a group of medical experts recently compiled a proposal for a systemic classification of personal contextual factors into domains, categories and items with respect to the ethical guidelines of the ICF (part I). In a second step the main issues have been transferred into the preliminary draft for a short version which is presented in this paper to give support for practical daily use in health insurance matters (part II). PMID:17347930

  6. Femoral Neck Version Affects Medial Femorotibial Loading

    PubMed Central

    Papaioannou, T. A.; Digas, Georgios; Bikos, Ch.; Karamoulas, V.; Magnissalis, E. A.

    2013-01-01

    The aim of this study was to provide a preliminary evaluation of the possible effect that femoral version may have on the bearing equilibrium conditions developed on the medial tibiofemoral compartment. A digital 3D solid model of the left physiological adult femur was used to create morphological variations of different neck-shaft angles (varus 115, normal 125, and valgus 135 degrees) and version angles (−10, 0, and +10 degrees). By means of finite element modeling and analysis techniques (FEM-FEA), a virtual experiment was executed with the femoral models aligned in a neutral upright position, distally supported on a fully congruent tibial tray and proximally loaded with a vertical only hip joint load of 2800 N. Equivalent stresses and their distribution on the medial compartment were computed and comparatively evaluated. Within our context, the neck-shaft angle proved to be of rather indifferent influence. Reduction of femoral version, however, appeared as the most influencing parameter regarding the tendency of the medial compartment to establish its bearing equilibrium towards posteromedial directions, as a consequence of the corresponding anteroposterior changes of the hip centre over the horizontal tibiofemoral plane. We found a correlation between femoral anteversion and medial tibiofemoral compartment contact pressure. Our findings will be further elucidated by more sophisticated FEM-FEA and by clinical studies that are currently planned. PMID:24959355

  7. Merged Sounding VAP Version 2.0

    SciTech Connect

    Troyan, D.; Jensen, M.; Turner, D.; Miloshevich, L.

    2010-03-15

    The Merged Sounding Value-Added Product (VAP) has been in the ARM and ASR pipeline since 2001. Output data streams have been added to the Evaluation Products section of the ARM website for the past five years. Currently, there are data for all of the ACRF fixed sites and all deployments of the Mobile Facility. Fifty-three years of Merged Sounding data is available as an evaluation product. The process of moving all to the ARM Data Archive has been started and will be completed shortly. A second version of the Merged Sounding VAP was developed to address several concerns: (1) Vaisala radiosondes have inherent problems obtaining an accurate measurement of relative humidity, (2) the profile can be extended from 20 km to 60 km above ground level based upon the height achieved by ECMWF profiles, and (3) ECMWF temperatures require adjustments at high altitude (between 1mb and 100 mb). Solutions to these issues have been incorporated in the new version of this VAP. Along with producing that second version of Merged Sounding, a secondary data stream - Sonde Adjust - was created. This VAP incorporates any humidity corrections to the Vaisala RS-80, RS-90, and RS-92 radiosondes. The algorithms used to perform these corrections are documented by Wang et. al. (2002), Turner et. al. (2003), and Miloshevich et. al. (2004, 2009).

  8. EPICS Version 4 - Implementing Complex Data Types

    SciTech Connect

    Marty Kraimer,; John dalesio

    2012-11-27

    Through phase 1 and phase 2 SBIR grants, s fully functional I/O Controller and communication protocol for version 4 of EPICS is completed. This new software architecture provides a flexible and extendible architecture. Version 4 is implemented fully in Java. The performance metrics look promising. The final portion of phase 2 is to optimize the communication mechanisms. Subsequent work on different aspects of this are required to provide a viable solutions in various areas. Version 3 of EPICS is able to provide a platform for implementing channel based control, because the channel and attributes for time stamping, alarm, display and control were narrow, well defined, and complete. To extend EPICS functionality beyond this, it is necessary to define attributes needed for archive data, array, image data, and directory services. The proper handling of several array types enables the development of middle layer servers such as orbit and bump control in accelerators. Phase 1 should produce a well defined, reviewed, and agreed upon definition of the metadata required for these services. A Phase 2 grant would provide tools that implemented archiving, general array, imaging, and directory applications.

  9. Effective glenoid version in professional baseball players.

    PubMed

    Drakos, Mark C; Barker, Joseph U; Osbahr, Daryl C; Lehto, Scott; Rudzki, Jonas R; Potter, Hollis; Coleman, Struan H; Allen, Answorth A; Altchek, David W

    2010-07-01

    The pathomechanics of the throwing shoulder have yet to be fully elucidated. The focus of this study reported here was to further characterize the morphology of the glenoid in a population of elite throwing athletes. We obtained magnetic resonance imaging scans of 38 professional baseball players (dominant shoulders) and of 35 age matched nonthrowing control patients (17 dominant and 18 nondominant shoulders). Seven measurements were made by 3 blinded reviewers on 3 axial images per patient: version of superior glenoid, middle glenoid, inferior glenoid, superior capsulolabral junction, middle capsulolabral junction, inferior capsulolabral junction, and depth of concavity of glenoid in a middle slice. Mean age of the 38 players (24 pitchers, 14 fielders) was 26.8 years, and mean age of the 35 control patients was 27.6 years. Intraclass correlation coefficients ranged from .55 to .84 for the version measurements. There were no statistically significant differences between the pitchers and the fielders on any of the 7 measurements, but such differences were found between the throwers and the dominant-shoulder control patients on all 7 measurements. There were only 2 differences (version of superior glenoid, depth of concavity of glenoid in a middle slice) between dominant- and nondominant- shoulder control patients. There was significantly more retroversion in the osseous and soft tissues of the elite throwing athletes than in the nonthrowing control patients. This increased retroversion may play a role in development of internal impingement in the overhead athlete.

  10. Mission Data System Java Edition Version 7

    NASA Technical Reports Server (NTRS)

    Reinholtz, William K.; Wagner, David A.

    2013-01-01

    The Mission Data System framework defines closed-loop control system abstractions from State Analysis including interfaces for state variables, goals, estimators, and controllers that can be adapted to implement a goal-oriented control system. The framework further provides an execution environment that includes a goal scheduler, execution engine, and fault monitor that support the expression of goal network activity plans. Using these frameworks, adapters can build a goal-oriented control system where activity coordination is verified before execution begins (plan time), and continually during execution. Plan failures including violations of safety constraints expressed in the plan can be handled through automatic re-planning. This version optimizes a number of key interfaces and features to minimize dependencies, performance overhead, and improve reliability. Fault diagnosis and real-time projection capabilities are incorporated. This version enhances earlier versions primarily through optimizations and quality improvements that raise the technology readiness level. Goals explicitly constrain system states over explicit time intervals to eliminate ambiguity about intent, as compared to command-oriented control that only implies persistent intent until another command is sent. A goal network scheduling and verification process ensures that all goals in the plan are achievable before starting execution. Goal failures at runtime can be detected (including predicted failures) and handled by adapted response logic. Responses can include plan repairs (try an alternate tactic to achieve the same goal), goal shedding, ignoring the fault, cancelling the plan, or safing the system.

  11. Stabalized radiopharmaceutical compositions

    SciTech Connect

    Charleson, F.P.

    1989-11-14

    This patent describes a stabilized radiopharmaceutial composition. It comprises: a molecule containing a radioactive iodine atom and a stabilize, selected from the group consisting of ascorbic acid, nicotinamide and its corresponding amides, or a mixture of ascorbic acid and nicotinamide and its amides, in a sufficient amount to stabilize against radiolytic decomposition.

  12. Rapid brain scanning radiopharmaceutical

    DOEpatents

    Sargent, T.W. III; Shulgin, A.T.; Mathis, C.A.

    1987-03-03

    A method for detecting the blood flow in animals, particularly in the brain, is provided wherein a detectable amount of a novel radioactive compound of the formula 1 is administered to one animal: as given in figure in patent wherein R[sub 1] and R[sub 2] are independently alkyl of 1 to 6 carbon atoms or benzyl; R[sub 3] is alkyl of 1 to 6 carbon atoms, benzyl, cyclopropylalkyl of 4 to 6 carbon atoms, or cyanoalkyl of 2 to 6 carbon atoms; R[sub 4] is hydrogen, benzyl or alkyl of 1 to 6 carbon atoms; with the provisos that R[sub 4] is not isopropyl and when R[sub 4] is methyl, R[sub 3] is not benzyl; and X is a radioactive halogen. 2 figs.

  13. Rapid brain scanning radiopharmaceutical

    DOEpatents

    Sargent, III, Thornton W.; Shulgin, Alexander T.; Mathis, Chester A.

    1987-01-01

    A method for detecting the blood flow in animals, particularly in the brain, is provided wherein a detectable amount of a novel radioactive compound of the formula I is administered to one animal: ##STR1## wherein R.sub.1 and R.sub.2 are independently alkyl of 1 to 6 carbon atoms or benzyl; R.sub.3 is alkyl of 1 to 6 carbon atoms, benzyl, cyclopropylalkyl of 4 to 6 carbon atoms, or cyanoalkyl of 2 to 6 carbon atoms; R.sub.4 is hydrogen, benzyl or alkyl of 1 to 6 carbon atoms; with the provisos that R.sub.4 is not isopropyl and when R.sub.4 is methyl, R.sub.3 is not benzyl; and X is a radioactive halogen.

  14. Validity of the Spanish version of the Emotional Labour Scale.

    PubMed

    Picardo, Juan M; López-Fernández, Consuelo; Hervás, María José Abellán

    2014-06-01

    In this article we address concerns raised by Brumit and Glenn (2013) regarding the validity of the Spanish version of the Emotional Labour Scale (ELS). We respond to requests in relation to the translated version of the scale and the eigenvalue series. We also give an explanation of the differences in results between the original version and the Spanish version of the scale. PMID:24581889

  15. Progress Towards AIRS Science Team Version-7 at SRT

    NASA Technical Reports Server (NTRS)

    Susskind, Joel; Blaisdell, John; Iredell, Lena; Kouvaris, Louis

    2016-01-01

    The AIRS Science Team Version-6 retrieval algorithm is currently producing level-3 Climate Data Records (CDRs) from AIRS that have been proven useful to scientists in understanding climate processes. CDRs are gridded level-3 products which include all cases passing AIRS Climate QC. SRT has made significant further improvements to AIRS Version-6. At the last Science Team Meeting, we described results using SRT AIRS Version-6.22. SRT Version-6.22 is now an official build at JPL called 6.2.4. Version-6.22 results are significantly improved compared to Version-6, especially with regard to water vapor and ozone profiles. We have adapted AIRS Version-6.22 to run with CrIS/ATMS, at the Sounder SIPS which processed CrIS/ATMS data for August 2014. JPL AIRS Version-6.22 uses the Version-6 AIRS tuning coefficients. AIRS Version-6.22 has at least two limitations which must be improved before finalization of Version-7: Version-6.22 total O3 has spurious high values in the presence of Saharan dust over the ocean; and Version-6.22 retrieved upper stratospheric temperatures are very poor in polar winter. SRT Version-6.28 addresses the first concern. John Blaisdell ran the analog of AIRS Version-6.28 in his own sandbox at JPL for the 14th and 15th of every month in 2014 and all of July and October for 2014. AIRS Version-6.28a is hot off the presses and addresses the second concern.

  16. 48 CFR 3439.701 - Internet Protocol version 6.

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... 48 Federal Acquisition Regulations System 7 2014-10-01 2014-10-01 false Internet Protocol version... Requirements for Acquisition of Information Technology 3439.701 Internet Protocol version 6. The contracting officer must insert the clause at 3452.239-70 (Internet protocol version 6 (IPv6)) in all...

  17. 48 CFR 3439.701 - Internet Protocol version 6.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... 48 Federal Acquisition Regulations System 7 2013-10-01 2012-10-01 true Internet Protocol version 6... for Acquisition of Information Technology 3439.701 Internet Protocol version 6. The contracting officer must insert the clause at 3452.239-70 (Internet protocol version 6 (IPv6)) in all...

  18. 48 CFR 3439.701 - Internet Protocol version 6.

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... 48 Federal Acquisition Regulations System 7 2011-10-01 2011-10-01 false Internet Protocol version... Requirements for Acquisition of Information Technology 3439.701 Internet Protocol version 6. The contracting officer must insert the clause at 3452.239-70 (Internet protocol version 6 (IPv6)) in all...

  19. 48 CFR 3439.701 - Internet Protocol version 6.

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... 48 Federal Acquisition Regulations System 7 2012-10-01 2012-10-01 false Internet Protocol version... Requirements for Acquisition of Information Technology 3439.701 Internet Protocol version 6. The contracting officer must insert the clause at 3452.239-70 (Internet protocol version 6 (IPv6)) in all...

  20. Reliability Assessment for Two Versions of Vocabulary Levels Tests

    ERIC Educational Resources Information Center

    Xing, Peiling; Fulcher, Glenn

    2007-01-01

    This article reports a reliability study of two versions of the Vocabulary Levels Test at the 5000 word level. This study was motivated by a finding from an ongoing longitudinal study of vocabulary acquisition that Version A and Version B of Vocabulary Levels Test at the 5000 word level were not parallel. In order to investigate this issue,…

  1. CLIPS 6.0 - C LANGUAGE INTEGRATED PRODUCTION SYSTEM, VERSION 6.0 (MACINTOSH VERSION)

    NASA Technical Reports Server (NTRS)

    Riley, G.

    1994-01-01

    COOL (that is, a rule can pattern match on objects created using COOL). CLIPS 6.0 provides the capability to define functions, overloaded functions, and global variables interactively. In addition, CLIPS can be embedded within procedural code, called as a subroutine, and integrated with languages such as C, FORTRAN and Ada. CLIPS can be easily extended by a user through the use of several well-defined protocols. CLIPS provides several delivery options for programs including the ability to generate stand alone executables or to load programs from text or binary files. CLIPS 6.0 provides support for the modular development and execution of knowledge bases with the defmodule construct. CLIPS modules allow a set of constructs to be grouped together such that explicit control can be maintained over restricting the access of the constructs by other modules. This type of control is similar to global and local scoping used in languages such as C or Ada. By restricting access to deftemplate and defclass constructs, modules can function as blackboards, permitting only certain facts and instances to be seen by other modules. Modules are also used by rules to provide execution control. The CRSV (Cross-Reference, Style, and Verification) utility included with previous version of CLIPS is no longer supported. The capabilities provided by this tool are now available directly within CLIPS 6.0 to aid in the development, debugging, and verification of large rule bases. COSMIC offers four distribution versions of CLIPS 6.0: UNIX (MSC-22433), VMS (MSC-22434), MACINTOSH (MSC-22429), and IBM PC (MSC-22430). Executable files, source code, utilities, documentation, and examples are included on the program media. All distribution versions include identical source code for the command line version of CLIPS 6.0. This source code should compile on any platform with an ANSI C compiler. Each distribution version of CLIPS 6.0, except that for the Macintosh platform, includes an executable for the

  2. CLIPS 6.0 - C LANGUAGE INTEGRATED PRODUCTION SYSTEM, VERSION 6.0 (IBM PC VERSION)

    NASA Technical Reports Server (NTRS)

    Donnell, B.

    1994-01-01

    COOL (that is, a rule can pattern match on objects created using COOL). CLIPS 6.0 provides the capability to define functions, overloaded functions, and global variables interactively. In addition, CLIPS can be embedded within procedural code, called as a subroutine, and integrated with languages such as C, FORTRAN and Ada. CLIPS can be easily extended by a user through the use of several well-defined protocols. CLIPS provides several delivery options for programs including the ability to generate stand alone executables or to load programs from text or binary files. CLIPS 6.0 provides support for the modular development and execution of knowledge bases with the defmodule construct. CLIPS modules allow a set of constructs to be grouped together such that explicit control can be maintained over restricting the access of the constructs by other modules. This type of control is similar to global and local scoping used in languages such as C or Ada. By restricting access to deftemplate and defclass constructs, modules can function as blackboards, permitting only certain facts and instances to be seen by other modules. Modules are also used by rules to provide execution control. The CRSV (Cross-Reference, Style, and Verification) utility included with previous version of CLIPS is no longer supported. The capabilities provided by this tool are now available directly within CLIPS 6.0 to aid in the development, debugging, and verification of large rule bases. COSMIC offers four distribution versions of CLIPS 6.0: UNIX (MSC-22433), VMS (MSC-22434), MACINTOSH (MSC-22429), and IBM PC (MSC-22430). Executable files, source code, utilities, documentation, and examples are included on the program media. All distribution versions include identical source code for the command line version of CLIPS 6.0. This source code should compile on any platform with an ANSI C compiler. Each distribution version of CLIPS 6.0, except that for the Macintosh platform, includes an executable for the

  3. CLIPS 6.0 - C LANGUAGE INTEGRATED PRODUCTION SYSTEM, VERSION 6.0 (UNIX VERSION)

    NASA Technical Reports Server (NTRS)

    Donnell, B.

    1994-01-01

    COOL (that is, a rule can pattern match on objects created using COOL). CLIPS 6.0 provides the capability to define functions, overloaded functions, and global variables interactively. In addition, CLIPS can be embedded within procedural code, called as a subroutine, and integrated with languages such as C, FORTRAN and Ada. CLIPS can be easily extended by a user through the use of several well-defined protocols. CLIPS provides several delivery options for programs including the ability to generate stand alone executables or to load programs from text or binary files. CLIPS 6.0 provides support for the modular development and execution of knowledge bases with the defmodule construct. CLIPS modules allow a set of constructs to be grouped together such that explicit control can be maintained over restricting the access of the constructs by other modules. This type of control is similar to global and local scoping used in languages such as C or Ada. By restricting access to deftemplate and defclass constructs, modules can function as blackboards, permitting only certain facts and instances to be seen by other modules. Modules are also used by rules to provide execution control. The CRSV (Cross-Reference, Style, and Verification) utility included with previous version of CLIPS is no longer supported. The capabilities provided by this tool are now available directly within CLIPS 6.0 to aid in the development, debugging, and verification of large rule bases. COSMIC offers four distribution versions of CLIPS 6.0: UNIX (MSC-22433), VMS (MSC-22434), MACINTOSH (MSC-22429), and IBM PC (MSC-22430). Executable files, source code, utilities, documentation, and examples are included on the program media. All distribution versions include identical source code for the command line version of CLIPS 6.0. This source code should compile on any platform with an ANSI C compiler. Each distribution version of CLIPS 6.0, except that for the Macintosh platform, includes an executable for the

  4. A strategy for the study of cerebral amino acid transport using iodine-123-labeled amino acid radiopharmaceutical: 3-iodo-alpha-methyl-L-tyrosine

    SciTech Connect

    Kawai, K.; Fujibayashi, Y.; Saji, H.; Yonekura, Y.; Konishi, J.; Kubodera, A.; Yokoyama, A. )

    1991-05-01

    We examined the brain accumulation of iodine-123-iodo-alpha-methyl-L-tyrosine ({sup 123}I-L-AMT) in mice and rats. I-L-AMT showed high brain accumulation in mice, and in rats; rat brain uptake index exceeded that of {sup 14}C-L-tyrosine. The brain uptake index and the brain slice studies indicated the affinity of I-L-AMT for carrier-mediated and stereoselective active transport systems, respectively; both operating across the blood-brain barrier and cell membranes of the brain. The tissue homogenate analysis revealed that most of the accumulated radioactivity belonged to intact I-L-AMT, an indication of its stability. Thus, {sup 123}I-L-AMT appears to be a useful radiopharmaceutical for the selective measurement of cerebral amino acid transport.

  5. Synthesis of the first radiolabeled 188Re N-heterocyclic carbene complex and initial studies on its potential use in radiopharmaceutical applications

    PubMed Central

    Wagner, Thomas; Zeglis, Brian M.; Groveman, Sam; Hille, Claudia; Pöthig, Alexander; Francesconi, Lynn C.; Herrmann, Wolfgang A.; Kühn, Fritz E.; Reiner, Thomas

    2015-01-01

    A novel approach towards the synthesis of radiolabeled organometallic rhenium complexes is presented. We successfully synthesized and analyzed the first 188Re-labeled N-heterocyclic biscarbene complex, trans-dioxobis(1,1′-methylene-bis(3,3′-diisopropylimidazolium-2-ylidene))188rhenium(V) hexafluorophosphate (188Re-4) via transmetalation using an air-stable and moisture-stable silver(I) biscarbene complex. In order to assess the viability of this complex as a potential lead structure for in vivo applications, the stability of the 188Re-NHC complex was tested in physiologically relevant media. Ultimately, our studies illustrate that the complex we synthesized dissociates rapidly and is therefore unsuitable for use in radiopharmaceuticals. However, it is clear that the transmetalation approach we have developed is a rapid, robust, and mild method for the synthesis of new 188Re-labeled carbene complexes. PMID:24889257

  6. Modular syntheses of H₄octapa and H₂dedpa, and yttrium coordination chemistry relevant to ⁸⁶Y/⁹⁰Y radiopharmaceuticals.

    PubMed

    Price, Eric W; Cawthray, Jacqueline F; Adam, Michael J; Orvig, Chris

    2014-05-21

    The ligands H2dedpa, H4octapa, p-SCN-Bn-H2dedpa, and p-SCN-Bn-H4octapa were synthesized using a new protection chemistry approach, with labile tert-butyl esters replacing the previously used methyl esters as protecting groups for picolinic acid moieties. Additionally, the ligands H2dedpa and p-SCN-Bn-H2dedpa were synthesized using nosyl protection chemistry for the first time. The use of tert-butyl esters allows for deprotection at room temperature in trifluoroacetic acid (TFA), which compares favorably to the harsh conditions of refluxing HCl (6 M) or LiOH that were previously required for methyl ester cleavage. H4octapa has recently been shown to be a very promising (111)In and (177)Lu ligand for radiopharmaceutical applications; therefore, coordination chemistry studies with Y(3+) are described to assess its potential for use with (86)Y/(90)Y. The solution chemistry of H4octapa with Y(3+) is shown to be suitable via solution NMR studies of the [Y(octapa)](-) complex and density functional theory (DFT) calculations of the predicted structure, suggesting properties similar to those of the analogous In(3+) and Lu(3+) complexes. The molecular electrostatic potential (MEP) was mapped onto the molecular surface of the DFT-calculated coordination structures, suggesting very similar and even charge distributions between both the Lu(3+) and Y(3+) complexes of octapa(4-), and coordinate structures between 8 (ligand only) and 9 (ligand and one H2O). Potentiometric titrations determined H4octapa to have a formation constant (log K(ML)) with Y(3+) of 18.3 ± 0.1, revealing high thermodynamic stability. This preliminary work suggests that H4octapa may be a competent ligand for future (86)Y/(90)Y radiopharmaceutical applications.

  7. Comparative evaluation of glutamate-sensitive radiopharmaceuticals: Technetium-99m-glutamic acid and technetium-99m-diethylenetriaminepentaacetic acid-bis(glutamate) conjugate for tumor imaging.

    PubMed

    Kakkar, Dipti; Tiwari, Anjani K; Chuttani, Krishna; Kaul, Ankur; Singh, Harpal; Mishra, Anil K

    2010-12-01

    Single-photon emission computed tomography has become a significant imaging modality with huge potential to visualize and provide information of anatomic dysfunctions that are predictive of future diseases. This imaging tool is complimented by radiopharmaceuticals/radiosubstrates that help in imaging specific physiological aspects of the human body. The present study was undertaken to explore the utility of technetium-99m (⁹⁹(m)Tc)-labeled glutamate conjugates for tumor scintigraphy. As part of our efforts to further utilize the application of chelating agents, glutamic acid was conjugated with a multidentate ligand, diethylenetriaminepentaacetic acid (DTPA). The DTPA-glutamate conjugate [DTPA-bis(Glu)] was well characterized by IR, NMR, and mass spectroscopy. The biological activity of glutamic acid was compared with its DTPA conjugate by radiocomplexation with ⁹⁹(m)Tc (labeling efficiency ≥98%). In vivo studies of both the radiolabeled complexes ⁹⁹(m)Tc-Glu and ⁹⁹(m)Tc-DTPA-bis(Glu) were then carried out, followed by gamma scintigraphy in New Zealand albino rabbits. Improved serum stability of ⁹⁹(m)Tc-labeled DTPA conjugate indicated that ⁹⁹(m)Tc remained bound to the conjugate up to 24 hours. Blood clearance showed a relatively slow washout of the DTPA conjugate when compared with the labeled glutamate. Biodistribution characteristics of the conjugate in Balb/c mice revealed that DTPA conjugation of glutamic acid favors less accumulation in the liver and bone and rapid renal clearance. Tumor scintigraphy in mice showed increasing tumor accumulation, stable up to 4 hours. These preliminary studies show that ⁹⁹(m)Tc-DTPA-bis(Glu) can be a useful radiopharmaceutical for diagnostic applications in single-photon emission computed tomography imaging.

  8. Rhenium and technetium tricarbonyl, {M(CO)3} (+) (M = Tc, Re), binding to mammalian metallothioneins: new insights into chemical and radiopharmaceutical implications.

    PubMed

    Lecina, Joan; Palacios, Òscar; Atrian, Sílvia; Capdevila, Mercè; Suades, Joan

    2015-04-01

    This paper deals with the binding of the four mammalian metallothioneins (MTs) to the organometallic metal fragment {fac-M(CO)3}(+) (M = (99)Tc, Re), which is highly promising for the preparation of second-generation radiopharmaceuticals. The study of the transmetallation reaction between zinc and rhenium in Zn7-MT1 by means of UV-vis and CD spectroscopy demonstrated the incorporation of the {fac-Re(CO)3}(+) fragment to the MTs. This reaction should be performed at 70 °C to accelerate the reaction rate, a result that is consistent with the reported reactivity of the rhenium fragment. ESI-TOF MS demonstrated the formation of mixed-metal species as Zn6,{Re(CO)3}-MT, Zn6,{Re(CO)3}2-MT, and Zn5,{Re(CO)3}3-MT, as well as the different reactivity of the four MT isoforms. Hence, Zn-MT3 showed the highest reactivity, in agreement with its high Cu-thionein character, whereas Zn-MT2 exhibited the lowest reactivity, in line with its high Zn-thionein character. The reactivity of the Zn-loaded forms of MT1 and MT4 is intermediate between those of MT3 and MT2. The study of the binding of the {fac-(99)Tc(CO)3}(+) fragment to MTs showed a significant and very interesting different reactivity in relation to rhenium. The transmetallation reaction is much more effective with technetium than with rhenium and significant amounts of mixed Zn x ,{(99)Tc(CO)3} y -MT species were formed with the four MT isoforms whereas only MT3 rendered similar amounts of rhenium derivatives. The results obtained in this study support the possible use of technetium for labelling mammalian metallothioneins and also for possible radiopharmaceutical applications.

  9. A Method to Predict Response of Cell Populations to Cocktails of Chemotherapeutics and Radiopharmaceuticals: Validation with Daunomycin, Doxorubicin, and the Alpha Particle Emitter 210Po

    PubMed Central

    Akudugu, John M.; Howell, Roger W.

    2012-01-01

    There is considerable interest in the use of α-emitting radionuclides in radioimmunotherapy. However, the high toxicity of α-emitting radionuclides often does not permit administration of high activities for fear of normal tissue toxicity. Accordingly, targeting procedures need to be optimized for improved tumor control and minimized normal tissue toxicity. To guide design of effective cocktails of α-emitting radiopharmaceuticals and chemotherapy drugs, approaches that can predict biological response of a cell population on a cell-by-cell basis are needed. Methods Cells were concomitantly treated with the α-particle emitting radiochemical 210Po-citrate and daunomycin, or with 210Po-citrate and doxorubicin. The responses of the treated cell populations were measured with a colony forming assay. The nonuniform cellular incorporation of the radiochemical and drugs was determined simultaneously on a cell-by-cell basis using flow cytometry. Monte Carlo methods were used to simulate cell survival on the of basis individual cell incorporation of each cytotoxic agent and validated by direct comparison with the experimental clonogenic cell survival. Results Both daunomycin and doxorubicin enhanced the toxicity of the α-particles with a magnitude greater than expected based on single-agent toxicities. Cell survival obtained by Monte Carlo simulation was in good agreement with clonogenic cell survival for the combination treatments. Conclusion Flow cytometry assisted Monte Carlo simulations can be used to predict toxicity of cocktails of α-emitting radiopharmaceuticals and chemotherapy drugs in a manner that takes into account the effects of nonuniform distributions of agents within cell populations. PMID:22503536

  10. Design of Ga-DOTA-based bifunctional radiopharmaceuticals: two functional moieties can be conjugated to radiogallium-DOTA without reducing the complex stability.

    PubMed

    Mukai, Takahiro; Suwada, Jun; Sano, Kohei; Okada, Mayumi; Yamamoto, Fumihiko; Maeda, Minoru

    2009-07-01

    From the X-ray crystal structures of Ga-DOTA chelates, we were able to deduce that two free carboxylate groups of the radiogallium-DOTA complex may be utilized for coupling to functional moieties that recognize molecular targets for in vivo imaging without reducing the radiogallium-complex stability. Thus, we designed 2,2'-[4,10-bis(2-{[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]amino}-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl]diacetic acid (DOTA-MN2) (7), employing a metronidazole moiety as the recognition site of hypoxic lesions, based on the drug design concept of bifunctional radiopharmaceuticals. Coupling of DOTA-bis(tert-butyl)ester 5 with 1-(2-aminoethyl)-2-methyl-5-nitroimidazole dihydrochloride, followed by deprotection, afforded the required 7 (DOTA-MN2). (67)Ga-labeling was carried out by reaction of DOTA-MN2 with (67)Ga-citrate. When (67)Ga-DOTA-MN2 was incubated in phosphate-buffered saline or mouse plasma, no measurable decomposition occurred over a 24-h period. In biodistribution experiments in NFSa tumor-bearing mice, (67)Ga-DOTA-MN2 displayed not only a significant tumor uptake, but also rapid blood clearance and low accumulations in nontarget tissues, resulting in high target-to-nontarget ratios of radioactivity. These results indicate the potential benefits of the drug design of (67)Ga-DOTA-MN2. The present findings provide helpful information for the development of radiogallium-labeled radiopharmaceuticals for SPECT and PET studies. PMID:19481944

  11. Fuzzy Versions of Epistemic and Deontic Logic

    NASA Technical Reports Server (NTRS)

    Gounder, Ramasamy S.; Esterline, Albert C.

    1998-01-01

    Epistemic and deontic logics are modal logics, respectively, of knowledge and of the normative concepts of obligation, permission, and prohibition. Epistemic logic is useful in formalizing systems of communicating processes and knowledge and belief in AI (Artificial Intelligence). Deontic logic is useful in computer science wherever we must distinguish between actual and ideal behavior, as in fault tolerance and database integrity constraints. We here discuss fuzzy versions of these logics. In the crisp versions, various axioms correspond to various properties of the structures used in defining the semantics of the logics. Thus, any axiomatic theory will be characterized not only by its axioms but also by the set of properties holding of the corresponding semantic structures. Fuzzy logic does not proceed with axiomatic systems, but fuzzy versions of the semantic properties exist and can be shown to correspond to some of the axioms for the crisp systems in special ways that support dependency networks among assertions in a modal domain. This in turn allows one to implement truth maintenance systems. For the technical development of epistemic logic, and for that of deontic logic. To our knowledge, we are the first to address fuzzy epistemic and fuzzy deontic logic explicitly and to consider the different systems and semantic properties available. We give the syntax and semantics of epistemic logic and discuss the correspondence between axioms of epistemic logic and properties of semantic structures. The same topics are covered for deontic logic. Fuzzy epistemic and fuzzy deontic logic discusses the relationship between axioms and semantic properties for these logics. Our results can be exploited in truth maintenance systems.

  12. TOUGH2 User's Guide Version 2

    SciTech Connect

    Pruess, K.; Oldenburg, C.M.; Moridis, G.J.

    1999-11-01

    TOUGH2 is a numerical simulator for nonisothermal flows of multicomponent, multiphase fluids in one, two, and three-dimensional porous and fractured media. The chief applications for which TOUGH2 is designed are in geothermal reservoir engineering, nuclear waste disposal, environmental assessment and remediation, and unsaturated and saturated zone hydrology. TOUGH2 was first released to the public in 1991; the 1991 code was updated in 1994 when a set of preconditioned conjugate gradient solvers was added to allow a more efficient solution of large problems. The current Version 2.0 features several new fluid property modules and offers enhanced process modeling capabilities, such as coupled reservoir-wellbore flow, precipitation and dissolution effects, and multiphase diffusion. Numerous improvements in previously released modules have been made and new user features have been added, such as enhanced linear equation solvers, and writing of graphics files. The T2VOC module for three-phase flows of water, air and a volatile organic chemical (VOC), and the T2DM module for hydrodynamic dispersion in 2-D flow systems have been integrated into the overall structure of the code and are included in the Version 2.0 package. Data inputs are upwardly compatible with the previous version. Coding changes were generally kept to a minimum, and were only made as needed to achieve the additional functionalities desired. TOUGH2 is written in standard FORTRAN77 and can be run on any platform, such as workstations, PCs, Macintosh, mainframe and supercomputers, for which appropriate FORTRAN compilers are available. This report is a self-contained guide to application of TOUGH2 to subsurface flow problems. It gives a technical description of the TOUGH2 code, including a discussion of the physical processes modeled, and the mathematical and numerical methods used. Illustrative sample problems are presented along with detailed instructions for preparing input data.

  13. Brazilian version of the Berg balance scale.

    PubMed

    Miyamoto, S T; Lombardi Junior, I; Berg, K O; Ramos, L R; Natour, J

    2004-09-01

    The purpose of the present study was to translate and adapt the Berg balance scale, an instrument for functional balance assessment, to Brazilian-Portuguese and to determine the reliability of scores obtained with the Brazilian adaptation. Two persons proficient in English independently translated the original scale into Brazilian-Portuguese and a consensus version was generated. Two translators performed a back translation. Discrepancies were discussed and solved by a panel. Forty patients older than 65 years and 40 therapists were included in the cultural adaptation phase. If more than 15% of therapists or patients reported difficulty in understanding an item, that item was reformulated and reapplied. The final Brazilian version was then tested on 36 elderly patients (over age 65). The average age was 72 years. Reliability of the measure was assessed twice by one physical therapist (1-week interval between assessments) and once by one independent physical therapist. Descriptive analysis was used to characterize the patients. The intraclass correlation coefficient (ICC) and Pearson's correlation coefficient were computed to assess intra- and interobserver reliability. Six questions were modified during the translation stage and cultural adaptation phase. The ICC for intra- and interobserver reliability was 0.99 (P < 0.001) and 0.98 (P < 0.001), respectively. The Pearson correlation coefficient for intra- and interobserver reliability was 0.98 (P < 0.001) and 0.97 (P < 0.001), respectively. We conclude that the Brazilian version of the Berg balance scale is a reliable instrument to be used in balance assessment of elderly Brazilian patients.

  14. National Hydropower Plant Dataset, Version 1

    DOE Data Explorer

    Samu, Nicole; Kao, Shih-Chieh; O'Connor, Patrick

    2016-09-30

    The 2016 National Hydropower Plant Dataset, Version 1, includes geospatial point-level locations and key characteristics of online existing hydropower plants in the United States that are currently licensed, exempt, or awaiting relicensing. These data are a subset extracted from NHAAP’s Existing Hydropower Assets (EHA) internal database, which is a cornerstone of NHAAP’s EHA effort that has supported multiple U.S. hydropower R&D research initiatives related to market acceleration, environmental impact reduction, technology-to-market activities, and climate change impact assessment. For more information on NHAAP’s EHA effort, please visit the project web page at: http://nhaap.ornl.gov/existing-hydropower.

  15. A multi-threaded version of MCFM

    NASA Astrophysics Data System (ADS)

    Campbell, John M.; Ellis, R. Keith; Giele, Walter T.

    2015-06-01

    We report on our findings modifying MCFM using OpenMP to implement multi-threading. By using OpenMP, the modified MCFM will execute on any processor, automatically adjusting to the number of available threads. We modified the integration routine VEGAS to distribute the event evaluation over the threads, while combining all events at the end of every iteration to optimize the numerical integration. Special care has been taken that the results of the Monte Carlo integration are independent of the number of threads used, to facilitate the validation of the OpenMP version of MCFM.

  16. UQTk version 2.0 user manual.

    SciTech Connect

    Debusschere, Bert J.; Sargsyan, Khachik; Safta, Cosmin

    2013-10-01

    The UQ Toolkit (UQTk) is a collection of libraries and tools for the quanti cation of uncer- tainty in numerical model predictions. Version 2.0 o ers intrusive and non-intrusive methods for propagating input uncertainties through computational models, tools for sensitivity anal- ysis, methods for sparse surrogate construction, and Bayesian inference tools for inferring parameters from experimental data. This manual discusses the download and installation process for UQTk, provides pointers to the UQ methods used in the toolkit, and describes some of the examples provided with the toolkit.

  17. LMR Transient Calculation Code System (version 5).

    1993-09-01

    Version: 00 The Liquid Metal Reactor (LMR) may undergo an unscrammed Transient Over-Power (TOP) or a Loss of Heat Sink (LOHS) type of accident involving power, temperature, and reactivity changes. The LTC (LMR Transient Calculation) Program calculates the time dependent reactor temperatures, reactivities, and power of the LMR after the initiation of the accident. A printout of the results including the input table of data is offered after the program run. No graphics are usedmore » in the program and the LTC.EXE (Quick Basic compiled) can make use of a math co-processor if available (GW Basic doesn't).« less

  18. FOC Cycle 6 PSF Monitoring - Version 2

    NASA Astrophysics Data System (ADS)

    Nota, Antonella

    1996-07-01

    This proposal has two parts. The first part is a COSTAR DOB move to adjust the COSTAR focus position for the FOC to the value that will ensure that the FOC focus is within +/- 1.5-2 microns over the next three months. The second part consists of images of a spectrophotometric standard star in the f/96 relay to verify whether the DOB move executed was correct. Data will be taken 4 times during the cycle. This version has visits 5 and 7 removed, and the timing for visits 6 and 8 is changed to unlink it from visit 1.

  19. External RNA Controls Consortium Beta Version Update.

    PubMed

    Lee, Hangnoh; Pine, P Scott; McDaniel, Jennifer; Salit, Marc; Oliver, Brian

    2016-01-01

    Spike-in RNAs are valuable controls for a variety of gene expression measurements. The External RNA Controls Consortium developed test sets that were used in a number of published reports. Here we provide an authoritative table that summarizes, updates, and corrects errors in the test version that ultimately resulted in the certified Standard Reference Material 2374. We have noted existence of anti-sense RNA controls in the material, corrected sub-pool memberships, and commented on control RNAs that displayed inconsistent behavior. PMID:27512518

  20. External RNA Controls Consortium Beta Version Update

    PubMed Central

    Lee, Hangnoh; Pine, P. Scott; McDaniel, Jennifer; Salit, Marc; Oliver, Brian

    2016-01-01

    Spike-in RNAs are valuable controls for a variety of gene expression measurements. The External RNA Controls Consortium developed test sets that were used in a number of published reports. Here we provide an authoritative table that summarizes, updates, and corrects errors in the test version that ultimately resulted in the certified Standard Reference Material 2374. We have noted existence of anti-sense RNA controls in the material, corrected sub-pool memberships, and commented on control RNAs that displayed inconsistent behavior. PMID:27512518

  1. A multi-threaded version of MCFM

    DOE PAGES

    Campbell, John M.; Ellis, R. Keith; Giele, Walter T.

    2015-06-03

    We report on our findings modifying MCFM using OpenMP to implement multi-threading. By using OpenMP, the modified MCFM will execute on any processor, automatically adjusting to the number of available threads. We then modified the integration routine VEGAS to distribute the event evaluation over the threads, while combining all events at the end of every iteration to optimize the numerical integration. Furthermore, we took special care so that the results of the Monte Carlo integration were independent of the number of threads used, to facilitate the validation of the OpenMP version of MCFM.

  2. ALT-3 Target & CMU Version 4

    SciTech Connect

    Griego, Jeffrey R; Atchison, Walter L.; Holtkamp, David; Oro, David M.; Reinovsky, Robert E.; Rousculp, Christopher L.; Tabaka, Leonard J.

    2012-06-11

    The third Advance Liner Technology (ALT-3) experiment is the next in a long tradition of collaborations between LANL and RFNC/VNIIEF in high-explosive pulsed-power. Here a VNIIEF provided Disk Explosive Magnetic Generator (DEMG) will drive a LANL provided experimental load and diagnostic package. The objective of the experiment is to explore the use of a cylindrical liner-ontarget in tera-Pascal equation of state measurement. This presentation will discuss version 4 of the experimental target and central measuring unit (CMU) along with R & D already performed in fabrication of the target.

  3. Version 5 product improvements from the atmospheric infrared sounder (AIRS)

    NASA Astrophysics Data System (ADS)

    Pagano, Thomas S.; Aumann, Hartmut H.; Chahine, Moustafa T.; Manning, Evan; Friedman, Steve; Broberg, Steven E.; Licata, Stephen J.; Elliott, Denis A.; Irion, Fredrick W.; Kahn, Brian H.; Fishbein, Evan; Olsen, Edward; Granger, Stephanie; Susskind, Joel; Keita, Fricky; Blaisdell, John; Strow, Larrabee; DeSouza-Machado, Sergio; Barnet, Chris

    2006-12-01

    The AIRS instrument was launched in May 2002 into a polar sun-synchronous orbit onboard the EOS Aqua Spacecraft. Since then we have released three versions of the AIRS data product to the scientific community. AIRS, in conjunction with the Advanced Microwave Sounding Unit (AMSU), produces temperature profiles with 1K/km accuracy on a global scale, as well as water vapor profiles and trace gas amounts. The first version of software, Version 2.0 was available to scientists shortly after launch with Version 3.0 released to the public in June 2003. Like all AIRS product releases, all products are accessible to the public in order to have the best user feedback on issues that appear in the data. Fortunately the products have had exceptional accuracy and stability. This paper presents the improvement between AIRS Version 4.0 and Version 5.0 products and shows examples of the new products available in Version 5.0.

  4. Satellite Data Simulator Unit (SDSU) version 2

    NASA Astrophysics Data System (ADS)

    Masunaga, H.

    2009-12-01

    The Satellite Data Simulator Unit (SDSU) is a Fortran package to compute synthetic satellite data from user-provided geophysical parameters such as cloud-resolving model (CRM) output. The SDSU is designed to simulate microwave brightness temperature, radar reflectivity, radar path-integrated attenuation (PIA), visible and near-infrared radiances, and thermal infrared brightness temperature. The SDSU package also includes a beam convolution routine to adjust the spatial resolution to a sensor field of view and a Mie lookup table generator to improve computational efficiency. The SDSU version 2 (SDSU-v2), the latest version as of September 2009, includes the user interface to explicitly characterize the particle size distribution (PSD) model of each hydrometeor species simulated. An adequate characterization of the PSD models is crucial because some satellite sensors, in particular radars, are sensitive to hydrometeor particle size as well as to the water mixing ratio. The SDSU PSD library not only provides pre-installed PSD templates for popular microphysical models such as exponential and gamma PSDs, but also allows users to create their own PSD models. The SDSU-v2 currently supports arbitrary single- and two-moment bulk microphysical schemes. This talk will briefly review the SDSU design and present some recent results applied to different CRM outputs.

  5. About the Portuguese VIM3 version

    NASA Astrophysics Data System (ADS)

    Pellegrino, O.; Cruz, A.; Oliveira, J. C.; Filipe, E.

    2015-02-01

    For the first time, a unique Portuguese version of the International Vocabulary of Metrology (VIM) was organized and published by the National Metrology Institutes (NMIs) of Portugal and Brazil. This challenge could be met thanks to the experiences of the respective translations of the previous editions of the VIM and to the new Orthographic Agreement (AO) of the Portuguese speaking countries. After a brief historical review of the VIMs and their Portuguese versions, this communication aims to display the main steps that led to the final joint translation. Advantage was taken of this 3rd edition and of the AO to update the Portuguese multiplicative prefix writing "kilo" in coherence with the respective symbol "k". By way of answer to the questions raised by the recent edition of the VIM (VIM3) that stresses on the concepts associated to the terms, some suggestions are proposed and inconsistencies are identified, in order to facilitate the understanding and the dissemination of the document. These few suggestions for the next edition of the VIM also intended to standardize the terminology found in normative texts of different scientific fields which unfortunately does not necessarily tend to be consistent between them.

  6. Version 1 of the Hubble Source Catalog

    NASA Astrophysics Data System (ADS)

    Whitmore, Bradley C.; Allam, Sahar S.; Budavari, Tamas; Donaldson, Tom; Lubow, Stephen H.; Quick, Lee; Strolger, Louis-Gregory; Wallace, Geoff; White, Richard L.

    2015-01-01

    The Hubble Source Catalog (HSC) is an initiative to combine the tens of thousands of visit-based Hubble Legacy Archive (HLA - available at http://hla.stsci.edu) source lists into a single master catalog. The HSC currently includes ACS/WFC, WFPC2, and WFC3 source lists generated using the Source Extractor software (Bertin & Arnouts 1996), cross-matched using the technique described in Budavari & Lubow (2012). The astrometric residuals for the HSC individual objects are typically within 10 mas and the magnitude residuals between repeats are generally within 0.10 mag. Version 1 of the HSC is scheduled to be released in winter 2015. Some of the primary improvements over the current Beta 0.3 version of the HSC include: 1) improved WFC3 source lists, 2) two more years of WFC3 data, 3) improved matching algorithms, 4) a draft paper to be submitted to PASP, 5) inclusion in the MAST Discovery Portal (http://mast.stsci.edu), and 6) a CasJobs capability for advanced searches. Demonstrations will be provided at the Space Telescope Science Institute booth during the conference and people will have the opportunity to use the system interactively. The URL for the HSC is http://archive.stsci.edu/hst/hsc/ .

  7. FORTRAN Versions of Reformulated HFGMC Codes

    NASA Technical Reports Server (NTRS)

    Arnold, Steven M.; Aboudi, Jacob; Bednarcyk, Brett A.

    2006-01-01

    Several FORTRAN codes have been written to implement the reformulated version of the high-fidelity generalized method of cells (HFGMC). Various aspects of the HFGMC and its predecessors were described in several prior NASA Tech Briefs articles, the most recent being HFGMC Enhancement of MAC/GMC (LEW-17818-1), NASA Tech Briefs, Vol. 30, No. 3 (March 2006), page 34. The HFGMC is a mathematical model of micromechanics for simulating stress and strain responses of fiber/matrix and other composite materials. The HFGMC overcomes a major limitation of a prior version of the GMC by accounting for coupling of shear and normal stresses and thereby affords greater accuracy, albeit at a large computational cost. In the reformulation of the HFGMC, the issue of computational efficiency was addressed: as a result, codes that implement the reformulated HFGMC complete their calculations about 10 times as fast as do those that implement the HFGMC. The present FORTRAN implementations of the reformulated HFGMC were written to satisfy a need for compatibility with other FORTRAN programs used to analyze structures and composite materials. The FORTRAN implementations also afford capabilities, beyond those of the basic HFGMC, for modeling inelasticity, fiber/matrix debonding, and coupled thermal, mechanical, piezo, and electromagnetic effects.

  8. micrOMEGAs: Version 1.3

    NASA Astrophysics Data System (ADS)

    Bélanger, G.; Boudjema, F.; Pukhov, A.; Semenov, A.

    2006-04-01

    We present the latest version of micrOMEGAs, a code that calculates the relic density of the lightest supersymmetric particle (LSP) in the minimal supersymmetric standard model (MSSM). All tree-level processes for the annihilation of the LSP are included as well as all possible coannihilation processes with neutralinos, charginos, sleptons, squarks and gluinos. The cross-sections extracted from CalcHEP are calculated exactly using loop-corrected masses and mixings as specified in the SUSY Les Houches Accord. Relativistic formulae for the thermal average are used and care is taken to handle poles and thresholds by adopting specific integration routines. The input parameters can be either the soft SUSY parameters in a general MSSM or the parameters of a SUGRA model specified at the GUT scale. In the latter case, a link with Suspect, SOFTSUSY, Spheno and Isajet allows one to calculate the supersymmetric spectrum, Higgs masses, as well as mixing matrices. Higher-order corrections to Higgs couplings to quark pairs including QCD as well as some SUSY corrections ( Δm) are implemented. Routines calculating (, b→sγ and B→μμ are also included. In particular the b→sγ routine includes an improved NLO for the SM and the charged Higgs while the SUSY large tanβ effects beyond leading-order are included. This new version also provides cross-sections for any 2→2 process as well as partial decay widths for two-body final states in the MSSM allowing for easy simulation at colliders. Program summaryProgram title:micrOMEGAs1.3 Catalogue identifier:ADQR_v1_3 Program summary URL:http://cpc.cs.qub.ac.uk/summaries/ADQR_v1_3 Program obtainable from: CPC Program Library, Queen's University of Belfast, N. Ireland Licensing provisions:none Computer:PC, Alpha, Silicon graphics, Sun Programming language:C and Fortran Operating system:UNIX (Linux, OSF1, IRIX64, SunOS) RAM:20 MB depending on the number of processes required No of lines in distributed program, including test data, etc

  9. CAP88-PC Version 4, an updated radionuclide NESHAPS model.

    PubMed

    Wood, Raymond; Stuenkel, David; Rosnick, Reid

    2013-08-01

    The latest version of the CAP88-PC computer model, Version 4, has many changes and improvements from previous versions. The most significant of these changes from a user perspective are the incorporation of age-dependent radionuclide dose and risk factors for ingestion and inhalation, the increase in the number of included radionuclides, and a change in the file management system used by the program. Other changes less visible to the user include new code architecture, incorporation of numerical solvers for the calculation of radioactive decay chains, including the ingrowth of decay products during air transport and ground surface deposition, enhanced error messages, updated on-line help, and a utility for migrating Version 3 datasets, wind files, and population files to Version 4. The modifications have produced a significant improvement in speed and stability for Version 4 relative to Version 3 and eliminated the solution approximations used in Version 3. The U.S. Environmental Protection Agency has implemented an extensive testing and documentation program for CAP88-PC Version 4 to address user concerns with past versions, resulting in enhanced documentation supporting compatibility with user software quality assurance programs. PMID:23803671

  10. CAP88-PC Version 4, an updated radionuclide NESHAPS model.

    PubMed

    Wood, Raymond; Stuenkel, David; Rosnick, Reid

    2013-08-01

    The latest version of the CAP88-PC computer model, Version 4, has many changes and improvements from previous versions. The most significant of these changes from a user perspective are the incorporation of age-dependent radionuclide dose and risk factors for ingestion and inhalation, the increase in the number of included radionuclides, and a change in the file management system used by the program. Other changes less visible to the user include new code architecture, incorporation of numerical solvers for the calculation of radioactive decay chains, including the ingrowth of decay products during air transport and ground surface deposition, enhanced error messages, updated on-line help, and a utility for migrating Version 3 datasets, wind files, and population files to Version 4. The modifications have produced a significant improvement in speed and stability for Version 4 relative to Version 3 and eliminated the solution approximations used in Version 3. The U.S. Environmental Protection Agency has implemented an extensive testing and documentation program for CAP88-PC Version 4 to address user concerns with past versions, resulting in enhanced documentation supporting compatibility with user software quality assurance programs.

  11. PAV ontology: provenance, authoring and versioning

    PubMed Central

    2013-01-01

    Background Provenance is a critical ingredient for establishing trust of published scientific content. This is true whether we are considering a data set, a computational workflow, a peer-reviewed publication or a simple scientific claim with supportive evidence. Existing vocabularies such as Dublin Core Terms (DC Terms) and the W3C Provenance Ontology (PROV-O) are domain-independent and general-purpose and they allow and encourage for extensions to cover more specific needs. In particular, to track authoring and versioning information of web resources, PROV-O provides a basic methodology but not any specific classes and properties for identifying or distinguishing between the various roles assumed by agents manipulating digital artifacts, such as author, contributor and curator. Results We present the Provenance, Authoring and Versioning ontology (PAV, namespace http://purl.org/pav/): a lightweight ontology for capturing “just enough” descriptions essential for tracking the provenance, authoring and versioning of web resources. We argue that such descriptions are essential for digital scientific content. PAV distinguishes between contributors, authors and curators of content and creators of representations in addition to the provenance of originating resources that have been accessed, transformed and consumed. We explore five projects (and communities) that have adopted PAV illustrating their usage through concrete examples. Moreover, we present mappings that show how PAV extends the W3C PROV-O ontology to support broader interoperability. Method The initial design of the PAV ontology was driven by requirements from the AlzSWAN project with further requirements incorporated later from other projects detailed in this paper. The authors strived to keep PAV lightweight and compact by including only those terms that have demonstrated to be pragmatically useful in existing applications, and by recommending terms from existing ontologies when plausible. Discussion

  12. SPECT Imaging of Mice with 99mTc-Radiopharmaceuticals Obtained from 99Mo Produced by 100Mo(n,2n)99Mo and Fission of 235U

    NASA Astrophysics Data System (ADS)

    Hashimoto, Kazuyuki; Nagai, Yasuki; Kawabata, Masako; Sato, Nozomi; Hatsukawa, Yuichi; Saeki, Hideya; Motoishi, Shoji; Ohta, Masayuki; Konno, Chikara; Ochiai, Kentaro; Kawauchi, Yukimasa; Ohta, Akio; Shiina, Takayuki; Takeuchi, Nobuhiro; Ashino, Hiroki; Nakahara, Yuto

    2015-04-01

    The distribution of 99mTc-radiopharmaceutical in mouse was determined by single photon emission computed tomography (SPECT) for the first time using 99mTc, which was separated by thermochromatography from 99Mo produced via the 100Mo(n,2n)99Mo reaction with accelerator neutrons. The SPECT image was comparable to that obtained using the fission product 99Mo. Radionuclidic and radiochemical purities of the separated 99mTc and its aluminum concentration met the United States Pharmacopeia regulatory requirements for 99mTc from the fission product 99Mo. These results provide important evidence that the 99mTc-radiopharmaceutical formulated using the (n,2n) 99Mo can be a promising substitute for the fission product 99Mo. The current and forthcoming problem of ensuring a reliable and constant supply of 99Mo in Japan can be partially mitigated.

  13. mpiP Version 3.0

    2006-08-07

    For applications that make use of MPI communication libraries, the lightweight MPI profiling tool mpiP Version 3 provides a library that can generate MPI profile data based on time spent in MPI calls, the communication volume of the MPI calls and the volume of I/O from MPI-I/O calls. The mpiP out put is generated as a text report that can present summary information or specific detail of the call site data for each task. Themore » library also provides an API that users and tool developers can use to access mpiP functionality, such as timers, stack traces, and PC address-to-source translation.« less

  14. FLEXAN (version 2.0) user's guide

    NASA Technical Reports Server (NTRS)

    Stallcup, Scott S.

    1989-01-01

    The FLEXAN (Flexible Animation) computer program, Version 2.0 is described. FLEXAN animates 3-D wireframe structural dynamics on the Evans and Sutherland PS300 graphics workstation with a VAX/VMS host computer. Animation options include: unconstrained vibrational modes, mode time histories (multiple modes), delta time histories (modal and/or nonmodal deformations), color time histories (elements of the structure change colors through time), and rotational time histories (parts of the structure rotate through time). Concurrent color, mode, delta, and rotation, time history animations are supported. FLEXAN does not model structures or calculate the dynamics of structures; it only animates data from other computer programs. FLEXAN was developed to aid in the study of the structural dynamics of spacecraft.

  15. Tool Gear Version 2.3

    SciTech Connect

    2011-12-05

    Tool Gear Version 2 is an expanded collection of programs and software libraries that form the infrastructure on which software tools may be built. The software tools help application developers understand the performance of the programs or help them find programming errors. Tool Gear includes components for gathering data from target programs, either through direct instrumentations or by parsing the output of third-party tools, transmitting the data to a databse, organizing and storing the data, presenting it through a variety of graphical interfaces. Tool Gear is designed to be an extensible system, so users can manage a variety of data and create new ways to present it. Too Gear is sesigned to work with both sequential and parallel programs on multiple computer platforms

  16. A New And Improved Version Of HULLAC

    SciTech Connect

    Klapisch, M.; Busquet, M.; Bar-Shalom, A.

    2007-08-02

    We present a new version of the collisional radiative model (CRM) generator code HULLAC. The main features are: (i) input considerably simplified and flexible, (ii) capacity of 'post-averaging' configurations and superconfigurations in mixed mode, (iii) a new fitting formula for cross sections, completely correcting the problems of the classical Sampson and Golden formula, (iv) a new algorithm for solving the rate equations of the CRM, more robust and giving more insight in the quality of the model than the biconjugate gradient method, (v) thanks to thorough comparisons with the LANL code, some errors were corrected, and very good agreement has been obtained on all types of transitions, (vi) finally, most of the code has been re-written according to up-to-date standards. This code is now ready for distribution.

  17. Schedule:DRMAAc, Version 0.8

    2004-04-22

    This Perl module is an implementation of the DRMAA specification. The DRMAA specification is one that makes a common API to distribute jobs via a DRM (Distributed Resource Manager), such as (SGE, LSF, OpenPBS, etc.). The specification is in review stages now (see http://www.drmaa.org) and will be, in my opinion, a defacto standard in a short time. Currently, only SGE has a working interface to the DRMAA, which will be released with version 6.0 ofmore » the product in May of 2004. Other DRM vendors have compliance plans in the works. DRMA does not provide an API for configuring DRMs, just for submitting jobs to them.« less

  18. LARCRIM user's guide, version 1.0

    NASA Technical Reports Server (NTRS)

    Davis, John S.; Heaphy, William J.

    1993-01-01

    LARCRIM is a relational database management system (RDBMS) which performs the conventional duties of an RDBMS with the added feature that it can store attributes which consist of arrays or matrices. This makes it particularly valuable for scientific data management. It is accessible as a stand-alone system and through an application program interface. The stand-alone system may be executed in two modes: menu or command. The menu mode prompts the user for the input required to create, update, and/or query the database. The command mode requires the direct input of LARCRIM commands. Although LARCRIM is an update of an old database family, its performance on modern computers is quite satisfactory. LARCRIM is written in FORTRAN 77 and runs under the UNIX operating system. Versions have been released for the following computers: SUN (3 & 4), Convex, IRIS, Hewlett-Packard, CRAY 2 & Y-MP.

  19. Tool Gear Version 2.3

    2011-12-05

    Tool Gear Version 2 is an expanded collection of programs and software libraries that form the infrastructure on which software tools may be built. The software tools help application developers understand the performance of the programs or help them find programming errors. Tool Gear includes components for gathering data from target programs, either through direct instrumentations or by parsing the output of third-party tools, transmitting the data to a databse, organizing and storing the data,more » presenting it through a variety of graphical interfaces. Tool Gear is designed to be an extensible system, so users can manage a variety of data and create new ways to present it. Too Gear is sesigned to work with both sequential and parallel programs on multiple computer platforms« less

  20. LIMS Version 6 Level 3 Dataset

    NASA Technical Reports Server (NTRS)

    Remsberg, Ellis E.; Lingenfelser, Gretchen

    2010-01-01

    This report describes the Limb Infrared Monitor of the Stratosphere (LIMS) Version 6 (V6) Level 3 data products and the assumptions used for their generation. A sequential estimation algorithm was used to obtain daily, zonal Fourier coefficients of the several parameters of the LIMS dataset for 216 days of 1978-79. The coefficients are available at up to 28 pressure levels and at every two degrees of latitude from 64 S to 84 N and at the synoptic time of 12 UT. Example plots were prepared and archived from the data at 10 hPa of January 1, 1979, to illustrate the overall coherence of the features obtained with the LIMS-retrieved parameters.

  1. DISFRAC Version 2.0 Users Guide

    SciTech Connect

    Cochran, Kristine B; Erickson, Marjorie A; Williams, Paul T; Klasky, Hilda B; Bass, Bennett Richard

    2013-01-01

    DISFRAC is the implementation of a theoretical, multi-scale model for the prediction of fracture toughness in the ductile-to-brittle transition temperature (DBTT) region of ferritic steels. Empirically-derived models of the DBTT region cannot legitimately be extrapolated beyond the range of existing fracture toughness data. DISFRAC requires only tensile properties and microstructural information as input, and thus allows for a wider range of application than empirical, toughness data dependent models. DISFRAC is also a framework for investigating the roles of various microstructural and macroscopic effects on fracture behavior, including carbide particle sizes, grain sizes, strain rates, and material condition. DISFRAC s novel approach is to assess the interaction effects of macroscopic conditions (geometry, loading conditions) with variable microstructural features on cleavage crack initiation and propagation. The model addresses all stages of the fracture process, from microcrack initiation within a carbide particle, to propagation of that crack through grains and across grain boundaries, finally to catastrophic failure of the material. The DISFRAC procedure repeatedly performs a deterministic analysis of microcrack initiation and propagation within a macroscopic crack plastic zone to calculate a critical fracture toughness value for each microstructural geometry set. The current version of DISFRAC, version 2.0, is a research code for developing and testing models related to cleavage fracture and transition toughness. The various models and computations have evolved significantly over the course of development and are expected to continue to evolve as testing and data collection continue. This document serves as a guide to the usage and theoretical foundations of DISFRAC v2.0. Feedback is welcomed and encouraged.

  2. The Community Climate System Model Version 4

    SciTech Connect

    Gent, Peter R.; Danabasoglu, Gokhan; Donner, Leo J.; Holland, Marika M.; Hunke, Elizabeth C.; Jayne, Steve R.; Lawrence, David M.; Neale, Richard; Rasch, Philip J.; Vertenstein, Mariana; Worley, Patrick; Yang, Zong-Liang; Zhang, Minghua

    2011-10-01

    The fourth version of the Community Climate System Model (CCSM4) was recently completed and released to the climate community. This paper describes developments to all the CCSM components, and documents fully coupled pre-industrial control runs compared to the previous version, CCSM3. Using the standard atmosphere and land resolution of 1{sup o} results in the sea surface temperature biases in the major upwelling regions being comparable to the 1.4{sup o} resolution CCSM3. Two changes to the deep convection scheme in the atmosphere component result in the CCSM4 producing El Nino/Southern Oscillation variability with a much more realistic frequency distribution than the CCSM3, although the amplitude is too large compared to observations. They also improve the representation of the Madden-Julian Oscillation, and the frequency distribution of tropical precipitation. A new overflow parameterization in the ocean component leads to an improved simulation of the deep ocean density structure, especially in the North Atlantic. Changes to the CCSM4 land component lead to a much improved annual cycle of water storage, especially in the tropics. The CCSM4 sea ice component uses much more realistic albedos than the CCSM3, and the Arctic sea ice concentration is improved in the CCSM4. An ensemble of 20th century simulations runs produce an excellent match to the observed September Arctic sea ice extent from 1979 to 2005. The CCSM4 ensemble mean increase in globally-averaged surface temperature between 1850 and 2005 is larger than the observed increase by about 0.4 C. This is consistent with the fact that the CCSM4 does not include a representation of the indirect effects of aerosols, although other factors may come into play. The CCSM4 still has significant biases, such as the mean precipitation distribution in the tropical Pacific Ocean, too much low cloud in the Arctic, and the latitudinal distributions of short-wave and long-wave cloud forcings.

  3. SPARK Version 1. 1 user manual

    SciTech Connect

    Weissenburger, D.W.

    1988-01-01

    This manual describes the input required to use Version 1.1 of the SPARK computer code. SPARK 1.1 is a library of FORTRAN main programs and subprograms designed to calculate eddy currents on conducting surfaces where current flow is assumed zero in the direction normal to the surface. Surfaces are modeled with triangular and/or quadrilateral elements. Lorentz forces produced by the interaction of eddy currents with background magnetic fields can be output at element nodes in a form compatible with most structural analysis codes. In addition, magnetic fields due to eddy currents can be determined at points off the surface. Version 1.1 features eddy current streamline plotting with optional hidden-surface-removal graphics and topological enhancements that allow essentially any orientable surface to be modeled. SPARK also has extensive symmetry specification options. In order to make the manual as self-contained as possible, six appendices are included that present summaries of the symmetry options, topological options, coil options and code algorithms, with input and output examples. An edition of SPARK 1.1 is available on the Cray computers at the National Magnetic Fusion Energy Computer Center at Livermore, California. Another more generic edition is operational on the VAX computers at the Princeton Plasma Physics Laboratory and is available on magnetic tape by request. The generic edition requires either the GKS or PLOT10 graphics package and the IMSL or NAG mathematical package. Requests from outside the United States will be subject to applicable federal regulations regarding dissemination of computer programs. 22 refs.

  4. FEAT - FAILURE ENVIRONMENT ANALYSIS TOOL (UNIX VERSION)

    NASA Technical Reports Server (NTRS)

    Pack, G.

    1994-01-01

    saved as a library file which represents a generic digraph structure for a class of components. The Generate Model feature can then use library files to generate digraphs for every component listed in the modeling tables, and these individual digraph files can be used in a variety of ways to speed generation of complete digraph models. FEAT contains a preprocessor which performs transitive closure on the digraph. This multi-step algorithm builds a series of phantom bridges, or gates, that allow accurate bi-directional processing of digraphs. This preprocessing can be time-consuming, but once preprocessing is complete, queries can be answered and displayed within seconds. A UNIX X-Windows port of version 3.5 of FEAT, XFEAT, is also available to speed the processing of digraph models created on the Macintosh. FEAT v3.6, which is only available for the Macintosh, has some report generation capabilities which are not available in XFEAT. For very large integrated systems, FEAT can be a real cost saver in terms of design evaluation, training, and knowledge capture. The capability of loading multiple digraphs and schematics into FEAT allows modelers to build smaller, more focused digraphs. Typically, each digraph file will represent only a portion of a larger failure scenario. FEAT will combine these files and digraphs from other modelers to form a continuous mathematical model of the system's failure logic. Since multiple digraphs can be cumbersome to use, FEAT ties propagation results to schematic drawings produced using MacDraw II (v1.1v2 or later) or MacDraw Pro. This makes it easier to identify single and double point failures that may have to cross several system boundaries and multiple engineering disciplines before creating a hazardous condition. FEAT v3.6 for the Macintosh is written in C-language using Macintosh Programmer's Workshop C v3.2. It requires at least a Mac II series computer running System 7 or System 6.0.8 and 32 Bit QuickDraw. It also requires a math

  5. A Monte Carlo approach to small-scale dosimetry of solid tumour microvasculature for nuclear medicine therapies with (223)Ra-, (131)I-, (177)Lu- and (111)In-labelled radiopharmaceuticals.

    PubMed

    Amato, Ernesto; Leotta, Salvatore; Italiano, Antonio; Baldari, Sergio

    2015-07-01

    The small-scale dosimetry of radionuclides in solid-tumours is directly related to the intra-tumoral distribution of the administered radiopharmaceutical, which is affected by its egress from the vasculature and dispersion within the tumour. The aim of the present study was to evaluate the combined dosimetric effects of radiopharmaceutical distribution and range of the emitted radiation in a model of tumour microvasculature. We developed a computational model of solid-tumour microenvironment around a blood capillary vessel, and we simulated the transport of radiation emitted by (223)Ra, (111)In, (131)I and (177)Lu using the GEANT4 Monte Carlo. For each nuclide, several models of radiopharmaceutical dispersion throughout the capillary vessel were considered. Radial dose profiles around the capillary vessel, the Initial Radioactivity (IR) necessary to deposit 100 Gy of dose at the edge of the viable tumour-cell region, the Endothelial Cell Mean Dose (ECMD) and the Tumour Edge Mean Dose (TEMD), i.e. the mean dose imparted at the 250-μm layer of tissue, were computed. The results for beta and Auger emitters demonstrate that the photon dose is about three to four orders of magnitude lower than that deposited by electrons. For (223)Ra, the beta emissions of its progeny deliver a dose about three orders of magnitude lower than that delivered by the alpha emissions. Such results may help to characterize the dose inhomogeneities in solid tumour therapies with radiopharmaceuticals, taking into account the interplay between drug distribution from vasculature and range of ionizing radiations. PMID:25979209

  6. A Monte Carlo approach to small-scale dosimetry of solid tumour microvasculature for nuclear medicine therapies with (223)Ra-, (131)I-, (177)Lu- and (111)In-labelled radiopharmaceuticals.

    PubMed

    Amato, Ernesto; Leotta, Salvatore; Italiano, Antonio; Baldari, Sergio

    2015-07-01

    The small-scale dosimetry of radionuclides in solid-tumours is directly related to the intra-tumoral distribution of the administered radiopharmaceutical, which is affected by its egress from the vasculature and dispersion within the tumour. The aim of the present study was to evaluate the combined dosimetric effects of radiopharmaceutical distribution and range of the emitted radiation in a model of tumour microvasculature. We developed a computational model of solid-tumour microenvironment around a blood capillary vessel, and we simulated the transport of radiation emitted by (223)Ra, (111)In, (131)I and (177)Lu using the GEANT4 Monte Carlo. For each nuclide, several models of radiopharmaceutical dispersion throughout the capillary vessel were considered. Radial dose profiles around the capillary vessel, the Initial Radioactivity (IR) necessary to deposit 100 Gy of dose at the edge of the viable tumour-cell region, the Endothelial Cell Mean Dose (ECMD) and the Tumour Edge Mean Dose (TEMD), i.e. the mean dose imparted at the 250-μm layer of tissue, were computed. The results for beta and Auger emitters demonstrate that the photon dose is about three to four orders of magnitude lower than that deposited by electrons. For (223)Ra, the beta emissions of its progeny deliver a dose about three orders of magnitude lower than that delivered by the alpha emissions. Such results may help to characterize the dose inhomogeneities in solid tumour therapies with radiopharmaceuticals, taking into account the interplay between drug distribution from vasculature and range of ionizing radiations.

  7. National Radiobiology Archives Distributed Access User's Manual, Version 1. 1

    SciTech Connect

    Smith, S.K.; Prather, J.C.; Ligotke, E.K.; Watson, C.R.

    1992-06-01

    This supplement to the NRA Distributed Access User's manual (PNL-7877), November 1991, describes installation and use of Version 1.1 of the software package; this is not a replacement of the previous manual. Version 1.1 of the NRA Distributed Access Package is a maintenance release. It eliminates several bugs, and includes a few new features which are described in this manual. Although the appearance of some menu screens has changed, we are confident that the Version 1.0 User's Manual will provide an adequate introduction to the system. Users who are unfamiliar with Version 1.0 may wish to experiment with that version before moving on to Version 1.1.

  8. Development of more efficacious {Tc}-99m organ imaging agents for use in nuclear medicine by analytical characterization of radiopharmaceuticals. Annual technical progress report, September 1, 1992--August 31, 1993

    SciTech Connect

    Heineman, W.R.

    1993-05-03

    This research program is detailed at development of more efficacious technetium-99m radiopharmaceuticals for use as imaging agents in diagnostic nuclear medicine. We seek to isolate and develop distinct site imaging agents to provide diagnostic information concerning a given pathological condition. Analytical techniques are being developed to enable complete analysis of radiopharmaceutical preparations so that individual complexes can be characterized with respect to imaging efficacy and to enable a radiopharmaceutical to be monitored after injection into a test animal to determine the species that actually accumulates in an organ to provide the image. Administration of the isolated, single most effective imaging complex, rather than a mixture of technetium-containing complexes, wi-11 minimize radiation exposure to the patient and maximize diagnostic information available to the clinician. This report specifically describes the development of capillary electrophoresis (CE) for characterizating diphosphonate skeletal imaging agents. Advances in the development of electrochemical and fiber optic sensors for Tc and Re imaging agents are described. These sensors will ultimately be capable of monitoring a specific chemical state of an imaging agent in vivo after injection into a test animal by implantation in the organ of interest.

  9. Verification of RESRAD-RDD. (Version 2.01)

    SciTech Connect

    Cheng, Jing-Jy; Flood, Paul E.; LePoire, David; Kamboj, Sunita; Yu, Charley

    2015-09-01

    In this report, the results generated by RESRAD-RDD version 2.01 are compared with those produced by RESRAD-RDD version 1.7 for different scenarios with different sets of input parameters. RESRAD-RDD version 1.7 is spreadsheet-driven, performing calculations with Microsoft Excel spreadsheets. RESRAD-RDD version 2.01 revamped version 1.7 by using command-driven programs designed with Visual Basic.NET to direct calculations with data saved in Microsoft Access database, and re-facing the graphical user interface (GUI) to provide more flexibility and choices in guideline derivation. Because version 1.7 and version 2.01 perform the same calculations, the comparison of their results serves as verification of both versions. The verification covered calculation results for 11 radionuclides included in both versions: Am-241, Cf-252, Cm-244, Co-60, Cs-137, Ir-192, Po-210, Pu-238, Pu-239, Ra-226, and Sr-90. At first, all nuclidespecific data used in both versions were compared to ensure that they are identical. Then generic operational guidelines and measurement-based radiation doses or stay times associated with a specific operational guideline group were calculated with both versions using different sets of input parameters, and the results obtained with the same set of input parameters were compared. A total of 12 sets of input parameters were used for the verification, and the comparison was performed for each operational guideline group, from A to G, sequentially. The verification shows that RESRAD-RDD version 1.7 and RESRAD-RDD version 2.01 generate almost identical results; the slight differences could be attributed to differences in numerical precision with Microsoft Excel and Visual Basic.NET. RESRAD-RDD version 2.01 allows the selection of different units for use in reporting calculation results. The results of SI units were obtained and compared with the base results (in traditional units) used for comparison with version 1.7. The comparison shows that RESRAD

  10. Development of additive [11C]CO2 target system in the KOTRON-13 cyclotron and its application for [11C]radiopharmaceutical production

    NASA Astrophysics Data System (ADS)

    Moon, Byung Seok; Lee, Hong Jin; Lee, Won Kyung; Hur, Min Goo; Yang, Seung Dae; Lee, Byung Chul; Kim, Sang Eun

    2015-08-01

    The KOTRON-13 cyclotron, which was developed in South Korea for the production of medical radioisotopes, has the structural limitation of only one beam-output port, restricting the production of the carbon-11 isotope. In the present study, we investigate the design of a switchable target system and develop an effective carbon-11 target in the KOTRON-13 cyclotron, for combination with the fluorine-18 target. The target system was designed by introducing a sliding-type element between the fluorine-18 and carbon-11 targets, a tailor-made C-11 target and its cooling system. For the efficient production of [11C]CO2, the desirable target shape and internal volume were determined by a Stopping and Range of Ions in Matter (SRIM) simulation program, and the target grid was modified to resist the cavity pressure during beam irradiation. We evaluated the [11C]CO2 production while varying the material and thickness of the target foil, oxygen content of the nitrogen gas, and target loading pressure. Using sliding-type equipment including an additional gate valve and a high vacuum in a beam line, the bi-directional conversion between the fluorine-18 and carbon-11 targets was efficient regarding the accurate beam irradiation on both targets. The optimal [11C]CO2 production for 30 min irradiation at 60 μA (86.6 ± 1.7 GBq in the target at EOB) was observed at a thickness of 19 μm with HAVAR® material as a target foil and a target loading pressure of 24 bar with nitrogen plus 300 ppb of oxygen gas. Additionally, the coolant cavity system in the target grid and target chamber is useful to remove the heat transferred to the target body by the internal convection of water and thereby ensure the stability of the [11C]CO2 production under a high beam current. In the application of C-11 labeled radiopharmaceuticals such as [11C]PIB, [11C]DASB, [11C]PBR28, [11C]Methionine and [11C]Clozapine, the radiochemical yields were shown to be 25-38% (decay corrected) with over 166 GBq/μmol of

  11. Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer's disease: A post-mortem study with PET radiopharmaceuticals.

    PubMed

    Vidal, Benjamin; Sebti, Johan; Verdurand, Mathieu; Fieux, Sylvain; Billard, Thierry; Streichenberger, Nathalie; Troakes, Claire; Newman-Tancredi, Adrian; Zimmer, Luc

    2016-10-01

    PET imaging studies using 5-HT1A receptor radiotracers show a decreased density of this receptor in hippocampi of patients with Alzheimer's disease (AD) at advanced stages. However, current 5-HT1A receptor radiopharmaceuticals used in neuroimaging are antagonists, thought to bind to 5-HT1A receptors in different functional states (i.e., both the one which displays high affinity for agonists and is thought to mediate receptor activation, as well as the state which has low affinity for agonists). Comparing the PET imaging obtained using an agonist radiotracer, which binds selectively to functional receptors, with the PET imaging obtained using an antagonist radiotracer would therefore provide original information on 5-HT1A receptor impairment during AD. Quantitative autoradiography using [(18)F]F13640 and [(18)F]MPPF, a 5-HT1A agonist and antagonist, respectively, was measured in hippocampi of patients with AD (n = 25, at different Braak stages) and control subjects (n = 9). The neuronal density was measured in the same tissues by NeuN immunohistochemistry. The specific binding of both radiotracers was determined by addition of WAY-100635, a selective 5-HT1A receptor antagonist. The autoradiography distribution of both 5-HT1A PET radiotracers varied across hippocampus regions. The highest binding density was in the pyramidal layer of CA1. Incubation with Gpp(NH)p, a non-hydrolysable analogue of GTP, reduced significantly [(18)F]F13640 binding in hippocampal regions, confirming its preferential interaction with G-coupled receptors, and slightly increased [(18)F]MPPF binding. In the CA1 subfield, [(18)F]F13640 binding was significantly decreased at Braak stages I/II (-19%), Braak stages III/IV (-23%), and Braak stages V/VI (-36%) versus control. In contrast, [(18)F]MPPF binding was statistically reduced only at the most advanced Braak stages V/VI compared to control (-33%). Since [(18)F]F13640 and [(18)F]MPPF can be used in vivo in humans, this

  12. NETS - A NEURAL NETWORK DEVELOPMENT TOOL, VERSION 3.0 (MACHINE INDEPENDENT VERSION)

    NASA Technical Reports Server (NTRS)

    Baffes, P. T.

    1994-01-01

    allows the user to generate C code to implement the network loaded into the system. This permits the placement of networks as components, or subroutines, in other systems. In short, once a network performs satisfactorily, the Generate C Code option provides the means for creating a program separate from NETS to run the network. Other features: files may be stored in binary or ASCII format; multiple input propagation is permitted; bias values may be included; capability to scale data without writing scaling code; quick interactive testing of network from the main menu; and several options that allow the user to manipulate learning efficiency. NETS is written in ANSI standard C language to be machine independent. The Macintosh version (MSC-22108) includes code for both a graphical user interface version and a command line interface version. The machine independent version (MSC-21588) only includes code for the command line interface version of NETS 3.0. The Macintosh version requires a Macintosh II series computer and has been successfully implemented under System 7. Four executables are included on these diskettes, two for floating point operations and two for integer arithmetic. It requires Think C 5.0 to compile. A minimum of 1Mb of RAM is required for execution. Sample input files and executables for both the command line version and the Macintosh user interface version are provided on the distribution medium. The Macintosh version is available on a set of three 3.5 inch 800K Macintosh format diskettes. The machine independent version has been successfully implemented on an IBM PC series compatible running MS-DOS, a DEC VAX running VMS, a SunIPC running SunOS, and a CRAY Y-MP running UNICOS. Two executables for the IBM PC version are included on the MS-DOS distribution media, one compiled for floating point operations and one for integer arithmetic. The machine independent version is available on a set of three 5.25 inch 360K MS-DOS format diskettes (standard

  13. NETS - A NEURAL NETWORK DEVELOPMENT TOOL, VERSION 3.0 (MACINTOSH VERSION)

    NASA Technical Reports Server (NTRS)

    Phillips, T. A.

    1994-01-01

    allows the user to generate C code to implement the network loaded into the system. This permits the placement of networks as components, or subroutines, in other systems. In short, once a network performs satisfactorily, the Generate C Code option provides the means for creating a program separate from NETS to run the network. Other features: files may be stored in binary or ASCII format; multiple input propagation is permitted; bias values may be included; capability to scale data without writing scaling code; quick interactive testing of network from the main menu; and several options that allow the user to manipulate learning efficiency. NETS is written in ANSI standard C language to be machine independent. The Macintosh version (MSC-22108) includes code for both a graphical user interface version and a command line interface version. The machine independent version (MSC-21588) only includes code for the command line interface version of NETS 3.0. The Macintosh version requires a Macintosh II series computer and has been successfully implemented under System 7. Four executables are included on these diskettes, two for floating point operations and two for integer arithmetic. It requires Think C 5.0 to compile. A minimum of 1Mb of RAM is required for execution. Sample input files and executables for both the command line version and the Macintosh user interface version are provided on the distribution medium. The Macintosh version is available on a set of three 3.5 inch 800K Macintosh format diskettes. The machine independent version has been successfully implemented on an IBM PC series compatible running MS-DOS, a DEC VAX running VMS, a SunIPC running SunOS, and a CRAY Y-MP running UNICOS. Two executables for the IBM PC version are included on the MS-DOS distribution media, one compiled for floating point operations and one for integer arithmetic. The machine independent version is available on a set of three 5.25 inch 360K MS-DOS format diskettes (standard

  14. NETS - A NEURAL NETWORK DEVELOPMENT TOOL, VERSION 3.0 (MACHINE INDEPENDENT VERSION)

    NASA Technical Reports Server (NTRS)

    Baffes, P. T.

    1994-01-01

    allows the user to generate C code to implement the network loaded into the system. This permits the placement of networks as components, or subroutines, in other systems. In short, once a network performs satisfactorily, the Generate C Code option provides the means for creating a program separate from NETS to run the network. Other features: files may be stored in binary or ASCII format; multiple input propagation is permitted; bias values may be included; capability to scale data without writing scaling code; quick interactive testing of network from the main menu; and several options that allow the user to manipulate learning efficiency. NETS is written in ANSI standard C language to be machine independent. The Macintosh version (MSC-22108) includes code for both a graphical user interface version and a command line interface version. The machine independent version (MSC-21588) only includes code for the command line interface version of NETS 3.0. The Macintosh version requires a Macintosh II series computer and has been successfully implemented under System 7. Four executables are included on these diskettes, two for floating point operations and two for integer arithmetic. It requires Think C 5.0 to compile. A minimum of 1Mb of RAM is required for execution. Sample input files and executables for both the command line version and the Macintosh user interface version are provided on the distribution medium. The Macintosh version is available on a set of three 3.5 inch 800K Macintosh format diskettes. The machine independent version has been successfully implemented on an IBM PC series compatible running MS-DOS, a DEC VAX running VMS, a SunIPC running SunOS, and a CRAY Y-MP running UNICOS. Two executables for the IBM PC version are included on the MS-DOS distribution media, one compiled for floating point operations and one for integer arithmetic. The machine independent version is available on a set of three 5.25 inch 360K MS-DOS format diskettes (standard

  15. NETS - A NEURAL NETWORK DEVELOPMENT TOOL, VERSION 3.0 (MACINTOSH VERSION)

    NASA Technical Reports Server (NTRS)

    Phillips, T. A.

    1994-01-01

    allows the user to generate C code to implement the network loaded into the system. This permits the placement of networks as components, or subroutines, in other systems. In short, once a network performs satisfactorily, the Generate C Code option provides the means for creating a program separate from NETS to run the network. Other features: files may be stored in binary or ASCII format; multiple input propagation is permitted; bias values may be included; capability to scale data without writing scaling code; quick interactive testing of network from the main menu; and several options that allow the user to manipulate learning efficiency. NETS is written in ANSI standard C language to be machine independent. The Macintosh version (MSC-22108) includes code for both a graphical user interface version and a command line interface version. The machine independent version (MSC-21588) only includes code for the command line interface version of NETS 3.0. The Macintosh version requires a Macintosh II series computer and has been successfully implemented under System 7. Four executables are included on these diskettes, two for floating point operations and two for integer arithmetic. It requires Think C 5.0 to compile. A minimum of 1Mb of RAM is required for execution. Sample input files and executables for both the command line version and the Macintosh user interface version are provided on the distribution medium. The Macintosh version is available on a set of three 3.5 inch 800K Macintosh format diskettes. The machine independent version has been successfully implemented on an IBM PC series compatible running MS-DOS, a DEC VAX running VMS, a SunIPC running SunOS, and a CRAY Y-MP running UNICOS. Two executables for the IBM PC version are included on the MS-DOS distribution media, one compiled for floating point operations and one for integer arithmetic. The machine independent version is available on a set of three 5.25 inch 360K MS-DOS format diskettes (standard

  16. Color enhanced version of 360-degree panorama

    NASA Technical Reports Server (NTRS)

    1997-01-01

    This is a 'geometrically improved, color enhanced' version of the 360-degree panorama heretofore known as the 'Gallery Pan', the first contiguous, uniform panorama taken by the Imager for Mars Pathfinder (IMP) over the course of Sols 8, 9, and 10. Different regions were imaged at different times over the three Martian days to acquire consistent lighting and shadow conditions for all areas of the panorama.

    The IMP is a stereo imaging system that, in its fully deployed configuration, stands 1.8 meters above the Martian surface, and has a resolution of two millimeters at a range of two meters. In this geometrically improved version of the panorama, distortion due to a 2.5 degree tilt in the IMP camera mast has been removed, effectively flattening the horizon.

    The IMP has color capability provided by 24 selectable filters -- twelve filters per 'eye.' Its red, green, and blue filters were used to take this image. The color was digitally balanced according to the color transmittance capability of a high-resolution TV at the Jet Propulsion Laboratory (JPL), and is dependent on that device. In this color enhanced version of the panorama, detail in surface features are brought out via changes to saturation and intensity, holding the original hue constant. A threshold was applied to avoid changes to the sky.

    At left is a Lander petal and a metallic mast which is a portion of the low-gain antenna. Misregistration in the antenna and other Lander features is due to parallax in the extreme foreground. On the horizon the double 'Twin Peaks' are visible, about 1-2 kilometers away. The rock 'Couch' is the dark, curved rock at right of Twin Peaks. Another Lander petal is at left-center, showing the fully deployed forward ramp at far left, and rear ramp at right, which rover Sojourner used to descend to the surface of Mars on July 5. Immediately to the left of the rear ramp is the rock 'Barnacle Bill', which scientists found to be andesitic, possibly indicating that it is a

  17. SPAM- SPECTRAL ANALYSIS MANAGER (UNIX VERSION)

    NASA Technical Reports Server (NTRS)

    Solomon, J. E.

    1994-01-01

    machine environments. There is a DEC VAX/VMS version with a central memory requirement of approximately 242K of 8 bit bytes and a machine independent UNIX 4.2 version. The display device currently supported is the Raster Technologies display processor. Other 512 x 512 resolution color display devices, such as De Anza, may be added with minor code modifications. This program was developed in 1986.

  18. Sequence database versioning for command line and Galaxy bioinformatics servers

    PubMed Central

    Dooley, Damion M.; Petkau, Aaron J.; Van Domselaar, Gary; Hsiao, William W.L.

    2016-01-01

    Motivation: There are various reasons for rerunning bioinformatics tools and pipelines on sequencing data, including reproducing a past result, validation of a new tool or workflow using a known dataset, or tracking the impact of database changes. For identical results to be achieved, regularly updated reference sequence databases must be versioned and archived. Database administrators have tried to fill the requirements by supplying users with one-off versions of databases, but these are time consuming to set up and are inconsistent across resources. Disk storage and data backup performance has also discouraged maintaining multiple versions of databases since databases such as NCBI nr can consume 50 Gb or more disk space per version, with growth rates that parallel Moore's law. Results: Our end-to-end solution combines our own Kipper software package—a simple key-value large file versioning system—with BioMAJ (software for downloading sequence databases), and Galaxy (a web-based bioinformatics data processing platform). Available versions of databases can be recalled and used by command-line and Galaxy users. The Kipper data store format makes publishing curated FASTA databases convenient since in most cases it can store a range of versions into a file marginally larger than the size of the latest version. Availability and implementation: Kipper v1.0.0 and the Galaxy Versioned Data tool are written in Python and released as free and open source software available at https://github.com/Public-Health-Bioinformatics/kipper and https://github.com/Public-Health-Bioinformatics/versioned_data, respectively; detailed setup instructions can be found at https://github.com/Public-Health-Bioinformatics/versioned_data/blob/master/doc/setup.md Contact: Damion.Dooley@Bccdc.Ca or William.Hsiao@Bccdc.Ca Supplementary information: Supplementary data are available at Bioinformatics online. PMID:26656932

  19. TAE+ 5.2 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.2 (SUN4 VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    programs to display and control the user interfaces. Since the WPTs access the workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides a means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System and the Open Software Foundation's Motif. The HP 9000 Series 700/800 version of TAE 5.2 requires Version 11 Release 5 of the X Window System. All other machine versions of TAE 5.2 require Version 11, Release 4 of the X Window System. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus was developed in 1989 and version 5.2 was released in 1993. TAE Plus 5.2 is available on media suitable for five different machine platforms: (1) IBM RS/6000 series workstations running AIX (.25 inch tape cartridge in UNIX tar format), (2) DEC RISC

  20. TAE+ 5.2 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.2 (DEC RISC ULTRIX VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    programs to display and control the user interfaces. Since the WPTs access the workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides a means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System and the Open Software Foundation's Motif. The HP 9000 Series 700/800 version of TAE 5.2 requires Version 11 Release 5 of the X Window System. All other machine versions of TAE 5.2 require Version 11, Release 4 of the X Window System. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus was developed in 1989 and version 5.2 was released in 1993. TAE Plus 5.2 is available on media suitable for five different machine platforms: (1) IBM RS/6000 series workstations running AIX (.25 inch tape cartridge in UNIX tar format), (2) DEC RISC

  1. TAE+ 5.2 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.2 (SILICON GRAPHICS VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    programs to display and control the user interfaces. Since the WPTs access the workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides a means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System and the Open Software Foundation's Motif. The HP 9000 Series 700/800 version of TAE 5.2 requires Version 11 Release 5 of the X Window System. All other machine versions of TAE 5.2 require Version 11, Release 4 of the X Window System. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus was developed in 1989 and version 5.2 was released in 1993. TAE Plus 5.2 is available on media suitable for five different machine platforms: (1) IBM RS/6000 series workstations running AIX (.25 inch tape cartridge in UNIX tar format), (2) DEC RISC

  2. TAE+ 5.2 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.2 (IBM RS/6000 VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    programs to display and control the user interfaces. Since the WPTs access the workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides a means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System and the Open Software Foundation's Motif. The HP 9000 Series 700/800 version of TAE 5.2 requires Version 11 Release 5 of the X Window System. All other machine versions of TAE 5.2 require Version 11, Release 4 of the X Window System. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus was developed in 1989 and version 5.2 was released in 1993. TAE Plus 5.2 is available on media suitable for five different machine platforms: (1) IBM RS/6000 series workstations running AIX (.25 inch tape cartridge in UNIX tar format), (2) DEC RISC

  3. CLIPS 6.0 - C LANGUAGE INTEGRATED PRODUCTION SYSTEM, VERSION 6.0 (IBM PC VERSION)

    NASA Technical Reports Server (NTRS)

    Donnell, B.

    1994-01-01

    COOL (that is, a rule can pattern match on objects created using COOL). CLIPS 6.0 provides the capability to define functions, overloaded functions, and global variables interactively. In addition, CLIPS can be embedded within procedural code, called as a subroutine, and integrated with languages such as C, FORTRAN and Ada. CLIPS can be easily extended by a user through the use of several well-defined protocols. CLIPS provides several delivery options for programs including the ability to generate stand alone executables or to load programs from text or binary files. CLIPS 6.0 provides support for the modular development and execution of knowledge bases with the defmodule construct. CLIPS modules allow a set of constructs to be grouped together such that explicit control can be maintained over restricting the access of the constructs by other modules. This type of control is similar to global and local scoping used in languages such as C or Ada. By restricting access to deftemplate and defclass constructs, modules can function as blackboards, permitting only certain facts and instances to be seen by other modules. Modules are also used by rules to provide execution control. The CRSV (Cross-Reference, Style, and Verification) utility included with previous version of CLIPS is no longer supported. The capabilities provided by this tool are now available directly within CLIPS 6.0 to aid in the development, debugging, and verification of large rule bases. COSMIC offers four distribution versions of CLIPS 6.0: UNIX (MSC-22433), VMS (MSC-22434), MACINTOSH (MSC-22429), and IBM PC (MSC-22430). Executable files, source code, utilities, documentation, and examples are included on the program media. All distribution versions include identical source code for the command line version of CLIPS 6.0. This source code should compile on any platform with an ANSI C compiler. Each distribution version of CLIPS 6.0, except that for the Macintosh platform, includes an executable for the

  4. External cephalic version experiences in Korea

    PubMed Central

    Kim, Mi-Young; Park, Min-Young

    2016-01-01

    Objective The aim of this study was to evaluate obstetric outcomes of external cephalic version (ECV) performed at or near term. Methods Single pregnant woman with breech presentation at or near term (n=145), who experienced ECV by one obstetrician from November 2009 to July 2014 in our institution were included in the study. Maternal baseline characteristic and fetal ultrasonographic variables were checked before the procedure. After ECV, the delivery outcomes of the women were gathered. Variables affecting the success or failure of ECV were evaluated. Results Success rate of ECV was 71.0% (n=103). Four variables (parity, amniotic fluid index, fetal spine position and rotational direction) were observed to be in correlation with success or failure of ECV. In contactable 83 individuals experienced successful ECV, cesarean delivery rates were 18.1%, 28.9%, and 5.3% in total, nulliparas, and multiparas, respectively. Conclusion Based on the results, ECV is proposed to be safe for both mother and her fetus. In addition, it is a valuable procedure that increases probability of vaginal delivery for women with breech presentation. PMID:27004197

  5. IMPACTS-BRC, Version 2. 0

    SciTech Connect

    O'Neal, B.L. ); Lee, C.E. )

    1990-04-01

    This manual describes the procedures for implementing IMPACT-BRC Version 2.0. IMPACTS-BRC is a generic, radiological assessment code intended to be used by the US Nuclear Regulatory Commission (NRC) to evaluate petitions to classify specific waste streams as below regulatory concern (BRC). The code is designed to demonstrate compliance to BRC standards by modeling and calculating annual radiological impacts to the maximal individual, critical groups, and the general population as the result of transportation treatment, disposal, and post-disposal activities involving low-level radioactive waste. Impacts are calculated for multiple nuclides and pathways depending on data input and treatment and disposal options specified by the code user. The treatment and disposal options include onsite incineration, offsite incineration at municipal and hazardous waste landfills. Included within the disposal options is the ability to calculate impacts from the sorting and/or recycling of metal containers and metal and glass materials. Nuclide-specific accounting is provided to facilitate identification of the critical nuclides and pathways contributing to the impacts. Default environmental and facility parameters are developed from reference treatment/disposal sites. The user has the option to replace default parameters with site-specific parameters to provide more realistic estimation of impacts. 8 refs., 10 figs., 44 tabs.

  6. Upgrades to Monteburns, version 3.0

    SciTech Connect

    Galloway, J. D.; Trellue, H. R.

    2012-07-01

    Monteburns, a Monte Carlo burnup code which has the flexibility to model time-dependent isotopic changes for a variety of nuclear systems by linking the neutron transport code MCNP/X to a production/depletion code, has undergone several performance upgrades recently that have increased the code's capabilities. Once limited to a specific number of regions, enhancements have been implemented that afford a much greater number of burn materials, such that users will be more limited by the physical constraints of their computing environment as opposed to inherent limits built into the coding of Monteburns. In conjunction with the increase in the number of burn materials, parallel execution of a production/depletion code of choice has been implemented, such that users have the option of using CINDER90, 0RIGEN2, or the newly released version of ORIGEN. Finally, the recoverable energy per fission calculation was upgraded to include capture gamma energy deposited in all specified materials as a function of irradiation time. The sum of the prompt and delayed recoverable energies from fission was obtained as before. These upgrades were first tested on a rigorous 1/8 core model of a Pressurized Water Reactor with fresh, once- and twice-burned fuel. We can now model several orders of magnitude more materials using Monte Carlo techniques, which is a significant advance in the reactor modeling world. (authors)

  7. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.

    PubMed

    Cheetham, Philippa J; Petrylak, Daniel P

    2012-04-01

    Approximately 85% to 90% of men with castration-resistant prostate cancer (CRPC) have radiological evidence of bone metastases. To date, however, therapies to manage bone metastases have been primarily palliative. Among CRPC patients with bone metastases, there is a significant unmet need for active antitumor treatment options that are highly efficacious and have a favorable safety profile. This article will present current information about alpha-pharmaceuticals, a new class of targeted cancer therapy for the treatment of patients with CRPC and bone metastases. It will review preclinical and clinical studies of the experimental radiopharmaceutical radium-223 chloride (Alpharadin), a first-in-class, highly targeted and well-tolerated alpha-pharmaceutical under development to improve survival in patients with bone metastases from advanced prostate cancer. Alpharadin kills cancer cells via alpha radiation from the decay of radium-223, a calcium mimetic that naturally self-targets to bone metastases. The mechanism of action of Alpharadin and specifics of administration, radiation protection, and patient management will be discussed.

  8. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.

    PubMed

    Eder, Matthias; Neels, Oliver; Müller, Miriam; Bauder-Wüst, Ulrike; Remde, Yvonne; Schäfer, Martin; Hennrich, Ute; Eisenhut, Michael; Afshar-Oromieh, Ali; Haberkorn, Uwe; Kopka, Klaus

    2014-06-30

    The detection of prostate cancer lesions by PET imaging of the prostate-specific membrane antigen (PSMA) has gained highest clinical impact during the last years. 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) represents a successful novel PSMA inhibitor radiotracer which has recently demonstrated its suitability in individual first-in-man studies. The radiometal chelator HBED-CC used in this molecule represents a rather rarely used acyclic complexing agent with chemical characteristics favourably influencing the biological functionality of the PSMA inhibitor. The simple replacement of HBED-CC by the prominent radiometal chelator DOTA was shown to dramatically reduce the in vivo imaging quality of the respective 68Ga-labelled PSMA-targeted tracer proving that HBED-CC contributes intrinsically to the PSMA binding of the Glu-urea-Lys(Ahx) pharmacophore. Owing to the obvious growing clinical impact, this work aims to reflect the properties of HBED-CC as acyclic radiometal chelator and presents novel preclinical data and relevant aspects of the radiopharmaceutical production process of [68Ga]Ga-PSMA-HBED-CC.

  9. A novel device for automatic withdrawal and accurate calibration of 99m-technetium radiopharmaceuticals to minimise radiation exposure to nuclear medicine staff and patient.

    PubMed

    Nazififard, Mohammad; Mahdizadeh, Simin; Meigooni, A S; Alavi, M; Suh, Kune Y

    2012-09-01

    A Joint Automatic Dispenser Equipment (JADE) has been designed and fabricated for automatic withdrawal and calibration of radiopharmaceutical materials. The thermoluminescent dosemeter procedures have shown a reduction in dose to the technician's hand with this novel dose dispenser system JADE when compared with the manual withdrawal of (99m)Tc. This system helps to increase the precision of calibration and to minimise the radiation dose to the hands and body of the workers. This paper describes the structure of this device, its function and user-friendliness, and its efficacy. The efficacy of this device was determined by measuring the radiation dose delivered to the hands of the nuclear medicine laboratory technician. The user-friendliness of JADE has been examined. The automatic withdrawal and calibration offered by this system reduces the dose to the technician's hand to a level below the maximum permissible dose stipulated by the international protocols. This research will serve as a backbone for future study about the safe use of ionising radiation in medicine.

  10. The first experience of using 99mTc-Al2O3-based radiopharmaceutical for the detection of sentinel lymph nodes in cervical cancer patients

    NASA Astrophysics Data System (ADS)

    Sinilkin, I. G.; Chernov, V. I.; Lyapunov, A. Yu.; Medvedeva, A. A.; Zelchan, R. V.; Chernyshova, A. L.; Kolomiets, L. A.

    2016-08-01

    The purpose of the study was to evaluate the feasibility of using 99mTc-Al2O3-based radiopharmaceutical, a novel molecular imaging agent for sentinel lymph node detection in patients with invasive cervical cancer. The study included 23 cervical cancer patients (T1aNxMx-T2bNxMx) treated at the Tomsk Cancer Research Institute. In the 18 hours before surgery, 80 MBq of the 99mTc-Al2O3 in peritumoral injected, followed by single-photon emission computed tomography (SPECT) of the pelvis and intraoperative SLN identification. Twenty-seven SLNs were detected by SPECT, and 34 SLNs were identified by intraoperative gamma probe. The total number of identified SLNs per patient ranged from 1 to 3 (the mean number of SLNs was 1.4 per patient). The most common site for SLN detection was the external iliac region (57.2%), followed by the internal iliac (14%), obturator (14%), presacral and retrosacral regions (14%), and the parametrial region (1%). Sensitivity in detecting SLNs was 100% for intraoperative SLN identification and 79% for SPECT image.

  11. Validation of a Portuguese Version of the Children's Hope Scale

    ERIC Educational Resources Information Center

    Marques, Susana C.; Pais-Ribeiro, J. L.; Lopez, Shane J.

    2009-01-01

    The article describes the development of the Portuguese version of the Children's Hope Scale and the examination of its psychometric properties. A sample of 367 Portuguese students completed the Portuguese-language versions of the Children's Hope Scale (CHS; Snyder et al., 1997), Students' Life Satisfaction Scale (SLSS; Huebner, 1991), Global…

  12. Development of the Gerotranscendence Scale Type 2: Japanese Version

    ERIC Educational Resources Information Center

    Hoshino, Kazumi; Zarit, Steven H.; Nakayama, Makoto

    2012-01-01

    This study developed the Japanese version of the Gerotranscendence Scale Type 2 (the GST2) and examined reliability and validity of the scale. In Japan, 525 community-dwelling older adults (Male = 260, Female = 265) answered a questionnaire. An exploratory factor analysis of the Japanese version of the GST2 revealed the same three-factor structure…

  13. MODEL VERSION CONTROL FOR GREAT LAKES MODELS ON UNIX SYSTEMS

    EPA Science Inventory

    Scientific results of the Lake Michigan Mass Balance Project were provided where atrazine was measured and modeled. The presentation also provided the model version control system which has been used for models at Grosse Ile for approximately a decade and contains various version...

  14. Trace contaminant control simulation computer program, version 8.1

    NASA Technical Reports Server (NTRS)

    Perry, J. L.

    1994-01-01

    The Trace Contaminant Control Simulation computer program is a tool for assessing the performance of various process technologies for removing trace chemical contamination from a spacecraft cabin atmosphere. Included in the simulation are chemical and physical adsorption by activated charcoal, chemical adsorption by lithium hydroxide, absorption by humidity condensate, and low- and high-temperature catalytic oxidation. Means are provided for simulating regenerable as well as nonregenerable systems. The program provides an overall mass balance of chemical contaminants in a spacecraft cabin given specified generation rates. Removal rates are based on device flow rates specified by the user and calculated removal efficiencies based on cabin concentration and removal technology experimental data. Versions 1.0 through 8.0 are documented in NASA TM-108409. TM-108409 also contains a source file listing for version 8.0. Changes to version 8.0 are documented in this technical memorandum and a source file listing for the modified version, version 8.1, is provided. Detailed descriptions for the computer program subprograms are extracted from TM-108409 and modified as necessary to reflect version 8.1. Version 8.1 supersedes version 8.0. Information on a separate user's guide is available from the author.

  15. 78 FR 72755 - Version 5 Critical Infrastructure Protection Reliability Standards

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-12-03

    ... develop modifications to the CIP version 5 Standards and submit informational filings. DATES: This rule... below, we also direct NERC to submit informational filings regarding certain issues during and following implementation of the CIP version 5 Standards.\\2\\ \\2\\ We note that the informational filings directed in...

  16. LEGENDS OF KING ARTHUR. LITERATURE CURRICULUM III, STUDENT VERSION.

    ERIC Educational Resources Information Center

    KITZHABER, ALBERT R.

    A STUDENT VERSION OF A CURRICULUM GUIDE ON THE "LEGENDS OF KING ARTHUR" WAS DEVELOPED. SELECTED LEGENDS ARE REPRODUCED ALONG WITH AN INTRODUCTION, STUDY QUESTIONS, AND A PASSAGE FROM MALORY'S "LE MORTE D'ARTHUR" IN THE ORIGINAL LANGUAGE OF THE FIRST EDITION (1485). THE TEACHER VERSION IS ED 010 814. RELATED REPORTS ARE ED 010 129 THROUGH ED 010…

  17. Raptor: An Enterprise Knowledge Discovery Engine Version 2.0

    2011-08-31

    The Raptor Version 2.0 computer code uses a set of documents as seed documents to recommend documents of interest from a large, target set of documents. The computer code provides results that show the recommended documents with the highest similarity to the seed documents. Version 2.0 was specifically developed to work with SharePoint 2007 and MS SQL server.

  18. Quick Overview Scout 2008 Version 1.0

    EPA Science Inventory

    The Scout 2008 version 1.0 statistical software package has been updated from past DOS and Windows versions to provide classical and robust univariate and multivariate graphical and statistical methods that are not typically available in commercial or freeware statistical softwar...

  19. Validation of the English Version of the Dyadic Coping Inventory

    ERIC Educational Resources Information Center

    Levesque, Christine; Lafontaine, Marie-France; Caron, Angela; Fitzpatrick, Josée

    2014-01-01

    The purpose of this study was to validate the English version of the original German Dyadic Coping Inventory. Results indicated that the English version of the Dyadic Coping Inventory is a valid and reliable measure of dyadic coping in a sample of 709 heterosexual university students.

  20. GCFM Users Guide Revision for Model Version 5.0

    SciTech Connect

    Keimig, Mark A.; Blake, Coleman

    1981-08-10

    This paper documents alterations made to the MITRE/DOE Geothermal Cash Flow Model (GCFM) in the period of September 1980 through September 1981. Version 4.0 of GCFM was installed on the computer at the DOE San Francisco Operations Office in August 1980. This Version has also been distributed to about a dozen geothermal industry firms, for examination and potential use. During late 1980 and 1981, a few errors detected in the Version 4.0 code were corrected, resulting in Version 4.1. If you are currently using GCFM Version 4.0, it is suggested that you make the changes to your code that are described in Section 2.0. User's manual changes listed in Section 3.0 and Section 4.0 should then also be made.

  1. SPLICER - A GENETIC ALGORITHM TOOL FOR SEARCH AND OPTIMIZATION, VERSION 1.0 (MACINTOSH VERSION)

    NASA Technical Reports Server (NTRS)

    Wang, L.

    1994-01-01

    representation scheme. The SPLICER tool provides representation libraries for binary strings and for permutations. These libraries contain functions for the definition, creation, and decoding of genetic strings, as well as multiple crossover and mutation operators. Furthermore, the SPLICER tool defines the appropriate interfaces to allow users to create new representation libraries. Fitness modules are the only component of the SPLICER system a user will normally need to create or alter to solve a particular problem. Fitness functions are defined and stored in interchangeable fitness modules which must be created using C language. Within a fitness module, a user can create a fitness (or scoring) function, set the initial values for various SPLICER control parameters (e.g., population size), create a function which graphically displays the best solutions as they are found, and provide descriptive information about the problem. The tool comes with several example fitness modules, while the process of developing a fitness module is fully discussed in the accompanying documentation. The user interface is event-driven and provides graphic output in windows. SPLICER is written in Think C for Apple Macintosh computers running System 6.0.3 or later and Sun series workstations running SunOS. The UNIX version is easily ported to other UNIX platforms and requires MIT's X Window System, Version 11 Revision 4 or 5, MIT's Athena Widget Set, and the Xw Widget Set. Example executables and source code are included for each machine version. The standard distribution media for the Macintosh version is a set of three 3.5 inch Macintosh format diskettes. The standard distribution medium for the UNIX version is a .25 inch streaming magnetic tape cartridge in UNIX tar format. For the UNIX version, alternate distribution media and formats are available upon request. SPLICER was developed in 1991.

  2. The Warburg effect version 2.0

    PubMed Central

    Menendez, Javier A.; Joven, Jorge; Cufí, Sílvia; Corominas-Faja, Bruna; Oliveras-Ferraros, Cristina; Cuyàs, Elisabet; Martin-Castillo, Begoña; López-Bonet, Eugeni; Alarcón, Tomás; Vazquez-Martin, Alejandro

    2013-01-01

    When fighting cancer, knowledge on metabolism has always been important. Today, it matters more than ever. The restricted cataloging of cancer genomes is quite unlikely to achieve the task of curing cancer, unless it is integrated into metabolic networks that respond to and influence the constantly evolving cancer stem cell (CSC) cellular states. Once the genomic era of carcinogenesis had pushed the 1920s Otto Warburg’s metabolic cancer hypothesis into obscurity for decades, the most recent studies begin to support a new developing paradigm, in which the molecular logic behind the conversion of non-CSCs into CSCs can be better understood in terms of the “metabolic facilitators” and “metabolic impediments” that operate as proximate openings and roadblocks, respectively, for the transcriptional events and signal transduction programs that ultimately orchestrate the intrinsic and/or microenvironmental paths to CSC cellular states. Here we propose that a profound understanding of how human carcinomas install a proper “Warburg effect version 2.0” allowing them to “run” the CSCs’ “software” programs should guide a new era of metabolo-genomic-personalized cancer medicine. By viewing metabolic reprogramming of CSCs as an essential characteristic that allows dynamic, multidimensional and evolving cancer populations to compete successfully for their expansion on the organism, we now argue that CSCs bioenergetics might be another cancer hallmark. A definitive understanding of metabolic reprogramming in CSCs may complement or to some extent replace, the 30-y-old paradigm of targeting oncogenes to treat human carcinomas, because it can be possible to metabolically create non-permissive or “hostile” metabotypes to prevent the occurrence of CSC cellular states with tumor- and metastasis-initiating capacity. PMID:23549172

  3. Version 1 of the Hubble Source Catalog

    DOE PAGES

    Whitmore, Bradley C.; Allam, Sahar S.; Budavari, Tamas; Casertano, Stefano; Downes, Ronald A.; Donaldson, Thomas; Fall, S. Michael; Lubow, Stephen H.; Quick, Lee; Strolger, Louis -Gregory; et al

    2016-05-11

    The Hubble Source Catalog is designed to help optimize science from the Hubble Space Telescope by combining the tens of thousands of visit-based source lists in the Hubble Legacy Archive into a single master catalog. Version 1 of the Hubble Source Catalog includes WFPC2, ACS/WFC, WFC3/UVIS, and WFC3/IR photometric data generated using SExtractor software to produce the individual source lists. The catalog includes roughly 80 million detections of 30 million objects involving 112 different detector/filter combinations, and about 160 thousand HST exposures. Source lists from Data Release 8 of the Hubble Legacy Archive are matched using an algorithm developed by Budavari & Lubow (2012). The mean photometric accuracy for the catalog as a whole is better than 0.10 mag, with relative accuracy as good as 0.02 mag in certain circumstances (e.g., bright isolated stars). The relative astrometric residuals are typically within 10 mas, with a value for the mode (i.e., most common value) of 2.3 mas. The absolute astrometric accuracy is better thanmore » $$\\sim$$0.1 arcsec for most sources, but can be much larger for a fraction of fields that could not be matched to the PanSTARRS, SDSS, or 2MASS reference systems. In this paper we describe the database design with emphasis on those aspects that enable the users to fully exploit the catalog while avoiding common misunderstandings and potential pitfalls. Here, we provide usage examples to illustrate some of the science capabilities and data quality characteristics, and briefly discuss plans for future improvements to the Hubble Source Catalog.« less

  4. Version 1 of the Hubble Source Catalog

    NASA Astrophysics Data System (ADS)

    Whitmore, Bradley C.; Allam, Sahar S.; Budavári, Tamás; Casertano, Stefano; Downes, Ronald A.; Donaldson, Thomas; Fall, S. Michael; Lubow, Stephen H.; Quick, Lee; Strolger, Louis-Gregory; Wallace, Geoff; White, Richard L.

    2016-06-01

    The Hubble Source Catalog is designed to help optimize science from the Hubble Space Telescope (HST) by combining the tens of thousands of visit-based source lists in the Hubble Legacy Archive (HLA) into a single master catalog. Version 1 of the Hubble Source Catalog includes WFPC2, ACS/WFC, WFC3/UVIS, and WFC3/IR photometric data generated using SExtractor software to produce the individual source lists. The catalog includes roughly 80 million detections of 30 million objects involving 112 different detector/filter combinations, and about 160,000 HST exposures. Source lists from Data Release 8 of the HLA are matched using an algorithm developed by Budavári & Lubow. The mean photometric accuracy for the catalog as a whole is better than 0.10 mag, with relative accuracy as good as 0.02 mag in certain circumstances (e.g., bright isolated stars). The relative astrometric residuals are typically within 10 mas, with a value for the mode (i.e., most common value) of 2.3 mas. The absolute astrometric accuracy is better than 0''\\hspace{-0.5em}. 1 for most sources, but can be much larger for a fraction of fields that could not be matched to the PanSTARRS, SDSS, or 2MASS reference systems. In this paper we describe the database design with emphasis on those aspects that enable the users to fully exploit the catalog while avoiding common misunderstandings and potential pitfalls. We provide usage examples to illustrate some of the science capabilities and data quality characteristics, and briefly discuss plans for future improvements to the Hubble Source Catalog.

  5. GENII Version 2 Software Design Document

    SciTech Connect

    Napier, Bruce A.; Strenge, Dennis L.; Ramsdell, James V.; Eslinger, Paul W.; Fosmire, Christian J.

    2004-03-08

    appropriate risk factors to the effective dose equivalent or organ dose. In addition, Version 2 uses cancer risk factors from Federal Guidance Report 13 to estimate risk to specific organs or tissues.

  6. Space Images for NASA JPL Android Version

    NASA Technical Reports Server (NTRS)

    Nelson, Jon D.; Gutheinz, Sandy C.; Strom, Joshua R.; Arca, Jeremy M.; Perez, Martin; Boggs, Karen; Stanboli, Alice

    2013-01-01

    This software addresses the demand for easily accessible NASA JPL images and videos by providing a user friendly and simple graphical user interface that can be run via the Android platform from any location where Internet connection is available. This app is complementary to the iPhone version of the application. A backend infrastructure stores, tracks, and retrieves space images from the JPL Photojournal and Institutional Communications Web server, and catalogs the information into a streamlined rating infrastructure. This system consists of four distinguishing components: image repository, database, server-side logic, and Android mobile application. The image repository contains images from various JPL flight projects. The database stores the image information as well as the user rating. The server-side logic retrieves the image information from the database and categorizes each image for display. The Android mobile application is an interfacing delivery system that retrieves the image information from the server for each Android mobile device user. Also created is a reporting and tracking system for charting and monitoring usage. Unlike other Android mobile image applications, this system uses the latest emerging technologies to produce image listings based directly on user input. This allows for countless combinations of images returned. The backend infrastructure uses industry-standard coding and database methods, enabling future software improvement and technology updates. The flexibility of the system design framework permits multiple levels of display possibilities and provides integration capabilities. Unique features of the software include image/video retrieval from a selected set of categories, image Web links that can be shared among e-mail users, sharing to Facebook/Twitter, marking as user's favorites, and image metadata searchable for instant results.

  7. Assessment of radionuclide databases in CAP88 mainframe version 1.0 and Windows-based version 3.0.

    PubMed

    LaBone, Elizabeth D; Farfán, Eduardo B; Lee, Patricia L; Jannik, G Timothy; Donnelly, Elizabeth H; Foley, Trevor Q

    2009-09-01

    In this study the radionuclide databases for two versions of the Clean Air Act Assessment Package-1988 (CAP88) computer model were assessed in detail. CAP88 estimates radiation dose and the risk of health effects to human populations from radionuclide emissions to air. This program is used by several U.S. Department of Energy (DOE) facilities to comply with National Emission Standards for Hazardous Air Pollutants regulations. CAP88 Mainframe, referred to as version 1.0 on the U.S. Environmental Protection Agency Web site (http://www.epa.gov/radiation/assessment/CAP88/), was the very first CAP88 version released in 1988. Some DOE facilities including the Savannah River Site still employ this version (1.0) while others use the more user-friendly personal computer Windows-based version 3.0 released in December 2007. Version 1.0 uses the program RADRISK based on International Commission on Radiological Protection Publication 30 as its radionuclide database. Version 3.0 uses half-life, dose, and risk factor values based on Federal Guidance Report 13. Differences in these values could cause different results for the same input exposure data (same scenario), depending on which version of CAP88 is used. Consequently, the differences between the two versions are being assessed in detail at Savannah River National Laboratory. The version 1.0 and 3.0 database files contain 496 and 838 radionuclides, respectively, and though one would expect the newer version to include all the 496 radionuclides, 35 radionuclides are listed in version 1.0 that are not included in version 3.0. The majority of these has either extremely short or long half-lives or is no longer in production; however, some of the short-lived radionuclides might produce progeny of great interest at DOE sites. In addition, 122 radionuclides were found to have different half-lives in the two versions, with 21 over 3 percent different and 12 over 10 percent different.

  8. ASSESSMENT OF RADIONUCLIDES DATABASES IN CAP88 MAINFRAME VERSION 1.0 AND WINDOWS-BASED VERSION 3.0

    SciTech Connect

    Farfan, E.; Lee, P.; Jannik, T.; Donnelly, E.

    2008-09-16

    In this study the radionuclide databases for two versions of the Clean Air Act Assessment Package-1988 (CAP88) computer model were assessed in detail. CAP88 estimates radiation dose and the risk of health effects to human populations from radionuclide emissions to air. This program is used by several Department of Energy (DOE) facilities to comply with National Emission Standards for Hazardous Air Pollutants (NESHAP) regulations. CAP88 Mainframe, referred to as Version 1.0 on the Environmental Protection Agency (EPA) website (http://www.epa.gov/radiation/assessment/CAP88/), was the very first CAP88 version released in 1988. Some DOE facilities including the Savannah River Site still employ this version (1.0) while others use the more user-friendly personal computer Windows-based Version 3.0 released in December 2007. Version 1.0 uses the program RADRISK based on International Commission on Radiological Protection (ICRP) Publication 30 as its radionuclide database. Version 3.0 uses half-life, dose and risk factor values based on Federal Guidance Report 13. Differences in these values could cause different results for the same input exposure data (same scenario), depending on which version of CAP88 is used. Consequently, the differences between the two versions are being assessed in detail at Savannah River National Laboratory. The version 1.0 and 3.0 database files contain 496 and 838 radionuclides, respectively, and though one would expect the newer version to include all the 496 radionuclides, thirty-five radionuclides are listed in version 1.0 that are not included in version 3.0. The majority of these has either extremely short or long half-lives or is no longer in production; however, some of the short-lived radionuclides might produce progeny of great interest at DOE sites. In addition, one hundred and twenty-two radionuclides were found to have different half-lives in the two versions, with 21 over 3 percent different and 12 over 10 percent different.

  9. CLIPS - C LANGUAGE INTEGRATED PRODUCTION SYSTEM (MACINTOSH VERSION)

    NASA Technical Reports Server (NTRS)

    Culbert, C.

    1994-01-01

    The C Language Integrated Production System, CLIPS, is a shell for developing expert systems. It is designed to allow artificial intelligence research, development, and delivery on conventional computers. The primary design goals for CLIPS are portability, efficiency, and functionality. For these reasons, the program is written in C. CLIPS meets or outperforms most micro- and minicomputer based artificial intelligence tools. CLIPS is a forward chaining rule-based language. The program contains an inference engine and a language syntax that provide a framework for the construction of an expert system. It also includes tools for debugging an application. CLIPS is based on the Rete algorithm, which enables very efficient pattern matching. The collection of conditions and actions to be taken if the conditions are met is constructed into a rule network. As facts are asserted either prior to or during a session, CLIPS pattern-matches the number of fields. Wildcards and variables are supported for both single and multiple fields. CLIPS syntax allows the inclusion of externally defined functions (outside functions which are written in a language other than CLIPS). CLIPS itself can be embedded in a program such that the expert system is available as a simple subroutine call. Advanced features found in CLIPS version 4.3 include an integrated microEMACS editor, the ability to generate C source code from a CLIPS rule base to produce a dedicated executable, binary load and save capabilities for CLIPS rule bases, and the utility program CRSV (Cross-Reference, Style, and Verification) designed to facilitate the development and maintenance of large rule bases. Five machine versions are available. Each machine version includes the source and the executable for that machine. The UNIX version includes the source and binaries for IBM RS/6000, Sun3 series, and Sun4 series computers. The UNIX, DEC VAX, and DEC RISC Workstation versions are line oriented. The PC version and the Macintosh

  10. CLIPS - C LANGUAGE INTEGRATED PRODUCTION SYSTEM (IBM PC VERSION)

    NASA Technical Reports Server (NTRS)

    Riley, G.

    1994-01-01

    The C Language Integrated Production System, CLIPS, is a shell for developing expert systems. It is designed to allow artificial intelligence research, development, and delivery on conventional computers. The primary design goals for CLIPS are portability, efficiency, and functionality. For these reasons, the program is written in C. CLIPS meets or outperforms most micro- and minicomputer based artificial intelligence tools. CLIPS is a forward chaining rule-based language. The program contains an inference engine and a language syntax that provide a framework for the construction of an expert system. It also includes tools for debugging an application. CLIPS is based on the Rete algorithm, which enables very efficient pattern matching. The collection of conditions and actions to be taken if the conditions are met is constructed into a rule network. As facts are asserted either prior to or during a session, CLIPS pattern-matches the number of fields. Wildcards and variables are supported for both single and multiple fields. CLIPS syntax allows the inclusion of externally defined functions (outside functions which are written in a language other than CLIPS). CLIPS itself can be embedded in a program such that the expert system is available as a simple subroutine call. Advanced features found in CLIPS version 4.3 include an integrated microEMACS editor, the ability to generate C source code from a CLIPS rule base to produce a dedicated executable, binary load and save capabilities for CLIPS rule bases, and the utility program CRSV (Cross-Reference, Style, and Verification) designed to facilitate the development and maintenance of large rule bases. Five machine versions are available. Each machine version includes the source and the executable for that machine. The UNIX version includes the source and binaries for IBM RS/6000, Sun3 series, and Sun4 series computers. The UNIX, DEC VAX, and DEC RISC Workstation versions are line oriented. The PC version and the Macintosh

  11. Users guide for ENVSTD program Version 2. 0 and LTGSTD program Version 2. 0

    SciTech Connect

    Crawley, D.B.; Riesen, P.K.; Briggs, R.S.

    1989-02-01

    On January 30, 1989, the US Department of Energy (DOE) promulgated 10 CFR Part 435, Subpart A, an Interim Rule entitled ''Energy Conservation Voluntary Performance Standards for New Commercial and Multi-Family High Rise Residential Buildings; Mandatory for New Federal Buildings.'' As a consequence, federal agencies must design all future federal commercial and multifamily high rise residential buildings in accordance with the Standards, or show that their current standards already meet or exceed the energy-efficiency requirements of the Standards. Although these newly enacted Standards do not regulate the design of nonfederal buildings, DOE recommends that all design professionals use the Standards as guidelines for designing energy-conserving buildings. To encourage private sector use, the Standards were presented in the January 30, 1989, Federal Register in the format typical of commercial standards rather than a federal regulation. As a further help, DOE supported the development of various microcomputer programs to ease the use of the Standards. Two of these programs/emdash/ENVSTD (Version 2.0) and LTGSTD (Version 2.0)/emdash/are detailed in this users guide and provided on the accompanying diskette. This package, developed by Pacific Northwest Laboratory (PNL), is intended to facilitate the designer's use of the Standards dealing specifically with a building's envelope and lighting system designs. Using these programs will greatly simplify the designer's task of performing the sometimes complex calculations needed to determine a design's compliance with the Standards. 3 refs., 6 figs.

  12. AIRS Science Accomplishments Version 4.0/Plans for Version 5

    NASA Technical Reports Server (NTRS)

    Pagano, Thomas S.; Aumann, Hartmut; Elliott, Denis; Granger, Stephanie; Kahn, Brain; Eldering, Annmarie; Irion, Bill; Fetzer, Eric; Olsen, Ed; Lee, Sung-Yung; Okonek, Sharon; Friedman, Steve; Fishbein, Evan; Gaiser, Steve

    2006-01-01

    This talk is about accomplishments with AIRS data and what we have learned from almost three years of data what part of this is emerging in Version 4.0 what part we would like to see filtering into Version 5.0 and what part constitute limitations in the AIRS requirements, such as spectral and spatial resolution, which have to be deferred to the wish list for the next generation hyperspectral sounder. The AIRS calibration accuracy at the 1OOmK and stability at the 6 mK/year level are amazing. It establishes the unique capability of a cooled grating array spectrometer in Earth orbit for climate research. Data which are sufficiently clear to match the radiometric accuracy of the instrument, have a yield of less than 1%. This is OK for calibration. The 2616/cm window channel combined with the RTG.SST for tropical ocean allow excellent assessment radiometric calibration accuracy and stability. For absolute calibration verification 100mK is the limit due to cloud contamination. The 10 micron window channels can be used for stability assessment, but accuracy is limited at 300mK due to water continuum absorption uncertainties.

  13. Science Opportunity Analyzer (SOA) Version 8

    NASA Technical Reports Server (NTRS)

    Witoff, Robert J.; Polanskey, Carol A.; Aguinaldo, Anna Marie A.; Liu, Ning; Hofstadter, Mark D.

    2013-01-01

    SOA allows scientists to plan spacecraft observations. It facilitates the identification of geometrically interesting times in a spacecraft s orbit that a user can use to plan observations or instrument-driven spacecraft maneuvers. These observations can then be visualized multiple ways in both two- and three-dimensional views. When observations have been optimized within a spacecraft's flight rules, the resulting plans can be output for use by other JPL uplink tools. Now in its eighth major version, SOA improves on these capabilities in a modern and integrated fashion. SOA consists of five major functions: Opportunity Search, Visualization, Observation Design, Constraint Checking, and Data Output. Opportunity Search is a GUI-driven interface to existing search engines that can be used to identify times when a spacecraft is in a specific geometrical relationship with other bodies in the solar system. This function can be used for advanced mission planning as well as for making last-minute adjustments to mission sequences in response to trajectory modifications. Visualization is a key aspect of SOA. The user can view observation opportunities in either a 3D representation or as a 2D map projection. Observation Design allows the user to orient the spacecraft and visualize the projection of the instrument field of view for that orientation using the same views as Opportunity Search. Constraint Checking is provided to validate various geometrical and physical aspects of an observation design. The user has the ability to easily create custom rules or to use official project-generated flight rules. This capability may also allow scientists to easily assess the cost to science if flight rule changes occur. Data Output allows the user to compute ancillary data related to an observation or to a given position of the spacecraft along its trajectory. The data can be saved as a tab-delimited text file or viewed as a graph. SOA combines science planning functionality unique to

  14. SealSim Version 1.1

    2005-05-16

    SealSim 1.1 is a state-of-the-art, Microsoft Windows based computer program developed for the U.S. Department of Energy by Aspen Research Corporation with Contracted support from TNO TPD. It is intended to be used by manufacturers, engineers, educators, students, architects, and others to help determine the relative durability of Insulating Glass Units (IGU). As a function of time, SealSim 1.1 simulates the behaviour of an Insulating Glass Unit, exposed to realistic or user-defined weather climates. Stressesmore » and strains in the IGU are calculated as a function of time, together with temperature distributions, gas permeation effects (gas loss, desiccant loading), dew point temperature, U-factor, etc. The current version of SealSim 1.1 supports double-glazing Units. where the spacer system is either a Thermo Plastic Spacer (TPS) or Box type spacer. For the determination of solar properties of glazing systems, SealSim 1.1 uses the Tntemational Glazing Database of LBNL, which is also used by OPTICS and WINDOW. The goal of the SealSim 1.1 simulations is to predict the IGU’s average lifetime, expressed in terms of the "Durability Index", together with the associated failure mechanisms. The Durability Index of a particular IGU and its most probable failure mechanism can be compared with other IGU’s. How the predicted Durability Index relates to the actual durability of an IGU is not known, simply because sufficient experimental data is lacking for describing the behaviour of IG Units over extended periods of time together with a lack of knowledge of the conditions it is subjected to and initial state of the CU at the time of manufacturing. In order to simulate the IGU behaviour in time, the conditions of the IGU must be defined; together with the weather and or climate that the IGU is subjected to. Using physical models of the IGU, SealSim 1.1 calculates tte response of the CU in time. These physical models are described in more detail in separate documents

  15. SealSim Version 1.1

    SciTech Connect

    2005-05-16

    SealSim 1.1 is a state-of-the-art, Microsoft Windows based computer program developed for the U.S. Department of Energy by Aspen Research Corporation with Contracted support from TNO TPD. It is intended to be used by manufacturers, engineers, educators, students, architects, and others to help determine the relative durability of Insulating Glass Units (IGU). As a function of time, SealSim 1.1 simulates the behaviour of an Insulating Glass Unit, exposed to realistic or user-defined weather climates. Stresses and strains in the IGU are calculated as a function of time, together with temperature distributions, gas permeation effects (gas loss, desiccant loading), dew point temperature, U-factor, etc. The current version of SealSim 1.1 supports double-glazing Units. where the spacer system is either a Thermo Plastic Spacer (TPS) or Box type spacer. For the determination of solar properties of glazing systems, SealSim 1.1 uses the Tntemational Glazing Database of LBNL, which is also used by OPTICS and WINDOW. The goal of the SealSim 1.1 simulations is to predict the IGU’s average lifetime, expressed in terms of the "Durability Index", together with the associated failure mechanisms. The Durability Index of a particular IGU and its most probable failure mechanism can be compared with other IGU’s. How the predicted Durability Index relates to the actual durability of an IGU is not known, simply because sufficient experimental data is lacking for describing the behaviour of IG Units over extended periods of time together with a lack of knowledge of the conditions it is subjected to and initial state of the CU at the time of manufacturing. In order to simulate the IGU behaviour in time, the conditions of the IGU must be defined; together with the weather and or climate that the IGU is subjected to. Using physical models of the IGU, SealSim 1.1 calculates tte response of the CU in time. These physical models are described in more detail in separate documents provided with

  16. A comparison of an electronic version of the SF-36 General Health Questionnaire to the standard paper version.

    PubMed

    Ryan, Judy M; Corry, John R; Attewell, Robyn; Smithson, Michael J

    2002-02-01

    Because of its sound psychometric properties the SF-36 General Health Questionnaire is used throughout the world, yet it is difficult to analyse and score. Using a newly developed software package, onto which any questionnaire can be loaded, we developed an electronic version of the SF-36 General Health Questionnaire. The purpose of this study is test the effect of the electronic mode of administration on the measurement properties of the SF-36. In a randomised cross-over design study 79 healthy individuals and 36 chronic pain patients completed both electronic and paper versions of the SF-36. Seventy-one percent preferred the electronic SF-36, 7% stated no preference, and 22% preferred the paper version. Completion time for the electronic SF-36 was slightly less, and there were no missing or problematical responses, whereas 44% of participants had at least one missing or problematical response in the paper version. Data entry and auditing time was 8 hours. There was less than 4% inter-version difference for any of the SF-36 sub-scales. The electronic SF-36 was well accepted and slightly quicker to complete than the paper version. We conclude that the electronic SF-36 is equivalent in performance and more effective than the paper version.

  17. TAE+ 5.2 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.2 (IBM RS/6000 VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    programs to display and control the user interfaces. Since the WPTs access the workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides a means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System and the Open Software Foundation's Motif. The HP 9000 Series 700/800 version of TAE 5.2 requires Version 11 Release 5 of the X Window System. All other machine versions of TAE 5.2 require Version 11, Release 4 of the X Window System. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus was developed in 1989 and version 5.2 was released in 1993. TAE Plus 5.2 is available on media suitable for five different machine platforms: (1) IBM RS/6000 series workstations running AIX (.25 inch tape cartridge in UNIX tar format), (2) DEC RISC

  18. TAE+ 5.2 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.2 (DEC RISC ULTRIX VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    programs to display and control the user interfaces. Since the WPTs access the workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides a means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System and the Open Software Foundation's Motif. The HP 9000 Series 700/800 version of TAE 5.2 requires Version 11 Release 5 of the X Window System. All other machine versions of TAE 5.2 require Version 11, Release 4 of the X Window System. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus was developed in 1989 and version 5.2 was released in 1993. TAE Plus 5.2 is available on media suitable for five different machine platforms: (1) IBM RS/6000 series workstations running AIX (.25 inch tape cartridge in UNIX tar format), (2) DEC RISC

  19. TAE+ 5.2 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.2 (SILICON GRAPHICS VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    programs to display and control the user interfaces. Since the WPTs access the workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides a means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System and the Open Software Foundation's Motif. The HP 9000 Series 700/800 version of TAE 5.2 requires Version 11 Release 5 of the X Window System. All other machine versions of TAE 5.2 require Version 11, Release 4 of the X Window System. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus was developed in 1989 and version 5.2 was released in 1993. TAE Plus 5.2 is available on media suitable for five different machine platforms: (1) IBM RS/6000 series workstations running AIX (.25 inch tape cartridge in UNIX tar format), (2) DEC RISC

  20. TAE+ 5.2 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.2 (SUN4 VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    programs to display and control the user interfaces. Since the WPTs access the workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides a means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System and the Open Software Foundation's Motif. The HP 9000 Series 700/800 version of TAE 5.2 requires Version 11 Release 5 of the X Window System. All other machine versions of TAE 5.2 require Version 11, Release 4 of the X Window System. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus was developed in 1989 and version 5.2 was released in 1993. TAE Plus 5.2 is available on media suitable for five different machine platforms: (1) IBM RS/6000 series workstations running AIX (.25 inch tape cartridge in UNIX tar format), (2) DEC RISC

  1. Evaluation of H2CHXdedpa, H2dedpa- and H2CHXdedpa-N,N'-propyl-2-NI ligands for (64)Cu(ii) radiopharmaceuticals.

    PubMed

    Ramogida, Caterina F; Boros, Eszter; Patrick, Brian O; Zeisler, Stefan K; Kumlin, Joel; Adam, Michael J; Schaffer, Paul; Orvig, Chris

    2016-08-16

    The chiral acyclic "pa" ligand (pa = picolinic acid) H2CHXdedpa (N4O2) and two NI-containing dedpa analogues (H2CHXdedpa-N,N'-propyl-2-NI, H2dedpa-N,N'-propyl-2-NI, NI = nitroimidazole) were studied as chelators for copper radiopharmaceuticals (CHX = cyclohexyl, H2dedpa = 1,2-[[carboxypyridin-2-yl]methylamino]ethane). The hexadentate ligand H2CHXdedpa was previously established as a superb system for (67/68)Ga radiochemistry. The solid state X-ray crystal structures of [Cu(CHXdedpa-N,N'-propyl-2-NI)] and [Cu(dedpa-N,N'-propyl-2-NI)] reveal the predicted hexadentate, distorted octahedral binding of the copper(ii) ion. Cyclic voltammetry of [Cu(dedpa-N,N'-propyl-2-NI)] shows that there is one reversible couple associated with the NI redox, and one irreversible but reproducible couple attributed to the Cu(ii)/Cu(i) redox cycle. Quantitative radiolabeling (>99%) of CHXdedpa(2-) and (dedpa-N,N'-propyl-2-NI)(2-) with (64)Cu was achieved under fast and efficient labeling conditions (10 min, RT, 0.5 M sodium acetate buffer, pH 5.5) at ligand concentrations as low as 10(-6) M. In vitro kinetic inertness studies of the (64)Cu labelled complexes were studied in human serum at 37 °C over 24 hours; [(64)Cu(CHXdedpa)] was found to be 98% stable compared to previously investigated [(64)Cu(dedpa)] which was only 72% intact after 24 hours. PMID:27161975

  2. Binding of ReO4(-) with an engineered MoO4(2-)-binding protein: towards a new approach in radiopharmaceutical applications.

    PubMed

    Aryal, Baikuntha P; Brugarolas, Pedro; He, Chuan

    2012-01-01

    Radiolabeled biomolecules are routinely used for clinical diagnostics. (99m)Tc is the most commonly used radioactive tracer in radiopharmaceuticals. (188)Re and (186)Re are also commonly used as radioactive tracers in medicine. However, currently available methods for radiolabeling are lengthy and involve several steps in bioconjugation processes. In this work we present a strategy to engineer proteins that may selectively recognize the perrhenate (ReO(4)(-)) ion as a new way to label proteins. We found that a molybdate (MoO(4)(2-))-binding protein (ModA) from Escherichia coli can bind perrhenate with high affinity. Using fluorescence and isothermal titration calorimetry measurements, we determined the dissociation constant of ModA for ReO(4)(-) to be 541 nM and we solved a crystal structure of ModA with a bound ReO(4)(-). On the basis of the structure we created a mutant protein containing a disulfide linkage, which exhibited increased affinity for perrhenate (K(d) = 104 nM). High-resolution crystal structures of ModA (1.7 Å) and A11C/R153C mutant (2.0 Å) were solved with bound perrhenate. Both structures show that a perrhenate ion occupies the molybdate binding site using the same amino acid residues that are involved in molybdate binding. The overall structure of the perrhenate-bound ModA is unchanged compared with that of the molybdate-bound form. In the mutant protein, the bound perrhenate is further stabilized by the engineered disulfide bond.

  3. Production, biodistribution, and dosimetry of (47)Sc-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid as a bone-seeking radiopharmaceutical.

    PubMed

    Fathi, Fatemeh; Moghaddam-Banaem, Leila; Shamsaei, Mojtaba; Samani, Ali; Maragheh, Mohammad G

    2015-01-01

    In this study 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid (DOTMP) was used as the polyaminophosphonic acid carrier ligand and the therapeutic potential of the bone seeking radiopharmaceutical (47)Sc-DOTMP was assessed by measuring its dosage-dependent skeletal uptake and then the absorbed radiation dose of human organs was estimated. Because of limited availability of (47)Sc we performed some preliminary studies using (46)Sc. (46)Sc was produced with a specific activity of 116.58 MBq/mg (3.15 mCi/mg) and radionuclide purity of 98%. (46)Sc-DOTMP was prepared and an activity of 1.258 MBq (34 μCi) at a chelant-to-metal ratio of 60:1 was administered to five groups of mice with each group containing 3 mice that were euthanized at 4, 24, 48, 96 and 192 h post administration. The heart, lungs, liver, spleen, kidneys, intestine, skin, muscle, and a femur were excised, weighed, and counted. The data were analyzed to determine skeletal uptake and source organ residence times and cumulated activities for (47)Sc-DOTMP. (46)Sc-DOTMP complex was prepared in radiochemical purity about 93%. In vitro stability of complex was evaluated at room temperature for 48 h. Biodistribution studies of complex in mice were studied for 7 days. The data were analyzed to estimate skeletal uptake and absorbed radiation dose of human organs using biodistribution data from mice. By considering the results, (47)Sc-DOTMP is a possible therapeutic agent for using in palliation of bone pain due to metastatic skeletal lesions from several types of primary cancers in prostate, breast, etc.

  4. High performance liquid chromatography-tandem mass spectrometry method for ex vivo metabolic studies of a rhenium-labeled radiopharmaceutical for liver cancer.

    PubMed

    Chen, Wei-Hsi; Liao, Chen-Wei; Luo, Tsai-Yueh; Chang, Yu; Men, Lee-Chung; Hsieh, Yi-Cheng

    2014-01-01

    The radio-isotope rhenium-labeled N-[2-(triphenylmethyl)thioethyl]-3-aza-19-ethyloxycarbonyl-3-[2-(triphenylmethyl)thioethyl] octadecanoate) ligand (188Re-MN-16ET) is a novel therapeutic agent under preclinical evaluation for hepatoma. A reversed-phase high performance liquid chromatography coupled with a tandem mass spectrometric analysis method and diode array detector (DAD) involving a T type splitter was developed to characterize this pharmaceutical in rat liver tissue solution and determine its biotransformation rate. The separation was accomplished on a C18 column (chromolith silica, 4.6 mm x 100 mm) using an acetonitrile-ammonium acetate buffer gradient as the mobile phase. The detection was achieved by DAD set at 250nm and tandem mass spectrometry using electrospray ionization in the positive ion mode. Re-MN-16ET displayed a retention time of 23.2 min and a transition ion pair corresponding to m/z677 --> 631 for multiple reaction monitoring. Its biotransformation reaction in rat liver homogenate proceeded for 90 min in a 37°C water bath. The characterization was conducted using aliquots that were extracted and concentrated from the reaction mixture for various incubation times. Re-MN-16ET exhibited a biotransformation half-life (t1/2) of 8-9 min in liver tissue solution and was almost completely exhausted after 90 min. Two of its metabolites, consisting of the Re-labeled carboxylic acid derivative, predominately, and its corresponding demetallized disulfide ligand were found in the liver homogenate, providing a metabolism pathway for the radio-pharmaceutical.

  5. Application programmer`s guide for SDDS version

    SciTech Connect

    Borland, M.

    1995-12-31

    SDDS is a file protocol for Self Describing Data Sets. This document describes Version 1 of the SDDS protocol and the function library that supports it. It is intended for those who wish to develop programs that use SDDS files.

  6. FATHOM (Version 3) Commercial Software Validation and Configuration Control

    SciTech Connect

    HEARD, F.J.

    2000-01-20

    FATHOM (Version 3) an incompressible flow piping network modeling and analysis computer program from Applied Flow Technology was installed for use at the U.S. Department of Energy Hanford Site near Richland, Washington.

  7. Database versioning and its implementation in geoscience information systems

    NASA Astrophysics Data System (ADS)

    Le, Hai Ha; Schaeben, Helmut; Jasper, Heinrich; Görz, Ines

    2014-09-01

    Many different versions of geoscience data concurrently exist in a database for different geological paradigms, source data, and authors. The aim of this study is to manage these versions in a database management system. Our data include geological surfaces, which are triangulated meshes in this study. Unlike revision/version/source control systems, our data are stored in a central database without local copies. The main contributions of this study include (1) a data model with input/output/manage functions, (2) a mesh comparison function, (3) a version merging strategy, and (4) the implementation of all of the concepts in PostgreSQL and gOcad. The software has been tested using synthetic surfaces and a simple tectonic model of a deformed stratigraphic horizon.

  8. The ESA/ESO/NASA Photoshop fits Liberator Version 2

    NASA Astrophysics Data System (ADS)

    Christensen, L. L.; Nielsen, L. H.; Nielsen, K. K.; Johansen, T.

    2005-12-01

    Since the fi rst version of the FITS Liberator software was released on the 8th July 2004 more than 50,000 people worldwide have looked over the scientists' shoulders and worked with digital images from telescopes in space and on the ground themselves. In this way the Liberator has become the `industry standard' for the production of astronomical colour images. The new version 2 of the software has recently been released and opens up a signifi cant number of new possibilities.

  9. OMI Total and Tropospheric Column Nitrogen Dioxide: Version 2 Status

    NASA Technical Reports Server (NTRS)

    Gleason, James

    2007-01-01

    The at-launch version of the OM1 NO2 total and tropospheric NO2 algorithm made a number of assumptions about instrument performance. Our knowledge of tropospheric NO2 has increased in the 3 years since the inital version was delivered. The results of the post-launch validation campaigns and improved atmospheric modelling has lead to changes in the NO2 retrieval algorithm. The algorithm changes and the impacts on the data products will be presented.

  10. PI-RADS Version 2: A Pictorial Update.

    PubMed

    Purysko, Andrei S; Rosenkrantz, Andrew B; Barentsz, Jelle O; Weinreb, Jeffrey C; Macura, Katarzyna J

    2016-01-01

    The Prostate Imaging Reporting and Data System (PI-RADS) is the result of an extensive international collaborative effort. PI-RADS provides a comprehensive yet practical set of guidelines for the interpretation and reporting of prostate multiparametric magnetic resonance (MR) imaging that will promote the use of this modality for detecting clinically significant prostate cancer. The revised PI-RADS version (PI-RADS version 2) introduces important changes to the original system used for assessing the level of suspicion for clinically significant cancer with multiparametric MR imaging. For peripheral zone abnormalities in PI-RADS version 2, the score obtained from the apparent diffusion coefficient (ADC) map in combination with diffusion-weighted imaging (DWI) performed with high b values (≥1400 sec/mm(2)) is the dominant parameter for determining the overall level of suspicion for clinically significant cancer. For transition zone abnormalities, the score obtained from T2-weighted MR imaging is dominant for overall lesion assessment. Dynamic contrast material-enhanced MR imaging has ancillary roles in the characterization of peripheral zone lesions considered equivocal for clinically significant cancer on the basis of the DWI-ADC combination and in the detection of lesions missed with other multiparametric MR pulse sequences. Assessment with dynamic contrast-enhanced MR imaging is also simplified, being considered positive or negative on the basis of qualitative evaluation for a focal area of rapid enhancement matching an abnormality on DWI-ADC or T2-weighted MR images. In PI-RADS version 2, MR spectroscopic imaging is not incorporated into lesion assessment. In this article, a pictorial overview is provided of the revised PI-RADS version 2 assessment categories for the likelihood of clinically significant cancer. PI-RADS version 2 is expected to evolve with time, with updated versions being released as experience in the use of PI-RADS version 2 increases and as

  11. Psychometric Properties of the Persian Version of Self-Transcendence Scale: Adolescent Version

    PubMed Central

    Farahani, Azam Shirinabadi; Rassouli, Maryam; Yaghmaie, Farideh; Majd, Hamid Alavi; Sajjadi, Moosa

    2016-01-01

    Background: Given the greater tendency during adolescence toward risk-taking, identifying and measuring the factors affecting the adolescents’ health is highly important to ensure the efficacy of health promoting interventions. One of these factors is self-transcendence. The aim of this study was to assess the psychometric features of the Self-Transcendence Scale (adolescents’ version) in students in Tehran, the capital city of Iran. Methods: This research was conducted in 2015. For this purpose, 1210 high school students were selected through the multistage cluster sampling method. After the backward-forward translation, the psychometric properties of the scale were examined through the assessment of the (face and construct) validity and reliability (internal consistency and stability) of the scale. The construct validity was assessed using two methods, factor analysis, and convergence of the scale with the Hopefulness Scale for Adolescents. Results: The result of face validity was minor modifications in some words. The exploratory factor analysis resulted in the extraction of two dimensions, with explaining 52.79% of the variance collectively. In determining the convergent validity, the correlation between hopefulness score and self-transcendence score was r=0.47 (P<0.001). The internal consistency of the scale was determined using Cronbach’s alpha of 0.82 for the whole scale and 0.75 and 0.70 for each of the sub-scales. The stability reliability was found to have an ICC of 0.86 and a confidence interval of 95%. Conclusion: The Persian version of the Adolescents’ Self-Transcendence Scale showed an acceptable validity and reliability and can be used in the assessment of self-transcendence in Iranian adolescents. PMID:27218113

  12. TAE+ 5.1 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.1 (VAX VMS VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    programs to display and control the user interfaces. Since the WPTs access the workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides a means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System, Version 11 Release 4, and the Open Software Foundation's Motif. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus was developed in 1989 and version 5.2 was released in 1993. TAE Plus 5.2 is expected to be available on media suitable for seven different machine platforms: 1) DEC VAX computers running VMS (TK50 cartridge in VAX BACKUP format), 2) IBM RS/6000 series workstations running AIX (.25 inch tape cartridge in UNIX tar format), 3) DEC RISC workstations running ULTRIX (TK50 cartridge in UNIX tar format), 4) HP9000 Series 300

  13. TAE+ 5.1 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.1 (SUN3 VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. The Silicon Graphics version of TAE Plus now has a font caching scheme and a color caching scheme to make color allocation more efficient. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides an extremely powerful means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System, Version 11 Release 4, and the Open Software Foundation's Motif Toolkit 1.1 or 1.1.1. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus comes with InterViews and idraw, two software packages developed by Stanford University and integrated in TAE Plus. TAE Plus was developed in 1989 and version 5.1 was released in 1991. TAE Plus is currently available on media suitable for eight different machine platforms: 1) DEC VAX computers running VMS 5.3 or higher (TK

  14. TAE+ 5.1 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.1 (DEC VAX ULTRIX VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. The Silicon Graphics version of TAE Plus now has a font caching scheme and a color caching scheme to make color allocation more efficient. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides an extremely powerful means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System, Version 11 Release 4, and the Open Software Foundation's Motif Toolkit 1.1 or 1.1.1. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus comes with InterViews and idraw, two software packages developed by Stanford University and integrated in TAE Plus. TAE Plus was developed in 1989 and version 5.1 was released in 1991. TAE Plus is currently available on media suitable for eight different machine platforms: 1) DEC VAX computers running VMS 5.3 or higher (TK

  15. Japanese consensus guidelines for pediatric nuclear medicine. Part 1: Pediatric radiopharmaceutical administered doses (JSNM pediatric dosage card). Part 2: Technical considerations for pediatric nuclear medicine imaging procedures.

    PubMed

    Koizumi, Kiyoshi; Masaki, Hidekazu; Matsuda, Hiroshi; Uchiyama, Mayuki; Okuno, Mitsuo; Oguma, Eiji; Onuma, Hiroshi; Kanegawa, Kimio; Kanaya, Shinichi; Kamiyama, Hiroshi; Karasawa, Kensuke; Kitamura, Masayuki; Kida, Tetsuo; Kono, Tatsuo; Kondo, Chisato; Sasaki, Masayuki; Terada, Hitoshi; Nakanishi, Atsushi; Hashimoto, Teisuke; Hataya, Hiroshi; Hamano, Shin-ichiro; Hirono, Keishi; Fujita, Yukihiko; Hoshino, Ken; Yano, Masayuki; Watanabe, Seiichi

    2014-06-01

    The Japanese Society of Nuclear Medicine has recently published the consensus guidelines for pediatric nuclear medicine. This article is the English version of the guidelines. Part 1 proposes the dose optimization in pediatric nuclear medicine studies. Part 2 comprehensively discusses imaging techniques for the appropriate conduct of pediatric nuclear medicine procedures, considering the characteristics of imaging in children.

  16. FEAT - FAILURE ENVIRONMENT ANALYSIS TOOL (UNIX VERSION)

    NASA Technical Reports Server (NTRS)

    Pack, G.

    1994-01-01

    saved as a library file which represents a generic digraph structure for a class of components. The Generate Model feature can then use library files to generate digraphs for every component listed in the modeling tables, and these individual digraph files can be used in a variety of ways to speed generation of complete digraph models. FEAT contains a preprocessor which performs transitive closure on the digraph. This multi-step algorithm builds a series of phantom bridges, or gates, that allow accurate bi-directional processing of digraphs. This preprocessing can be time-consuming, but once preprocessing is complete, queries can be answered and displayed within seconds. A UNIX X-Windows port of version 3.5 of FEAT, XFEAT, is also available to speed the processing of digraph models created on the Macintosh. FEAT v3.6, which is only available for the Macintosh, has some report generation capabilities which are not available in XFEAT. For very large integrated systems, FEAT can be a real cost saver in terms of design evaluation, training, and knowledge capture. The capability of loading multiple digraphs and schematics into FEAT allows modelers to build smaller, more focused digraphs. Typically, each digraph file will represent only a portion of a larger failure scenario. FEAT will combine these files and digraphs from other modelers to form a continuous mathematical model of the system's failure logic. Since multiple digraphs can be cumbersome to use, FEAT ties propagation results to schematic drawings produced using MacDraw II (v1.1v2 or later) or MacDraw Pro. This makes it easier to identify single and double point failures that may have to cross several system boundaries and multiple engineering disciplines before creating a hazardous condition. FEAT v3.6 for the Macintosh is written in C-language using Macintosh Programmer's Workshop C v3.2. It requires at least a Mac II series computer running System 7 or System 6.0.8 and 32 Bit QuickDraw. It also requires a math

  17. Special population planner, version 4.0.

    SciTech Connect

    Kuiper, J.; Tanzman, E.; Metz, W.

    2007-03-26

    Emergencies happen every day. Many are caused by storms or auto accidents and can be planned for, if not predicted. Emergencies resulting from natural hazards often affect a large number of people, and planning for them can be difficult, since knowledge of the needs of the people involved is generally unavailable. Emergencies resulting from accidents at industrial and military facilities can also be large scale in nature if people must be evacuated or sheltered in place. Federal planning for large scale emergencies is the responsibility of the Federal Emergency Management Agency (FEMA), which provides assistance to various emergency management agencies at the national, state and local level. More information about FEMA is available at http://www.fema.gov/. The purpose of the Special Population Planner (SPP) is to help emergency planners address the needs of persons with special needs. The exact definition of 'special population' is a policy decision. Policymakers have included a variety of groups in this term, such as persons with disabilities, those who do not have vehicles with which to evacuate, children who are unattended at times (latchkey children), and many others. The SPP was developed initially for the Alabama Emergency Management Agency as part of its Chemical Stockpile Emergency Preparedness Program (CSEPP), which aids emergency planning and preparedness in communities surrounding military installations across the United States where chemical weapons are stored pending their destruction under federal law. Like that specialized application, this open-source version contains a set of specialized Geographic Information System (GIS) tools to facilitate emergency planning on behalf of persons with special needs, regardless of how the term is defined. While the original SPP system was developed for emergency planning relating to chemical hazards, it can be applied to other threats as well. It is apparent from Hurricane Katrina and other natural and man

  18. COMPPAP - COMPOSITE PLATE BUCKLING ANALYSIS PROGRAM (UNIX VERSION)

    NASA Technical Reports Server (NTRS)

    Smith, J. P.

    1994-01-01

    The Composite Plate Buckling Analysis Program (COMPPAP) was written to help engineers determine buckling loads of orthotropic (or isotropic) irregularly shaped plates without requiring hand calculations from design curves or extensive finite element modeling. COMPPAP is a one element finite element program that utilizes high-order displacement functions. The high order of the displacement functions enables the user to produce results more accurate than traditional h-finite elements. This program uses these high-order displacement functions to perform a plane stress analysis of a general plate followed by a buckling calculation based on the stresses found in the plane stress solution. The current version assumes a flat plate (constant thickness) subject to a constant edge load (normal or shear) on one or more edges. COMPPAP uses the power method to find the eigenvalues of the buckling problem. The power method provides an efficient solution when only one eigenvalue is desired. Once the eigenvalue is found, the eigenvector, which corresponds to the plate buckling mode shape, results as a by-product. A positive feature of the power method is that the dominant eigenvalue is the first found, which is this case is the plate buckling load. The reported eigenvalue expresses a load factor to induce plate buckling. COMPPAP is written in ANSI FORTRAN 77. Two machine versions are available from COSMIC: a PC version (MSC-22428), which is for IBM PC 386 series and higher computers and compatibles running MS-DOS; and a UNIX version (MSC-22286). The distribution medium for both machine versions includes source code for both single and double precision versions of COMPPAP. The PC version includes source code which has been optimized for implementation within DOS memory constraints as well as sample executables for both the single and double precision versions of COMPPAP. The double precision versions of COMPPAP have been successfully implemented on an IBM PC 386 compatible running

  19. COMPPAP - COMPOSITE PLATE BUCKLING ANALYSIS PROGRAM (IBM PC VERSION)

    NASA Technical Reports Server (NTRS)

    Smith, J. P.

    1994-01-01

    The Composite Plate Buckling Analysis Program (COMPPAP) was written to help engineers determine buckling loads of orthotropic (or isotropic) irregularly shaped plates without requiring hand calculations from design curves or extensive finite element modeling. COMPPAP is a one element finite element program that utilizes high-order displacement functions. The high order of the displacement functions enables the user to produce results more accurate than traditional h-finite elements. This program uses these high-order displacement functions to perform a plane stress analysis of a general plate followed by a buckling calculation based on the stresses found in the plane stress solution. The current version assumes a flat plate (constant thickness) subject to a constant edge load (normal or shear) on one or more edges. COMPPAP uses the power method to find the eigenvalues of the buckling problem. The power method provides an efficient solution when only one eigenvalue is desired. Once the eigenvalue is found, the eigenvector, which corresponds to the plate buckling mode shape, results as a by-product. A positive feature of the power method is that the dominant eigenvalue is the first found, which is this case is the plate buckling load. The reported eigenvalue expresses a load factor to induce plate buckling. COMPPAP is written in ANSI FORTRAN 77. Two machine versions are available from COSMIC: a PC version (MSC-22428), which is for IBM PC 386 series and higher computers and compatibles running MS-DOS; and a UNIX version (MSC-22286). The distribution medium for both machine versions includes source code for both single and double precision versions of COMPPAP. The PC version includes source code which has been optimized for implementation within DOS memory constraints as well as sample executables for both the single and double precision versions of COMPPAP. The double precision versions of COMPPAP have been successfully implemented on an IBM PC 386 compatible running

  20. TAE+ 5.1 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.1 (SUN3 VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. The Silicon Graphics version of TAE Plus now has a font caching scheme and a color caching scheme to make color allocation more efficient. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides an extremely powerful means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System, Version 11 Release 4, and the Open Software Foundation's Motif Toolkit 1.1 or 1.1.1. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus comes with InterViews and idraw, two software packages developed by Stanford University and integrated in TAE Plus. TAE Plus was developed in 1989 and version 5.1 was released in 1991. TAE Plus is currently available on media suitable for eight different machine platforms: 1) DEC VAX computers running VMS 5.3 or higher (TK

  1. TAE+ 5.1 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.1 (DEC VAX ULTRIX VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. The Silicon Graphics version of TAE Plus now has a font caching scheme and a color caching scheme to make color allocation more efficient. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides an extremely powerful means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System, Version 11 Release 4, and the Open Software Foundation's Motif Toolkit 1.1 or 1.1.1. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus comes with InterViews and idraw, two software packages developed by Stanford University and integrated in TAE Plus. TAE Plus was developed in 1989 and version 5.1 was released in 1991. TAE Plus is currently available on media suitable for eight different machine platforms: 1) DEC VAX computers running VMS 5.3 or higher (TK

  2. The NERC Vocabulary Server: Version 2.0

    NASA Astrophysics Data System (ADS)

    Leadbetter, A.; Lowry, R.; Clements, O.

    2012-04-01

    The NERC Vocabulary Server (NVS) has been used to publish controlled vocabularies of terms relevant to the marine environmental sciences domain since 2006 (version 0) with version 1 being introduced in 2007. It has been used for • metadata mark-up with verifiable content • populating dynamic drop down lists • semantic cross-walk between metadata schemata • so-called smart search • and the semantic enablement of Open Geospatial Consortium Web Processing Services in projects including: the NERC Data Grid; SeaDataNet; Geo-Seas; and the European Marine Observation and Data Network (EMODnet). The NVS is based on the Simple Knowledge Organization System (SKOS) model and following a version change for SKOS in 2009 there was a desire to upgrade the NVS to incorporate the changes in this standard. SKOS is based on the "concept", which it defines as a "unit of thought", that is an idea or notion such as "oil spill". The latest version of SKOS introduces the ability to aggregate concepts in both collections and schemes. The design of version 2 of the NVS uses both types of aggregation: schemes for the discovery of content through hierarchical thesauri and collections for the publication and addressing of content. Other desired changes from version 1 of the NVS included: • the removal of the potential for multiple Uniform Resource Names for the same concept to ensure consistent identification of concepts • the addition of content and technical governance information in the payload documents to provide an audit trail to users of NVS content • the removal of XML snippets from concept definitions in order to correctly validate XML serializations of the SKOS • the addition of the ability to map into external knowledge organization systems in order to extend the knowledge base • a more truly RESTful approach URL access to the NVS to make the development of applications on top of the NVS easier • and support for multiple human languages to increase the user

  3. Update of the European Landslide Susceptibility Map (ELSUS Version 2)

    NASA Astrophysics Data System (ADS)

    Wilde, Martina; Günther, Andreas; Malet, Jean-Philippe; Reichenbach, Paola; Hervás, Javier

    2015-04-01

    We present an update of the initial version of the European Landslide Susceptibility Map (ELSUS Version 1) that was released in 2012 through the EU Joint Research Centre (JRC) European Soil Data Centre (ESDAC). The susceptibility evaluation methodology employed for the updated map ELSUS Version 2 presented in this paper is identical to the previous approach, and comprises the differentiation of the analyzed European area into seven climate-physiographical model zones, the use of a reduced set of spatial susceptibility predictors (shallow subsurface lithology, slope angle, and land cover), and model zone-specific heuristic spatial multicriteria evaluations (SMCE) for susceptibility mapping. The most important improvement for ELSUS version 2 is the replacement of the original "lithology" data set consisting of soil parent material information derived from the European Soil Database (ESDB) by new information derived from the digital version of the International Hydrogeological Map of Europe at scale 1 : 1.5 Million (IHME 1500). IHME lithology describes both consolidated and unconsolidated shallow geological materials over Europe and can be shown to have a higher significance for landslide susceptibility evaluation than the soil parent material derived from ESDB. Other improvements consist in the change of the mapping unit from 1 km to 200 m grid size and the incorporation of terrains not covered by ELSUS version 1 (e.g., Iceland, the Faroers, the Shetlands, and Cyprus). Additionally, the new ELSUS version 2 was calibrated and validated with an updated pan-European landslide inventory now containing more than 155,000 landslides (30% more than used for ELSUS version 1). The enhanced and updated landslide inventory and the higher quality of the "lithology" data enabled us to establish more consistent SMCE-schemes for the individual model zones. The enhancements of ELSUS Version 2 result in an overall increase of the predictive power of the map for about 10%, as indicated

  4. Global Mapping Project - Applications and Development of Version 2 Dataset

    NASA Astrophysics Data System (ADS)

    Ubukawa, T.; Nakamura, T.; Otsuka, T.; Iimura, T.; Kishimoto, N.; Nakaminami, K.; Motojima, Y.; Suga, M.; Yatabe, Y.; Koarai, M.; Okatani, T.

    2012-07-01

    The Global Mapping Project aims to develop basic geospatial information of the whole land area of the globe, named Global Map, through the cooperation of National Mapping Organizations (NMOs) around the world. The Global Map data can be a base of global geospatial infrastructure and is composed of eight layers: Boundaries, Drainage, Transportation, Population Centers, Elevation, Land Use, Land Cover and Vegetation. The Global Map Version 1 was released in 2008, and the Version 2 will be released in 2013 as the data are to be updated every five years. In 2009, the International Steering Committee for Global Mapping (ISCGM) adopted new Specifications to develop the Global Map Version 2 with a change of its format so that it is compatible with the international standards, namely ISO 19136 and ISO 19115. With the support of the secretariat of ISCGM, the project participating countries are accelerating their data development toward the completion of the global coverage in 2013, while some countries have already released their Global Map version 2 datasets since 2010. Global Map data are available from the Internet free of charge for non-commercial purposes, which can be used to predict, assess, prepare for and cope with global issues by combining with other spatial data. There are a lot of Global Map applications in various fields, and further utilization of Global Map is expected. This paper summarises the activities toward the development of the Global Map Version 2 as well as some examples of the Global Map applications in various fields.

  5. An Arabic language version of the health promotion lifestyle profile.

    PubMed

    Haddad, L G; al-Ma'aitah, R M; Cameron, S J; Armstrong-Stassen, M

    1998-04-01

    The purpose of this study was to assess the validity and reliability of an Arabic version of the Health-Promoting Lifestyle Profile instrument in Jordan, whose society and culture differ from that of North America, where the instrument was developed. The instrument was translated into Arabic, back-translated, and pilot tested to ascertain cultural sensitivity. The Arabic version was then evaluated using a convenience sample of 950 adults in the northern part of Jordan using a principal components factor analysis. The order of factors was not entirely identical to those isolated previously during the psychometric assessment of the English language version. Only the structure of three factors--self actualization, health responsibility--and exercise were the same as those obtained in the English version. The forced, six factor solution explained only 39.3% of the variance in the measure. The alpha reliability coefficients were 0.89 for the total scale and ranged from 0.85 to 0.60 for the subscales. It was concluded that the Arabic version of the Health-Promoting Lifestyle Profile has demonstrated initial reliability and validity. Further testing is recommended.

  6. TAE+ 5.1 - TRANSPORTABLE APPLICATIONS ENVIRONMENT PLUS, VERSION 5.1 (VAX VMS VERSION)

    NASA Technical Reports Server (NTRS)

    TAE SUPPORT OFFICE

    1994-01-01

    programs to display and control the user interfaces. Since the WPTs access the workbench-generated resource files during each execution, details such as color, font, location, and object type remain independent from the application code, allowing changes to the user interface without recompiling and relinking. In addition to WPTs, TAE Plus can control interaction of objects from the interpreted TAE Command Language. TCL provides a means for the more experienced developer to quickly prototype an application's use of TAE Plus interaction objects and add programming logic without the overhead of compiling or linking. TAE Plus requires MIT's X Window System, Version 11 Release 4, and the Open Software Foundation's Motif. The Workbench and WPTs are written in C++ and the remaining code is written in C. TAE Plus is available by license for an unlimited time period. The licensed program product includes the TAE Plus source code and one set of supporting documentation. Additional documentation may be purchased separately at the price indicated below. The amount of disk space required to load the TAE Plus tar format tape is between 35Mb and 67Mb depending on the machine version. The recommended minimum memory is 12Mb. Each TAE Plus platform delivery tape includes pre-built libraries and executable binary code for that particular machine, as well as source code, so users do not have to do an installation. Users wishing to recompile the source will need both a C compiler and either GNU's C++ Version 1.39 or later, or a C++ compiler based on AT&T 2.0 cfront. TAE Plus was developed in 1989 and version 5.2 was released in 1993. TAE Plus 5.2 is expected to be available on media suitable for seven different machine platforms: 1) DEC VAX computers running VMS (TK50 cartridge in VAX BACKUP format), 2) IBM RS/6000 series workstations running AIX (.25 inch tape cartridge in UNIX tar format), 3) DEC RISC workstations running ULTRIX (TK50 cartridge in UNIX tar format), 4) HP9000 Series 300

  7. 177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.

    PubMed

    Hoppmann, Susan; Qi, Shibo; Miao, Zheng; Liu, Hongguang; Jiang, Han; Cutler, Cathy S; Bao, Ande; Cheng, Zhen

    2012-06-01

    Epidermal growth factor receptor 1 (EGFR) is an attractive target for radionuclide therapy of head and neck carcinomas. Affibody molecules against EGFR (Z(EGFR)) show excellent tumor localizations in imaging studies. However, one major drawback is that radiometal-labeled Affibody molecules display extremely high uptakes in the radiosensitive kidneys which may impact their use as radiotherapeutic agents. The purpose of this study is to further explore whether radiometal-labeled human serum albumin (HSA)-Z(EFGR) bioconjugates display desirable profiles for the use in radionuclide therapy of EGFR-positive head and neck carcinomas. The Z(EFGR) analog, Ac-Cys-Z(EGFR:1907), was site-specifically conjugated with HSA. The resulting bioconjugate 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A)-HSA-Z(EGFR:1907) was then radiolabeled with either (64)Cu or (177)Lu and subjected to in vitro cell uptake and internalization studies using the human oral squamous carcinoma cell line SAS. Positron emission tomography (PET), single photon emission computed tomography (SPECT), and biodistribution studies were conducted using SAS-tumor-bearing mice. Cell studies revealed a high (8.43 ± 0.55 % at 4 h) and specific (0.95 ± 0.09 % at 4 h) uptake of (177)Lu-DO3A-HSA-Z(EGFR:1907) as determined by blocking with nonradioactive Z(EGFR:1907). The internalization of (177)Lu-DO3A-HSA-Z(EGFR:1907) was verified in vitro and found to be significantly higher than that of (177)Lu-labeled Z(EFGR) at 2-24 h of incubation. PET and SPECT studies showed good tumor imaging contrasts. The biodistribution of (177)Lu-DO3A-HSA-Z(EGFR:1907) in SAS-tumor-bearing mice displayed high tumor uptake (5.1 ± 0.44 % ID/g) and liver uptake (31.5 ± 7.66 % ID/g) and moderate kidney uptake (8.5 ± 1.08 % ID/g) at 72 h after injection. (177)Lu-DO3A-HSA-Z(EGFR:1907) shows promising in vivo profiles and may be a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas

  8. Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials

    PubMed Central

    Tunio, Mutahir; Al Asiri, Mushabbab; Al Hadab, Abdulrehman; Bayoumi, Yasser

    2015-01-01

    Background A meta-analysis was conducted to assess the impact of radiopharmaceuticals (RPs) in castration-resistant prostate cancer (CRPC) on pain control, symptomatic skeletal events (SSEs), toxicity profile, quality of life (QoL), and overall survival (OS). Materials and methods The PubMed/MEDLINE, CANCERLIT, EMBASE, Cochrane Library database, and other search engines were searched to identify randomized controlled trials (RCTs) comparing RPs with control (placebo or radiation therapy) in metastatic CRPC. Data were extracted and assessed for the risk of bias (Cochrane’s risk of bias tool). Pooled data were expressed as odds ratio (OR), with 95% confidence intervals (CIs; Mantel–Haenszel fixed-effects model). Results Eight RCTs with a total patient population of 1,877 patients were identified. The use of RP was associated with significant reduction in pain intensity and SSE (OR: 0.63, 95% CI: 0.51–0.78, I2=27%, P,0.0001), improved QoL (OR: 0.71, 95% CI: 0.55–0.91, I2=65%, three trials, 1,178 patients, P=0.006), and a minimal improved OS (OR: 0.84, 95% CI: 0.64–1.04, I2=47%, seven trials, 1,845 patients, P=0.11). A subgroup analysis suggested an improved OS with radium-223 (OR: 0.68, 95% CI: 0.51–0.90, one trial, 921 patients) and strontium-89 (OR: 0.21, 95% CI: 0.05–0.91, one trial, 49 patients). Strontium-89 (five trials) was associated with increased rates of grade 3 and 4 thrombocytopenia (OR: 4.26, 95% CI: 2.22–8.18, P=0.01), leucopenia (OR: 7.98, 95% CI: 1.82–34.95, P=0.02), pain flare (OR: 6.82, 95% CI: 3.42–13.55, P=0.04), and emesis (OR: 3.61, 95% CI: 1.76–7.40, P=0.02). Conclusion The use of RPs was associated with significant reduction in SSEs and improved QoL, while the radium-223-related OS benefit warrants further large, RCTs in docetaxel naive metastatic CRPC patients. PMID:26451085

  9. DF-224 Version 7.3 FS Installation

    NASA Astrophysics Data System (ADS)

    Boyce, Leslye

    1990-12-01

    Version 7.3 will implement a three logical memory unit contingency plan. It removes under utilized DF-224 code to recover memory margins and restructures code. The installation of DF-224, version 7.3 will be broken into a Installation, Regression test, and Contingency Back-out time. In addition, it eliminates the 10 and 300 second processing rate. It is highly desirable to implement the version of the flight software ASAP. Due to the complexity of the installation, dedicated spacecraft time is required to minimize spacecraft risk In summary, this proposal requests 14 orbits of dedicated spacecraft time for installation, regression test, and contingency back_out time for DF-224 FS V7.3 to be scheduled in the first few days of SMS 054.

  10. [Development of a Japanese version of the TALE scale].

    PubMed

    Ochiai, Tsutomu; Oguchi, Takashi

    2013-12-01

    The Thinking About Life Experiences (TALE) Scale (Bluck & Alea, 2011) has three subscales that assess the self, social, and directive functions of autobiographical memory. This study constructs a Japanese version of the TALE Scale and examines its reliability and validity. Fifteen items that assess the three functions of autobiographical memory were translated into Japanese. We conducted an online investigation with 600 men and women between 20-59 years of age. In Study 1, exploratory and confirmatory factor analysis identified that the three-factor structure of the Japanese version of the TALE Scale was the same as the original TALE Scale. Sufficient internal consistency of the scale was found, and the construct validity of the scale was supported by correlation analysis. Study 2 confirmed that the test-retest reliabilities of the three subscales were sufficient. Thus, this Japanese version of the TALE Scale is useful to assess autobiographical memory functions in Japan.

  11. EPDL97: the evaluated photo data library `97 version

    SciTech Connect

    Cullen, D.E.; Hubbell, J.H.; Kissel, L.

    1997-09-19

    The Evaluated Photon Data Library, 1997 version (EPLD97), is designed for use in photon transport calculations at Lawrence Livermore National Laboratory. This library includes photon interaction data for all elements with atomic number between Z = 1 (hydrogne) and 100 (fermium), including: photoionization, photoexcitation, coherent and incoherent scattering, and pair and triplet porduction cross sections. For use in applications data is provided for all elements over the energy range 1 eV to 100 GeV. This report documents the sources and treatment of the data included inthis library. EPDL97 completely supersedes the earlier 1989 version of EPDL and it is highly recommended that useres only use the most recent version of this library.

  12. Modified version of the combined model of photonucleon reactions

    SciTech Connect

    Ishkhanov, B. S.; Orlin, V. N.

    2015-07-15

    A refined version of the combined photonucleon-reaction model is described. This version makes it possible to take into account the effect of structural features of the doorway dipole state on photonucleon reactions in the energy range of E{sub γ} ≤ 30 MeV. In relation to the previous version of the model, the treatment of isospin effects at the preequilibrium and evaporation reaction stages is refined; in addition, the description of the semidirect effect caused by nucleon emission from the doorway dipole state is improved. The model in question is used to study photonucleon reactions on the isotopes {sup 35-56}Ca and {sup 102-134}Sn in the energy range indicated above.

  13. p-version finite element modeling for NDE

    NASA Astrophysics Data System (ADS)

    Issa, Camille A.; Balasubramaniam, Krishnan

    The formulation for the quadrilateral element of a p-version FEM for NDE is presented. Nodal shape, side shape, and internal shape functions are derived. The problem of wave propagation in solids is investigated using a Newmark direct integration scheme applied to p-version FEM meshes. It is found that numerical noise prevails for all the time steps and along the whole structure, and that there is no apparent wave propagation phenomenon in the displacement time-history. The numerical noise suggests that the abrupt change in the element material properties between the different layers of composite material and glue resin is a fatal modeling defect. The negative effect of using higher order p-version elements and the abrupt change of the element material properties should be countered by using a greater number of elements to model each layer and higher order mapping functions in the mapping process.

  14. SRT Evaluation of AIRS Version-6.02 and Version-6.02 AIRS Only (6.02 AO) Products

    NASA Technical Reports Server (NTRS)

    Susskind, Joel; Iredell, Lena; Molnar, Gyula; Blaisdell, John

    2012-01-01

    Version-6 contains a number of significant improvements over Version-5. This report compares Version-6 products resulting from the advances listed below to those from Version-5. 1. Improved methodology to determine skin temperature (T(sub s)) and spectral emissivity (Epsilon(sub v)). 2. Use of Neural-net start-up state. 3. Improvements which decrease the spurious negative Version-5 trend in tropospheric temperatures. 4. Improved QC methodology. Version-6 uses separate QC thresholds optimized for Data Assimilation (QC=0) and Climate applications (QC=0,1) respectively. 5. Channel-by-channel clear-column radiances R-hat(sub tau) QC flags. 6. Improved cloud parameter retrieval algorithm. 7. Improved OLR RTA. Our evaluation compared V6.02 and V6.02 AIRS Only (V6.02 AO) Quality Controlled products with those of Version-5.0. In particular we evaluated surface skin temperature T(sub s), surface spectral emissivity Epsilon(sub v), temperature profile T(p), water vapor profile q(p), OLR, OLR(sub CLR), effective cloud fraction alpha-Epsilon, and cloud cleared radiances R-hat(sub tau) . We conducted two types of evaluations. The first compared results on 7 focus days to collocated ECMWF truth. The seven focus days are: September 6, 2002; January 25, 2003; September 29, 2004; August 5, 2005; February 24, 2007; August 10, 2007; and May 30, 2010. In these evaluations, we show results for T(sub s), Epsilon(sub v), T(p), and q(p) in terms of yields, and RMS differences and biases with regard to ECMWF. We also show yield trends as well as bias trends of these quantities relative to ECMWF truth. We also show yields and accuracy of channel by channel QC d values of R-hat(sub tau) for V6.02 and V6.02 AO. Version-5 did not contain channel by channel QC d values of R-hat(sub tau). In the second type of evaluation, we compared V6.03 monthly mean Level-3 products to those of Version-5.0, for four different months: January, April, July, and October; in 3 different years 2003, 2007, and 2011

  15. Algebra I California Content Standards: Standards Deconstruction Project. Version 2.0

    ERIC Educational Resources Information Center

    Preibisius, Eric; Boswell, Bonnie; Capacia, Nemie; Dreher, Dolores; Hartman, Jim; Hovde, Peg; Nichols, Terrie; Orr, Michael; Parvini, Shahrokh; Teegarden, Terrie; Vargas, Mailei

    2008-01-01

    The original version, Version 1.0, of this document was first published in 2005. This current version, Version 2.0, includes updates based on feedback from faculty across the state. Also a listing of the Algebra I California Content Standards organized into clusters has been added in Appendix #1. Cal-PASS is unique in that it is the only data…

  16. CLIPS 6.0 - C LANGUAGE INTEGRATED PRODUCTION SYSTEM, VERSION 6.0 (DEC VAX VMS VERSION)

    NASA Technical Reports Server (NTRS)

    Donnell, B.

    1994-01-01

    COOL (that is, a rule can pattern match on objects created using COOL). CLIPS 6.0 provides the capability to define functions, overloaded functions, and global variables interactively. In addition, CLIPS can be embedded within procedural code, called as a subroutine, and integrated with languages such as C, FORTRAN and Ada. CLIPS can be easily extended by a user through the use of several well-defined protocols. CLIPS provides several delivery options for programs including the ability to generate stand alone executables or to load programs from text or binary files. CLIPS 6.0 provides support for the modular development and execution of knowledge bases with the defmodule construct. CLIPS modules allow a set of constructs to be grouped together such that explicit control can be maintained over restricting the access of the constructs by other modules. This type of control is similar to global and local scoping used in languages such as C or Ada. By restricting access to deftemplate and defclass constructs, modules can function as blackboards, permitting only certain facts and instances to be seen by other modules. Modules are also used by rules to provide execution control. The CRSV (Cross-Reference, Style, and Verification) utility included with previous version of CLIPS is no longer supported. The capabilities provided by this tool are now available directly within CLIPS 6.0 to aid in the development, debugging, and verification of large rule bases. COSMIC offers four distribution versions of CLIPS 6.0: UNIX (MSC-22433), VMS (MSC-22434), MACINTOSH (MSC-22429), and IBM PC (MSC-22430). Executable files, source code, utilities, documentation, and examples are included on the program media. All distribution versions include identical source code for the command line version of CLIPS 6.0. This source code should compile on any platform with an ANSI C compiler. Each distribution version of CLIPS 6.0, except that for the Macintosh platform, includes an executable for the

  17. Solar Advisor Model User Guide for Version 2.0

    SciTech Connect

    Gilman, P.; Blair, N.; Mehos, M.; Christensen, C.; Janzou, S.; Cameron, C.

    2008-08-01

    The Solar Advisor Model (SAM) provides a consistent framework for analyzing and comparing power system costs and performance across the range of solar technologies and markets, from photovoltaic systems for residential and commercial markets to concentrating solar power and large photovoltaic systems for utility markets. This manual describes Version 2.0 of the software, which can model photovoltaic and concentrating solar power technologies for electric applications for several markets. The current version of the Solar Advisor Model does not model solar heating and lighting technologies.

  18. APS beamline standard components handbook, Version 1. 3

    SciTech Connect

    Hahn, U.; Shu, D.; Kuzay, T.M.

    1993-02-01

    This Handbook in its current version (1.3) contains descriptions, specifications, and preliminary engineering design drawings for many of the standard components. The design status and schedules have been provided wherever possible. In the near future, the APS plans to update engineering drawings of identified standard beamline components and complete the Handbook. The completed version of this Handbook will become available to both the CATs and potential vendors. Use of standard components should result in major cost reductions for CATs in the areas of beamline design and construction.

  19. User's manual for the Macintosh version of PASCO

    NASA Technical Reports Server (NTRS)

    Lucas, S. H.; Davis, Randall C.

    1991-01-01

    A user's manual for Macintosh PASCO is presented. Macintosh PASCO is an Apple Macintosh version of PASCO, an existing computer code for structural analysis and optimization of longitudinally stiffened composite panels. PASCO combines a rigorous buckling analysis program with a nonlinear mathematical optimization routine to minimize panel mass. Macintosh PASCO accepts the same input as mainframe versions of PASCO. As output, Macintosh PASCO produces a text file and mode shape plots in the form of Apple Macintosh PICT files. Only the user interface for Macintosh is discussed here.

  20. GEMPAK 5.1 - A GENERAL METEOROLOGICAL PACKAGE (UNIX VERSION)

    NASA Technical Reports Server (NTRS)

    Desjardins, M. L.

    1994-01-01

    GEMPAK is a general meteorological software package developed at NASA/Goddard Space Flight Center. It includes programs to analyze and display surface, upper-air, and gridded data, including model output. There are very general programs to list, edit, and plot data on maps, to display profiles and time series, to draw and fill contours, to draw streamlines, to plot symbols for clouds, sky cover, and pressure tendency, and draw cross sections in the case of gridded data and sounding data. In addition, there are Barnes objective analysis programs to grid surface and upper-air data. The programs include the capabilities to derive meteorological parameters from those found in the dataset, to perform vertical interpolations of sounding data to different coordinate systems, and to compute an extensive set of gridded diagnostic quantities by specifying various nested combinations of scalars and vector arithmetic, algebraic, and differential operators. The GEMPAK 5.1 graphics/transformation subsystem, GEMPLT, provides device-independent graphics. GEMPLT also has the capability to display output in a variety of map projections or overlaid on satellite imagery. GEMPAK 5.1 is written in FORTRAN 77 and C-language and has been implemented on VAX computers under VMS and on computers running the UNIX operating system. During installation and normal use, this package occupies approximately 100Mb of hard disk space. The UNIX version of GEMPAK includes drivers for several graphic output systems including MIT's X Window System (X11,R4), Sun GKS, PostScript (color and monochrome), Silicon Graphics, and others. The VMS version of GEMPAK also includes drivers for several graphic output systems including PostScript (color and monochrome). The VMS version is delivered with the object code for the Transportable Applications Environment (TAE) program, version 4.1 which serves as a user interface. A color monitor is recommended for displaying maps on video display devices. Data for rendering

  1. ELAS - SCIENCE & TECHNOLOGY LABORATORY APPLICATIONS SOFTWARE (MASSCOMP VERSION)

    NASA Technical Reports Server (NTRS)

    Walters, D.

    1994-01-01

    the flexibility to process data elements exceeding 8 bits in length, including floating point (noninteger) elements and 16 or 32 bit integers. Thus it is able to analyze and process "non-standard" nonimage data. The VAX (ERL-10017) and Concurrent (ERL-10013) versions of ELAS 9.0 are written in FORTRAN and ASSEMBLER for DEC VAX series computers running VMS and Concurrent computers running MTM. The Sun (SSC-00019), Masscomp (SSC-00020), and Silicon Graphics (SSC-00021) versions of ELAS 9.0 are written in FORTRAN 77 and C-LANGUAGE for Sun4 series computers running SunOS, Masscomp computers running UNIX, and Silicon Graphics IRIS computers running IRIX. The Concurrent version requires at least 15 bit addressing and a direct memory access channel. The VAX and Concurrent versions of ELAS both require floating-point hardware, at least 1Mb of RAM, and approximately 70Mb of disk space. Both versions also require a COMTAL display device in order to display images. For the Sun, Masscomp, and Silicon Graphics versions of ELAS, the disk storage required is approximately 115Mb, and a minimum of 8Mb of RAM is required for execution. The Sun version of ELAS requires either the X-Window System Version 11 Revision 4 or Sun OpenWindows Version 2. The Masscomp version requires a GA1000 display device and the associated "gp" library. The Silicon Graphics version requires Silicon Graphics' GL library. ELAS display functions will not work with a monochrome monitor. The standard distribution medium for the VAX version (ERL10017) is a set of two 9-track 1600 BPI magnetic tapes in DEC VAX BACKUP format. This version is also available on a TK50 tape cartridge in DEC VAX BACKUP format. The standard distribution medium for the Concurrent version (ERL-10013) is a set of two 9-track 1600 BPI magnetic tapes in Concurrent BACKUP format. The standard distribution medium for the Sun version (SSC-00019) is a .25 inch streaming magnetic tape cartridge in UNIX tar format. The standard distribution medium

  2. SAGE Version 7.0 Algorithm: Application to SAGE II

    NASA Technical Reports Server (NTRS)

    Damadeo, R. P; Zawodny, J. M.; Thomason, L. W.; Iyer, N.

    2013-01-01

    This paper details the Stratospheric Aerosol and Gas Experiments (SAGE) version 7.0 algorithm and how it is applied to SAGE II. Changes made between the previous (v6.2) and current (v7.0) versions are described and their impacts on the data products explained for both coincident event comparisons and time-series analysis. Users of the data will notice a general improvement in all of the SAGE II data products, which are now in better agreement with more modern data sets (e.g. SAGE III) and more robust for use with trend studies.

  3. ELAS - SCIENCE & TECHNOLOGY LABORATORY APPLICATIONS SOFTWARE (SUN VERSION)

    NASA Technical Reports Server (NTRS)

    Walters, D.

    1994-01-01

    the flexibility to process data elements exceeding 8 bits in length, including floating point (noninteger) elements and 16 or 32 bit integers. Thus it is able to analyze and process "non-standard" nonimage data. The VAX (ERL-10017) and Concurrent (ERL-10013) versions of ELAS 9.0 are written in FORTRAN and ASSEMBLER for DEC VAX series computers running VMS and Concurrent computers running MTM. The Sun (SSC-00019), Masscomp (SSC-00020), and Silicon Graphics (SSC-00021) versions of ELAS 9.0 are written in FORTRAN 77 and C-LANGUAGE for Sun4 series computers running SunOS, Masscomp computers running UNIX, and Silicon Graphics IRIS computers running IRIX. The Concurrent version requires at least 15 bit addressing and a direct memory access channel. The VAX and Concurrent versions of ELAS both require floating-point hardware, at least 1Mb of RAM, and approximately 70Mb of disk space. Both versions also require a COMTAL display device in order to display images. For the Sun, Masscomp, and Silicon Graphics versions of ELAS, the disk storage required is approximately 115Mb, and a minimum of 8Mb of RAM is required for execution. The Sun version of ELAS requires either the X-Window System Version 11 Revision 4 or Sun OpenWindows Version 2. The Masscomp version requires a GA1000 display device and the associated "gp" library. The Silicon Graphics version requires Silicon Graphics' GL library. ELAS display functions will not work with a monochrome monitor. The standard distribution medium for the VAX version (ERL10017) is a set of two 9-track 1600 BPI magnetic tapes in DEC VAX BACKUP format. This version is also available on a TK50 tape cartridge in DEC VAX BACKUP format. The standard distribution medium for the Concurrent version (ERL-10013) is a set of two 9-track 1600 BPI magnetic tapes in Concurrent BACKUP format. The standard distribution medium for the Sun version (SSC-00019) is a .25 inch streaming magnetic tape cartridge in UNIX tar format. The standard distribution medium

  4. ELAS - SCIENCE & TECHNOLOGY LABORATORY APPLICATIONS SOFTWARE (DEC VAX VERSION)

    NASA Technical Reports Server (NTRS)

    Junkin, B. G.

    1994-01-01

    the flexibility to process data elements exceeding 8 bits in length, including floating point (noninteger) elements and 16 or 32 bit integers. Thus it is able to analyze and process "non-standard" nonimage data. The VAX (ERL-10017) and Concurrent (ERL-10013) versions of ELAS 9.0 are written in FORTRAN and ASSEMBLER for DEC VAX series computers running VMS and Concurrent computers running MTM. The Sun (SSC-00019), Masscomp (SSC-00020), and Silicon Graphics (SSC-00021) versions of ELAS 9.0 are written in FORTRAN 77 and C-LANGUAGE for Sun4 series computers running SunOS, Masscomp computers running UNIX, and Silicon Graphics IRIS computers running IRIX. The Concurrent version requires at least 15 bit addressing and a direct memory access channel. The VAX and Concurrent versions of ELAS both require floating-point hardware, at least 1Mb of RAM, and approximately 70Mb of disk space. Both versions also require a COMTAL display device in order to display images. For the Sun, Masscomp, and Silicon Graphics versions of ELAS, the disk storage required is approximately 115Mb, and a minimum of 8Mb of RAM is required for execution. The Sun version of ELAS requires either the X-Window System Version 11 Revision 4 or Sun OpenWindows Version 2. The Masscomp version requires a GA1000 display device and the associated "gp" library. The Silicon Graphics version requires Silicon Graphics' GL library. ELAS display functions will not work with a monochrome monitor. The standard distribution medium for the VAX version (ERL10017) is a set of two 9-track 1600 BPI magnetic tapes in DEC VAX BACKUP format. This version is also available on a TK50 tape cartridge in DEC VAX BACKUP format. The standard distribution medium for the Concurrent version (ERL-10013) is a set of two 9-track 1600 BPI magnetic tapes in Concurrent BACKUP format. The standard distribution medium for the Sun version (SSC-00019) is a .25 inch streaming magnetic tape cartridge in UNIX tar format. The standard distribution medium

  5. ELAS - SCIENCE & TECHNOLOGY LABORATORY APPLICATIONS SOFTWARE (CONCURRENT VERSION)

    NASA Technical Reports Server (NTRS)

    Pearson, R. W.

    1994-01-01

    the flexibility to process data elements exceeding 8 bits in length, including floating point (noninteger) elements and 16 or 32 bit integers. Thus it is able to analyze and process "non-standard" nonimage data. The VAX (ERL-10017) and Concurrent (ERL-10013) versions of ELAS 9.0 are written in FORTRAN and ASSEMBLER for DEC VAX series computers running VMS and Concurrent computers running MTM. The Sun (SSC-00019), Masscomp (SSC-00020), and Silicon Graphics (SSC-00021) versions of ELAS 9.0 are written in FORTRAN 77 and C-LANGUAGE for Sun4 series computers running SunOS, Masscomp computers running UNIX, and Silicon Graphics IRIS computers running IRIX. The Concurrent version requires at least 15 bit addressing and a direct memory access channel. The VAX and Concurrent versions of ELAS both require floating-point hardware, at least 1Mb of RAM, and approximately 70Mb of disk space. Both versions also require a COMTAL display device in order to display images. For the Sun, Masscomp, and Silicon Graphics versions of ELAS, the disk storage required is approximately 115Mb, and a minimum of 8Mb of RAM is required for execution. The Sun version of ELAS requires either the X-Window System Version 11 Revision 4 or Sun OpenWindows Version 2. The Masscomp version requires a GA1000 display device and the associated "gp" library. The Silicon Graphics version requires Silicon Graphics' GL library. ELAS display functions will not work with a monochrome monitor. The standard distribution medium for the VAX version (ERL10017) is a set of two 9-track 1600 BPI magnetic tapes in DEC VAX BACKUP format. This version is also available on a TK50 tape cartridge in DEC VAX BACKUP format. The standard distribution medium for the Concurrent version (ERL-10013) is a set of two 9-track 1600 BPI magnetic tapes in Concurrent BACKUP format. The standard distribution medium for the Sun version (SSC-00019) is a .25 inch streaming magnetic tape cartridge in UNIX tar format. The standard distribution medium

  6. ELAS - SCIENCE & TECHNOLOGY LABORATORY APPLICATIONS SOFTWARE (SILICON GRAPHICS VERSION)

    NASA Technical Reports Server (NTRS)

    Walters, D.

    1994-01-01

    the flexibility to process data elements exceeding 8 bits in length, including floating point (noninteger) elements and 16 or 32 bit integers. Thus it is able to analyze and process "non-standard" nonimage data. The VAX (ERL-10017) and Concurrent (ERL-10013) versions of ELAS 9.0 are written in FORTRAN and ASSEMBLER for DEC VAX series computers running VMS and Concurrent computers running MTM. The Sun (SSC-00019), Masscomp (SSC-00020), and Silicon Graphics (SSC-00021) versions of ELAS 9.0 are written in FORTRAN 77 and C-LANGUAGE for Sun4 series computers running SunOS, Masscomp computers running UNIX, and Silicon Graphics IRIS computers running IRIX. The Concurrent version requires at least 15 bit addressing and a direct memory access channel. The VAX and Concurrent versions of ELAS both require floating-point hardware, at least 1Mb of RAM, and approximately 70Mb of disk space. Both versions also require a COMTAL display device in order to display images. For the Sun, Masscomp, and Silicon Graphics versions of ELAS, the disk storage required is approximately 115Mb, and a minimum of 8Mb of RAM is required for execution. The Sun version of ELAS requires either the X-Window System Version 11 Revision 4 or Sun OpenWindows Version 2. The Masscomp version requires a GA1000 display device and the associated "gp" library. The Silicon Graphics version requires Silicon Graphics' GL library. ELAS display functions will not work with a monochrome monitor. The standard distribution medium for the VAX version (ERL10017) is a set of two 9-track 1600 BPI magnetic tapes in DEC VAX BACKUP format. This version is also available on a TK50 tape cartridge in DEC VAX BACKUP format. The standard distribution medium for the Concurrent version (ERL-10013) is a set of two 9-track 1600 BPI magnetic tapes in Concurrent BACKUP format. The standard distribution medium for the Sun version (SSC-00019) is a .25 inch streaming magnetic tape cartridge in UNIX tar format. The standard distribution medium

  7. Major Upgrades to the AIRS Version-6 Water Vapor Profile Methodology

    NASA Technical Reports Server (NTRS)

    Susskind, Joel; Blaisdell, John; Iredell, Lena

    2015-01-01

    This research is a continuation of part of what was shown at the last AIRS Science Team Meeting and the AIRS 2015 NetMeeting. AIRS Version 6 was finalized in late 2012 and is now operational. Version 6 contained many significant improvements in retrieval methodology compared to Version 5. Version 6 retrieval methodology used for the water vapor profile q(p) and ozone profile O3(p) retrievals is basically unchanged from Version 5, or even from Version 4. Subsequent research has made significant improvements in both water vapor and O3 profiles compared to Version 6.

  8. APT - NASA ENHANCED VERSION OF AUTOMATICALLY PROGRAMMED TOOL SOFTWARE - STAND-ALONE VERSION

    NASA Technical Reports Server (NTRS)

    Premo, D. A.

    1994-01-01

    The APT code is one of the most widely used software tools for complex numerically controlled (N/C) machining. APT is an acronym for Automatically Programmed Tools and is used to denote both a language and the computer software that processes that language. Development of the APT language and software system was begun over twenty years ago as a U. S. government sponsored industry and university research effort. APT is a "problem oriented" language that was developed for the explicit purpose of aiding the N/C machine tools. Machine-tool instructions and geometry definitions are written in the APT language to constitute a "part program." The APT part program is processed by the APT software to produce a cutter location (CL) file. This CL file may then be processed by user supplied post processors to convert the CL data into a form suitable for a particular N/C machine tool. This June, 1989 offering of the APT system represents an adaptation, with enhancements, of the public domain version of APT IV/SSX8 to the DEC VAX-11/780 for use by the Engineering Services Division of the NASA Goddard Space Flight Center. Enhancements include the super pocket feature which allows concave and convex polygon shapes of up to 40 points including shapes that overlap, that leave islands of material within the pocket, and that have one or more arcs as part of the pocket boundary. Recent modifications to APT include a rework of the POCKET subroutine and correction of an error that prevented the use within a macro of a macro variable cutter move statement combined with macro variable double check surfaces. Former modifications included the expansion of array and buffer sizes to accommodate larger part programs, and the insertion of a few user friendly error messages. The APT system software on the DEC VAX-11/780 is organized into two separate programs: the load complex and the APT processor. The load complex handles the table initiation phase and is usually only run when changes to the

  9. Aircraft noise prediction program propeller analysis system IBM-PC version user's manual version 2.0

    NASA Technical Reports Server (NTRS)

    Nolan, Sandra K.

    1988-01-01

    The IBM-PC version of the Aircraft Noise Prediction Program (ANOPP) Propeller Analysis System (PAS) is a set of computational programs for predicting the aerodynamics, performance, and noise of propellers. The ANOPP-PAS is a subset of a larger version of ANOPP which can be executed on CDC or VAX computers. This manual provides a description of the IBM-PC version of the ANOPP-PAS and its prediction capabilities, and instructions on how to use the system on an IBM-XT or IBM-AT personal computer. Sections within the manual document installation, system design, ANOPP-PAS usage, data entry preprocessors, and ANOPP-PAS functional modules and procedures. Appendices to the manual include a glossary of ANOPP terms and information on error diagnostics and recovery techniques.

  10. Spanish and English Versions of the PTSD Checklist – Civilian Version (PCL-C): Testing for Differential Item Functioning

    PubMed Central

    Miles, Jeremy N.V.; Marshall, Grant N.; Schell, Terry L.

    2010-01-01

    Interpretation of ethnic differences in PTSD is predicated on demonstration that differences are not due to measurement bias. This is difficult when multiple languages are used in the assessment. This study used confirmatory factor analysis to examine possible differential item functioning (DIF) across English and Spanish versions of the PTSD Checklist-Civilian Version (PCL-C). Data were derived from two assessments of Hispanics (Ns = 304, 213), who were hospitalized with physical injuries. After correction for multiple testing, univariate tests revealed no statistically significant DIF effects; multivariate tests revealed some indication of DIF at the initial assessment only. This bias was inconsistent across waves and unlikely to be substantively consequential, indicating that the two versions of the PCL-C were generally equivalent. PMID:18720394

  11. An Internet Version of the Diagnostic Interview Schedule for Children (DISC-IV) : Correspondence of the ADHD Section with the Paper-and-Pencil Version

    ERIC Educational Resources Information Center

    Steenhuis, Mark-Peter; Serra, Marike; Minderaa, Rudolf Boudewijn; Hartman, Catharina Annette

    2009-01-01

    The authors recently developed an Internet version of the Diagnostic Interview Schedule for Children-Version 4 (DISC-IV), parent version (D. Shaffer, P. Fisher, C. P. Lucas, M. K. Dulcan, & M. E. Schwab-Stone, 2000), with the main purpose of using it at home without an interviewer. This offers many advantages (e.g., extended applicability, fast…

  12. Integrated Farm System Model Version 4.1 and Dairy Gas Emissions Model Version 3.1 software release and distribution

    Technology Transfer Automated Retrieval System (TEKTRAN)

    Animal facilities are significant contributors of gaseous emissions including ammonia (NH3) and nitrous oxide (N2O). Previous versions of the Integrated Farm System Model (IFSM version 4.0) and Dairy Gas Emissions Model (DairyGEM version 3.0), two whole-farm simulation models developed by USDA-ARS, ...

  13. A comparison of dose results from the Clean Air Act Assessment Package-1988, personal computer (CAP88-PC), version 3 to previous versions.

    PubMed

    Rhoads, Kathleen; Snyder, Sandra; Staven, Lissa

    2013-08-01

    Computer software packages approved by the U.S. Environmental Protection Agency (U.S. EPA), including CAP88-PC, are used by U.S. Department of Energy (U.S. DOE) sites to demonstrate compliance with the radionuclide air emission standard under the Clean Air Act. CAP88-PC version 3, was approved by the U.S. EPA in February 2006 for use by U.S. DOE facilities. Version 3 incorporates several major changes that have the potential to affect calculated doses relative to calculations using earlier versions. This analysis examined the types and magnitudes of changes to dose estimates for specific radionuclides calculated using the version 3 software compared with the previous versions. For parent radionuclides and for the total dose from radionuclide chains, total effective dose calculated with version 3 was compared to effective dose equivalent calculated with previous versions. Various comparisons were also performed to determine which of the updates in version 3 accounted for changes in overall dose estimates. CAP88-PC version 3 would produce substantially different results relative to previous versions of the code for a number of radionuclides, including some isotopes that may be present at U.S. DOE facilities, as well as those used for industrial and medical applications. In general, doses for many radionuclides were lower using version 3 but doses for a few key radionuclides increased relative to the previous versions.

  14. Swedish Version of Mood Spectrum Self-Report Questionnaire: Psychometric Properties of Lifetime and Last-week Version

    PubMed Central

    Ioannou, Michael; Dellepiane, Marzia; Benvenuti, Antonella; Feloukatzis, Konstantinos; Skondra, Nektaria; Dell'Osso, Liliana; Steingrímsson, Steinn

    2016-01-01

    Background: Mood Spectrum Self Report (MOODS-SR) is an instrument that assesses mood spectrum symptomatology including subthreshold manifestations and temperamental features. There are different versions of the MOODS-SR for different time frames of symptom assessment: lifetime (MOODS-LT), last-month and last-week (MOODS-LW) versions. Objective: To evaluate the psychometric properties of the MOODS-LT the MOODS-LW. Methods: The reliability of the MOODS-LT and MOODS-LW was evaluated in terms of internal consistency and partial correlations among domains and subdomains. The known-group validity was tested by comparing out-patients with bipolar disorder (n=27), unipolar depression (n=8) healthy controls (n=68). The convergent and divergent validity of MOODS-LW were evaluated using the Montgomery Åsberg Depression Rating Scale (MADRS), the Young-Ziegler Mania Rating Scale (YMRS) in outpatients as well the General Health Questionnaire (GHQ-12) in healthy controls. Results: Both MOODS-LT and MOOODS-LW showed high internal consistency with the Kuder-Richardson coefficient ranging from 0.823 to 0.985 as well as consistent correlations for all domains and subdomains. The last-week version correlated significantly with MADRS (r= 0.79) and YMRS (r=0.46) in outpatients and with GHQ-12 (r= 0.50 for depression domain, r= 0.29 for rhythmicity) in healthy controls. Conclusion: The Swedish version of the MOODS-LT showed similar psychometric properties to other translated versions. Regarding MOODS-LW, this first published psychometric evaluation of the scale showed promising psychometric properties including good correlation to established symptom assessment scales. In healthy controls, the depression and rhythmicity domain scores of the last-week version correlated significantly with the occurrence of mild psychological distress. PMID:27346997

  15. Documentation for the machine-readable version of the SAO-HD-GC-DM cross index version 1983

    NASA Technical Reports Server (NTRS)

    Roman, N. G.; Warren, W. H., Jr.; Schofield, N., Jr.

    1983-01-01

    An updated and extended machine readable version of the Smithsonian Astrophysical Observatory star catalog (SAO) is described. A correction of all errors which were found since preparation of the original catalog which resulted from misidentifications and omissions of components in multiple star systems and missing Durchmusterung numbers (the common identifier) in the SAO Catalog are included and component identifications from the Index of Visual Double Stars (IDS) are appended to all multiple SAO entries with the same DM numbers, and lower case letter identifiers for supplemental BD stars are added. A total of 11,398 individual corrections and data additions is incorporated into the present version of the cross index.

  16. Documentation for the machine-readable version of the Smithsonian Astrophysical Observatory Star catalogue (SAO) version 1984

    NASA Technical Reports Server (NTRS)

    Roman, N. G.; Warren, W. H., Jr.

    1984-01-01

    An updated, corrected and extended machine readable version of the Smithsonian Astrophysical Observatory star catalog (SAO) is described. Published and unpublished errors discovered in the previous version have been corrected, and multiple star and supplemental BD identifications added to stars where more than one SAO entry has the same Durchmusterung number. Henry Draper Extension (HDE) numbers have been added for stars found in both volumes of the extension. Data for duplicate SAO entries (those referring to the same star) have been blanked out, but the records themselves have been retained and flagged so that sequencing and record count are identical to the published catalog.

  17. IDC Use Case Model Survey Version 1.1.

    SciTech Connect

    Harris, James Mark; Carr, Dorthe B.

    2015-02-01

    This document contains the brief descriptions for the actors and use cases contained in the IDC Use Case Model. REVISIONS Version Date Author/Team Revision Description Authorized by V1.0 12/2014 SNL IDC Reengineering Project Team Initial delivery M. Harris V1.1 2/2015 SNL IDC Reengineering Project Team Iteration I2 Review Comments M. Harris

  18. IDC Use Case Model Survey Version 1.0.

    SciTech Connect

    Carr, Dorthe B.; Harris, James M.

    2014-12-01

    This document contains the brief descriptions for the actors and use cases contained in the IDC Use Case Model Survey. REVISIONS Version Date Author/Team Revision Description Authorized by V1.0 12/2014 IDC Re- engineering Project Team Initial delivery M. Harris

  19. A Survey Version of Full-Profile Conjoint Analysis.

    ERIC Educational Resources Information Center

    Chrzan, Keith

    Two studies were conducted to test the viability of a survey version of full-profile conjoint analysis. Conjoint analysis describes a variety of analytic techniques for measuring subjects'"utilities," or preferences for the individual attributes or levels of attributes that constitute objects under study. The first study compared the developed…

  20. Validating the Chinese Version of the Inventory of School Motivation

    ERIC Educational Resources Information Center

    King, Ronnel B.; Watkins, David A.

    2013-01-01

    The aim of this study is to assess the cross-cultural applicability of the Chinese version of the Inventory of School Motivation (ISM; McInerney & Sinclair, 1991) in the Hong Kong context using both within-network and between-network approaches to construct validation. The ISM measures four types of achievement goals: mastery, performance, social,…

  1. 78 FR 76986 - Version 5 Critical Infrastructure Protection Reliability Standards

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-12-20

    ... of Tuesday, December 3, 2013 (78 FR 72755). The regulations approved certain reliability standards... issued in this docket.' \\27\\'' In FR Doc. 2013-28628 appearing on page 72758 in the Federal Register of... Energy Regulatory Commission 18 CFR Part 40 Version 5 Critical Infrastructure Protection...

  2. MISR Level 3 Land Surface and Aerosol Versioning

    Atmospheric Science Data Center

    2013-04-01

    ... summary of Level 2. This page covers changes to the Level 3 software itself for each product version, but you should also consult the  ... Data Product Specification Rev K  (PDF). Update to work with new format of input PGE 9 files.   ...

  3. ELAS - SCIENCE & TECHNOLOGY LABORATORY APPLICATIONS SOFTWARE (MASSCOMP VERSION)

    NASA Technical Reports Server (NTRS)

    Walters, D.

    1994-01-01

    the flexibility to process data elements exceeding 8 bits in length, including floating point (noninteger) elements and 16 or 32 bit integers. Thus it is able to analyze and process "non-standard" nonimage data. The VAX (ERL-10017) and Concurrent (ERL-10013) versions of ELAS 9.0 are written in FORTRAN and ASSEMBLER for DEC VAX series computers running VMS and Concurrent computers running MTM. The Sun (SSC-00019), Masscomp (SSC-00020), and Silicon Graphics (SSC-00021) versions of ELAS 9.0 are written in FORTRAN 77 and C-LANGUAGE for Sun4 series computers running SunOS, Masscomp computers running UNIX, and Silicon Graphics IRIS computers running IRIX. The Concurrent version requires at least 15 bit addressing and a direct memory access channel. The VAX and Concurrent versions of ELAS both require floating-point hardware, at least 1Mb of RAM, and approximately 70Mb of disk space. Both versions also require a COMTAL display device in order to display images. For the Sun, Masscomp, and Silicon Graphics versions of ELAS, the disk storage required is approximately 115Mb, and a minimum of 8Mb of RAM is required for execution. The Sun version of ELAS requires either the X-Window System Version 11 Revision 4 or Sun OpenWindows Version 2. The Masscomp version requires a GA1000 display device and the associated "gp" library. The Silicon Graphics version requires Silicon Graphics' GL library. ELAS display functions will not work with a monochrome monitor. The standard distribution medium for the VAX version (ERL10017) is a set of two 9-track 1600 BPI magnetic tapes in DEC VAX BACKUP format. This version is also available on a TK50 tape cartridge in DEC VAX BACKUP format. The standard distribution medium for the Concurrent version (ERL-10013) is a set of two 9-track 1600 BPI magnetic tapes in Concurrent BACKUP format. The standard distribution medium for the Sun version (SSC-00019) is a .25 inch streaming magnetic tape cartridge in UNIX tar format. The standard distribution medium

  4. ELAS - SCIENCE & TECHNOLOGY LABORATORY APPLICATIONS SOFTWARE (DEC VAX VERSION)

    NASA Technical Reports Server (NTRS)

    Junkin, B. G.

    1994-01-01

    the flexibility to process data elements exceeding 8 bits in length, including floating point (noninteger) elements and 16 or 32 bit integers. Thus it is able to analyze and process "non-standard" nonimage data. The VAX (ERL-10017) and Concurrent (ERL-10013) versions of ELAS 9.0 are written in FORTRAN and ASSEMBLER for DEC VAX series computers running VMS and Concurrent computers running MTM. The Sun (SSC-00019), Masscomp (SSC-00020), and Silicon Graphics (SSC-00021) versions of ELAS 9.0 are written in FORTRAN 77 and C-LANGUAGE for Sun4 series computers running SunOS, Masscomp computers running UNIX, and Silicon Graphics IRIS computers running IRIX. The Concurrent version requires at least 15 bit addressing and a direct memory access channel. The VAX and Concurrent versions of ELAS both require floating-point hardware, at least 1Mb of RAM, and approximately 70Mb of disk space. Both versions also require a COMTAL display device in order to display images. For the Sun, Masscomp, and Silicon Graphics versions of ELAS, the disk storage required is approximately 115Mb, and a minimum of 8Mb of RAM is required for execution. The Sun version of ELAS requires either the X-Window System Version 11 Revision 4 or Sun OpenWindows Version 2. The Masscomp version requires a GA1000 display device and the associated "gp" library. The Silicon Graphics version requires Silicon Graphics' GL library. ELAS display functions will not work with a monochrome monitor. The standard distribution medium for the VAX version (ERL10017) is a set of two 9-track 1600 BPI magnetic tapes in DEC VAX BACKUP format. This version is also available on a TK50 tape cartridge in DEC VAX BACKUP format. The standard distribution medium for the Concurrent version (ERL-10013) is a set of two 9-track 1600 BPI magnetic tapes in Concurrent BACKUP format. The standard distribution medium for the Sun version (SSC-00019) is a .25 inch streaming magnetic tape cartridge in UNIX tar format. The standard distribution medium

  5. ELAS - SCIENCE & TECHNOLOGY LABORATORY APPLICATIONS SOFTWARE (SUN VERSION)

    NASA Technical Reports Server (NTRS)

    Walters, D.

    1994-01-01

    the flexibility to process data elements exceeding 8 bits in length, including floating point (noninteger) elements and 16 or 32 bit integers. Thus it is able to analyze and process "non-standard" nonimage data. The VAX (ERL-10017) and Concurrent (ERL-10013) versions of ELAS 9.0 are written in FORTRAN and ASSEMBLER for DEC VAX series computers running VMS and Concurrent computers running MTM. The Sun (SSC-00019), Masscomp (SSC-00020), and Silicon Graphics (SSC-00021) versions of ELAS 9.0 are written in FORTRAN 77 and C-LANGUAGE for Sun4 series computers running SunOS, Masscomp computers running UNIX, and Silicon Graphics IRIS computers running IRIX. The Concurrent version requires at least 15 bit addressing and a direct memory access channel. The VAX and Concurrent versions of ELAS both require floating-point hardware, at least 1Mb of RAM, and approximately 70Mb of disk space. Both versions also require a COMTAL display device in order to display images. For the Sun, Masscomp, and Silicon Graphics versions of ELAS, the disk storage required is approximately 115Mb, and a minimum of 8Mb of RAM is required for execution. The Sun version of ELAS requires either the X-Window System Version 11 Revision 4 or Sun OpenWindows Version 2. The Masscomp version requires a GA1000 display device and the associated "gp" library. The Silicon Graphics version requires Silicon Graphics' GL library. ELAS display functions will not work with a monochrome monitor. The standard distribution medium for the VAX version (ERL10017) is a set of two 9-track 1600 BPI magnetic tapes in DEC VAX BACKUP format. This version is also available on a TK50 tape cartridge in DEC VAX BACKUP format. The standard distribution medium for the Concurrent version (ERL-10013) is a set of two 9-track 1600 BPI magnetic tapes in Concurrent BACKUP format. The standard distribution medium for the Sun version (SSC-00019) is a .25 inch streaming magnetic tape cartridge in UNIX tar format. The standard distribution medium

  6. ELAS - SCIENCE & TECHNOLOGY LABORATORY APPLICATIONS SOFTWARE (SILICON GRAPHICS VERSION)

    NASA Technical Reports Server (NTRS)

    Walters, D.

    1994-01-01

    the flexibility to process data elements exceeding 8 bits in length, including floating point (noninteger) elements and 16 or 32 bit integers. Thus it is able to analyze and process "non-standard" nonimage data. The VAX (ERL-10017) and Concurrent (ERL-10013) versions of ELAS 9.0 are written in FORTRAN and ASSEMBLER for DEC VAX series computers running VMS and Concurrent computers running MTM. The Sun (SSC-00019), Masscomp (SSC-00020), and Silicon Graphics (SSC-00021) versions of ELAS 9.0 are written in FORTRAN 77 and C-LANGUAGE for Sun4 series computers running SunOS, Masscomp computers running UNIX, and Silicon Graphics IRIS computers running IRIX. The Concurrent version requires at least 15 bit addressing and a direct memory access channel. The VAX and Concurrent versions of ELAS both require floating-point hardware, at least 1Mb of RAM, and approximately 70Mb of disk space. Both versions also require a COMTAL display device in order to display images. For the Sun, Masscomp, and Silicon Graphics versions of ELAS, the disk storage required is approximately 115Mb, and a minimum of 8Mb of RAM is required for execution. The Sun version of ELAS requires either the X-Window System Version 11 Revision 4 or Sun OpenWindows Version 2. The Masscomp version requires a GA1000 display device and the associated "gp" library. The Silicon Graphics version requires Silicon Graphics' GL library. ELAS display functions will not work with a monochrome monitor. The standard distribution medium for the VAX version (ERL10017) is a set of two 9-track 1600 BPI magnetic tapes in DEC VAX BACKUP format. This version is also available on a TK50 tape cartridge in DEC VAX BACKUP format. The standard distribution medium for the Concurrent version (ERL-10013) is a set of two 9-track 1600 BPI magnetic tapes in Concurrent BACKUP format. The standard distribution medium for the Sun version (SSC-00019) is a .25 inch streaming magnetic tape cartridge in UNIX tar format. The standard distribution medium

  7. ELAS - SCIENCE & TECHNOLOGY LABORATORY APPLICATIONS SOFTWARE (CONCURRENT VERSION)

    NASA Technical Reports Server (NTRS)

    Pearson, R. W.

    1994-01-01

    the flexibility to process data elements exceeding 8 bits in length, including floating point (noninteger) elements and 16 or 32 bit integers. Thus it is able to analyze and process "non-standard" nonimage data. The VAX (ERL-10017) and Concurrent (ERL-10013) versions of ELAS 9.0 are written in FORTRAN and ASSEMBLER for DEC VAX series computers running VMS and Concurrent computers running MTM. The Sun (SSC-00019), Masscomp (SSC-00020), and Silicon Graphics (SSC-00021) versions of ELAS 9.0 are written in FORTRAN 77 and C-LANGUAGE for Sun4 series computers running SunOS, Masscomp computers running UNIX, and Silicon Graphics IRIS computers running IRIX. The Concurrent version requires at least 15 bit addressing and a direct memory access channel. The VAX and Concurrent versions of ELAS both require floating-point hardware, at least 1Mb of RAM, and approximately 70Mb of disk space. Both versions also require a COMTAL display device in order to display images. For the Sun, Masscomp, and Silicon Graphics versions of ELAS, the disk storage required is approximately 115Mb, and a minimum of 8Mb of RAM is required for execution. The Sun version of ELAS requires either the X-Window System Version 11 Revision 4 or Sun OpenWindows Version 2. The Masscomp version requires a GA1000 display device and the associated "gp" library. The Silicon Graphics version requires Silicon Graphics' GL library. ELAS display functions will not work with a monochrome monitor. The standard distribution medium for the VAX version (ERL10017) is a set of two 9-track 1600 BPI magnetic tapes in DEC VAX BACKUP format. This version is also available on a TK50 tape cartridge in DEC VAX BACKUP format. The standard distribution medium for the Concurrent version (ERL-10013) is a set of two 9-track 1600 BPI magnetic tapes in Concurrent BACKUP format. The standard distribution medium for the Sun version (SSC-00019) is a .25 inch streaming magnetic tape cartridge in UNIX tar format. The standard distribution medium

  8. NetState : a network version tracking system.

    SciTech Connect

    Van Randwyk, Jamie A.; Durgin, Nancy Ann; Mai, Yuqing

    2005-02-01

    Network administrators and security analysts often do not know what network services are being run in every corner of their networks. If they do have a vague grasp of the services running on their networks, they often do not know what specific versions of those services are running. Actively scanning for services and versions does not always yield complete results, and patch and service management, therefore, suffer. We present Net-State, a system for monitoring, storing, and reporting application and operating system version information for a network. NetState gives security and network administrators the ability to know what is running on their networks while allowing for user-managed machines and complex host configurations. Our architecture uses distributed modules to collect network information and a centralized server that stores and issues reports on that collected version information. We discuss some of the challenges to building and operating NetState as well as the legal issues surrounding the promiscuous capture of network data. We conclude that this tool can solve some key problems in network management and has a wide range of possibilities for future uses.

  9. User's Manual for LEWICE Version 3.2

    NASA Technical Reports Server (NTRS)

    Wright, William

    2008-01-01

    A research project is underway at NASA Glenn to produce a computer code which can accurately predict ice growth under a wide range of meteorological conditions for any aircraft surface. This report will present a description of the code inputs and outputs from version 3.2 of this software, which is called LEWICE. This version differs from release 2.0 due to the addition of advanced thermal analysis capabilities for de-icing and anti-icing applications using electrothermal heaters or bleed air applications, the addition of automated Navier-Stokes analysis, an empirical model for supercooled large droplets (SLD) and a pneumatic boot option. An extensive effort was also undertaken to compare the results against the database of electrothermal results which have been generated in the NASA Glenn Icing Research Tunnel (IRT) as was performed for the validation effort for version 2.0. This report will primarily describe the features of the software related to the use of the program. Appendix A has been included to list some of the inner workings of the software or the physical models used. This information is also available in the form of several unpublished documents internal to NASA. This report is intended as a replacement for all previous user manuals of LEWICE. In addition to describing the changes and improvements made for this version, information from previous manuals may be duplicated so that the user will not need to consult previous manuals to use this software.

  10. Factor Structure of Japanese Versions of Two Emotional Intelligence Scales

    ERIC Educational Resources Information Center

    Fukuda, Eriko; Saklofske, Donald H.; Tamaoka, Katsuo; Fung, Tak Shing; Miyaoka, Yayoi; Kiyama, Sachiko

    2011-01-01

    This article reports the psychometric properties of two emotional intelligence measures translated into Japanese. Confirmatory factor analysis (CFA) was conducted to examine the factor structure of a Japanese version of the Wong and Law Emotional Intelligence Scale (WLEIS) completed by 310 Japanese university students. A second study employed CFA…

  11. X-ray Photoelectron Spectroscopy Database (Version 4.1)

    National Institute of Standards and Technology Data Gateway

    SRD 20 X-ray Photoelectron Spectroscopy Database (Version 4.1) (Web, free access)   The NIST XPS Database gives access to energies of many photoelectron and Auger-electron spectral lines. The database contains over 22,000 line positions, chemical shifts, doublet splittings, and energy separations of photoelectron and Auger-electron lines.

  12. Engestrom's Version of Activity Theory: A Conservative Praxis?

    ERIC Educational Resources Information Center

    Avis, James

    2007-01-01

    This article examines Engestrom's version of activity theory, one rooted in Marxism. It is argued that whilst this approach holds progressive possibilities, its radicalism is undermined by a restricted conceptualisation of transformation and the marginalisation of a politicised notion of social antagonism. As a consequence, this approach to…

  13. Transformation or Transformism: Engestrom's Version of Activity Theory?

    ERIC Educational Resources Information Center

    Avis, James

    2009-01-01

    The paper examines Engestrom's version of activity theory. It seeks to locate this within the socio-economic and theoretical context in which notions of co-configuration and knotworking are set. Although this theoretical approach offers radical possibilities it is limited by its neglect of the wider social context in which activity systems are…

  14. Psychometric Evaluation of the Simplified Chinese Version of Flourishing Scale

    ERIC Educational Resources Information Center

    Tang, Xiaoqing; Duan, Wenjie; Wang, Zhizhang; Liu, Tianyuan

    2016-01-01

    Objectives: The Flourishing Scale (FS) was developed to measure psychological well-being from the eudaimonic perspective, highlighting the flourishing of human functioning. This article evaluated the psychometric characteristics of the simplified Chinese version of FS among a Chinese community population. Method: A total of 433 participants from…

  15. ECONOMIC GROWTH ANALYSIS SYSTEM: USER'S GUIDE - VERSION 3.0

    EPA Science Inventory

    The two-volume report describes the development of, and provides information needed to operate, the Economic Growth Analysis System (E-GAS) Version 3.0 model. The model will be used to project emissions inventories of volatile organic compounds, oxides of nitrogen, and carbon mon...

  16. ECONOMIC GROWTH ANALYSIS SYSTEM: REFERENCE MANUAL VERSION 3.0

    EPA Science Inventory

    The two-volume report describes the development of, and provides information needed to operate, the Economic Growth Analysis System (E-GAS) Version 3.0 model. The model will be used to project emissions inventories of volatile organic compounds, oxides of nitrogen, and carbon mon...

  17. Functional Overview of SWRL/IMS Version 3.

    ERIC Educational Resources Information Center

    McManus, John F.

    Version 3 of the Southwest Regional Laboratory's (SWRL) Instructional Management System (IMS) is a fully automated system which accepts pupil criterion exercises from remote sites and returns various reports to the same location. This paper briefly describes the SWRL/IMS system design and functional characteristics. The instructional system…

  18. Atmospheric Trace Molecule Spectroscopy (ATMOS) Experiment Version 3 data retrievals.

    PubMed

    Irion, Fredrick W; Gunson, Michael R; Toon, Geoff C; Chang, Albert Y; Eldering, Annmarie; Mahieu, Emmanuel; Manney, Gloria L; Michelsen, Hope A; Moyer, Elizabeth J; Newchurch, Michael J; Osterman, Gregory B; Rinsland, Curtis P; Salawitch, Ross J; Sen, Bhaswar; Yung, Yuk L; Zander, Rodolphe

    2002-11-20

    Version 3 of the Atmospheric Trace Molecule Spectroscopy (ATMOS) experiment data set for some 30 trace and minor gas profiles is available. From the IR solar-absorption spectra measured during four Space Shuttle missions (in 1985, 1992, 1993, and 1994), profiles from more than 350 occultations were retrieved from the upper troposphere to the lower mesosphere. Previous results were unreliable for tropospheric retrievals, but with a new global-fitting algorithm profiles are reliably returned down to altitudes as low as 6.5 km (clouds permitting) and include notably improved retrievals of H2O, CO, and other species. Results for stratospheric water are more consistent across the ATMOS spectral filters and do not indicate a net consumption of H2 in the upper stratosphere. A new sulfuric-acid aerosol product is described. An overview of ATMOS Version 3 processing is presented with a discussion of estimated uncertainties. Differences between these Version 3 and previously reported Version 2 ATMOS results are discussed. Retrievals are available at http://atmos.jpl.nasa.gov/atmos.

  19. ECONOMIC GROWTH ANALYSIS SYSTEM: REFERENCE MANUAL VERSION 2.0

    EPA Science Inventory

    The two-volume report describes the development of and provides information needed to operate, the Economic Growth Analysis System (E-GAS) Version 2.0 model. The model will be used to project emissions inventories of volatile organic compounds (VOCs), oxides of nitrogen (NOx), a...

  20. ECONOMIC GROWTH ANALYSIS SYSTEM: USER'S GUIDE VERSION 2.0

    EPA Science Inventory

    The two-volume report describes the development of and provides information needed to operate, the Economic Growth Analysis System (E-GAS) Version 2.0 model. The model will be used to project emissions inventories of volatile organic compounds (VOCs), oxides of nitrogen (NOx), a...